New approaches in the targeting of cell cycle, cell death and cancer progression by Giessrigl, Benedikt
 
 
 
DISSERTATION 
Titel der Dissertation 
 
NEW APPROACHES IN THE TARGETING OF CELL CYCLE, 
CELL DEATH AND CANCER PROGRESSION: 
MODELS FOR IMPROVED TUMOR THERAPY 
Verfasser 
Mag.pharm. Benedikt Giessrigl 
angestrebter akademischer Grad 
Doktor der Naturwissenschaften (Dr.rer.nat.) 
Wien, 2011  
Studienkennzahl lt. Studienblatt: A 091 449 
Dissertationsgebiet  lt. Studienblatt: Pharmazie 
Betreuerin / Betreuer: Ao. Univ.-Prof. Dr. Walter Jäger 
 
 
 
 
ACKNOWLEDGEMENTS 
 
 
I would like to express my gratitude to my supervisor, Ao. Univ.-Prof. Dr. Walter Jäger 
(Department of Clinical Pharmacy and Diagnostics, University of Vienna) for his scientific 
supervision, his helpful support and his constant encouragement throughout my thesis. 
 
 
I am extremely grateful to Ao. Univ.-Prof. Dr. Georg Krupitza (Clinical Institute for 
Pathology, Medical University of Vienna) for providing me with this project, for his 
cooperativeness and his constant interest and support. His constructive suggestions and 
critical appreciation throughout my PhD study made the thesis possible. 
 
 
Finally, I would also like to thank all my other colleagues for their constant interest in my 
work and their support. 
 
TABLE OF CONTENTS 
 
 
1 SUMMERY................................................................................ 1 
2 ZUSAMMENFASSUNG .......................................................... 3 
3 INTRODUCTION..................................................................... 7 
3.1 Cancer – a major public health problem .................................................7 
3.2 Development and biology of cancer .......................................................7 
3.2.1 Hallmarks of cancer.......................................................................................... 8 
3.2.1.1 Self-sufficiency in growth signals............................................................... 8 
3.2.1.2 Insensitivity to growth-inhibitory signals ................................................... 9 
3.2.1.3 Evasion of programmed cell death............................................................ 10 
3.2.1.4 Limitless replicative potential ................................................................... 10 
3.2.1.5 Sustained angiogenesis.............................................................................. 11 
3.2.1.6 Metastasis.................................................................................................. 12 
3.2.1.7 Additional hallmarks and enabling characteristics ................................... 12 
3.2.2 The cell cycle.................................................................................................... 13 
3.2.2.1 Regulation of the cell cycle....................................................................... 14 
3.2.2.2 Checkpoints............................................................................................... 15 
3.2.2.3 Cdc25 phosphatases – important players in cell cycle progression .......... 16 
3.2.3 Cell death ......................................................................................................... 19 
3.2.3.1 Apoptosis .................................................................................................. 19 
3.2.3.2 Necrotic cell death..................................................................................... 20 
3.2.4 Metastasis – the leading cause for cancer deaths......................................... 21 
3.2.4.1 Mechanisms of cell invasion..................................................................... 22 
3.2.4.2 Endothelial transmigration ........................................................................ 24 
3.2.5 The tumor microenvironment ....................................................................... 24 
3.3 Pancreatic cancer...................................................................................25 
3.3.1 Genetic profiles of pancreatic cancer............................................................ 25 
3.3.2 Treatment options........................................................................................... 26 
3.4 Heat shock proteins ...............................................................................27 
3.4.1 Hsp90................................................................................................................ 27 
4 REFERENCES........................................................................ 29 
5 AIMS OF THE THESIS......................................................... 47 
6 RESULTS................................................................................. 49 
6.1 Original papers and manuscripts...........................................................49 
6.1.1  Madlener S., Rosner M., Krieger S., Giessrigl B., Gridling M., Vo 
T.P., Leisser C., Lackner A., Raab I., Grusch M., Hengstschläger M., 
Dolznig H. and Krupitza G. Short 42 degrees C heat shock induces 
phosphorylation and degradation of Cdc25A which depends on 
p38MAPK, Chk2 and 14.3.3. Hum Mol Genet. 18: 1990-2000, 2009. ..... 53 
6.1.2  Ozmen A., Madlener S., Bauer S., Krasteva S., Vonach C., Giessrigl 
B., Gridling M., Viola K., Stark N., Saiko P., Michel B., Fritzer-
Szekeres M., Szekeres T., Askin-Celik T., Krenn L. and Krupitza G. 
In vitro anti-leukemic activity of the ethno-pharmacological plant 
Scutellaria orientalis ssp. carica endemic to western Turkey. 
Phytomedicine 17: 55-62, 2010. ................................................................ 67 
6.1.3  Khan M., Giessrigl B., Vonach C., Madlener S., Prinz S., Herbaceck 
I., Hölzl C., Bauer S., Viola K., Mikulits W., Quereshi R.A., 
Knasmüller S., Grusch M., Kopp B. and Krupitza G. Berberine and a 
Berberis lycium extract inactivate Cdc25A and induce alpha-tubulin 
acetylation that correlate with HL-60 cell cycle inhibition and 
apoptosis. Mutat Res. 683: 123-130, 2010. ............................................... 77 
6.1.4  Madlener S., Saiko P., Vonach C., Viola K., Huttary N., Stark N., 
Popescu R., Gridling M., Vo N.T., Herbacek I., Davidovits A., 
Giessrigl B., Venkateswarlu S., Geleff S., Jäger W., Grusch M., 
Kerjaschki D., Mikulits W., Golakoti T., Fritzer-Szekeres M., 
Szekeres T. and Krupitza G. Multifactorial anticancer effects of 
digalloyl-resveratrol encompass apoptosis, cell-cycle arrest, and 
inhibition of lymphendothelial gap formation in vitro. Br. J. Cancer 
102: 1361-137, 2010.................................................................................. 87 
6.1.5  Saiko P., Graser G., Giessrigl B., Lackner A., Grusch M., Krupitza 
G., Basu A., Sinha B.N., Jayaprakash V., Jaeger W., Fritzer-Szekeres 
M. and Szekeres T. A novel N-hydroxy-N'-aminoguanidine derivative 
inhibits ribonucleotide reductase activity: Effects in human HL-60 
promyelocytic leukemia cells and synergism with 
arabinofuranosylcytosine (Ara-C). Biochem Pharmacol. 81: 50-59, 
2011. .......................................................................................................... 99 
6.1.6  Jäger W., Gruber A., Giessrigl B., Krupitza G., Szekeres T. and 
Sonntag D. Metabolomic analysis of resveratrol-induced effects in the 
human breast cancer cell lines MCF-7 and MDA-MB-231. OMICS 
15: 9-14, 2011.......................................................................................... 111 
6.1.7  Vonach C., Viola K., Giessrigl B., Huttary N., Raab I., Kalt R., 
Krieger S., Vo T.P., Madlener S., Bauer S., Marian B., Hämmerle M., 
Kretschy N., Teichmann M., Hantusch B., Stary S., Unger C., 
Seelinger M., Eger A., Mader R., Jäger W., Schmidt W., Grusch M., 
Dolznig H., Mikulits W. and Krupitza G. NF-κB mediates the 12(S)-
HETE-induced endothelial to mesenchymal transition of 
lymphendothelial cells during the intravasation of breast carcinoma 
cells. Br. J. Cancer 105: 263-271, 2011. ................................................. 119 
6.1.8  Bauer S., Singhuber J., Seelinger M., Unger C., Viola K., Vonach C., 
Giessrigl B., Madlener S., Stark N., Wallnofer B., Wagner K.H., 
Fritzer-Szekeres M., Szekeres T., Diaz R., Tut F., Frisch R., Feistel 
B., Kopp B., Krupitza G. and Popescu R. Separation of anti-
neoplastic activities by fractionation of a Pluchea odorata extract. 
Front Biosci. (Elite Ed) 1: 1326-36, 2011. .............................................. 131 
6.1.9  Viola K., Vonach C., Kretschy N., Teichmann M., Rarova L., Strnad 
M., Giessrigl B., Huttary N., Raab I., Stary S., Krieger S., Keller T, 
Bauer S, Jarukamjorn K., Hantusch B., Szekeres T., de Martin R., 
Jäger W., Knasmüller S., Mikulits W., Dolznig H.,  Krupitza G. and 
Grusch M. Bay11-7082 and xanthohumol inhibit breast cancer 
spheroid-triggered disintegration of the lymphendothelial barrier; the 
role of lymphendothelial NF-κB. Br. J. Cancer, submitted. ................... 145 
6.1.10  Seelinger M., Popescu R., Seephonkai P., Singhuber J., Giessrigl B., 
Unger C., Bauer S., Wagner K.H., Fritzer-Szekeres M., Szekeres T., 
Diaz R., Tut F.T., Frisch R., Feistel B., Kopp B. and Krupitza G. 
Fractionation of an anti-neoplastic extract of Pluchea odorata 
eliminates a property typical for a migratory cancer phenotype. 
Evidence-based Compl. and Alt. Medicine, submitted............................ 179 
6.1.11 Giessrigl B., Yazici G., Teichmann M., Kopf S., Ghassemi S., 
Atanasov A.G., Dirsch V.M., Grusch M., Jäger W., Özmen A. and 
Krupitza G. Effects of Scrophularia Extracts on Tumor Cell 
Proliferation, Death and Intravasation through Lymphendothelial Cell 
Barriers. Evidence-based Compl. and Alt. Medicine, submitted............. 205 
6.1.12  Saiko P., Graser G., Giessrigl B., Lackner A., Grusch M., Krupitza 
G., Jaeger W., Golakoti T., Fritzer-Szekeres M. and Szekeres. 
Digalloylresveratrol, a novel resveratrol analog attenuates the growth 
of human pancreatic cancer cells by inhibition of ribonucleotide 
reductase in situ activity. J. of Gastroenterology, submitted. ................. 237 
6.1.13  Giessrigl B., Krieger S., Huttary N., Saiko P., Alami M., Maciuk A., 
Gollinger M., Mazal P., Szekeres T., Jäger W. and Krupitza G. Hsp90 
stabilises Cdc25A and counteracts heat shock mediated Cdc25A 
degradation and cell cycle attenuation in pancreas carcinoma cells. 
Hum Mol Genet., submitted. ................................................................... 275 
7 CURRICULUM VITAE....................................................... 303 
8 LIST OF SCIENTIFIC PUBLICATIONS......................... 305 
 
ABBREVIATIONS 
 
 
ADP    Adenosine diphosphate 
ATM    Ataxia telangiectasia mutated protein 
ATP    Adenosine triphosphate 
ATR    Ataxia telangiectasia and Rad3-related protein 
Bcl-2    B-cell lymphoma 2 
BH3    Bcl-2-homology 3 
CAK    CDK activation kinase 
CAT    Collective to amoeboid transition 
Cdc    Cell division cycle 
CDK    Cyclin dependant kinase 
CDKI    Cyclin dependant kinase inhibitor 
Chk    Checkpoint kinase 
CSC    Cancer stem cell 
DISC    Death-inducing signaling complex 
ECM    Extracellular matrix 
EMT    Epithelial to mesenchymal transition 
FGF    Fibroblast growth factor  
HETE    Hydroxyeicosatetraenoic acid 
Hsp    Heat shock protein 
LEC    Lymphatic endothelial cell 
LOX    Lipoxygenase 
MAPK   Mitogen activated protein kinase 
MAT    Mesenchymal to amoeboid transition 
MET    Mesenchymal to epithelial transition 
MMP    Matrix-metalloprotease 
PARP    Poly-(ADP-ribose) polymerase 
PDGF    Platelet derived growth factor 
PI3 kinase   Phosphatidylinositol 3-kinase 
RB    Retinoblastoma protein 
RIP    Ribosome inactivating protein 
ROS    Reactive oxygen species 
TNF    Tumor necrosis factor 
TNFR    Tumor necrosis factor receptor 
TSP-1    Thrombospondin 1 
VEGF    Vascular endothelial growth factor 
1 SUMMERY 
 
Cancer represents a major public health problem in many parts of the world and, besides 
heart diseases, cancer is the leading cause of death. Although there has been lots of 
progress in both, the understanding of biological principles leading to tumor 
development and their treatment, even today therapy concepts are partly limited. 
Therefore, exploration of new, innovative and target specific therapies represent a major 
part of cancer research. 
The aims of this thesis were investigations about novel therapy concepts for an 
improved tumor treatment with the main focus to inhibit the increased proliferation of 
tumor cells, to elicit cell death and to find possibilities to prevent metastasis. 
Natural products have played a significant role in human healthcare for thousands of 
years and even today, more than 60% of all drugs are either natural products or directly 
derived thereof, and therefore the effects of different natural extracts on various cell 
lines were investigated. Different medicinal plants, used as folk remedies mainly against 
acute and chronic inflammations, showed distinct proliferation inhibiting and apoptosis 
promoting properties and western blot experiments elucidated the underlying 
mechanisms. Furthermore, a total methanol extract of Scrophularia lucida, collected in 
the south of Turkey, showed anti-metastatic effects in a recently developed in vitro 
model. In this model, intravasation of tumor cells into the lymphatic vessels is 
resembled by generating circular defects in the integrity of a lymphatic endothelial cell 
layer (LEC) by MCF-7 breast cancer spheroids. Formation of these ruptures is known to 
be mediated by 12(S)-HETE metabolized from arachidonic acid by the hypoxia-
inducible enzymes ALOX12 or ALOX15. Inhibition of NF-κB activity with the 
synthetic inhibitor Bay 11-7082 also repressed the generation of these circular defects 
and therefore, the NF-κB pathway could be identified as a second mediator leading to 
the ruptures in the LEC monolayer. As treatment with Scrophularia lucida showed a 
distinct inhibition of NF-κB activity in a luciferase assay, the anti-metastatic properties 
of this medicinal plant extract could be attributed to NF-κB inhibition. 
Inhibition of NF-κB activity represents also one of the anti-neoplastic mechanisms of 
resveratrol. Its chemo- preventive and growth inhibiting properties are well described. 
In contrast, there is not much information about metabolic alterations caused by 
resveratrol and therefore, the influence of this natural compound on the cellular 
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concentrations of different catabolic metabolites have been investigated in two breast 
cancer cell lines. It could be demonstrated that treatment with resveratrol leads to 
increased synthesis of amino acids and biogenic amines. Furthermore, an increased 
release of arachidonic acid could be observed leading in raised synthesis of 12(S)-
HETE. This was most likely the reason that resveratrol, despite inhibiting NF-κB, was 
only weakly inhibiting the formation of MCF-7 spheroid induced circular defects in 
LEC monolayers. 
 
Investigations about the influence of short hyperthermia and the inhibition of the heat 
shock protein 90 (Hsp90) on the proliferation of tumor cells were a second major point 
of this work. In case of exposure to different stresses such as hypoxia, ischemia, 
exposure to UV light or chemicals, nutritional deficiencies or increased temperatures, 
this chaperone protects various client proteins. It could be shown that the dual specific 
phosphatase Cdc25A, a proto-oncogene over-expressed in various different human 
cancers, represents a client protein of Hsp90 and that short hyperthermia leads to its 
degradation in HEK and HELA cells. Furthermore, in combination with the Hsp90 
inhibitor geldanamycin the same effect could be observed in different pancreatic and 
breast cancer cell lines. Regularly, DNA damage leads to activation of ATR and ATM 
and subsequent phosphorylation and activation of the checkpoint kinases Chk1 and 
Chk2 resulting in Cdc25A degradation and cell cycle arrest. By western blot analysis 
and specific knockdown of Hsp90 with lentiviral packaged shRNA we could discover a 
hitherto unknown cell cycle regulation and demonstrated that the observed Cdc25A 
degradation by heat shock and Hsp90 inhibition was DNA checkpoint independent. 
Furthermore, we could show an additive effect on the inhibition of the proliferation in 
the human pancreatic cancer cell line BxPC3 for the combination of this novel therapy 
concept together with the checkpoint dependent Cdc25A inhibition by gemcitabine. 
In summary, this work demonstrates the huge potential of natural compounds and 
medicinal plants, that are used since ancient times, regarding their potential as anti 
cancer remedies. Further investigations and isolation of the active agents could lead to 
novel lead compounds for potent anti cancer drugs. Furthermore, it could be shown that 
a comparatively simple and therapy (hyperthermia/fever) can exhibit distinct inhibiting 
effects on the proliferation of cancer cells and that this innovative therapy concept 
represents an interesting treatment option against multi resistant pancreatic cancer.  
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2 ZUSAMMENFASSUNG 
 
In der westlichen Welt stellt Krebs nach Herz Kreislauferkrankungen die zweithäufigste 
Todesursache dar, und obwohl es in den letzten Jahren zu massiven Fortschritten 
sowohl in der Aufklärung der biologischen Grundlagen als auch in der Behandlung 
gekommen ist, sind die Therapiemöglichkeiten auch heute noch teilweise sehr 
beschränkt, und somit kommt der Erforschung innovativer zielgerichteter Heilverfahren 
großer Bedeutung zu.   
Im Rahmen dieser Arbeit wurden in verschiedenen Projekten neuartige Ansätze für eine 
verbesserte Tumortherapie untersucht, mit dem Hauptaugenmerk die gesteigerte 
Proliferationsrate von Tumorzellen zu hemmen, Zelltod auszulösen bzw. Konzepte zum 
Verhindern von Metastasierung zu erstellen.  
Da Naturstoffe selbst oder zumindest als Leitsubstanz mehr als 60% der heute 
verwendeten Arzneistoffe ausmachen, wurde die Wirkung einiger pflanzlicher Extrakte 
auf unterschiedliche Zelllinien ausgetestet. Dabei wurden für verschiedene, 
volksmedizinisch vor allem gegen chronische und akute Entzündungen verwendete 
Heilpflanzen ausgeprägte wachstumshemmende und Apoptose fördernde Wirkungen 
nachgewiesen und mittels Western Blot Untersuchungen konnten die zugrunde 
liegenden Mechanismen erhellt werden. Für die Braunwurz Scrophularia lucida konnte 
neben den schon erwähnten anti-kanzerogenen Eigenschaften auch eine deutliche 
Metastasierung hemmende Wirkung gezeigt werden. Das hierfür verwendete, erst 
kürzlich entwickelte in vitro Modell imitiert das Eindringen von Brustkrebszellen in die 
Lymphgefäße, indem MCF-7 Tumorzellspheroide Spaltformationen in einen 
Lymphendothelzellen-Monolayer induzieren. Mittels Hemmung der NF-κB Aktivität 
mit dem synthetischen Inhibitor Bay 11-7082 und damit verbundener stark verminderter 
Spaltbildung konnte neben der bereits bekannten und beschriebenen Lipoxigenasen 
abhängigen Sezernierung von 12(S)-HETE auch der NF-κB Pathway als weitere 
wichtige Signalkaskade für die Lochbildung ausgemacht werden. Behandlung mit 
Scrophularia lucida zeigte in einem NF-κB Luciferase Assay eine ausgeprägte 
Hemmung dieses Signalweges, wodurch die durch diesen Extrakt hervorgerufene anti-
metastatische Wirkung auf NF-κB Inaktivierung zurückzuführen ist. 
Hemmung der NF-κB Aktivität ist auch ein Angriffspunkt von Resveratrol, dessen 
chemopräventive und wachstumshemmende Eigenschaften im Rahmen zahlreicher 
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Studien belegt sind. Da es jedoch kaum Information über metabolische Veränderungen 
hervorgerufen durch Resveratrol gibt, wurde der Einfluss dieses Naturstoffes auf die 
zellulären Konzentrationen verschiedener Stoffwechselprodukte in zwei 
Brustkrebszelllinien untersucht. Es konnte gezeigt werden, dass Behandlung mit 
Resveratrol zu gesteigerter Synthese von Aminosäuren und biogenen Aminen führt, 
sowie die Freisetzung von Arachidonsäure und die damit verbundene erhöhte 12(S)-
HETE Konzentration fördert. Dadurch läst sich auch erklären, dass Resveratrol trotz 
seiner NF-κB hemmenden Wirkung nur einen sehr geringen Einfluss auf das 
Unterdrücken der MCF-7 Spheroid induzierten Lochbildung in einen LEC Monolayer 
besitzt. 
 
Untersuchungen über den Einfluss von kurzer Hyperthermie auf die Proliferation von 
Krebszellen stellten einen weiteren Schwerpunkt dieser Arbeit dar, wobei auf das Heat 
Shock Protein Hsp90 ein Hauptaugenmerk gelegt wurde. Dieses Chaperon schützt unter 
verschiedenen Stresssituationen (u. a. unphysiologisch erhöhten Temperaturen) einige 
Substratproteine. Es konnte gezeigt werden, dass auch Cdc25A, ein Proto-Onkogen, 
überexprimiert in einer Vielzahl humaner Tumore, ein Targetprotein von Hsp90 ist, und 
kurze Hyperthermie in HEK- und HELA Zellen zu dessen Degradierung führt. Ferner 
konnte dieser Effekt in Kombination mit dem Hsp90 Inhibitor Geldanamycin auch für 
Pankreaskarzinomzellen gezeigt werden. In der Regel führt DNA-Schädigung via 
ATM/ATR zu Phosphorylierung und damit verbundener Aktivierung der Checkpoint 
Kinasen Chk 1 und Chk 2 und in weiterer Folge zur Degradierung von Cdc25A und 
somit zur Arretierung des Zellzyklus. Western Blot Untersuchungen und spezifischer 
Knockdown von Hsp90 mit lentiviral verpackter shRNA zeigten, dass die Cdc25A 
Degradierung nach Hsp90 Hemmung und Heatshock jedoch Checkpoint unabhängig ist, 
und somit konnte im Rahmen dieser Arbeit ein neuer Zellzyklus regulierender 
Mechanismus ausgemacht werden. Darüber hinaus führte die Kombination dieses neuen 
Therapieansatzes mit der Checkpoint abhängigen Cdc25A Hemmung durch 
Gemcitabin, der Standardtherapie für Pankreaskrebs, zu signifikant positivem Effekt auf 
die Proliferation von Pankreaszellen. 
Zusammenfassend veranschaulicht diese Arbeit zum einen das große Potential, das in 
Naturstoffen steckt, und dass genaue Untersuchungen weiterer verschiedener seit 
Jahrhunderten volksmedizinisch angewandten Heilpflanzen und Isolierung der 
wirksamen Bestandteile neuartige Leitsubstanzen für potente Arzneistoffe liefern 
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können. Zum anderen konnte gezeigt werden, dass sich eine vergleichsweise einfache 
Therapieform (Hyperthermie/Fieber) deutlich auf das Wachstum von Krebszellen 
auswirkt, und dass dieser innovative Therapieansatz gerade bei gegenüber fast allen 
Chemotherapeutika resistentem Pankreaskrebs eine äußerst interessante Option darstellt. 
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3 INTRODUCTION 
 
3.1 Cancer – a major public health problem 
 
Cancer represents a major public health problem in many parts of the world and 
currently 1 in 4 deaths in the United States is due to that disease [Jemal et al., 2010]. 
Besides heart diseases, cancer is the leading cause of death among men and women 
aged older than 40 years in western countries and the lifetime probability of being 
diagnosed with an invasive cancer ranges around 40% for men and women. Whereas 
prostate (28%), lung (15%) colon (9%) and urinary bladder (7%) represent the 4 most 
common cancers in men, in women cancers of the breast (28%), lung (14%), colon 
(10%) and uterine corpus (6%) are most frequent cancers [Jemal et al., 2010]. However, 
in both sexes approx. 30% of cancer deaths is related to lung cancer. Metastasis is the 
main cancer death reason as 90% of all cancer deaths are not related to the primary 
tumor but to disseminated tumors that destroy the function of infested organs [Sporn, 
1996]. Due to progress in early diagnosis and improved treatment options, there have 
been notable improvements in the relative 5-year survival rates for many cancer sites 
with the exception of lung and pancreatic cancer [Jemal et al., 2010]. Although there is 
huge progress in developing powerful therapies, acquired resistance represents one of 
the major problems in cancer treatment and therefore, of course besides further 
improvements in early diagnosis, finding new target specific treatment options must be 
a focal point of research.  
 
 
3.2 Development and biology of cancer 
 
Decades of intensive research about development and biology of cancer led to the 
assumption that different mutations produce oncogenes with increased function and 
tumor suppressor genes with loss of function [Bishop and Weinberg, 1996]. Generally, 
transformation of normal cells into malignant derivatives is a multistep process 
requiring alterations of the genome at multiple sites [Kinzler and Vogelstein, 1996]. 
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3.2.1 Hallmarks of cancer 
 
In their seminal publication [2000] an in an update [2011] D. Hanahan and R. A. 
Weinberg specified a small number of underlying principles responsible for this 
transformation: 
 
- Self-sufficiency in growth signals 
- Insensitivity to growth-inhibitory signals 
- Evasion of programmed cell death (apoptosis) 
- Limitless replicative potential 
- Sustained angiogenesis 
- Tissue invasion and metastasis 
 
These six hallmarks of cancer were proposed to be shared in perhaps all types of cancer 
leading progressively to a neoplastic state. Furthermore, D. Hanahan and R. A. 
Weinberg noted that tumors are not just an isolated mass of proliferating cells, but 
rather a tissue complex of multiple distinct cell types where even normal cells, such as 
fibroblasts and endothelial cells, are active participants of tumorigenesis and that this 
“tumor microenvironment” plays a crucial role in understanding the biology of tumors. 
 
3.2.1.1 Self-sufficiency in growth signals 
In contrast to normal cells, that require mitogenic growth signals for moving into an 
active proliferative state, tumor cells show a clearly reduced dependence to exogenous 
growth stimulation resulting in the disruption of important homeostatic mechanisms. 
Different reasons for this self-sufficiency have been identified. Besides autocrine 
stimulation (the ability to produce their growth factors for their own), cancer cells may 
stimulate normal cells of the tumor-associated stroma to produce various growth factors 
[Fedi et al., 1997; Cheng et al., 2008]. Over-expression of growth factor receptors 
accompanying hyper-responsiveness to ambient growth factor levels is another common 
attitude for increased proliferation in tumor cells [Fedi et al., 1997]. Furthermore, over-
expression or structural alteration of growth factor receptors can result in ligand-
independent signalling [DiFiore et al., 1987]. Besides these factors related to growth 
factor receptors, switching the types of extracellular matrix receptors (integrins) to pro-
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growth signals transmitting ones [Lukashev and Werb, 1998; Giancotti and Ruoslahti, 
1999] and alterations in the downstream cytoplasmic signal cascade (e.g. the SOS-Ras-
Raf-MAPK cascade) [Medema and Bos, 1993] are further possibilities for increased 
proliferation. 
 
 
 
Figure 1 The hallmarks of cancer (Hanahan and Weinberg, 2000) 
 
 
3.2.1.2 Insensitivity to growth-inhibitory signals 
To maintain tissue homeostasis normal cells exhibit multiple anti-proliferative 
mechanisms including soluble growth inhibitors as well as immobilized inhibitors 
embedded in the extracellular matrix. These anti-growth signals can force cells into the 
quiescent (G0) phase of the cell cycle or, alternatively, may induce cell differentiation 
associated with attrition of their proliferation potential. Tumor cells have to circumvent 
these programs. Besides several others, retinoblastoma-associated (RB) and p53 
proteins form two prototypical tumor suppressors that are both defective in most, if not 
all, human cancers [Polager and Ginsberg, 2009]. Besides the prevention of antigrowth 
signals, tumor cells can avoid cell differentiation by various strategies. Over-expression 
of the oncogene Myc, as seen in many tumors, for example, has been shown to inhibit 
cell differentiation [Lüscher, 2001]. 
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3.2.1.3 Evasion of programmed cell death 
Beside the cell proliferation rate also the rate of cell death contributes to the population 
size and acquired resistance toward apoptosis is another hallmark of perhaps all types of 
cancer. The apoptotic machinery consists of two major circuits – the extrinsic and the 
intrinsic apoptotic program [Adams and Cory, 2007]. The sensors of the extrinsic 
program include different cell surface death receptors like the Fas- or the TNF- receptor 
[Ashkenazi and Dixit, 1999]. In contrast, abnormalities like DNA damage, hypoxia or 
survival factor insufficiency activate intracellular sentinels [Evan and Littlewood, 
1998]. Many of these signals induce release of mitochondrial cytochrome C, the most 
important pro-apoptotic signalling protein [Green and Reid, 1998]. Cytochrome C 
release is controlled by bcl-2 family members that have either pro-apoptotic (Bax, Bak, 
Bim) or anti-apoptotic function (Bcl-2, bcl-xL) [Adams and Cory, 2007]. However, 
different intracellular proteases are the ultimate effectors of apoptosis [Thornberry and 
Lazebnik, 1998]. The two gatekeeper caspases (-8 and -9), triggered by death receptors 
or cytochrome C, activate different effector caspases, that execute the death program.  
Tumor cells can acquire resistance to apoptosis through a variety of strategies and 
several abnormality sensors have been identified [Lowe et al., 2004], where mutations 
of the p53 tumor suppressor gene, seen in more than 50% of human cancers,  play the 
most important role [Harris, 1996; Juntilla and Evan, 2009]. Other reasons for resistance 
to apoptosis include increasing expression of anti-apoptotic regulators (Bcl-2, Bcl-xL), 
down-regulation of pro-apoptotic factors (Bax, Bim) or abnormalities in the PI3 kinase-
Akt/PKB pathway [Evan and Littlewood, 1998; Juntilla and Evan, 2009]. 
 
3.2.1.4 Limitless replicative potential 
In contrast to normal cells, cancer cells exhibit unlimited replicative potential in order to 
generate a macroscopic tumor [Hayflick, 1997]. Normally, cells can pass only through a 
limited number of cell divisions [Hornsby, 2007]. The two barriers to proliferation are 
senescence and crisis. Senescence is characterised by irreversible entrance into a non-
proliferative but viable state. Cells circumventing this barrier enter a second state 
(crisis), where most cells of the population die. However, rarely single cells can emerge 
from a population in crisis and continue proliferating without limit, a trait called 
immortalization [Wright et al., 1989]. 
Telomeres, composed of several thousand repeats of a short hexanucleotide element, 
protect the ends of chromosomes [Blasco, 2005]. Due to the inability of DNA 
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polymerases to completely replicate 3’ ends of chromosomal DNA, each cell cycle 
leads to loss of small parts of telomeres resulting in the deficit to protect the 
chromosomal DNA and subsequent crisis [Counter et al., 1992]. In nearly all types of 
malignant cells telomere maintenance is evident and in about 90% of them telomerase, 
the specialized DNA polymerase that adds telomere repeat segments, is expressed at 
functionally significant levels. Hence, the expression of this enzyme correlates with 
resistance to induction of both senescence and crisis [Zvereva et al., 2010]. 
Recent research indicates that delayed activation of telomerase may both limit and 
foster neoplastic progression. Studies demonstrated that some incipient cancer cells 
undergo telomere loss-induced crisis in a quite early stage of the multistep tumor 
progression suggesting that these cells have passed through substantial telomere-
shortening cell division during their evolution from a normal to a neoplastic cell [Hansel 
et al., 2006]. In contrast, studies of mutant mice lacking both p53 and telomerase 
function [Artandi and DePinho, 2010] give indication that the absence of p53 tumor 
suppressor initiated control permits tumor cells to survive initial telomere loss allowing 
these cells to become even more malignant because of additional alterations. 
 
3.2.1.5 Sustained angiogenesis 
Like normal tissue, tumor cells require blood vessels for the supply of nutrients and 
oxygen as well as the evacuation of metabolic waste and carbon dioxide. In contrast to 
normal cells where angiogenesis is only transiently turned on, tumor cells develop an 
“angiogenic switch”, that is almost always activated [Hanahan and Folkman, 1996]. 
This angiogenic switch is regulated by different factors that either induce (e.g. VEGF, 
FGF) or inhibit (e. g. TSP-1) angiogenesis [Baeriswyl and Christofori, 2009]. Sustained 
tumor angiogenesis is generated for example by oncogene mediated up-regulation of 
pro-angiogenic factors [Ferrara, 2009] or their release and activation out of the 
extracellular matrix by extracellular matrix-degrading proteases (e.g. MMP-9) 
[Kessenbrock et al., 2010]. The unbalanced mix of angiogenic signals in tumors lead to 
blood vessels that are typical aberrant [Nagy et al., 2010]. While historically tumor 
angiogenesis was thought to occur only in macroscopic tumors, different analyses of 
premalignant, non-invasive lesions suggest that angiogenesis also occurs quite early in 
the multistep tumorigenesis, attesting its crucial role [Raica et al., 2009].  
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3.2.1.6 Metastasis 
Like tumorigenesis, invasion and metastasis is a multistep process beginning with local 
invasion, followed by intravasation into blood and lymphatic vessels, transit through 
lymphatic and hematogenous systems, extravasation, formation of micrometastases and 
finally growth of a macroscopic tumor [Fidler, 2003]. Chapter 1.2.4. gives detailed 
attention to the illustration of this complex process.  
 
3.2.1.7 Additional hallmarks and enabling characteristics 
In their updated publication [2011] Hanahan and Weinberg describe two additional 
hallmarks and two enabling characteristics of tumorigenesis. Although e.g. epigenetic 
modifications (DNA methylation or histone modifications) can influence gene 
expression, development of genomic instability represents the basic fundament for the 
formation and the progression of cancer by generating the mutations that are essential 
for increased proliferation, prevention of apoptosis and metastasis and cancer cells can 
increase rates of mutations by increased sensitivity to mutagenic agents and breakdown 
of different components of the genomic maintenance machinery [Berdasco and Esteller, 
2010; Negrini et al. 2010]. Besides that, inflammation by immune cells that are found in 
virtually every neoplastic lesion supports the multiple hallmark capabilities as a second 
enabling characteristic. By supplying bioactive molecules to the tumor 
microenvironment (e.g. growth factors, survival factors, extracellular matrix modifying 
enzymes etc.) and by the release of different chemicals such as actively mutagenic 
reactive oxygen species the tumor associated inflammatory response can enhance 
tumorigenesis and progression [DeNardo et al., 2010; Grivennikov et al., 2010]. 
Moreover, chronic infections and inflammation frequently lead to cancer development 
and tumor progression [Mantovani at al., 2010]. 
Reprogramming of the cancer cells energy metabolism and avoiding of immune 
destruction are two emerging hallmarks [Hanahan and Weinberg, 2011]. Up-regulation 
of glucose transporters and a metabolic switch to aerobic glycolysis provide the energy 
to the cancer cells required for increased proliferation. The fact that cancer cells avoid 
immunological destruction represents a second emerging hallmark although it is still 
unresolved how the cancer cells manage to circumvent detection by various arms of the 
immune system. 
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3.2.2 The cell cycle 
 
In the development of cancer the disruption of the fine tuned regulation of cell cycle 
progression and division is an essential step. Lots of different regulatory factors and 
signals dictate the cell to proliferate or, in case of DNA damage, to die. As mammalian 
DNA is under constant attack by different agents, cells have developed several 
defensive mechanisms. Although these repair mechanisms are extremely powerful, they 
are not perfect, and damage of DNA can result in the development of cancer. DNA 
breakdown leads to halting of the cell cycle progression via activation of different cell 
cycle checkpoints until elimination of the damage, or if the cell is not able to repair this 
defect, to programmed cell death [Hartwell and Weinert, 1989].  
 
The cell cycle is a well regulated series of events in order to duplicate DNA and 
subsequent cell division and in eukaryotic cell it consists of four distinct phases 
[Norbury and Nurse, 1992]: 
 
- G1-phase (gap phase 1): cellular growth and preparation for DNA synthesis 
- S-phase:   duplication of the genome 
- G2-phase (gap phase 2): preparation for Mitosis 
- M-phase:   mitosis (cell division) 
 
 
 
Figure 2 Mammalian cell cycle (simplified) (van den Heuvel 2005) 
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G1-, S- and G2-phase together form the interphase, while the M-phase could be divided 
in the metaphase (chromosomal alignment), the anaphase (segregation of sister 
chromosome) and the telophase (decondensation of chromosomes and formation of 
nuclear membranes) [McDonald and El-Deiry, 2000]. Besides these four phases, cells in 
G1-phase may temporarily or permanently leave the cell cycle in dependence on 
developmental or environmental signals entering a quiescent phase termed G0. Both, 
cell external and cell intrinsic signals together decide whether cells should enter a 
division cycle, but after achievement of a restriction point, progression through the cell 
cycle is controlled only by the intrinsic cell cycle machinery [van den Heuvel at al., 
2005].  
 
3.2.2.1 Regulation of the cell cycle 
Regulation of the progression from one phase to another is mediated by different cyclin-
dependant kinases (CDKs), that are activated after binding to regulatory proteins 
(cyclins) [Hartwell and Kastan, 1994; Michalides, 1999]. These CDK/Cyclin complexes 
do not only trigger cell cycle progression, but in case of DNA damage activated 
checkpoints arrest cells in either G1-, S-, or G2-phase allowing to repair the genetic 
material [Mailand et al., 2000]. 
Four CDKs have been identified to be responsible for controlling the different stages of 
the cell cycle (CDK1, CDK2, CDK4 and CDK6) [Elledge, 1996]. Although CDK 
protein levels are constant during the cell cycle, they are only functional during distinct 
intervals [Meeran and Katiyar, 2008]. While CDK4/6 regulate the entry into S-phase, 
CDK2 remains active through the S-phase and decrease in its activity leads to exit from 
S-phase. In contrast, CDK1 becomes active in G2-phase and during mitosis [Sherr, 
1996].  
As mentioned above, association of CDKs with cyclins is essential for their activation. 
Two types of cyclins have been identified, the cell cycle related cyclins (Cyclins A, B, 
D and E) and the non cell cycle related cyclins that share structural homology (Cyclins 
H and C) [Sherr, 1996]. Cyclin D1 and Cyclin E were shown to be frequently 
deregulated in human cancers [Robles et al., 1998; Porter et al., 2001]. Together with its 
catalytic subunit, cyclin E has a pivotal role in the regulation of G1-S transition and in 
the initiation of DNA replication [Krude et al., 1997] and its constitutive over-
expression at all phases of the cell cycle was observed in different cancers like breast 
cancer [Bortner and Rosenberg, 1997] or ovarian cancer [Sui et al., 2001].  
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Besides the activating cyclins, there are two families of CDK inhibitors (CDKIs) that 
can repress CDK function, the Cip1/p21 family and the INK4 family. While members 
of the Cip1/p21 family (p21Cip1, p27Kip1 and p57Kip2) represent universal cyclin/CDK 
inhibitors, that bind both cyclin and CDK molecules simultaneously, members of the 
INK4 family (p15INK4, p16INK4 and p19INK4) exhibit specificity for cyclin D/CDK4/6 
complexes [Meeran and Katiyar, 2008]. Inhibition of growth stimulatory signaling 
pathways has been shown to stimulate CDKI expression associated with cell growth 
arrest [Grana and Reddy, 1995]. 
 
3.2.2.2 Checkpoints 
Although cells are under constant attack by different agents that may cause mutations of 
their DNA, manifestation of a mutation and development of a pathological tumor is a 
rare result. Detection of DNA damage and arresting the cell cycle in order to repair or 
trigger cell death of the affected cell are the main tasks of different checkpoints and 
failures of the quality control of these checkpoints or the downstream signal cascades 
play a major role in the development of cancer [Meeran and Katiyar, 2008]. Besides the 
ATM/ATR-Chk2/Chk1-mediated response to DNA damage that leads to a delay of cell 
cycle progression in G1-, S- or G2-phases [Kastan and Bartek, 2004], the tumor 
suppressor gene p53 is one of the key players in these pathways and mutations or loss of 
this important tumor suppressor gene are associated with an increased risk of cancer 
[El-Deiry et al., 1994]. 
 
The G1 and G1/S checkpoint 
To avoid replication of damaged DNA, the G1/S checkpoint becomes activated and 
abnormalities at this checkpoint appear to be a crucial step in the development and 
progression of cancer [Meeran and Katiyar, 2008]. Activation of this checkpoint leads 
to inhibition of cyclin E/CDK2 complexes via two pathways. Phosphorylation of Chk1 
leads to degradation of Cdc25A, with the effect that CDK2 does not get activated. 
Furthermore, p53 becomes phosphorylated resulting in its stabilization and 
accumulation and, subsequent, in the activation of Cip1/p21 that silences the G1/S 
promoting cyclin E/CDK2 complex [Wahl and Carr, 2001]. The Cdc25A degradation 
cascade is much faster than the slower operating p53 pathway, but delays the G1/S 
transition only for a few hours in contrast to the p53 dependent mechanism that 
prolongs the G1 arrest [Kastan and Bartek, 2004].  
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The S-phase checkpoint 
The intra-S-phase checkpoint is regulated by two distinct pathways to avoid duplication 
of damaged DNA [Falck et al., 2002]. The first one, similar to G1 checkpoint, leads to 
down-regulation of Cdc25A and subsequent inactivation of cyclin E/CDK2 complexes. 
Furthermore, inhibition of CDK2 activity blocks the Cdc45 loading onto chromatin, a 
protein that is required for recruitment of DNA polymerase α. In the second pathway, 
Nbs1 becomes phosphorylated by ATM on several sites resulting in the activation of the 
Nbs1-Mre11-Rad50 double strand DNA break repair complex [Lim et al., 2000]. 
 
The G2/M checkpoint 
The G2/M checkpoint avoids entrance into mitosis when DNA damage occurred during 
G2-phase or when unrepaired DNA was carried from G1- or S-phase [Nyberg et al., 
2002]. The mitosis promoting activity of the cyclin B/CDK1 complex represents the 
crucial target of this checkpoint. Besides Chk1/2 or p38-kinase mediated degradation of 
Cdc25 family phosphatases resulting in the prevention of CDK1 activation, p53-
dependent mechanisms are also important for the maintenance of G2-phase arrest. P53 
activation leads to the up-regulation of cell cycle inhibitors like p21, GADD45a and 14-
3-3 proteins [Taylor and Stark, 2001]. 
 
 
3.2.2.3 Cdc25 phosphatases – important players in cell cycle progression 
As mentioned before, Cdc25 phosphatases act as key regulators of the cell cycle 
[Nilsson and Hoffmann, 2000] and especially Cdc25A has been shown to be frequently 
over-expressed in a wide range of cancers like e.g. breast [Cangi et al., 2000], colorectal 
[Hernández et al., 2001], head and neck [Gasparotto et al., 1997] or nonsmall cell lung 
cancers [Wu et al., 1998].  
 
Structure of Cdc25 phosphatases 
In mammalian cells, three isoforms of Cdc25 phosphatases have been identified: 
Cdc25A, Cdc25B and Cdc25C [Boutros et al., 2007]. The human Cdc25 phosphatases 
are between 300 and 600 amino acids long and can be divided into two regions 
[Rudolph, 2007]. The N-terminal regulatory domains show low sequence homology and 
contain several sites for phosphorylation an ubiquitination and modifications at these 
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sites are involved in cell cycle control and response to checkpoint activation. In 
contrast, the catalytic C-terminal domains are more homologues. 
 
Function as activators of cell cycle progression 
Cyclin dependent kinases and their complexes with cyclins represent the central 
regulators of the eukaryotic cell cycle and their activation is crucial for cell cycle 
progression. Different control mechanisms have been elucidated like activating 
phosphorylations on Thr160/161 by the Cdk-activation kinase (CAK) or inhibitory 
phosphorylations on Thr14 and Tyr15 by the Wee1 and Myt1 kinases and 
dephosphorylation of pThr14 and pTyr15 by the dual specific Cdc25 phosphatases 
represents the essential step of the Cdk/cyclin complexes [Morgan, 1995]. Through their 
activity on Cdk1/cyclin A and Cdk1/cyclin B complexes, Cdc25B and Cdc25C are 
regulating the G2/M transition, while Cdc25A also activates the Cdk2/cylin E and 
Cdk2/Cyclin A complexes and consequently the G1/S transition [Busino et al., 2004; 
Kristjánsdóttir and Rudolph, 2004]. 
 
 
 
 
Figure 3 (Kristjánsdóttir and Rudolph, 2004) 
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Function as regulators after checkpoint activation 
Besides the their pivotal role in promoting cell cycle progression, Cdc25 phosphatases 
are also key components of the checkpoint pathways leading to cell cycle arrest and 
allowing DNA repair [Bouros et al., 2007]. Mailand et al. [2000] demonstrated that 
exposure of human cells to ultraviolet light or ionizing radiation resulted in rapid, 
ubiquitin- and proteasome-dependent protein degradation of Cdc25A and G1/S arrest. 
Furthermore, it could be shown that this response did not involve the p53 pathway but 
was a consequence to Chk1 protein kinase activation and that the persisting inhibitory 
phosphorylation of Tyr15 of Cdk2 blocked the entry into S-phase. Besides ultraviolet 
light and ionizing radiation also oxidative stress, replication inhibitors and other DNA 
damaging agents were shown to affect Cdc25 phosphatases expression [Ray and 
Kiyokawa, 2008; Kristjánsdóttir and Rudolph, 2004] by checkpoint activation via ATM 
and ATR or activation of the p38 mitogen-activated signalling pathway [Boutros et al., 
2007]. While ATM activation occurs primarily in response to double strand DNA 
breaks, ATR seems to be activated by regions of single stranded DNA [Hurley and 
Bunz, 2007]. Subsequently, these two kinases phosphorylate and activate the checkpoint 
kinases Chk1 and Chk2 [Niida and Nakanishi, 2006]. Beside other substrates, Cdc25 
phosphatases are important downstream targets of the Chks. Phosphorylation at 
different inhibitory sites (e.g. Ser75, Ser177 [Goloudina et al. 2003; Karlsson-Rosenthal 
and Millar, 2006]) creates a docking site for 14.3.3 leading to 14.3.3 mediated 
sequestration of the phosphatases [Kristjánsdóttir and Rudolph, 2004, Madlener et al., 
2009].  
 
Cdc25 phosphatases in cancer 
While different studies demonstrate increased expression of Cdc25A, Cdc25B or both 
in a wide range of human cancers, there is no incidence for Cdc25C over-expression 
[Rudolph, 2007]. Experimental date gives evidence that over-expression of Cdc25A or 
Cdc25B to push S-phase or M-phase entry even with incomplete replicated DNA 
[Karlsson et al., 1999; Sexl et al. 1999], but in different studies there was no correlation 
between over-expression and an increased rate of proliferation [Kristjánsdóttir and 
Rudolph, 2004]. As DNA damage results in the degradation of Cdc25 phosphatases it is 
possible that because of their over-expression these proteins are not completely 
degraded and inactivated allowing cell cycle expression even in the presence of DNA 
damages [Kiyokawa and Ray, 2008], thereby accumulating additional mutations. 
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Mechanisms of over-expression 
The mechanisms leading to deregulation and increased Cdc25 phosphatase expression 
are not fully clarified. Different studies show that there is no evidence that over-
expression is a result of gene amplification or other specific genetic mutations 
[Hernández et al., 2001; Wu et al., 1998; Kudo et al., 1997]. Posttranslational 
modifications of Cdc25A protein were found to lead to enhanced stability and increased 
half-life in breast cancer cell lines [Löffler et al., 2003]. Besides alterations concerning 
Cdc25 phosphatases themselves, changes in regulators of the Cdc25A/B stability could 
be responsible for increased expression of these oncogenes and in fact mutations of 
ATR and the Chk kinases have been described [Alderton et al., 2006; Bartek and Lukas, 
2003]. 
 
 
3.2.3 Cell death 
 
In multicellular organisms cell death is a crucial process during development, essential 
for maintaining tissue homeostasis and necessary for immune regulation and its 
dysregulation is associated with various pathologies [Duprez et al., 2009]. The different 
types of cell death can be defined by morphological, enzymological (depending on the 
involved classes of proteases), functional (programmed or accidental) or on 
immunological aspects (immunogenic or non-immunogenic) [Galluzzi et al., 2007]. 
Particularly apoptosis represents the major type of programmed cell death. 
 
3.2.3.1 Apoptosis 
Apoptosis is a cell-intrinsic programmed suicide and is associated with typical 
morphological alterations like cell shrinkage, membrane blebbing and chromatin 
condensation [Duprez et al., 2009]. Apoptotic cell death is immunologically silent 
without provoking an inflammation because the apoptotic vesicles are recognized and, 
before losing membrane integrity, taken up by surrounding cells [Krysko and 
Vandenabeele, 2008]. 
Cysteinyl aspartate-specific proteases (caspases) have been shown to be crucial for 
mediating the execution phase of apoptosis [Fuentes-Prior and Salvesen, 2007]. The 
apoptotic caspases in humans can be divided into initiator (caspase 8, 9, 10) and 
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executioner (caspase 3, 6, 7) caspases and are expressed as inactive proenzymes. In 
mammalian cells they can be activated by two different pathways, the intrinsic and the 
extrinsic pathway. 
Different stimuli, like DNA damage or cytotoxic insults, activate the intrinsic pathway 
that is controlled by the Bcl-2 family of proteins and acts through the mitochondria 
[Youle and Strasser, 2008]. In case of a DNA damage Bcl-2-homology 3 (BH3)-only 
proteins are activated and antagonize the anti-apoptotic Bcl-2 family members (Bcl-2, 
Bcl-x), that prevent the pro-apoptotic family Bcl-2 members Bax and Bak from collapse 
of the mitochondrial membrane potential Upon activation Bax and Bak, which control 
mitochondrial membrane pores, allow the release of cytochrome c (Cyt c). This forms a 
complex with Apaf 1 and recruits procaspase-9 finally resulting in its activation and this 
furtheron leads to cleavage of the executioner caspases-3, -6 and -7. 
The extrinsic pathway is activated upon stimulation of death receptors belonging to the 
tumor necrosis factor receptor (TNFR) family [Wilson et al., 2009]. Stimulation of these 
receptors leads to the formation of a death-inducing signaling complex (DISC). 
Recruitment and activation of the initiator caspases-8 and -10 lead to cleavage of the 
downstream executioner caspases. Additionally, the BH3-only protein Bid, activated by 
caspase 8, amplifies the death receptor induced cell death program by activating also the 
mitochondrial pathway. 
 
3.2.3.2 Necrotic cell death 
Necrosis has been considered for a long time as an uncontrolled form of cell death 
without underlying signaling events and this might be true for severe physical damage 
such as massive hyperthermia, but there is accumulating evidence for the existence of 
strictly regulated caspase independent pathways [Chautan et al., 1999]. However, in 
contrast to apoptosis, necrotic cell death is accompanied with cytoplasmic and organelle 
swelling and loss of cell membrane integrity resulting in the release of cellular contents 
into the surrounding extracellular space [Duprez et al., 2009]. 
Stimulation of death receptors like TNFR1 was shown to activate RIP1 that, after 
formation of a complex with RIP3, induces a wide range of necrotic mediators [Festjens 
et al., 2007]. Besides death receptors, pathogen recognition receptors have been shown 
to mediate necrosis in a RIP1 dependent fashion [Kalai et al., 2002], as well as 
hyperactivation of poly-(ADP-ribose) polymerase-1 (PARP-1) hyperactivation after 
extensive DNA damage [Jagtap and Szabo, 2005]. Among others, reactive oxygen 
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species (ROS), calcium, calpains and phospholipases are important mediators involved 
in the execution phase of necrotic cell death leading to destabilization of the plasma 
membrane, mitochondrial permeability and matrix swelling [Vanlangenakker et al., 
2008). These phenomena seem to be events resulting from severe cellular disregulations 
however, which are the result of exploited ATP pools unable to be replenished in time 
[Nicotera  et al. 2001, Tsujimoto 2001, Grusch et al. 2002]. 
 
 
3.2.4 Metastasis – the leading cause for cancer deaths 
 
As about 90% of all cancer deaths are not related to the primary tumor but to metastases 
that destroy the function of infested organs, prevention of cancer cell dissemination and 
secondary tumor formation is a major goal of cancer therapy [Sporn, 1996]. Metastasis 
is a multi-step process existing of a sequence of discrete steps [Eger and Mikulits, 
2005]: 
  
- local infiltration of tumor cells into the adjacent tissue 
- transendothelial migration of cancer cells into vessels (intravasation) 
- transit and survival in the circulatory system 
- extravasation 
- subsequent proliferation leading to colonization 
 
As less than 0.1% of disseminated cancer cells develop distal metastases, this process is 
very inefficient [Mack and Marshall, 2010]. There is an ongoing dicussion whether 
metastatic dissemination is one of the later steps of tumorigenesis or occurs already at 
the beginning of tumor development and there is evidence for both models [Klein, 
2009], but distinct genetic alterations of tumor cells at primary and distal sites argue for 
an early separation and independent development [van Zijl et al., 2011]. Besides the 
question about the time point of cancer cell dissemination, it also remains unclear where 
they develop the ability to colonize foreign tissues and two different models are 
discussed [Hanahan and Weinberg, 2011]. One the one hand side the capability to 
colonize may a fortuitous property as a result of a tumor’s particular developmental path 
prior dissemination. In contrast, response to the selective pressure of and adaption to the 
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foreign microenvironment might induce that ability. However, it was shown that the 
bone, the lung and the brain represent the major sites of metastasis of breast carcinoma, 
while colorectal and pancreatic cancer prefers the liver and the lung for distal 
colonization [Chambers et al., 2002].  
 
Although metastasis is a multistep process, physical dissemination of cancer cells to 
distant tissues and thereafter the adaption of these cells to foreign microenvironment 
resulting in successful colonization represent the two major phases [Hanahan and 
Weinberg, 2011]. The fact, that many patients develop lots of dormant micrometastases, 
demonstrates that successful colonization is not strictly coupled with physical 
dissemination [McGowan et al., 2009]. While explosive metastatic growth of dormant 
micrometastases after resection of the primary tumor substantiate the release of 
systemic suppressor factors by the primary tumor [Demicheli et al., 2008], other 
metastases take up to decades to develop macroscopic tumors after surgical removal or 
destruction of the primary tumor indicating that these micrometastases have solved the 
complex problem of tissue colonization [Barkan et al., 2010]. Adaption of disseminated 
cancer cells to the microenvironment, where they have landed, is complex procedure 
and each disseminated cell has to develop its own solutions to be successful in 
colonization depending on the cancer cell itself and the new tissue environment. [Gupta 
et al., 2005]. However, cell invasion and transmigration into blood and lymphatic 
vessels are the first steps in metastasis and knowledge about the biological mechanisms 
is essential to find treatment options to inhibit these processes. 
 
3.2.4.1 Mechanisms of cell invasion 
Cancer cells can invade other tissues as single cells via mesenchymal or amoeboid cell 
types or by moving collectively as detached clusters [Friedl and Wolf, 2003]. Tumor 
cells often experience a change in their plasticity by morphological and phenotypical 
conversions (epithelial to mesenchymal transition (EMT), collective to amoeboid 
transition (CAT), mesenchymal to amoeboid transition (MAT)) [van Zilj et al., 2011].  
 
Mesenchymal cell invasion 
EMT represents a crucial event in cancer progression and metastasis. This highly 
conserved process is regulated by different transcriptional factors (e.g. Zeb1/2) and 
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leads to down-regulation of epithelial and up-regulation of mesenchymal markers 
[Schmalhofer et al., 2009]. 
The best characterized alteration of EMT is the change from E- to N-cadherin, termed 
cadherin switch [Christofori, 2006]. Down-regulation of E-cadherin, an essential 
component of adherence junctions, and expression of N-cadherin, responsible for 
rearrangement of the cytoskeleton, leads to enhanced motility of the cancer cells. 
Furthermore, EMT also exhibits stem cell properties, prevents apoptosis and 
senescence, suppresses immune reactions and shows resistance against radio- and 
chemotherapy [Thiery et al., 2009].  Different factors, such as integrins, fibroblast 
growth factor (FGF), vascular endothelial growth factor (VEGF), platelet derived 
growth factor (PDGF) or transforming growth factor (TGF)-β have been demonstrated 
to induce EMT [Thiery et al., 2009]. To form new tumor colonies at a secondary site, 
cancer cells that have undergone EMT during invasion and dissemination may pass 
through the reverse process, referred to as mesenchymal to epithelial transition [Hugo et 
al., 2007]. 
 
Amoeboid cell invasion 
Cells undergoing CAT show reduced cell-ECM interaction and the ability of 
chemotaxis and these amoeboid cells are able to squeeze through gaps in the ECM 
barriers [Condeelis and Segall, 2003]. Motility of these amoeboid cells, in contrast to 
mesenchymal and collective cell invasion, is not protease dependent without remodeling 
the ECM and this kind of invasion is described as the fastest migratory phenotype 
[Friedl and Wolf, 2003]. In melanoma cells integrin blockage was shown to cause CAT 
resulting in the loss of cell-cell adhesion, cell detachment and transition to an amoeboid 
single-cell type [Hegerfeldt et al., 2002]. 
 
Collective cell invasion 
Collective cell invasion can occur either as a two dimensional monolayer or as a three 
dimensional cell strand or cluster. However, this type of invasion is characterized by 
three properties: intact cell-cell junctions; remodeling of the ECM and rearrangement of 
the basement membrane; traction force generation by multi-cellular coordination of 
polarity and cytoskeletal activity [van Zijl et al., 2011]. While most collectively 
invading cells maintain their intact epithelial cell to cell contacts, tip cells exhibit a 
rather mesenchymal phenotype and these leading cells are also mostly responsible for 
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remodeling the ECM (e.g. by secretion of MMP14) and the generation of traction force 
by e.g. expression of different substrate binding integrins [Friedl and Gilmour, 2009].  
 
3.2.4.2 Endothelial transmigration 
 
Besides the blood system, the lymphatic system has been shown to be a key player in 
cancer cell dissemination [Kerjaschki et al., 2004]. There is still discussion whether 
invasion of cancer cells into the lymphatic system is a passive occurrence or promoted 
by lymphnodes [Tammela and Alitalo, 2010]. However, recently it could be shown that 
breast cancer spheroids are able to generate circular defects in the integrity of a 
lymphatic endothelial cell (LEC) layer resulting in the penetration into lymphatic 
vessels of cancer cells through these ruptures mediated by 12(S)-hydroxy-
eicosatetraenoic acid (12(S)-HETE) metabolized from arachidonic acid by the hypoxia-
inducible enzymes ALOX12 or ALOX15 [Madlener et al., 2010; Kerjaschki et al., 
2011]. Furthermore, the NF-κB pathway was elucidated as a second signal cascade 
mediating the intravasation, by inhibiting the NF-κB translocation with Bay11-7082 and 
subsequent blockage of the MCF-7 spheroid induced gap formation of LECs [Vonach et 
al., 2011].   
 
 
3.2.5 The tumor microenvironment 
 
In contrast to the historical reductionist view that a tumor is just a collection of 
relatively homogeneous cancer cells, there is increasing evidence for heterotypic 
interactions of cancer cells with cells of the adjacent tumor associated stroma inducing 
the expression of more malignant phenotypes and that this crosstalk is involved in the 
acquired capability for invasive growth and metastasis [Karnoub and Weinberg, 2006-
2007; Egeblad et al., 2010]. This tumor associated microenvironment is composed of 
various different cell types including endothelial cells, pericytes, stromal fibroblasts, 
stem cells and bone marrow derived cells such as macrophages [van Zijl et al., 2011; 
Hanahan and Weinberg, 2011]. Cancer stem cells (CSC) seem to be a common 
constituent in many tumors and are defined through their ability to seed new tumors 
upon inoculation into recipient host mice [Cho and Clark, 2008]. Besides correlation of 
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the acquisition of CSCs and the EMT transdifferentiation program, CSCs are more 
resistant to various commonly used chemotherapeutic treatments [Singh and Settleman 
2010]. Whereas endothelial cells are necessary to for the tumor associated vasculature, 
other cell types like cancer associated fibroblasts or tumor associated macrophages 
promote tumor progression mainly by allocating growth factors, cytokines and matrix 
degrading enzymes thereby promoting tumor growth, cancer cell invasion and 
neoangiogenesis [Joyce and Pollard, 2009]. 
 
 
3.3 Pancreatic cancer 
 
Pancreatic cancer is the tenth most common type of cancer in western countries and 
ranks fourth in cancer mortality statistics and in spite of intensive research there is only 
little improvement in the survival of pancreatic cancer patients [Mihaljevic et al., 2010, 
Fahrig et al. 2006, Heinrich et al. 2011]. At the time of diagnosis around 15% of 
patients have tumors localized in pancreas, 40% have locally advanced cancer with 
tumors in adjacent organs and nearly 50% already show rapidly progressing aggressive 
metastatic pancreatic cancer [Borja-Cacho et al., 2008]. Because of the lack of early 
detection, the absence of symptoms and effective screening tests, high rate of relapse 
and limited effective therapies, prognosis is very poor with a 5 year survival rate of less 
than 5% and a 1 year survival rate of less than 20% [Evans et al., 2001]. Age, cigarette 
smoking, family history and diabetes mellitus have been elucidated as risk factors for 
pancreatic cancer [Michaud, 2004]. According to the origin of the tumor, there are two 
types of pancreatic cancer. While endocrine pancreatic cancer, originating from the islet 
cells, accounts for only 2-4% of the incidence, more than 95% of pancreatic cancer 
originates in the exocrine pancreas and with more than 80% of this exocrine pancreatic 
cancer infiltrating ductal adenocarcinoma represents the most common form [Li et al., 
2010].  
 
3.3.1 Genetic profiles of pancreatic cancer 
Caused by multiple genetic mutations accumulated over years pancreatic cancer is a 
genetic disease and the earliest recognizable defect is telomeres shortening leading to 
instability of chromosomes [van Heek et al., 2002]. Alterations of k-Ras, p53 and 
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SMAD4/DPC4 represent the most common mutations, simultaneously present in more 
than 75% of all pancreatic cancers [Rozenblum et al., 1997]. Mutations that activate the 
k-Ras oncogene were seen in more than 90% of pancreatic cancer [Radulovich et al., 
2008] resulting in the activation of several downstream effector pathways such as the 
RAF mitogen activated protein kinase or the phosphoinositide-3-kinase [Maitra and 
Hruban, 2008]. Activation of these pathways plays a critical role in pancreatic 
canceroginesis and cell proliferation. Besides k-Ras mutations, inactivation of the p53 
tumor suppressor gene, present in up to 75% of all pancreatic cancers, represents 
another widespread mutation allowing cells to proceed in division in the presence of 
damaged DNA, thereby leading to accumulation of additional genetic abnormalities [Li 
et al., 2010]. Amongst other actions, the tumor suppressor gene SMAD4/DPC4 is a 
mediator of the growth inhibitory effect of TGF-β and its inactivation is found in more 
than 50% of pancreatic cancers [Koliopanos et al. 2008].  
In contrast to normal pancreatic tissues, constitutive NF-κB activity could be found in 
70% of pancreatic adenocarcinomas [Chandler et al., 2004]. NF-κB can be activated by 
the k-Ras pathway leading to activation of multiple genes and pathways including anti 
apoptotic, cell survival, pro-invasive and angiogenic pathways [Mihaljevic et al., 2010]. 
Furthermore, pancreatic cancer expresses high levels of chemoresistance factors like 
mdr1 p-glycoprotein [Miller et al., 1996].  
 
3.3.2 Treatment options 
Due to metastasis into adjacent or distant organs more than 80% of these carcinomas are 
not resectable [Niederhuber et al., 1995] and therefore systemic chemotherapy plays an 
important role in the treatment of this extremely aggressive cancer with the goal to 
provide symptomatic relief and prolong survival. Besides 5-fluorouracil, gemcitabine 
was identified as the two main treatment options [Huguet et al., 2009] but in particular 
metastatic pancreatic cancer is highly chemoresistant and response rates of single agent 
therapies are less than 20% [Evans et al., 2001]. Although combinations with other 
chemotherapeutic agents like topoisomerase I inhibitors (irinotecan), platinums or 
taxanes improved response rate and progression free survival, there was no longer 
overall survival [Li et al., 2010]. Because of this lack of effective therapy, research for 
new capable treatment options represents an important challenge. 
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3.4 Heat shock proteins 
 
Heat shock proteins (Hsps) represent a highly conserved set of proteins that have a 
pivotal role in cell cycle progression and cell death (apoptosis) as well as in maintaining 
cellular homeostasis under stress [Khalil et al., 2011]. Various insults like hypoxia, 
ischemia, exposure to UV light or chemicals, nutritional deficiencies or other stress 
rapidly induce their expression [Cotto and Morimoto, 1999; Lindquist and Craig, 1998]. 
According to their size, mammalian Hsps have been classified into 6 families: Hsp100, 
Hsp90, Hsp70, Hsp60, Hsp40 and small Hsps (including Hsp27). While high weight 
Hsps act in an ATP dependent fashion, small Hsps are ATP independent [Khalil et al., 
2011]. Due to their function to accompany unfolded proteins during their cellular 
transport under normal conditions and to help to protect these proteins when subjected 
to stresses, Hsps are known as molecular chaperones [Kopecek et al., 2001]. These 
chaperones never work alone but form oligomers and are helped by different co-
chaperones such as HSC70 interacting protein (Hip) or Hsp organizing protein (Hop) 
[Khalil et al., 2011]. Besides their essential functions in the maintenance of normal 
cellular homeostasis, different Hsps were shown to be over-expressed in a broad range 
of neoplastic processes and it was shown that the Hsp-induced cytoprotection can be 
attributed partly to the suppression of apoptosis [Khalil et al., 2011].  
 
3.4.1 Hsp90 
Due to the chaotic architecture of the vasculature in solid tumors resulting in hypoxia 
and acidosis [Issels 2008] and exogenously applied factors, cancer cells have to handle 
extreme environmental stress and it is not surprising that molecular chaperones in 
general, and Hsp90 in particular, are highly expressed in most tumor cells [Neckers, 
2007]. Hsp90 over-expression was shown among others e.g. for pancreatic, breast and 
lung cancer and for leukemia [Khalil et al., 2011].  
 
Structure of Hsp90  
Hsp90 chaperons contain 3 domains: an N-terminal ATP-binding domain, a middle 
domain (M-domain) and a C-terminal dimerization domain [Prodromou and Pearl, 
2003]. There are two main isoforms of Hsp90, an inducible form (Hsp90α) and a 
constitutive form (Hsp90β) [Csermely et al., 1998].  
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Clients, role in cancer and function  
The role of Hsp90 includes formation of the correct conformation and activation of a 
wide range of proteins and more than 200 proteins have been identified as Hsp90 clients 
[McClellan et al., 2007]. Among these clients, there are several proteins that play 
pivotal roles in acquisition and maintenance of the six hallmarks of cancer defined by 
Hanahan and Weinberg [2000] [Neckers 2007]. NF-κB, nuclear receptors (e.g. steroid 
receptors), protein kinases (e.g. Chk1, Akt, Wee1), Her2 neu, Bcr-Abl or the tumor 
suppressor protein p53 were for example shown to be Hsp90 clients [Müller et al., 
2005; Bottoni et al. 2009; Tse et al., 2008; Fukuyo Y., 2009]. To accomplish its 
chaperon function, Hsp90 forms a dynamic complex known as the Hsp90 chaperone 
machinery with Hsp70 and different co-chaperones. [Pratt and Toft, 2003], thereby, 
besides regulating proteins essential for constitutive cell signaling adaptive stress 
responses, also protecting mutated and over-expressed oncogenes [Trepel et al., 2010]. 
Inhibition of Hsp90 by geldanamycin was shown to induce a compensatory induction of 
other Hsps, in particular Hsp70 and different studies clearly correlate the level of Hsp70 
over-expression with therapeutic resistance [Bottoni et al., 2009; Khalil et al., 2011]. 
Besides geldanamycin, the most prominent inhibitor of Hsp90 binding to the N-terminal 
ATP-binding pocket [Fukuyu et al., 2010], there are several known Hsp90 inhibitors 
with potent antitumor-activity in a wide range of malignancies [Taldone et al., 2008] 
and there are now 14 drug candidates targeting Hsp90 in different clinical trials in 
multiple indications as single agents or as part of a combination therapy [Khalil et al., 
2011].  
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5 AIMS OF THE THESIS 
 
Cancer is a major public health problem in many countries and due to increasing 
expectancy of life this disease will be even more relevant in future. In the last decades 
there has been huge progress in early detection and the development of target specific 
powerful therapies resulting in distinct increased surviving rates for lots of cancers. 
However, intrinsic and acquired resistance is a major problem in cancer treatment and 
new therapy concepts are essential to handle this challenge. The major aim of this work 
was to elucidate innovative strategies in the targeting of cell cycle, cell death and cancer 
progression.  
In former studies we could show that the dual specific phosphatase Cdc25A represents a 
client of Hsp90 and, because Cdc25 phosphatases act as key regulators of the cell cycle 
and especially Cdc25A has been shown to be frequently over-expressed in a wide range 
of cancers, this protein was selected to target via Hsp90 inhibition by geldanamycin. As 
pancreatic tumors are among the hardest to treat cancers with poor prognosis and high 
resistance rates, this cancer type was chosen for the investigations. Retardation of cell 
proliferation by inhibiting ribonucleotide reductase with digalloylresveratrol was 
another approach to decrease pancreatic cancer cell growth.  
Besides elucidating targets for inhibiting the cell cycle in pancreatic cancer cell lines, 
investigations of different natural compounds and medical plants used in folk medicine 
as remedies have been the second main objective of this work. Natural products have 
played a significant role in human healthcare for thousands of years and even today, 
more than 60% of all drugs are either natural products or directly derived thereof used 
to treat even diseases such as cancer. Among these are very important agents like 
vinblastine, vincristine, the camptothecin derivatives, topotecan and irinotecan, 
etoposide and paclitaxel. The multifactorial anticancer effects of different extracts of 
medicinal plants collected in Guatemala, Pakistan and Turkey should be tested on HL-
60 leukemia cells regarding their ability to inhibit cell growth and elicit cell death. 
As about 90% of all cancer deaths are not related to the primary tumor but to metastases 
that destroy the function of infested organs, prevention of cancer cell dissemination and 
secondary tumor formation must be a major goal of cancer therapy, investigation of this 
important step of tumorigenesis has been the third main objective. Breast cancer cells 
penetrate lymphatic vessels by generating circular defects in the integrity of a lymphatic 
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endothelial cell layer and that these ruptures are mediated by 12(S)-HETE metabolized 
from arachidonic acid by the hypoxia-inducible enzymes ALOX12 or ALOX15. 
Intravasation into blood and lymphatic vessels represents one of the first steps in the 
multistep process of metastasis and therefore, in this work, different natural compounds, 
in particular digalloylresveratrol and a methanol extract of Scrophularia lucida, should 
be tested about their ability to inhibit cell intravasation and, besides that, emphasis was 
placed on investigations about other pathways as the one mediated by 12(S)-HETE. 
The results from these studies should allow a better understanding in the role of cell 
specific targets in frequent human cancers. Knowledge about the underlying 
mechanisms could also increase the success of different existing and future 
chemotherapeutic drugs. 
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Short 428C heat shock induces phosphorylation
and degradation of Cdc25A which depends on
p38MAPK, Chk2 and 14.3.3
Sibylle Madlener1, Margit Rosner2, Sigurd Krieger1, Benedikt Giessrigl1, Manuela Gridling1,
Thanh Phuong Nha Vo1, Christina Leisser1, Andreas Lackner3, Ingrid Raab1, Michael Grusch3,
Markus Hengstschla¨ger2, Helmut Dolznig1 and Georg Krupitza1,
1Institute of Clinical Pathology, Medical University of Vienna, 2Department of Medical Genetic, Medical University of
Vienna and 3Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Waehringer
Guertel 18-20, A-1090 Vienna, Austria
Received January 14, 2009; Revised and Accepted March 12, 2009
The effects of heat shock (HS; 428C) on the cell cycle and underlying molecular mechanisms are astonish-
ingly unexplored. Here, we show that HS caused rapid Cdc25A degradation and a reduction of cell cycle
progression. Cdc25A degradation depended on Ser75–Cdc25A phosphorylation caused by p38MAPK and
Chk2, which phosphorylated Ser177–Cdc25A that is specific for 14.3.3 binding. Upon HS, Cdc25A rapidly
co-localized with 14.3.3 in the perinuclear space that was accompanied with a decrease of nuclear Cdc25A
protein levels. Consistently, a 14.3.3 binding-deficient Cdc25A double mutant (Ser177/Ala-Tyr507/Ala) was
not degraded in response to HS and there was no evidence for an increased co-localization of Cdc25A
with 14.3.3 in the cytosol. Therefore, upon HS, p38, Chk2 and 14.3.3 were antagonists of Cdc25A stability.
On the other hand, Cdc25A was protected by Hsp90 in HEK293 cells because the specific inhibition of
Hsp90 with Geldanamycin caused Cdc25A degradation in HEK293 implicating that Cdc25A is an Hsp90
client. Specific inhibition of Hsp90 together with HS caused and accelerated degradation of Cdc25A and
was highly cytotoxic. The results presented here show for the first time that Cdc25A is degraded by moderate
heat shock and protected by Hsp90. We describe the mechanisms explaining HS-induced cell cycle retar-
dation and provide a rationale for a targeted hyperthermia cancer therapy.
INTRODUCTION
Severe heat shock (HS; up to 44–458C) arrests the cell cycle
either dependent or independent of p53 through upregulation
of p21 and downregulation of cyclin D family members (1–
3). Mild to moderate HS (40–438C) reflects the conditions
of very high fever and is reached by hyperthermic cancer
therapy (fever range whole body hyperthermia; FR-WBH)
but the effects on the cell cycle and its regulators are rather
unexplored. Mild HS was shown to upregulate cyclin D1 (4)
implicating an induction of the lymphocyte cell cycle although
this has so far not been investigated in detail. Furthermore, HS
was shown to activate the stress protein p38MAPK (p38) (2,4).
Activated p38 can phosphorylate Ser75–Cdc25A (5–7) and
phosphorylation of Ser75–Cdc25A destabilizes the protein
(5,8). Toxic stress caused by various chemicals and clinical
drugs (9,10), UV (11) and ionizing radiation (12,13) leads to
degradation of Cdc25A through the activation of checkpoint
kinases (Chks) (14), which makes this cell cycle regulator
and oncogene a target for anticancer therapy. However,
Cdc25A was never studied in response to HS. We found that
moderate and short HS (428C; 20–60 min) destabilized
Cdc25A and studied the causal mechanisms. In short, HS
caused rapid phosphorylation of Cdc25A by p38 and Chk2,
and its nuclear export to the perinuclear space where it accu-
mulated in co-localization with 14.3.3, which was required for
its degradation.
There is an ongoing debate on the assumption that the more
often high fevers are experienced throughout a lifetime, the
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lower is the risk to develop certain types of cancer and also
hyperthermia treatment of patients suffering from liver,
kidney and bone cancer is successful, although locally
applied temperatures are much higher than the temperatures
described herein. Here, we provide a mechanistic rationale
for these observations.
Since Cdc25A is over-expressed in a variety of malignan-
cies such as breast-, pancreatic-, renal-, liver-, lung-,
thyroid-, oesophageal-, endometrial-, colorectal cancers,
malignant melanoma, glioma, and non-Hodgkin lymphomas
(15), the specific response of Cdc25A to HS could be
exploited in adjuvant thermo therapy applied either strictly
locally at the tumour site or systemically to also reach
distant micro-metastases.
RESULTS
Moderate heat shock downregulates Cdc25A
and inactivates Cdc2
It was shown that severe HS causes p532/p212-dependent as
well as p53-independent cell cycle arrest (1,3) suggesting that
also different mechanisms are responsible for the inhibition of
cell proliferation. Moderate HS was reported to even induce
cyclin D1 in lymphocytes implicating a lymphocytic growth
response as observed when fevering, i.e. upon infections
(2,4). In HEK293 cells, cyclin D1 was also upregulated at
39–408C (mild HS; Fig. 1A and B). Induction of p21 was
not observed at the tested temperatures (37–438C; data not
shown). When analysing the expression of Cdc25A protein
in response to moderate HS, we found its rapid downregula-
tion when HEK293 embryonic kidney cells (Fig. 1A–C) or
HeLa endometrial carcinoma cells (Fig. 1E) were exposed to
428C. Thus, HS downregulated the Cdc25A oncogene in
different cell types. As a consequence of Cdc25A depletion,
the phosphorylation of Tyr15-Cdc2 (Cdk1) peaked (16)
(Fig. 1C) because Tyr15-Cdc2 (Cdk1) is a substrate of acti-
vated Cdc25A phosphatase (15), and this reduced cell cycle
progression. In addition, also Cdc25B and Cdc25C levels
dropped in HEK293 cells (Fig. 1D) and HeLa cells (Fig. 1E)
upon 428C HS and this may have contributed to the accumu-
lation of Tyr15-phosphorylation of Cdc2 as well. Conversely,
in HEK 293 cells, 408C HS did not cause Tyr15-
phosphorylation of Cdc2 and only in HeLa cells Cdc25B
was strongly decreased after 408C HS. A significant number
of HEK293 cells accumulated in the G1 phase upon HS
(428C, 20 min) and subsequent cultivation for 24 and 48 h
(Fig. 1F). Heat shocking HEK293 cells for 60 and 90 min
(428C) led to severe apoptosis after 72 h post-incubation
time (Fig. 1I), and until the onset of apoptosis cells remained
growth retarded. The retardation of cell cycle progression
upon 428C HS was demonstrated by reduced cell proliferation
rate (Fig. 1G) and significantly reduced incorporation of BrdU
into the nascent DNA (Fig. 1H).
Heat shock activates p38 and induces Ser75–Cdc25A
phosphorylation
Searching for Cdc25A degrading signals upon HS, we studied
the expression of checkpoint kinase 1 (Chk1), which when
phosphorylated destabilizes Cdc25A. However, HS did not
activate Chk1 and a specific Chk1 inhibitor (C1I) did not influ-
ence Ser75–Cdc25A phosphorylation or stability (Fig. 2A,
left-side panels) and hence, Chk1 did not play a role upon
HS-induced destabilization. This was in contrast to UV- or
ionizing radiation (IR)-induced Cdc25A degradation, which
is triggered by Chk1 (11,12), and for control reasons we
show Chk1 activation upon exposure of HEK cells to 50 mJ
UV irradiation (Fig. 2A, right-side panels). Also p38 can phos-
phorylate Ser75–Cdc25A (5–7), and p38 is activated upon
severe as well as mild HS (2,4). In the context of HS, this
signal cascade (p38 to Ser75–Cdc25A) has not been studied
yet. HS induced the phosphorylation of Thr180/182 of p38
(indicative for its activation) and the phosphorylation of
Ser75–Cdc25A within 20 min was prevented by the specific
p38 inhibitor SB203580 and also the destabilization of the
Cdc25A protein level was blocked (Fig. 2B).
Heat shock activates checkpoint kinase 2 and induces
Ser177–Cdc25A phosphorylation
In search of downstream degrading mechanisms, the phos-
phorylation of Ser177–Cdc25A, a site phosphorylated by
Chk2 thereby forming a docking site for 14.3.3 (14,16) was
analysed. The binding of 14.3.3 to phospho-Ser177 could be
demonstrated, and the phosphorylation of Ser177–Cdc25A
is known to have a destabilizing effect (9,14,17). HS slightly
induced the phosphorylation of Thr68-Chk2 within 20 min.
At this time point also a slight electrophoretic upshift
became visible (also visible at the 60 min time-point) indicat-
ing an increase of additional (likely activating) phosphoryl-
ations at different site(s) (Fig. 3). Specific inhibition of Chk2
activity by Chk2 inhibitor (C2I) caused an electrophoretic
downshift equal to the migration of the control band and a
reduction of the phospho-specific signal intensity. Upon HS
also the phosphorylation of Ser177–Cdc25A became
induced within 20 and 60 min, which was reduced (but
not reversed to control levels) in the presence of C2I. This
indicated that Chk2 caused Ser177–Cdc25A phosphorylation.
The Cdc25A protein level was less reduced after 20 min com-
pared with HS-mediated depletion of Cdc25A protein level
shown in Figure 2. There are several reasons for this unsteady
response within 20 min of HS. First, the confluence of the cell
culture plays a role (the higher the confluence at the time of
the experiment, the higher the stability of Cdc25A). Secondly,
even slight fluctuations of the incubator temperature (0.5–
1.08C) may cause a remarkable difference in such short time
spans of HS (Fig. 1A), and so does the transfer time from
the maintenance incubator to the HS incubator. In pilot exper-
iments using water bath-controlled HS, similar fluctuations
were observed and therefore, we continued with incubator-
controlled HS. However, we want to point out that HS
induced the degradation of Cdc25A in every single experiment
(at least after 60 min), which is the major finding we want to
demonstrate. After 60 min of HS, Cdc25A protein expression
was strongly reduced (Fig. 3), whereas the phospho-specific
antibody still detected considerable phopho-Ser177 levels.
This implicated that low amounts of Cdc25A must have
been highly phosphorylated. Specific inhibition of Chk2 by
C2I, which also inhibited phosphorylation of Ser177–
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Cdc25A, somewhat stabilized Cdc25A protein expression
(Fig. 3) and this supported the notion that either the inhibition
was only partial (the data argue for this interpretation), or once
Cdc25A was tagged with destabilizing modifications, the
process of degradation was fast, and beyond a certain
threshold point, irreversible.
Binding to 14.3.3 destabilizes Cdc25A and heat shock
increases 14.3.3–Cdc25A co-localization
To further study the involvement of phosphorylation as trigger
mechanism of Cdc25A destabilization, it was tested whether
HS-mediated Cdc25A degradation was dependent on 14.3.3.
This protein was described as a mediator of nuclear-
cytoplasmic transport of Cdc25B and Cdc25C (14,18,19),
and as a tag for subsequent proteasomal degradation. A
double-mutated (dmt) Cdc25A construct that cannot become
phosphorylated at the Ser177Ala and Tyr506Ala mutated
residues is 14.3.3 binding-deficient (16). Upon HS, this
dmtCdc25A construct exhibited increased stability in
transfected HEK293 cells, whereas ectopic wild-type (wt)
Cdc25A was degraded, such as endogenous Cdc25A
(Fig. 4A, left-side panels show Cdc25A expression of those
cells that were transfected with wtCdc25A, right-side panels
the expression of dmtCdc25A-transfected cells). Ectopic myc-
tagged Cdc25A constructs were detected by an anti-myc anti-
body and endogenous Cdc25A by a monoclonal antibody
against Cdc25A (F6), which does not detect dmtCdc25A.
The Cdc25A-specific bands are indicated by arrow heads.
The transfection was carefully adjusted not to exceed 2–
3-fold overexpression (see Materials and Methods). The
experiment analysing the stability of dmtCdc25A supported
the hypothesis that Cdc25A stability upon HS was regulated
through Chk2 activation and the phosphorylation of Ser177–
Cdc25A. Then, it was analysed which of the 14.3.3 isoforms
co-precipitated Cdc25A. Co-transfection of wtCdc25A-V5
(fused to a 30-V5 tag) with each of the 14.3.3 isoforms listed
showed that 14.3.31 and 14.3.3u (t) were those isoforms
which pulled down high amounts of Cdc25A (Fig. 4B). For
unknown reasons HA-antibody precipitated 14.3.3s ineffi-
ciently and therefore we continued the studies with 14.3.3u
and myc-tagged Cdc25A.
Reciprocal pull-down assays confirmed that wtCdc25A
co-precipitated HA-14.3.3u, whereas a binding-deficient
HA-mt14.3.3 construct, which cannot associate with natural
14.3.3 binding partners, did not co-precipitate with Cdc25A
(20). Also dmtCdc25A was entirely 14.3.3 binding-deficient
(Fig. 4C). Next, we investigated where in the cell Cdc25A
Figure 2. HEK293 cells were exposed to 428C HS for 20 min and where indicated (A) Chk1 inhibitor SB218078 (C1I, 1 mM; as a phospho-Chk1 antibody control
cells were exposed to 50 mJ UV and post-incubated for 30 min, right-side panels), or (B) specific p38 inhibitor SB203580 (SB, 1 mM) was included. Then, cells
were lysed and subjected to western blot analysis using the indicated antibodies. HS induced Thr180/182-p38 phosphorylation (indicative for its activation) and
in consequence phosphorylation of Ser75–Cdc25A within 20 min and the reduction in Cdc25A protein level. The correct position of the phospho Ser75–
Cdc25A band was identified by overlaying this luminescence image with that of the Cdc25A blot, which was developed on the same membrane. Chk1,
which also phosphorylates Ser75–Cdc25A, did not become activated upon HS. b-Actin was used as loading control.
Figure 1. (A) HEK293 cells were exposed to increasing temperatures (as indicated) for 60 min and the expression of Cdc25A and cyclin D1 was analysed by
western blotting and (B) measured by densitometry that was calibrated to actin expression (numbers are in proportion to actin expression that was set as 1.0). (C,
D) HEK293 and (E) HeLa cells were exposed to 428C heat shock (HS; left-side panels) for 20 and 60 min, or 408C for 60 min (right-side panels), lysed and
prepared for western blot analysis using the indicated antibodies. After 60 min HS (428C), Cdc25A, B and C levels were decreased and phosphoTyr15-Cdc2
levels were increased. b-Actin was used as a loading control. (F) HEK293 cells were exposed to HS for 20 min and put back to 378C for the indicated
times. Then cells were prepared for FACS analysis. A significant accumulation of HS-treated cells in G1 was observed after 24 and 48 h. HEK cells were
exposed to 428C HS for 20 and 60 min and set back to 378C and (G) counted after 12 h, or (H) pulse-labelled subsequent to HS with BrdU for 2 h. Then,
BrdU incorporation was measured using a FACSCalibur flow cytometer, and compared with untreated controls. (I) HEK293 cells were exposed to 428C HS
for 60 and 90 min and put back to 378C for 48 and 72 h. Then, cells were stained with HO/PI, and analysed with fluorescence microscopy using a DAPI
filter. Experiments were performed in triplicate, asterisks indicate significance and error bars SEM.
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co-localized with 14.3.3 upon HS and for this, we used confo-
cal microscopy. HEK293 cells were inappropriate for this type
of experiment, because they detached from glass slides after
HS (even when slides were coated with matrigel or fibronec-
tin), thereby preventing a confocal in situ analysis, and there-
fore, HeLa cells were used for this investigation. Cells were
serum-starved overnight to downregulate endogenous c-Myc
and avoid interference with the myc-tag of the ectopic
Cdc25A constructs. In untreated control cells, the majority
of wtCdc25A and dmtCdc25A was located in the nucleus.
Upon 20 min HS, the levels of nuclear wtCdc25A decreased
but the co-localization of wtCdc25A with 14.3.3 increased in
the perinuclear space (Fig. 4D and E). dmtCdc25A persisted
in the nucleus and HS neither changed the protein level nor
the extent of perinuclear co-localization with 14.3.3 (Fig. 4D
and E). Zeiss software allowed quantifying the extent of
Cdc25A expression as well as 14.3.3 co-localization
(Fig. 4D). Since dmtCdc25A was completely 14.3.3 binding-
deficient (Fig. 4C), the measured co-localization in untreated
and HS-treated dmtCdc25A cells was non-specific (Fig. 4D).
Hence, we introduced a threshold (the green dashed line in
Fig. 4D) above which the Cdc25A-14.3.3 co-localization
was considered specific. This demonstrated that
Ser177-phosphorylation-dependent 14.3.3 binding played a
role in the subcellular distribution and degradation of
Cdc25A upon HS.
Cdc25A is an Hsp90 client in HEK293 cells
Since there exist antagonists of Cdc25A stability, one has to
also postulate the existence of protagonists that counteract
destabilization. We tested the idea that HS activated
chaperones of the heat shock protein family. Hsp90 was
shown to interact with its client Chk1 (21), and
cytarabine-activated Chk1, which was destabilized by the
specific Hsp90 inhibitor 17-AAG, resulted in attenuated degra-
dation of Cdc25A in HL60 cells (22), and this evidenced a
connection between Hsp90 and Cdc25A. Garcia-Morales
et al. (23) demonstrated that Cdc25C and Cdc2 are Hsp90
clients. Further, Akt and Raf1 are Hsp90 clients (24–26)
and Galaktionov et al. (27) showed that Cdc25A
co-immunoprecipitated with Raf and we provided evidence
that also Akt was associated with Cdc25A and Raf (28). It
therefore seemed likely that also Cdc25A is in complex with
Hsp90. Apparently, Hsp90 stabilizes various oncoproteins
and/or their oncogenic activity (29) and thus, targeting
Hsp90 is evaluated in clinical trials as anticancer therapeutic
concept (30–32). Geldanamycin (GD) specifically inhibits
Hsp90 by competing with ATP for the ATP/ADP-binding
pocket and thereby Hsp90 becomes inactivated in its chaper-
one function that is required for client stabilization. In case
Cdc25A is an Hsp90 client, such as other proto-oncogenes,
i.e. Raf1, Akt or c-jun (24,26,33), GD was expected to desta-
bilize Cdc25A. To confirm this, HEK293 and HeLa cells were
treated with 1 mM GD for 1 and 24 h and the stability of
Cdc25A and Akt (Hsp90 client) was analysed. As expected,
Akt was degraded in both cell lines within 24 h, whereas
Cdc25A became degraded only in HEK293 cells (Fig. 5A).
This implicated that specific co-chaperones required for
Cdc25A–Hsp90 binding and activity (34) are limited in
HeLa cells but not in HEK293 cells. Therefore, dependent
on the cellular context, Cdc25A was an Hsp90 client. Treat-
ment with GD caused an electrophoretic Cdc25A-upshift
after 24 h (Fig. 5A) and this phenomenon was accelerated in
combination with HS (Fig. 5B). Also Cdc25A depletion was
accelerated upon GD and HS co-treatment (after 20), which
further confirmed that Cdc25A was an Hsp90 client
(Fig. 5B). HS-mediated activation of p38 became additionally
induced by GD co-treatment and this correlated with a sub-
stantial increase in Ser75–Cdc25A phosphorylation, which
faded after 60 min HS.
To formally analyse whether Cdc25A and Hsp90 appear in
the same complex, Cdc25A–V5 was transiently over-
expressed and immunoprecipitated with anti-Cdc25A antibody
Figure 3. HEK293 cells were exposed to 428C heat shock (HS) for 20 and
60 min and where indicated a specific Chk2 inhibitor (C2I, 10 mM) was
included. Then cells were lysed and subjected to western blot analysis using
the indicated antibodies. After 20 and 60 min HS Chk2 was phosphorylated
at the activating Thr68 site. Furthermore, Cdc25A was phosphorylated at
the Chk2-specific phospho Ser177 site (arrowhead) after 20 and 60 min and
less phosphorylated after treatment with C2I. Chk2 protein level was
unchanged. b-Actin was used as loading control. To better illustrate the
HS-mediated phChk2 upshift, the panel at the right side gives a 2.5 magni-
fication of the control- and HS band (20 min). The correct position of the
phospho Ser177–Cdc25A bands (or the phospho Thr68-Chk2 bands) was
identified by overlaying this luminescence image with that of the Cdc25A
blot (or the Chk2 blot, respectively), which was developed on the same
membrane.
Figure 4. HEK293 cells were transfected with (A) wild-type (wt) Cdc25A-myc-tag cDNA (left-side panels) and double-mutated (dmt) Cdc25A-myc-tag cDNA
(right-side panels) and then exposed to HS for the indicated times (min). Then cells were lysed and subjected to western blot analysis using the listed antibodies.
Endogenous wt- and ectopic wtCdc25A-myc-tag was degraded after 20 min HS, whereas dmtCdc25A protein levels remained unchanged. The bars indicate the
72 kDa weight marker. b-Actin was used as loading control. (B) Co-immunoprecipitation of wtCdc25A-V5 with 14.3.3 isoforms: the indicated HA-tagged 14.3.3
cDNA isoforms and V5-tagged wtCdc25AcDNA were co-transfected into HEK293 cells and after 24–36 h cells were lysed and 14.3.3 was immunoprecipitated
with HA antibody and co-precipitated Cdc25A was detected with V5 antibody. (C) Pull-down assay: HEK293 cells were transfected with the indicated cDNAs
(wt14.3.3 u) and after 24–36 h cells were lysed by repeated freeze-thaw cycles under non-denaturing buffer conditions, and then Cdc25A was immunopreci-
pitated with monoclonal F6- or polyclonal M191 antibody. F6 was used to check the specificity of the Cdc25A/14.3.3 interaction. mt14.3.3 is a construct
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that cannot associate with natural 14.3.3 binding partners. The F6 antibody does not detect dmtCdc25A because it recognizes the C-terminus which is mutated in
dmtCdc25A (not shown). Therefore, the analysis was performed with M191 antibody, which also detects dmtCdc25A. 14.3.3 Constructs carried a HA-tag and
western blot analyses of co-immunoprecipitated 14.3.3 and lysate input was performed with HA antibody. (D) Serum-starved HeLa cells were grown on glass
slides, transfected with wtCdc25A-myc-tag cDNA and dmtCdc25A-myc-tag cDNA subjected to HS for 20 min, fixed and prepared for double-
immunofluorescence and examined under a confocal microscope. The green dashed line shows the threshold, below which co-localization is arbitrary,
whereas above co-localization is specific. After 20 min HS, the co-localization of wtCdc25A/14.3.3 increased approximately 3.5-fold compared with the
dmtCdc25A/14.3.3 co-localization, which remained unchanged. (E) Representative double immunofluorescence-stained examples of HS-treated HeLa cells
expressing wt- or dmtCdc25A. The red colour shows Cdc25A-myc-tag (anti-myc antibody), green 14.3.3, and blue shows the DAPI-stained nuclear chromatin;
yellow is the Cdc25A-myc-tag/14.3.3 merge. In controls, most of wtCdc25A and dmtCdc25A was located in the nucleus and the co-localization of wtCdc25A
with 14.3.3 was observed predominantly near the nucleus in the cytoplasm. The size bars indicate 10 mm.
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under non-denaturing conditions and the presence of Hsp90 in
the precipitate was confirmed by western blotting (Fig. 5C,
middle panel). The efficiency of the immunoprecipitates (IP)
was controlled by anti-V5 immunoblot. Reciprocal IP–
western analysis (IP: Hsp90; WB: V5) confirmed the speci-
ficity of the Cdc25A–Hsp90 interaction (Fig. 5C, left-side
panel). Also, after 428C HS (20 min) Hsp90 still
co-precipitated with Cdc25A (Fig. 5C, right-side panel).
Throughout the time span investigated, we did not observe a
change in the Hsp90 expression level (data not shown).
DISCUSSION
The dual-specificity phosphatase Cdc25A regulates the cell
cycle and was shown to be sensitive to UV, IR, osmotic-,
oxidative- and genotoxic stress (9–12). Here, we demonstrate
for the first time that Cdc25A was rapidly downregulated upon
HS at the high end of the physiological fever range (428C)
(4,35), and reduced cell cycle progression causing an accumu-
lation of cells in G1. Interestingly, also hyperthermic cancer
therapy (FR-WBH) is performed around 41.58C. Upon 408C,
HS Cdc25A expression was only moderately reduced.
Unlike UV or IR, which cause Chk1-mediated phosphoryl-
ation and degradation of Cdc25A through tagging with the
SCFb-TrCP ubiquitin–ligase complex at the phosphodegron
around Ser81/87–Cdc25A (13,36,37), HS activated the
kinases p38 and Chk2, but not Chk1. p38 phosphorylated
Ser75–Cdc25A (such as that described for Chk1) (8) and
this may have as well facilitated the subsequent phosphoryl-
ation of Ser81/87–Cdc25A and association with the SCFb-TrCP
ubiquitin–ligase complex followed by degradation (13,36).
Specific inhibition of p38-mediated Ser75–Cdc25A phos-
phorylation abrogated destabilization of Cdc25A only in a
small time-window and this evidenced that an additional
degrading mechanism was activated as well. HS-mediated
Figure 5. (A) HEK293 and HeLa cells were exposed to the specific Hsp90 inhibitor geldanamycin (GD, 1 mM) for 1 and 24 h. After 24 h of treatment, Cdc25A
was downregulated in HEK293 cells but not in HeLa cells. GD caused an electrophoretic upshift of Cdc25A in both cell lines after 24 h. (B) HEK293 cells were
exposed to HS for 20 and 60 min and wherever indicated 1 mM GD was included. Then cells were lysed and subjected to western blot analysis using the indicated
antibodies. b-Actin was used as loading control. HS and co-incubation with GD resulted in an increased phosphorylation of Ser75–Cdc25A and electrophoretic
retardation and degradation of Cdc25A. Also the phosphorylation of Thr180/182–p38 was increased when cells were treated with HS and GD. b-Actin was used
as loading control. (C) HEK293 cells were transfected with wtCdc25A-V5 cDNA and after 24–36 h cells were lysed by repeated freeze-thaw cycles under non-
denaturing buffer conditions. Then, Hsp90 (left-side panels) was immunoprecipitated with anti-Hsp90 from Abcam and Cdc25A was detected using anti-V5
antibody. Reciprocally, Cdc25A (middle and right-side panels) was immunoprecipitated with M191 antibody and co-precipitated Hsp90 was detected by
western blot analysis using anti-Hsp90 antibody from Cell Signaling. In the experiments that are depicted in the left and middle panels, cells were kept
under normal culture conditions (CO), and in the experiment that is shown in the right-side panel cells were heat shocked (428C; HS) for 20 min. Precipitation
efficiency was controlled by immunoblotting with anti-Hsp90 antibody from Cell Signaling (left side) or anti-V5 antibody (middle and right side).
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Chk2 activation led to the phosphorylation of Ser177–
Cdc25A (such as formerly described for Chk1) thereby, creat-
ing a 14.3.3 docking site (16). It was shown that the binding of
14.3.3 to Cdc25 family proteins is mediated by phosphoserines
within 14.3.3-binding consensus sequences of Cdc25 (38). A
second 14.3.3 docking site, Tyr506–Cdc25A, was reported
to become phosphorylated by Chk1 (14). The prevention of
14.3.3 binding by Ser177Ala-Tyr506Ala mutations (16) inhib-
ited the cytoplasmic sequestration of dmtCdc25A in HeLa
cells and its degradation. Since the phosphorylation sites
Ser75-, and Ser81/87 of Cdc25A were intact in the
dmtCdc25A construct described herein and the degradation
of Cdc25A was nevertheless blocked by a 14.3.3-binding
mutant, a hypothetic SCFb-TrCP ubiquitin–ligase-dependent
scenario was not the only cause for Cdc25A destabilization.
Thus, HS-induced Cdc25A destabilization depended on
binding to 14.3.3 and the relocation into the perinuclear
space (see model suggested in Fig. 6). It has been shown
that binding of 14.3.3 to the closely related family members,
Cdc25B and Cdc25C, caused their sequestration to the cyto-
plasm (14,18,19) and finally their degradation. Cdc25A can
largely compensate the deficiency in Cdc25B and Cdc25C
(demonstrated with respective knockout mice), whereas
Cdc25A(2/2) mice are embryonic lethal. Cdc25B and
Cdc25C are therefore, not as relevant for survival as
Cdc25A (15). Most recently, Cdc25A was identified as a rate-
limiting oncogene determining genomic stability and Cdc25A
over-expression promotes tumours induced by the ErbB2–Ras
pathway. Even a partial repression of Cdc25A is considered
beneficial, as it reduces aggressive tumour development and
improves prognosis in an MMTV-Ras/Cdc25A mouse model
(15). This justifies to search for therapeutic concepts targeting
Cdc25A (39).
The results support the interpretation that Hsp90 protected
Cdc25A of HEK293 cells through a Hsp90 co-chaperone
(Fig. 6), such as the Hsp90 co-chaperone AHA1 maintained
the activity of MEK1/2 and Erk1/2 (29). In our case
however, the hypothetical co-chaperone was absent in HeLa
cells. Currently, also the inhibition of Hsp90 is tested as anti-
cancer target and the combination of GD with checkpoint
inhibitors is considered as a promising approach. GD and
HS (instead of checkpoint inhibitors) seems to be a concept
with great potential, since HS treatment can be applied
within the physiological range.
Here, a novel regulation of the Cdc25A oncogene was dis-
covered providing a reasonable explanation for HS-induced
cell cycle retardation and for the mechanisms destabilizing/
stabilizing Cdc25A upon HS and GD treatment and this can
form a basis for a tailored Cdc25A-targeting hyperthermia
cancer therapy.
MATERIALS AND METHODS
Chemicals
Specific inhibitors against p38 (SB203580; SB), HSP90 (Gel-
danamycin; GD), Chk1 (SB218078; C1I) and Chk2 (Chk2
inhibitor; C2I) were purchased from Calbiochem. Antibodies
directed against ph(Tyr15)-Cdc2, ph(Thr180/182)-p38, p38,
ph(Ser345)-Chk1, Chk1, ph(Thr68)-Chk2, Chk2 and Hsp90
were from Cell Signaling, against ph(Ser75)-Cdc25A, and
Hsp90 from Abcam, against ph(Ser177)-Cdc25A from
Abgent, against myc-tag from Invitrogen, against cyclin D1,
p21, 14.3.3, Cdc25A (M191) and Cdc25A (F6) from Santa
Cruz, against Cdc2 and b-actin from Sigma, V5 from Invitro-
gen, HA (high affinity, clone 3F10) was purchased from
Roche, anti-mouse IgG was from Dako and anti-rabbit IgG
from GE-Healthcare. Alexa-Fluor green 488- and Alexa-Fluor
red 594-labelled antibodies were purchased from Molecular
Probes, and Mowiol from Sigma.
Cell culture
HEK293 and HeLa cells were purchased from ATCC. Cells
were grown in logarithmical growth phase at 378C in a
humidified atmosphere containing 5% CO2 in DMEM high
glucose (HEK293) and low glucose (HeLa), both media
were supplemented with 10% heat-inactivated fetal
Figure 6. Schematic presentation proposing the mechanism of HS-induced
Cdc25A degradation in HEK293 cells. (1) Hsp90 binds through an unidenti-
fied co-chaperone (CO) to Cdc25A. (2) 428C HS activates p38MAPK and
Chk2. This causes the phosphorylation of Cdc25A at S75 and S177. Hsp90
is still in complex (perhaps less stable) with Cdc25A. (3) 14.3.3 protein
binds to phospho-S177 resulting in nuclear export. Since Cdc25A becomes
degraded in the cytoplasm, we postulate that the protection by Hsp90
decreases throughout heat shock response (perhaps through loss of inter-
action), thereby allowing cell cycle retardation at the extreme end of the
fever range.
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calf serum, 1% L-Glutamine and 1% Penicillin/Streptomycin.
All media and supplements were obtained from Life
Technologies.
Transfection
HEK293 and HeLa cells were split into a 6-well plate and
grown to 70% confluence before transfection in Penicillin/
Streptomycin-free medium. 7.5 ml of Lipofectamin 2000
(Invitrogen) and 1 mg of DNA (wtCdc25A-myc, dmtCdc25A-
myc, wtCdc25A-V5 or the 14.3.3 isoforms) were mixed into
600 ml of OptiMEM transfection medium and incubated at
room temperature for 20 min. In the meantime, cells were
washed with phosphate-buffered saline and 1 ml of
OptiMEM medium and the DNA and Lipofectamin 2000
mixture was added to the cells and incubated over night.
Cdc25A cDNA (without stop codon) was ligated in frame
with a 3-terminal V5 tag into a pcDNA3.1-V5 vector (Invitro-
gen) and the frame was confirmed by DNA-sequencing.
Double-mutated Cdc25A (dmtCdc25A– Ser177Ala and
Tyr506Ala) was a generous gift of Dr Piwnica-Worms—this
construct is also referred to as Ser178Ala and Tyr507Ala
(when the starting N-terminal methionine is also counted).
Heat shock and inhibitor treatment
HEK293 and HeLa cells were grown to 90% confluence, then
cells were pre-incubated with 1 mM of GD for 1 h, or 10 mM of
C2I, 10 mM of SB, 1 mM C1I for 24 h and exposed to 428C HS
for 20 and 60 min. After HS treatment cells were prepared for
analyses as described thereafter.
Western blotting
After incubation with different inhibitors and exposure to
428C HS HEK293 cells were harvested, washed twice with
ice-cold PBS (pH 7.2) and lysed in a buffer containing
150 mM NaCl, 50 mM Tris-buffered saline (Tris pH 8.0), 1%
Triton X-100, 1 mM phenylmethylsulfonylfluoride (PMSF)
and protease inhibitor cocktail (PIC; from a 100 stock).
Then the lysate was centrifuged at 12 000 rpm for 20 min at
48C, and the supernatant was stored at 2208C until further
analysis. Equal amounts of protein samples were separated
by polyacrylamide gel electrophoresis (PAGE) and electro-
blotted onto PVDF membranes (Hybond, Amersham) over-
night at 48C. Equal sample loading was controlled by
staining membranes with Poinceau S. After washing with
PBS/Tween-20 (PBS/T) pH 7.2 or Tris/Tween-20 (TBS/T)
pH 7.6, membranes were blocked for 1 h in blocking solution
(5% non-fat dry milk in PBS containing 0.5% Tween-20 or in
TBS containing 0.1% Tween-20). Then, membranes were
incubated with the first antibody (in blocking solution, dilution
1:500 to 1:1000) by gently rocking at 48C, overnight. There-
after, the membranes were washed with PBS or TBS and
further incubated with the second antibody (peroxidase-
conjugated goat anti-rabbit IgG or anti-mouse IgG, dilution
1:2000 to 1:5000 in PBS/T or TBS/T) at room temperature
for 1 h. Chemoluminescence was developed by the ECL detec-
tion kit (Amersham, UK) and then membranes were exposed
to Amersham Hyperfilms.
Immunoprecipitation
Cells were harvested, washed with PBS and lysed in total lysis
buffer (containing 20 mM HEPES, pH 7.9, 0.4 mM NaCl, 2.5%
glycerol, 1 mM ethylenediamine tetraaceticacid, 1 mM PMSF,
0.5 mM NaF, 0.5 mM Na3VO4 supplemented with 2 mg/ml
aprotinin, 2 mg/ml leupeptin, 0.3 mg/ml benzamidin chloride
and 10 mg/ml trypsin inhibitor) by repeated freezing and
thawing. Supernatants were collected by centrifugation and
protein concentrations were determined using the Bio-Rad
protein assay. For immunoprecipitation, crude cell extracts
(150–300 mg) were precleared with 20 ml Protein G-
Sepharose beads at 48C for 30–60 min. Afterwards, the indi-
cated primary antibodies against Cdc25A (F6), Cdc25A
(M191), HA or Hsp90 were added and incubated with constant
rotation at 48C (overnight). After complex formation, immu-
noprecipitates were washed three times with buffer containing
50 mM Tris–HCl, pH 8.0, 1% NP-40, 150 mM NaCl, 10 mM
b-glycerophosphate, 1 mM NaF, 0.1 mM Na3VO4, 0.2 mM
PMSF supplemented with protease inhibitors. Immunoprecipi-
tated proteins were then denatured and separated from the
sepharose beads by adding SDS-sample buffer and boiling
for 5 min (40,41).
Cell cycle distribution analysis
HEK293 cells were seeded in 6-wells and incubated at 378C
for 24 h. At a confluence of 70%, cells were exposed to
428C for 20 min. After 12, 24 and 48 h, cells were harvested,
washed with 5 ml cold PBS, centrifuged (600 rpm for 5 min)
and re-suspended and fixed in 3 ml cold ethanol (70%) for
30 min at 48C. After two further washing steps with cold
PBS, RNaseA and propidium iodide were added to a final con-
centration of 50 mg/ml each and incubated at 48C for 60 min
before measurement. Cells were analysed on a FACSCalibur
flow cytometer (BD Biosciences, San Jose, CA, USA) and
cell cycle distribution was calculated with ModFit LT software
(Verity Software House, Topsham, ME, USA).
Immunofluorescence
HeLa cells transiently transfected with wtCdc25A and
dmtCdc25A were grown on chamber slides and exposed to
428C HS for 20 min. Then, cells were washed with PBS and
fixed in 4% paraformaldehyde (10 min at room temperature),
washed three times with PBS and permeabilized with 0.1%
Triton X-100 in PBS at room temperature for 10 min. Then,
cells were washed three times with PBS and incubated in
10% goat serum diluted with PBS pH 7.5 for 30 min to
block unspecific binding of the antibodies. Thereafter, the
cells were incubated with the primary antibody (dilution
1:50 in 2% BSA/PBS) in a humid chamber at room tempera-
ture for 45 min and then washed three times with PBS. After-
wards cells were incubated with fluorescence-labelled second
antibody (dilution 1:1000 in PBS) in a humid chamber at
room temperature for 45 min and then washed three times
with PBS. Finally, cells were incubated with DAPI (dilution
1:50 000) at room temperature for 1 min and washed with
PBS. The slides were covered with Mowiol and the analysis
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was performed using a Zeiss LSM5 Exicter confocal micro-
scope using a 63 objective.
BrdU incorporation
HEK293 cells were seeded in 6-wells, then exposed to 428C
for 20 and 60 min and post-incubated with 10 mM of BrdU
for 2 h. Cells were prepared following the instructions of the
manufacturer (BrdU Flow Kit, Cat. No.: 552598, BD Pharmin-
gen), except for the incubation with the fluorescent anti-BrdU
antibody, which was incubated overnight at 48C (dilution of
1:50). Afterwards, the BrdU incorporation was measured and
analysed by a FACSCalibur flow cytometer.
Determination of cell death—Hoechst 33258/propidium
iodide double-staining
To measure apoptosis in MCF-7 clones, cells were seeded in
6-well plates, grown to 30% confluence, treated for increasing
times with 428C HS, and were subsequently post-incubated at
378C for 48 and 72 h. Then, Hoechst 33258 and propidium
iodide (final concentrations 5 mg/ml and 2 mg/ml, respect-
ively) was directly added to the culture medium for 1 h, and
stained cells were examined under a fluorescence microscope
with a DAPI filter, photographed, analysed and counted.
Experiments were performed in triplicate.
Statistics
Experiments were performed in triplicate and analysed using
t-test (GraphPad Prism 4.0 program).
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a b s t r a c t
Aim of this study: Within the genus Scutellaria various species are used in different folk medicines
throughout Asia. Traditional Chinese Medicine (TCM) uses S. baicalensis (Labiatae) to treat various
inflammatory conditions. The root shows strong anticancer properties in vitro and was suggested for
clinical trials against multiple myeloma. Further, S. barbata was successfully tested against metastatic
breast cancer in a phase I/II trial. Therefore, we investigated the anti-cancer properties of S. orientalis L.
ssp. carica Edmondson, an endemic subspecies from the traditional medicinal plant S. orientalis L. in
Turkey, which is used to promote wound healing and to stop haemorrhage.
Materials and methods: Freeze-dried plant material was extracted with petroleum ether, dichloro-
methane, ethyl acetate, and methanol and the bioactivity of these extracts was analysed by proliferation
assay, cell death determination, and by investigating protein expression profiles specific for cell cycle
arrest and apoptosis.
Results: The strongest anti-leukemic activity was shown by the methanol extract, which contained
apigenin, baicalein, chrysin, luteolin and wogonin, with an IpC50 of 43mg/ml (corresponding to 1.3mg/
ml of dried plant material) which correlated with cyclin D1- and Cdc25A suppression and p21
induction. At 132mg/ml ( ¼ 4mg/ml of the drug) this extract caused genotoxic stress indicated by
substantial phosphorylation of the core histone H2AX (g-H2AX) followed by activation of caspase 3 and
signature-type cleavage of PARP resulting in a 55% apoptosis rate after 48hours of treatment.
Conclusions: Here, we report for the first time that S. orientalis L. ssp. carica Edmondson exhibited potent
anti-leukaemic properties likely through the anti-proliferative effect of baicalein and the genotoxic
property of wogonin.
& 2009 Elsevier GmbH. All rights reserved.
Introduction
Some 60% of all drugs used in western medicine are derived
from natural compounds, which served as leads (Cragg et al.
2006). One approach to discover novel lead compounds against
cancer is the consideration of ancient ethno-medicinal knowledge
and the investigation of locally available natural resources
(Verpoorte 2000, Pieters and Vlietinck 2005).
A very rich plant diversity is found in Western Turkey which
includes Scutellaria species such as S. orientalis L. traditionally
used to promote wound healing or Scutellaria orientalis L. ssp.
carica Edmondson, an endemic subspecies. Recently, the genus
Scutellaria has gained considerable interest concerning anti-
cancer activities. Ethanol extracts of the species S. barbata
inhibited A549 cell growth with a mechanism that included
apoptotic effects (Yin et al. 2004). Three neoclerodane diterpe-
noids and five new neoclerodane diterpenoid alkoloids isolated
from S. barbata showed significant cytotoxic activities against
three human cancer cell lines; HONE-1, KB and HT29 (Dai et al.
2006, 2007). In HL-60 cells S. barbata extract caused apoptosis and
decreased the expression of cyclins and cyclin-dependent kinases
(Kim et al. 2007), and this plant was tested against metastatic
breast cancer in a phase I/II trial (http://tinyurl.com/2oyohu;
Rugo et al. 2007). Recent investigations demonstrated the anti-
proliferative effects of S. baicalensis in acute lymphatic leukaemia
(ALL)-, lymphoma- and myeloma cell lines. Growth inhibition
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correlated with increased levels of the Cdk inhibitor p27 and with
decreased levels of the c-myc proto-oncogene, whereas cytotoxi-
city was associated with mitochondrial damage and the modula-
tion of the bcl gene family (Kumagai et al. 2007). In the two
human prostate cancer cell lines LNCaP and PC-3 S. baicalensis
extract inhibited COX-2 activity and consequently reduced PGE2
synthesis, and this was accompanied by suppression of cyclin D1
and downregulation of Cdk1 activity (Ye et al. 2007). S. baicalensis,
known as Huang-qin or wogon, is the most commonly prescribed
plant in Traditional Chinese Medicine (TCM) and also extensively
used in Japanese Kampo medicines. TCM uses the root of
S. baicalensis (from Huang-Lian-Jie-Du-Tang) to treat various
inflammatory conditions and was suggested for clinical trials
against multiple myeloma (Ma et al. 2005). S. baicalensis and
S. rivularis have been reported to contain a large number of
flavonoids which inhibited the proliferation of HL-60 promyeloic
leukaemia cells (Sonoda et al. 2004), and the purified components
wogonin and baicalein have been studied in detail (Lee et al.
2008) and showed anticancer effects in human hepatoma cell
lines (Himeji et al. 2007). It has not been investigated though,
whether wogonin and baicalein are commonwithin the Scutellaria
genus and causal for the medicinal activity of the other species
(Cole et al. 2008). Here we analysed for the first time the
anti-leukaemic properties of extracts of S. orientalis ssp. carica in
p53-deficient HL-60 promyeloic leukaemia cells, determined the
concentration of wogonin and baicalein and compared the activity
profile of the methanolic extract with that of purified wogonin
and baicalein to elucidate the respective mechanisms responsible
for growth arrest and cell death induction.
Material methods
Plant material
Scutellaria orientalis ssp. carica has been collected in April 2007
from South-West of Turkey (Karacasu-AYDIN, 368m).
The botanical identification was made by Dr. Mesut Kirmaci
using the serial ‘‘Flora of Turkey and the East Aegean Islands’’
(Davis et al. 1965–1988). Voucher specimens were deposited in
the herbarium of Department of Biology, Adnan Menderes
University.
Sample preparation
Plants were freeze dried, then the plant material was milled
and extracted in a solvent-series of increasing polarity (petroleum
ether, dichloromethane, ethyl acetate and methanol). To 50 g of
plant material 500ml solvent were added. After finishing the first
soxhlet extraction (at 40 1C for approximately12h, until the
solvent became colourless) with petroleum ether, subsequent to
filtration the plant material was dried and subjected sequentially
to the second extraction with dichloromethane, the third extrac-
tion with ethyl acetate, and fourth extraction with methanol
(Krenn et al. 2003; Marchart et al. 2003; Dolezal et al. 2006). The
extracts were evaporated and yielded 8.24mg, 21.8mg, 6.48mg,
and 32.98mgper 1mg dried plant weight, respectively, and were
dissolved in 40ml ethanol. Baicalein and wogonin were dissolved
in DMSO (50mM stock solutions) and stored under nitrogen gas.
For the proliferation- and apoptosis assays following concentrations
(as calculated for dried plant material) were used: 500mg/ml,
1mg/ml, 4mg/ml, 20mg/ml. To exclude the effect of ethanol
on cell proliferation and apoptosis, controls were treated with
similar concentrations of ethanol as used for sample treatment
(in general 0.4% EtOH). Baicalein (Calbiochem) and wogonin
(Biomol) were used in a concentration range which covered the
wogonin and baicalein content determined in the methanolic
extract (0.1, 1, 5 and 10mM).
HPLC-analysis
The methanolic extract was analyzed by HPLC under the
following conditions: Column: 5mm ACE 3 C18 (1503mm, ACE,
Aberdeen, Great Britain); mobile phase: acetonitrile (A) and 0.3%
acetic acid (B); gradient elution: 0–20min 12–28% A; 20–50min
28–32% A; 50–55min 32–46% A; 55–56min 46–100% A;
56–66min 100% A; flow rate 0.4ml/min; wavelength of detection
270nm. The content of apigenin, baicalein, chrysin, luteolin and
wogonin in the methanolic extract was quantified by external
standardisation. Apigenin and luteolin were purchased from
Chromadex (USA), wogonin was from Calbiochem (San Diego),
baicalein from Biomol (Plymouth Meeting, PA), and chrysin from
C. Roth (Germany).
Reagents and antibodies
Hoechst 33258 and propidium iodide were purchased from
Sigma. Wogonin was purchased from Calbiochem and baicalein
from Biomol. Pierce ECL Western Blotting Substrate Cat# 32106
was from Pierce.
Antibodies: Mouse monoclonal (ascites fluid) anti-acetylated
tubulin clone 6-11B1 Cat# T6793, and mouse monoclonal (ascites
fluid) anti-b-actin clone AC-15 Cat# A5441, were from Sigma.
Rabbit polyclonal anti cdc25A (M191) Cat# sc-7157, anti a-tubulin
(TU-02) Cat# sc-8035, PARP-1 (F-2) Cat# sc-8007, anti-cyclin D1
(M-20) Cat# sc-718, and p21 (C-19) Cat# sc-397 were from Santa
Cruz Biotec. Inc. Rabbit monoclonal anti-active Caspase-3 (CPP32)
clone C92-605 Cat# 58404 was from Research Diagnostics Inc.
Polyclonal anti-MEK 1/2 Cat# 9122, polyclonal anti-phospho-MEK
1/2 (Ser 217/221) Cat# 9121m, monoclonal rabbit anti-p44/42
MAP Kinase (137F5) Cat# 4695, and mouse monoclonal anti-
phospho-p44/42 MAPK (Thr202/Tyr204) (E10) Cat# 9106 were
from Cell Signaling and rabbit polyclonal phospho detect anti-
H2AX (pSER139) Cat# dr-1017 was from Calbiochem. Anti mouse
IgG was from Dako and anti rabbit IgG from GE-Healthcare.
Amersham Hyperfilms ECL-High performance chemilumines-
cence film was from GE-Healthcare.
Cell culture
HL-60 promyeloic leukaemia cells were purchased from
ATCC. Cells were grown in RPMI 1640 medium supplemented
with 10% heat inactivated fetal calf serum, 1% L-glutamine and 1%
penicillin/streptomycin at 37 1C in a humidified atmosphere
containing 5% CO2. All media and supplements were obtained
from Life Technologies.
Proliferation inhibition assay
HL 60 cells were seeded in T-25 tissue culture flasks at a
concentration of 1105 cells per ml cell culture medium and
incubated with increasing concentrations of extracts correspond-
ing to 500mg/ml, 1mg/ml, 4mg/ml, 20mg/ml of dried plant
material and indicated concentrations of baicalein, wogonin, or
20-deoxy-5-fluorodeoxyuridine (5-FdUrd; Sigma Aldrich), which
was used as a positive control. Cell counts and IC50 values were
determined at 24 and 48h using the method described earlier
(Maier et al. 2006; Strasser et al. 2006).
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Hoechst 33258 and propidium iodide double staining
HL-60 cells (1105perml) were seeded in T-25 Nunc tissue
culture flask and exposed to increasing concentrations of plant
extracts corresponding to 500mg/ml, 1mg/ml, 4mg/ml, 20mg/ml
of the drug, or to the indicated concentrations of 5-FdUrd for 24
and 48hours. Cell death quantification by Hoechst 33258 and
propidium iodide staining, which facilitates to distinguish
between apoptosis and necrosis, was performed according to the
method described by Grusch et al. (2002).
Western blotting
HL-60 cells (1.5107) were seeded into T-75 Nunc tissue
culture flasks and incubated with 132mg/ml methanol extract
(corresponding to 4mg/ml dried plant material, which contains
490ng/ml and 150ng/ml baicalein and wogonin, respectively), or
with 1, 5 and 10mM baicalein and wogonin (10mM baicalein
corresponds to 2.7mg/ml, and 10mM wogonin corresponds to
2.84mg/ml) for 0.5, 2, 4, 8 and 24hours or with 250nM 5-FdUrd
for control reasons. Then 1106 cells were harvested (per
experimental point), and prepared for Western blot analyses as
described by Gridling et al. (2009).
Statistics
All experiments were done in triplicate and analysed by t-test
(GraphPad Prism 4.0 program).
Results
Anti-proliferative activity of the extracts, baicalein, wogonin
and 5-FdUrd
Four solvents of increasing polarity were subsequently used to
extract bioactive constituents from the freeze-dried material of
S. orientalis ssp. carica. After evaporation the dried extracts were
dissolved in ethanol and HL-60 cells were subjected to increasing
concentrations of the extracts or baicalein and wogonin. The
percentage of HL-60 cell cycle inhibition was calculated. In
general, extracts with increasing polarity exhibited increased
proliferation-inhibitory activity in HL-60 cells (Fig. 1a-d). The
highest activity was determined for the methanol extract with an
IpC50 of 43mg/ml (corresponding to appr. 1.3mg of dried plant
material/ml; Fig. 1d). Hence, further analyses were performed
with the methanol extract. As a control the methanol extract of
green salad was tested. 4mg/ml methanol extract of salad did not
exhibit cytostatic activity, whereas the 20mg/ml concentration
was slightly anti-proliferative, which suggested that polar
plant extracts generally contain weak growth-inhibitory
constituents (Fig. 1e). Baicalein inhibited HL-60 growth with a
similar efficiency as the methanolic extract, whereas wogoninwas
almost ineffective (10mM baicalein ¼ 2.7mg/ml); 16.5mg/ml
methanolic extract (corresponding to 0.5mg/ml dried plant
material) contain 61ng/ml baicalein and 19ng/ml wogonin;
(Figs. 1f-g). As a positive proliferation-inhibiting control
increasing concentrations 5-FdUrd were applied (Fig. 1h).
Downregulation of cyclin D1 and upregulation of p21 by the
methanol extract
Due to the strong anti-proliferative activity of the methanol
extract the expression profiles of positive and negative cell cycle
regulators (cyclin D1 and p21, respectively) were analyzed to
investigate by which mechanisms the anti-cancer activity was
accomplished. 132mg/ml extract markedly repressed cyclin D1
expression in HL-60 cells after 2 hours of treatment and Cdc25A
levels decreased after 8hours (Fig. 2a). Furthermore, this extract
transiently induced p21 after 30min, which dropped after 4 hours
(Fig. 2b). Since HL-60 cells are p53 deficient (Biroccio et al. 1999),
the upregulation of p21, which is a prominent transcriptional
target of p53, must have been triggered by another pathway.
Besides p53, also the activation of the MEK – Erk pathway was
shown to upregulate p21 (Park et al. 2004; Facchinetti et al. 2004).
Therefore, MEK – Erk signaling was investigated utilizing
phospho-specific antibodies. Erk became phosphorylated at
Tyr204 within 30min of treatment with 132mg/ml of the
extract and this correlated with the timing of p21 upregulation.
The phosphorylated form of Erk persisted at least for 8 h and
disappeared after 24h (Fig. 2b). This is an unusually long time
period for Erk activity, which is known in other contexts to last
only some 10–20min (Ebner et al. 2007). MEK was constitutively
phosphorylated and did not become further induced. There-
fore, Erk might have become phosphorylated and induced by a
kinase different from MEK. Erk became dose-dependently
phosphorylated also upon treatment with Baicalein and
wogonin. (Fig. 2c), and baicalein, but not wogonin, inhibited
Cdc25A after 8hours and also p21 was regulated after 24hours
such as by the methanolic plant extract within this time frame.
Interestingly, wogonin dose-dependently up-regulated Cdc25A
within 8hours of treatment. Further, we investigated whether the
methanol extract contained microtubule-directed activity.
Tubulin is the major constituent of microtubules, which
facilitate chromosome disjunction during mitosis, and therefore,
the affection of tubulin structures is incompatible with functional
cell division (Piperno and Fuller 1985). Hence it was investi-
gated whether cell cycle arrest can be attributed to tubulin
polymerization/de-polymerization as it is the case e.g. for taxol
(Geney et al. 2005). A monoclonal anti-acetylated-a-tubulin
antibody was used to analyse acetylated a-tubulin, which is an
indirect way of analyzing tubulin status (i.e. polymerization/de-
polymerization events). As shown in Fig. 2a, incubation of HL-60
cells with the methanol extract did not change the acetylation
pattern of a-tubulin. Therefore, this extract did not contain
tubulin-targeting activity. 250nM 5-FdUrd was used as a control
to monitor the effect on relevant cell cycle genes (as indicated in
Fig. 2d).
Induction of caspase 3 and apoptosis by the methanol extract
One major property of cytotoxic anticancer drugs is the
potential to elicit cancer cell death by apoptosis or by necrosis.
Most anti-cancer drugs dose-dependently elicit apoptosis. Beyond
a certain threshold level, at which the cellular ATP balance and
therefore energy supply becomes corrupted, cells cannot maintain
membrane integrity any longer and die by necrosis (Huetten-
brenner et al. 2003). The methanol extract elicited predominantly
apoptosis at lower concentrations 132mg/ml), whereas 660mg/ml
resulted in necrosis (Fig. 3a). As a positive apoptosis-inducing
control increasing concentrations 5-FdUrd were applied (Fig. 3b).
Western blot analysis showed that the induction of apoptosis
with 132mg/ml methanolic extract (corresponding to 4mg/ml
dried plant material) correlated with the activation of caspase 3
and the cleavage of its target PARP (Fig. 4). Thus, apoptotic cell
death triggered by the methanol extract of S. orientalis ssp. carica
was executed by caspase-3. To investigate whether genotoxicity of
the methanol extract was responsible for apoptosis induction the
phosphorylation status of histone H2AX (g-H2AX) was analysed,
because this core histone variant becomes rapidly phosphorylated
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in response to DNA double strand breaks (DSB). Incubation
of HL-60 cells with 132mg/ml methanol extract caused severe
phosphorylation of H2AX before a substantial activation of caspase
3 became visible and thereafter g-H2AX became ubiquitinylated
(Fig. 4a). Ubiquitin-conjugated proteins accumulate at sites of DSB
and are involved in the reorganization of chromatin in response
to DSB (Ikura et al. 2007). It has been recently shown that H2AX
also has non-nucleosomal functions, specifically, pro-apoptotic
activities in gastrointestinal stroma tumour cells (Liu et al. 2008).
Therefore, the methanol extract contained DNA-targeting activities,
which triggered cell death. Further, cells were treated with limiting
concentrations of baicalein and wogonin to test whether g-H2AX
occurs before caspase 3 cleavage and was therefore the cause
for apoptosis and not the consequence of apoptotic DNA
fragmentation. Whereas baicalein neither induced Caspase 3
cleavage nor g-H2AX at the applied concentrations, wogonin
induced g-H2AX but not caspase 3 and this evidenced that
g-H2AX was upstream of caspase 3 cleavage and therefore causal
for apoptosis induction and not a consequence of caspase-triggered
DNA strand breaks (Fig. 4b). The results support the notion that
wogonin was a pro-apoptotic factor and that baicalein caused
cell cycle arrest. 250nM 5-FdUrd was used as a control to monitor
the effect on relevant apoptosis-relevant genes (as indicated in
Fig. 4c).
Composition of the methanolic extract
HPLC-analyses of the methanolic extract showed flavonoids
as major compounds. The genins apigenin, baicalein, chrysin,
luteolin, oroxylin A and wogonin were identified by co-chromato-
graphy with authentic substances and comparison of PDA spectra
(Zhang et al. 2007; Campos and Markham 2007), respectively.
Additionally wogonoside, a second, more polar wogoninglycoside,
an oroxylinglycoside and a baicaleinglycoside were tentatively
identified via the PDA spectra (Fig. 5). The methanolic extract
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Fig. 1. Anti-proliferative effect of extracts of Scutellaria orientalis ssp. carica and of methanol extract of green salad (Lactuca sativa L. var capitata). HL-60 cells were seeded
into T-25 tissue culture flasks (1105 cells/ml), grown for 24hours to enter logarithmic growth phase, and incubated with amounts of extracts corresponding to 0.5, 1, 4,
and 20mg/ml of dry plant material (a-d), or 1mM, 5mM, and 10mM baicalein and wogonin (f, g) and for control reasons 50nM, 250nM and 1mM 5-FdUrd (h). ‘‘Solvent’’
controls received 0.4% EtOH. The other samples were adjusted to equal ethanol concentrations to achieve similar solvent conditions. ‘‘Controls’’ did not receive any
treatment. Cells were counted after 24 and 48hours of treatment and the percentage of proliferation within this time span was calculated in comparison to controls
(‘‘solvent’’ controls were considered as 100% proliferating cells and all other conditions were set in relation to this). For control reasons, cells were exposed to the methanol
extract of green salad (L. sativa, e). Error bars indicate SEM, and asterisks significant proliferation inhibition compared to control (po0.05).
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contained 1.282% apigenin, 1.210% luteolin, 0.374% baicalein,
0.281% chrysin and 0.115% wogonin.
Discussion
Species of the genus Scutellaria are used in TCM and
particularly the root of S. baicalensis (Scutellariae radix) is rich in
flavonoids and the main constituent from ‘‘Huang-Lian-Jie-
Du-Tang’’ (HLJDT) which is used against various inflammations
and shows strong anticancer properties in vitro (Ma et al. 2005).
Flavonoids are of interest for their anti-cancer and antioxidant
activity, but previous research has not investigated whether these
medicinally active phytochemicals are common to species within
the Scutellaria genus and may be linked to the medicinal activity
of these other species (Cole et al. 2008). Therefore, we studied the
anti-leukaemic activity of S. orientalis L. ssp. carica Edmondson, an
endemic medicinal plant used in Turkish folk medicine (called as
‘‘Kaside’’), which is traditionally used for wound healing and
stopping haemorrhage (Baytop 1999).
The major active principles of Scutellariae radix are the
flavonoids baicalein and wogonin, which exhibited distinct
activities on cellular functions (Chang et al. 2002; Nakahata
et al. 1998; Yano et al. 1994) and showed anticancer effects on
human hepatoma cell lines (Himeji et al. 2007). Other recent
reports demonstrated that wogonin significantly inhibited human
ovarian cancer cells A2780, human promyeloleukemic cells HL-60,
monocytic leukemia THP-1 cells, osteogenic sarcoma HOS cells,
bladder cancer KU-1- and EJ-1 cells, prostate cancer LNCaP- and
PC-3 cells, hepatocellular carcinoma SK-HEP-1, SMMC-7721 and
Bel-7402 cells, and murine sarcoma S180 cells and induced
apoptosis in human prostate carcinoma LNCaP and human colon
Fig. 2. Analysis of cell cycle-related protein and phospho-protein expression. HL-60 cells (1106 cells) were seeded into T-75 tissue culture flasks and allowed to grow for
24hours when cells were incubated with 132mg/ml methanol extract (corresponding to 4mg/ml dried plant material) of S. orientalis ssp. carica for 0.5, 2, 4, 8, and 24hours
(a, b), with 1mM, 5mM and 10mM concentrations baicalein and wogonin for 8 and 24hours (c), and for control reasons with 250nM 5-FdUrd for the indicated times (d).
Then, isolated protein samples were subjected to electrophoretic separation and subsequent Western blot analysis using the indicated antibodies (anti phospho-MEK ¼
pMEK, anti phospho Erk ¼ pErk, anti acetylated a-tubulin ¼ ac.a-tubulin). Equal sample loading was controled by Poinceau S staining, b-actin, and a-tubulin analysis.
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carcinoma HCT116 cells, whereas normal human prostate epithe-
lial PrEC cells remained unaffected (Chung et al. 2008, Lee et al.
2008). In this study, exposure to wogonin caused an increase in
p53, which was in agreement with our results showing an
induction of g-H2AX, because both responses reflect genotoxic
stress and DNA damage response (Wasco et al. 2008) which may
result in apoptosis. Histone H2AX has also non-nucleosomal
functions, specifically, proapoptotic activities in gastrointestinal
stromal tumor cells treated with the small molecule protein
kinase inhibitor imatinib mesylate (Gleevec) (Liu et al. 2008). The
incubation of HL-60 cells with132mg/ml methanol extract of
S. orientalis ssp carica caused phosphorylation of H2AX within
8–24hours followed by ubiquitination and activation of caspase 3
and finally cell death. Hence, genotoxic stress was also indicated
by ubiquitinated g-H2AX. Apoptosis induction upon exposure to
the methanol extract was independent of p53. Since more than
50% of all cancer types harbour a defective p53 pathway, which
is detrimental to successful therapeutic treatment, compounds
which exert anticancer activity independent of p53 are of
particular interest for clinical applications.
Another major anticancer drug property is to arrest the
cell cycle. The methanol extract of S. orientalis ssp. carica
dose-dependently inhibited cell proliferation of HL-60 cells
(IpC50 ¼ 43mg methanolic extract/ml culture medium corre-
sponding to 1.3mg/ml dry plant material). The extract caused
cell cycle arrest by two independent mechanisms:
(i) the downregulation of cyclin D1 and presumably inhibition of
Cdk4 and/or Cdk6.
(ii) the induction of p21Cip/Waf and therefore most likely the
inhibition of Cdk2.
The D-type family of cyclins has been associated with a wide
variety of proliferative diseases. Cyclin D1 was identified as the
product of the prad 1 oncogene, which is over-expressed in many
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Fig. 3. Induction of apoptosis and necrosis by the methanol extract of Scutellaria
orientalis ssp. carica. Cells were incubated with increasing extract concentrations
(a), and for control reasons with 5-FdUrd (b) for 24 and 48hours and then double
stained with Hoechst 33258 and propidium iodide. Afterwards cells were
examined under the microscope with UV light connected to a DAPI filter. Nuclei
with morphological changes which indicated apoptosis or necrosis (see ‘‘Meth-
ods’’) were counted and percentages of vital, apoptotic and necrotic cells were
calculated. Error bars indicate SEM, and asterisks significant apoptosis induction
compared to control (po0.05).
Fig. 4. Western blot analysis of pro-apoptotic Caspase 3, PARP, and phosphoryla-
tion of H2AX. HL-60 cells (1106 cells) were seeded into T-75 tissue culture flasks
and allowed to grow for 24hours when cells were incubated with 132mg/ml
methanol extract for 0.5, 2, 4, 8, and 24hours (a), with 1mM, 5mM and 10mM
baicalein and wogonin for 8 hours (b), and for control reasons with 250nM 5-
FdUrd for the indicated times (c). Then, isolated protein samples were subjected to
electrophoretic separation and subsequent Western blot analysis with the
indicated antibodies (anti phospho H2AX ¼ g-H2AX) . Equal sample loading was
controlled by Poinceau S staining and b-actin analysis. The anti-Caspase 3
antibody recognizes only the cleavage product indicating activation. Anti-PARP
antibody recognizes the full length form (116kDa) and the signature-type cleaved
product (85 kDa) which is generated by active Caspase 3.
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types of cancer (Alao 2007). Therefore, suppression of cyclin D1 is
a powerful measure to combat cancer. Since the methanol extract
suppressed cyclin D1, a prominent anti-cancer property of this
plant was elucidated. Furthermore, p21 as a specific inhibitor
of Cdks such as Cdk2, was induced. The p53 tumor suppressor
protein is a major regulator of p21. In HL-60 cells the increase
in p21 protein levels was independent of p53, because these cells
are p53 negative (Biroccio et al. 1999). Also MEK – Erk have
been reported to upregulate p21 (Park et al. 2004; Facchinetti
et al. 2004). Here we demonstrated that Erk, but not MEK, was
activated upon treatment with S. orientalis ssp. carica extract,
which was simultaneous with p21 induction and therefore,
this may have caused p21 induction. Since the phosphorylation
state of MEK was unchanged upon treatment with the methanolic
extract, Erk was either not phosphorylated and activated by MEK,
or MEK was activated through phosphorylations at additional
amino acid residues, which were not detected by the specific
phospho-MEK antibody used in this study.
The flavonoids apigenin and chrysin were reported to exhibit
also anti-cancer properties (Hu et al. 2008; Lee et al. 2007).
Both phytochemicals were found in the methanolic extract of
S. orientalis ssp. carica and certainly contributed to the bio-activity
of the tested constituens (baicalein and wogonin) of the
methanolic extract. This warrants further investigations regarding
the bio-active properties and constituents of this plant species.
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a b s t r a c t
Berberis lycium Royle (Berberidacea) from Pakistan and its alkaloids berberine and palmatine have been
reported to possess beneficial pharmacological properties. In the present study, the anti-neoplastic activ-
ities of different B. lycium root extracts and the major constituting alkaloids, berberine and palmatine
were investigated in p53-deficient HL-60 cells.
The strongest growth inhibitory and pro-apoptotic effects were found in the n-butanol (BuOH) extract
followed by the ethyl acetate (EtOAc)-, and the water (H2O) extract.
The chemical composition of the BuOH extract was analyzed by TLC and quantified by HPLC. 11.1 g
BuOH extract (that was gained from 1 mg dried root) contained 2.0 g berberine and 0.3 g/ml palmatine.
1.2 g/ml berberine inhibited cell proliferation significantly, while 0.5 g/ml palmatine had no effect.
Berberine and the BuOH extract caused accumulation of HL-60 cells in S-phase. This was preceded by a
strong activation of Chk2, phosphorylation and degradation of Cdc25A, and the subsequent inactivation
of Cdc2 (CDK1). Furthermore, berberine and the extract inhibited the expression of the proto-oncogene
cyclin D1. Berberine and the BuOH extract induced the acetylation of -tubulin and this correlated with
the induction of apoptosis. The data demonstrate that berberine is a potent anti-neoplastic compound
that acts via anti-proliferative and pro-apoptotic mechanisms independent of genotoxicity.
© 2009 Elsevier B.V. All rights reserved.
1. Introduction
Berberis taxa are important plants with various healing prop-
erties, and Berberis species are included in Indian and British
pharmacopeias. Berberis lycium Royle (Berberidacea) is a widely
used medical plant in Pakistan, known by the common name “Zyarh
larghai” or “Kashmal”, whereas its English name is Barberry [1].
Al-Biruni describes the plant under the name of Ambaribis and
mentions its Persian name as Zirkash [2]. The roots of the plant
known as “Darhald” are used as astringent, for diaphoretic- and
bleeding piles [3]. The roots of Berberis species are used for treating a
variety of ailments such as eye and ear diseases, rheumatism, jaun-
dice, diabetics, fever, stomach disorder, skin disease, malarial fever
and as tonic [4–7]. In particular, the powdered roots of B. lycium
∗ Corresponding author. Tel.: +43 1 40400 3487; fax: +43 1 40400 3707.
E-mail address: georg.krupitza@meduniwien.ac.at (G. Krupitza).
are used in combination with milk for the treatment of rheumatism
and muscular pain in Pakistan folk medicine, probably to protect
the gastric mucosa from damage [8]. The potential effectiveness of
Berberis is also indicated by its use in the Indian Ayurvedic, Unani,
and Chinese system of medicine since time immemorial [9]. The
active constituents of B. lycium are alkaloids and the major com-
pound is berberine [10]. Berberine and several Berberis species
show a wide range of biochemical and pharmacological activities
such as in amoebiasis, cholera and diarrhea [2], possess analgesic
and antipyretic effects [11], and were reported to exhibit anti-
arrhythmic-, anti-tumor- [12–14], anti-inflammatory- [15], and
rheumatic properties [11]. Little is known about the molecular and
cellular anti-tumor mechanisms that are triggered by berberine and
extracts of Berberis species. A recent study addressed the molec-
ular mechanisms of berberine-induced anti-proliferative effects
in osteosarcoma cells. The authors showed that berberine inhib-
ited cell proliferation through genotoxicity causing p53-dependent
G1 arrest and apoptosis, and p53-independent G2 arrest [16]. We
aimed to investigate the effects of berberine and B. lycium crude
0027-5107/$ – see front matter © 2009 Elsevier B.V. All rights reserved.
doi:10.1016/j.mrfmmm.2009.11.001
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Fig. 1. Chemical structures of (a) berberine and (b) palmatine.
extracts on the expression of cell cycle regulators and to elucidate
mechanisms that trigger apoptosis in p53-deficient HL-60 cells.
2. Materials and methods
2.1. Chemicals
Berberine chloride dihydrate (purity 98.92%) and palmatine chloride (purity
96.98%) were purchased from Phytolab (Vestenbergsreuth, Germany). Berbamine
dihydrochloride (purity >85%), toluene, ethyl acetate, acetonitrile, sodium 1-
heptansulfonate monohydrate, phosphoric acid, isopropanol and HPLC-grade
methanol were purchased from Sigma–Aldrich (Schnelldorf, Germany) and were
of the highest available purity. Codeine hydrochloride (purity 98.27%) was from
Heilmittelwerk Wien (Vienna, Austria). TLC Silica gel 60 F254 Aluminum sheets were
obtained from Merck (Darmstadt, Germany). All other chemicals and solvents were
of analytical grade.
In the experiments berberine chloride dihydrate and palmatine chloride were
used because of their improved solubility, and throughout the text and figures the
indicated berberine and palmatine concentrations refer to the alkaloid base and not
to the salt.
The structural formulas of berberine and palmatine are shown in Fig. 1.
2.2. Cell culture
HL-60 human promyelocytic cells were from the American Type Culture
Collection (Manassas, VA, USA). Cells were grown in RPMI 1640 medium sup-
plemented with 10% heat inactivated fetal calf serum, 1% l-glutamine and 1%
penicillin/streptomycin (Life Technologies, Paisley, Scotland) at 37 ◦C in a humidified
atmosphere containing 5% CO2 .
2.3. Collection and extraction of root powder
B. lycium was collected from Margalla Hills (Islamabad, Pakistan) and voucher
specimens No. 125174 submitted to the herbarium and identified by R.A. Quereshi in
the Department of Plant Sciences, Quaid-i-Azam University Islamabad. Roots were
washed, air dried and grounded. 20 g of powdered B. lycium root were extracted four
times with methanol (MeOH). These extracts were collected and concentrated with
a Rotavapor at 40 ◦C. The concentrated MeOH extract was dissolved in distilled water
and extracted three times each with ethyl acetate (EtOAc), and n-butanol (BuOH),
according to their increasing polarity. Thus, 0.044 g dried EtOAc extract, and 0.222 g
dried BuOH extract were obtained. The residue of the aqueous phase – 0.278 g dry
weight – was recovered and considered as H2O extract.
2.4. Thin layer chromatography (TLC) of the different B. lycium extracts
The constituents of the extracts were qualitatively and semi-
quantitatively determined by TLC. A solvent system consisting of toluene–ethyl
acetate–isopropanol–methanol–water (12:6:3:3:0.6) was used as mobile phase.
Two-chambered TLC tanks were used, whereas one chamber was filled with the
mobile phase and the other with concentrated ammonia. Prior to chromatographic
separation the chamber was saturated for 20 min with the mobile phase. Berberine
and related alkaloids were detected under UV366 .
2.5. High pressure liquid chromatography (HPLC) analysis of the different B.
lycium extracts
HPLC analysis of B. lycium extracts was carried out with a ShimadzuTM
system consisting of a DGU-14A degasser, a LC-10AD auto sampler, a SPD-
M10A VP diode array detector, a LC-10AD liquid chromatograph and a SCL-10A
system controller. Data acquisition and processing were performed using Lab-
solutions software (Shimadzu). Analysis was carried out on a Hypersil BDS-C18
analytical column (5 m, 4 mm×250 mm), protected by a Lichrosphere 100
RP-18 precolumn (5 m, 4 mm×4 mm). Baseline separation of the peaks was
achieved using gradient elution containing Na+ heptansulfonate monohydrate
(1.0 g in 390 ml H2O, adjusted to pH 2.8 with phosphoric acid = solvent A)
and acetonitrile (solvent B). Gradient was as follows: 0–12 min: 25–70% B,
12–13 min: 90. The flow rate was 1.3 ml/min, injection volume was 10 l and
HPLC chromatogram was monitored at 280 nm. Codeine was used as an internal
standard.
2.6. Growth inhibition assay
HL-60 cells were seeded in T-25 tissue culture flasks (Life Technologies, Paisley,
Scotland) at a concentration of 1×105 per ml and incubated with increasing con-
centrations of the different extracts of B. lycium or with berberine and palmatine.
Cell counts and IC50 values were determined in the different fractions after 48 and
72 h, using a KX 21 N microcell counter (Sysmex, Kobe, Japan).
2.7. Hoechst dye 33258 and propidium iodide double staining
Hoechst staining was performed according to the method described by Grusch
et al. [17]. HL-60 cells (0.1×106 per ml) were seeded in T-25 cell culture flasks
and exposed to increasing concentrations of B. lycium fractions and berberine for
48 h. Hoechst 33258 (HO) and propidium iodide (PI, both Sigma, St. Louis, MO) were
added directly to the cells to final concentrations of 5 and 2 mg/ml, respectively. After
60 min of incubation at 37 ◦C, the cells were examined under a fluorescence micro-
scope (Axiovert, Zeiss) equipped with a DAPI filter and a camera. This method allows
to discriminate between early apoptosis, late apoptosis, and necrosis. Cells were
judged according to their morphology and the integrity of their cell membranes,
which can easily be observed after PI staining.
2.8. Western blotting
HL-60 cells were preincubated for increasing time periods (from 2 to 48 h) with
11.1 g BuOH extract/ml and 1.2 g berberine/ml medium. Then, cells were placed
on ice, washed with ice-cold PBS (pH 7.2), centrifuged (1000 rpm, 4 ◦C, 4 min) and
the pellets lysed in 150 l buffer containing 150 mM NaCl, 50 mM Tris pH 8.0, 1%
Triton X-100, 2.5% 0.5 mM PMSF and PIC (Sigma, Schnelldorf, Germany). Debris was
removed by centrifugation (12,000 rpm, 4 ◦C, 20 min) and the supernatant collected.
Then, equal amounts of protein were loaded onto 10% polyacrylamide gels. Pro-
teins were electrophoresed for 2 h and then electroblotted onto PVDF membranes
(Hybond P, Amersham, Buckinghamshire, UK) at 4 ◦C for 1 h. To confirm equal sam-
ple loading, membranes were stained with Poinceau S. After washing with TBS, the
membranes were blocked for 1 h in blocking solution containing 5% skimmed milk
in TBS and 0.5% Tween 20, washed three times in TBS/T, and incubated by gentle
rocking with primary antibodies in blocking solution at 4 ◦C overnight. Then, the
membranes were washed in TBS/T (3× for 5 min) and further incubated with the
second antibody (peroxidase-conjugated anti-rabbit IgG, or anti-mouse IgG dilution
1:2000 in Blotto), for 1 h at room temperature. The membranes were washed with
TBS/T and the chemoluminescence (ECL detection kit, Amersham, Buckinghamshire,
UK) was detected by exposure of the membranes to Amersham HyperfilmTM ECL. The
antibodies against Cdc2-p34 (17), Cdc25A (M-191), phospho-Cdc25A-(phSer17), -
tubulin, PARP and -tubulin were from Santa Cruz (Santa Cruz, CA, USA), against
cleaved caspase-3(Asp17), phospho-p38-MAPK (Thr180/Tyr182), p38-MAPK, cyclin
D1, p21, phospho-Cdc2(phTyr15), Chk2, and phospho-Chk2 (Thr68) were from Cell
Signaling (Danvers, MA, USA), against H2AX (phSer139) from Calbiochem (San
Diego, CA, USA), and phoshpho-Cdc25A-(phSer177) from Abgent (San Diego, CA,
USA), and against acetylated--tubulin and -actin were from Sigma (St. Louis, MO).
2.9. Cell cycle distribution analysis
HL-60 cells (0.5×106 per ml) were seeded in T-25 tissue culture flasks and incu-
bated with 5.6 g/ml BuOH extract, 0.6 g/ml berberine, or 0.3 g/ml palmatine,
which were equivalent to 0.5 mg/ml dried root powder, respectively. After 24 h,
the cells were harvested and suspended in 5 ml cold PBS, centrifuged (600 rpm,
5 min), resuspended and fixed in 3 ml cold ethanol (70%) for 30 min at 4 ◦C. After
two washing steps in cold PBS, RNAse A and PI were added to a final concentra-
tion of 50 mg/ml each and incubated at 4 ◦C for 60 min before analyses. Cells were
analyzed with a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA)
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Fig. 2. Anti-proliferative effect of B. lycium extracts and its bio-active constituents berberine and palmatine. HL-60 cells were seeded into T-25 tissue culture flasks (1×105
cells/ml), grown for 24 h to enter logarithmic growth phase, and incubated with increasing concentrations (a) EtOAc extract (17.5, 35.0 and 46.6 g/ml medium); (b) BuOH
extract (2.8, 5.6 and 11.1 g/ml); (c) H2O extract (69.5, 139.0 and 208.5 g/ml); (d) berberine (0.6, 1.2, and 1.8 g/ml); and (e) palmatine (0.3, 0.5 and 0.7 g/ml). Cells
were counted after 24, 48 and 72 h of treatment (white, light gray and dark gray columns, respectively) and the percentage of proliferation was calculated and compared to
DMSO-controls (Control). Controls were considered as cells with a maximal proliferation rate (100%). Experiments were done in triplicate. Error bars indicate SEM, asterisks
significance (p < 0.05).
Fig. 3. Analysis of cell cycle proteins. HL-60 cells (1×106 cells) were seeded into T-25 tissue culture flasks and allowed to grow for 48 h when cells were incubated with
11.1 g BuOH extract/ml medium (left side panels) and 1.2 g berberine/ml medium (right side panels) for 2, 4, 8, 24 and 48 h. Then, isolated protein samples were subjected
to 10% SDS-PAGE separation and subsequent Western blot analysis using antibodies against p21waf and cyclin D1. Equal sample loading was controlled by Poinceau S staining
and -actin analysis.
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and cell cycle distribution was calculated with ModFit LT software (Verity Software
House, Topsham, ME, USA).
2.10. Single cell gel electrophoresis (SCGE)/comet assay
The experiments were conducted according to the guidelines of Tice et al. [18].
After treatment of the cells with BuOH extract or berberine, the cells were cen-
trifuged (400× g, 5 min, 23 ◦C, Sigma–Aldrich, 4K 15C, Germany) and the pellet
resuspended with 200 l PBS. The cytotoxicity was determined with trypan blue
[19], which is a measure for the integrity of the cell membrane. Only cultures with
survival rates ≥80% were analyzed for comet formation. To monitor DNA migration
0.05×106 cells were mixed with 80 l low melting agarose (0.5%, Gibco, Paisley,
Scotland) and transferred to agarose-coated slides. The slides were immersed in lysis
solution (1% Triton X, 10% DMSO, 2.5 M NaCl, 10 mM Tris, 100 mM Na2EDTA, pH 10.0)
at 4 ◦C for 1 h. After unwinding and electrophoresis (300 mA, 25 V, 20 min) under
alkaline conditions (pH > 13), which allows the determination of single and dou-
ble strand breaks, DNA–protein crosslinks and apurinic sites, the DNA was stained
with 40 l ethidium bromide (20 g/ml, Sigma–Aldrich, Munich, Germany) and the
percentage DNA in tail was analyzed with a computer aided image analysis sys-
tem (Comet IV, Perceptive Instruments Ltd., Haverhill, UK). From each experimental
point, one slide was prepared and 50 cells were scored per slide.
2.11. Statistical analyses
The results of the SCGE (single cell gel electrophoresis) experiments were ana-
lyzed with one-way ANOVA followed by Dunnett’s multiple comparison test, and the
apoptosis and proliferation experiments with t-test using GraphPad Prism version
4 (GraphPad Prim Sofware, Inc., San Diego, CA, USA).
3. Results
3.1. Analysis of B. lycium extract constituents by TLC and HPLC
The extraction of 1 g B. lycium roots with EtOAc, BuOH, and
H2O yielded 2.2 mg, 11.1 mg, and 13.9 mg extract, respectively.
Solutions of the EtOAc, BuOH, and H2O extracts were applied on
TLC plates and chromatographic separation was carried out as
previously described (Section 2.4). Berberine, berbamine and pal-
matine were used as reference compounds since they are known
constituents of various Berberis taxa with distinct anti-neoplastic
properties.
Fig. 4. Cell cycle distribution of HL-60 cells upon treatment with BuOH extract and berberine for 48 h. Logarithmically growing HL-60 cells were incubated with 5.6 g/ml
BuOH extract and 0.6 g/ml berberine and then subjected to FACS analysis. Experiments were done in triplicate. Representative FACS profiles are shown below the respective
diagrams. Error bars indicate SEM, and asterisks significance (p < 0.05).
82
M. Khan et al. / Mutation Research 683 (2010) 123–130 127
All extracts contained berberine (retention factor, Rf = 0.151)
and palmatine (Rf = 0.088), whereas the highest concentration of
both compounds was detected in the BuOH extract. Berbamine
(Rf = 0.405) was not found in any extract. Besides berberine and
palmatine another unknown band was present in all extracts.
For quantification HPLC was used under the above mentioned
conditions (Section 2.5). Retention times for codeine (internal stan-
dard), berberine, palmatine and berbamine were 4.52, 9.75, 9.19
and 8.06 min, respectively. Berbamine was reported to be a con-
stituent of B. lycium [10] while there was no evidence of its presence
in the here performed TLC and RP-HPLC analyses. The calculated
berberine content was 18.04%, 0.54% and 2.76% and palmatine con-
tent was 2.80%, 0.04% and 0.93% in the BuOH, EtOAc and H2O
extracts, respectively (data not shown). Thus, 11.1 g BuOH extract
contained 2.0 g berberine, and 0.3 g palmatine.
3.2. Inhibition of HL-60 cell proliferation by extracts of B. lycium,
berberine and palmatine
Logarithmically growing cells were incubated with increasing
concentrations of EtOAc, BuOH and H2O extract, or berberine and
palmatine for 72 h. Then, cells were counted and the inhibition of
proliferation was calculated. The BuOH extract showed the highest
toxicity against HL-60 cells (IC50 2.3 g extract/ml medium after
48 h of treatment), followed by the EtOH extract (23.5 g/ml) and
the H2O extract (110 g/ml) (Fig. 2). The data suggest that the mea-
sured differences in the extract activities were due to different
chemical compositions of the extracts. To evaluate which of the
major constituents of the BuOH extract may have caused growth
inhibition, HL-60 cells were treated with the measured equiva-
lent concentrations of berberine (0.6–1.8 g/ml) and palmatine
(0.3–0.7 g/ml). The IC50 for berberine was 1.2 g/ml after 48 h.
Palmatine did not inhibit cell growth after 48 h. The inhibition of
HL-60 proliferation that was observed upon treatment with BuOH
extract or berberine was preceded by the induction of p21waf, which
has been also observed by Liu et al. [16] and by a dramatic down-
regulation of the proto-oncogene cyclin D1 after 48 h (Fig. 3). Both,
the up-regulation of p21waf and the suppression of cyclin D1 are
potent mechanisms to block cancer cell growth.
3.3. Effect of BuOH extract, berberine and palmatine on cell cycle
distribution
HL-60 cells were exposed to 5.5 g BuOH extract/ml and 0.6 g
berberine/ml for 48 h to investigate the cell cycle distribution.
Both, the extract and the pure compound caused a reduction of G1
cells and accumulation of cells in the S-phase (Fig. 4), which was
most likely due to activation of intra S-phase checkpoint, because
checkpoint kinase 2 (Chk2) became highly activated [20] (Fig. 7).
Palmatine had no effect on cell cycle distribution (data not shown)
which was consistent with the observation that it did not have an
effect on growth inhibition.
3.4. Induction of apoptosis by extracts of B. lycium and berberine
HL-60 cells were treated with the three extracts (EtOAc, BuOH
and H2O) and berberine for 48 h and the induction of cell death
was analyzed. The three extract types induced apoptosis and the
BuOH extract was the most active followed by the EtOAc- and the
H2O extracts. Berberine was used at a comparable concentration
as contained in the BuOH extract and this concentration caused a
similar pro-apoptotic effect as the extract (Fig. 5).
Fig. 5. Induction of apoptosis by the B. lycium extracts and berberine. HL-60 cells were incubated with increasing extract and berberine concentrations for 48 h. Then,
cells were double stained with Hoechst 33258 and propidium iodide and examined under a fluorescence microscope and a DAPI filter. Nuclei with morphological changes
indicating apoptosis (Section 2) were counted and the percentages of vital and apoptotic cells calculated. Experiments were done in triplicate. Error bars indicate SEM,
asterisks significance (p < 0.05).
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Fig. 6. Analyses of pro-apoptotic mediators and effectors. (a) HL-60 cells (1×106 cells) were seeded into T-25 tissue culture flasks and allowed to grow for 48 h when cells
were incubated with BuOH extract (11.1 g/ml medium) and 1.2 g/ml berberine for 2, 4, 8, 24 and 48 h. Then, isolated protein samples were subjected to 10% SDS-PAGE
separation and subsequent Western blot analysis using antibodies against H2AX, acetylated--tubulin and -tubulin. Equal sample loading was controlled by Poinceau S
staining and -tubulin analysis. (b) Comet assay. The genotoxicity of increasing concentrations of BuOH extract and berberine was investigated in logarithmically growing
HL-60 cells. 50 M H2O2 was used as positive control and solvent-treated cells were used as negative control. Bars indicate means± SD of results obtained with three
independent cultures (from each culture 50 cells were evaluated). Statistical analysis: Dunnett’s test.
High concentrations of berberine (10–50 g/ml) were shown
to induce H2AX phosphorylation (H2AX) in osteosarcoma cells
indicating genotoxicity [16]. In the present study we demonstrate
that 0.6 and 1.2 g/ml berberine and the corresponding concentra-
tion of BuOH extract specifically induced apoptosis in HL-60 cells
without concomitant induction of H2AX (Fig. 6a). This observation
indicates that the anti-neoplastic effects have not been triggered by
berberine-caused genotoxicity. Comet assay detecting DNA single
strand breaks provided no evidence that berberine or the BuOH
extract cause DNA damage (Fig. 6b). Thus, other mechanisms must
be responsible for cell cycle inhibition and apoptosis. Interestingly,
berberine and the BuOH extract caused acetylation of -tubulin
(Fig. 6a), which is indicative for tubulin polymerization reminis-
cent of the mechanism of taxol. Tilting the fine-tuned equilibrium
of polymerized/de-polymerized microtubule is incompatible with
normal cell division and this causes not only cell cycle arrest but
also apoptosis.
3.5. Induction of stress response by extracts of B. lycium and
berberine
Cellular stress is a prominent inducer of apoptosis and cell cycle
arrest. Berberine and extract caused the transient phosphoryla-
tion of p38-MAPK ∼2-fold compared to untreated control after
8 h (Fig. 7). Also Chk2 became activated within 4 h treatment
(Fig. 7). This activation pattern correlated with the accumulation of
cells in S-phase and this was consistent with intra-S-phase arrest
as reported by Luo et al. [20]. Chk1 was not induced (data not
shown). Cdc25A became phosphorylated at Ser177 and therefore,
Cdc25A became inactivated (within 2 h, Fig. 7) leading finally to
its degradation [21]. This resulted in the accumulation of Tyr15
phosphorylation of Cdc2, which is a specific target site of the
Cdc25A phosphatase [22]. Tyr15-Cdc2 phosphorylation inactivates
this cell cycle specific kinase. The treatment with BuOH extract and
berberine changed also the phosphorylation pattern at Ser17 of
Cdc25A. The inactivation of the Cdc25A proto-oncogene was the
most immediate event elicited by the BuOH extract and berberine
(Fig. 7). This was followed by the acetylation of -tubulin (Fig. 6a),
the activation of Chk2 and p38, and the down-regulation of cyclin
D1.
4. Discussion
We studied the effects of root extracts of B. lycium in HL-60
human leukemia cells and compared them with those of the pure
alkaloids, i.e. berberine and palmitine. B. lycium is an erect small
rigid shrub about 1.0–2.5 m tall, with a thick woody shoot cov-
ered with a thin brittle bark [23] and is native to the Himalayan
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Fig. 7. Induction of stress response by the BuOH extract and berberine. HL-60 cells (1×106 cells) were seeded into T-25 tissue culture flasks and allowed to grow for
48 h when cells were incubated with 11.1 g BuOH extract/ml and 1.2 g berberine/ml medium for 2, 4, 8, 24 and 48 h. Then, isolated protein samples were subjected to
10% SDS-PAGE separation and subsequent Western blot analysis using antibodies against phospho-p38-MAPK, p38-MAPK, phospho-Chk2, Chk2, phospho-Ser17-Cdc25A,
phospho-Ser177-Cdc25A, Cdc25A, phospho-Cdc2, and Cdc2. Equal sample loading was controlled by Poinceau S staining and -actin analysis.
mountain system and widely distributed in temperate and semi-
temperate regions of India, Nepal, Afghanistan, Bangladesh and
Pakistan. The active constituents of B. lycium are alkaloids. The
major alkaloids are umbellatine, berberine [10], and oxyacanthine
[24]. Heterocyclic constituents e.g. berberisterol, berberifuranol
and berberilycine [25], the alkaloids sindamine, punjabine, gilgi-
tine [26], and berbericine [8] were also found in the roots of B.
lycium. Besides these, berbamine and tannins are also present in
small quantities [10].
In the present investigation berberine and the crude BuOH
extract regulated protein expression and protein activation in
HL-60 cells similarly. Also the growth inhibiting- and apoptosis-
inducing potential was similar and FACS- and Comet data were
almost identical. This is a strong indication that BuOH-mediated
cell cycle arrest was due to berberine. We show that the growth
inhibitory properties of berberine and BuOH extract correlated
directly with the inactivation and down-regulation of the proto-
oncogene Cdc25A. Also the inhibition of human nasopharyngeal
carcinoma CNE-2 cell growth by berberine was associated with
suppression of cyclin B1, CDK1 (Cdc2), and Cdc25C proteins [27].
In human glioblastoma T98G cells, berberine induced cell cycle
retardation in G1-phase through increased expression of p27 and
suppression of CDK2, CDK4, cyclin D, and cyclin E proteins [28]. Also
HL-60 cell growth was significantly inhibited by berberine in G1-
phase with a decrease in S-phase cells [29]. In another study, FACS
analyses indicated that berberine induced G2/M-phase arrest in HL-
60 cells and murine myelomonocytic leukemia WEHI-3 cells that
was accompanied by increased levels of Wee1 and 14-3-3sigma,
and decreased levels of Cdc25C, CDK1 and cyclin B1 [30]. This is in
contradiction to the reported G0/G1 arrest [28] and to the intra-S-
phase arrest observed in this study, but the differences were most
likely due to the different berberine concentrations used in these
investigations. Notably, intra-S-phase arrest correlated with the
activation of Chk2 and this was also demonstrated in the context
of ionizing radiation (20). In addition, the extract and the puri-
fied compound caused the down-regulation of the proto-oncogene
cyclin D1 after 48 h and this certainly added up to the cell division
arrest. Therefore, berberine and the BuOH extract down-regulated
two potent oncogenes, Cdc25A and cyclin D1.
Also the proliferation of human umbilical vein endothelial cells
(HUVECs) was inhibited upon incubation with 20 g/ml berber-
ine [31]. This phenomenon was accompanied by a significant
decrease of PCNA, and a typical apoptotic appearance correlated
with a marked decline in the mitochondrial membrane potential.
Berberine-mediated inhibition of vascular endothelial cell prolif-
eration suppressed neo-vascularization, and this might be one of
the mechanisms attenuating growth and metastasis of tumors. We
tested berberine and the BuOH extract in a 3-D metastasis model.
This model utilizes lymphendothelial cells layers onto which MCF-7
cell spheroids are placed that repulse the endothelial cells thereby
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generating gaps in the underneath lyphendothelium. Cancer cell
bulks penetrate through these gates. 5–50 M berberine dose-
dependently prevented lymphendothelial gap formation induced
by MCF-7 spheroids (manuscript submitted).
It was further reported that an ethanol extract of Coptis teeta,
which contains berberine and other components, as well as puri-
fied berberine-induced apoptosis of MCF-7 breast cancer cells [32].
Berberine-triggered cell death was reported also in several other
human cancer cell lines [33–35], such as in human glioblastoma
T98G cells that was concomitant with an increased Bax/Bcl-
2 ratio, disruption of the mitochondrial membrane potential,
and the activation of caspase-9 and caspase-3 [28]. Berberine-
induced apoptosis of human leukemia HL-60 cells was shown to
be associated with down-regulation of nucleophosmin/B23 and
telomerase activity [36]. Furthermore, Liu et al. [16] reported a cell
cycle inhibitory effect of berberine in a high concentration range
(between 10 and 50 M), which correlated with DNA damage. In
this study, the authors show that berberine inhibited osteosarcoma
cell proliferation and induced apoptosis through genotoxicity. In
contrast, we found that the inhibition of proliferation and the
induction of apoptosis occurred at berberine doses and extract con-
centrations that were devoid of genotoxic activity, although we
agree that high berberine concentrations could cause DNA strand
breaks. Our data suggest that another molecular/cellular mech-
anism transduced the pro-apoptotic properties of berberine and
BuOH extract and this correlated with -tubulin acetylation, which
is indicative for microfilament polymerization [37]. Therefore, the
anticancer properties of berberine and the BuOH extract are rem-
iniscent of that of taxol [38] and independent of genotoxicity. The
here used berberine and extract concentrations are equivalent to
∼9 g of dried B. lycium root per 80 kg body weight.
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Multifactorial anticancer effects of digalloyl-resveratrol encompass
apoptosis, cell-cycle arrest, and inhibition of lymphendothelial gap
formation in vitro
S Madlener1, P Saiko2, C Vonach1,3, K Viola1,3, N Huttary1, N Stark1, R Popescu1,4, M Gridling1, NT-P Vo1,3,
I Herbacek5, A Davidovits1, B Giessrigl1, S Venkateswarlu6, S Geleff1, W Ja¨ger3, M Grusch6, D Kerjaschki1,
W Mikulits5, T Golakoti 6, M Fritzer-Szekeres2, T Szekeres2 and G Krupitza*,1
1Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria; 2Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical
University of Vienna, Vienna, Austria; 3Department of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria; 4Department of
Pharmacognosy, University of Vienna, Vienna, Austria; 5Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna,
Austria; 6Laila Impex R&D Center Unit I, Vijayawada, Andhra Pradesh, India
BACKGROUND: Digalloyl-resveratrol (di-GA) is a synthetic compound aimed to combine the biological effects of the plant polyhydroxy
phenols gallic acid and resveratrol, which are both radical scavengers and cyclooxygenase inhibitors exhibiting anticancer activity.
Their broad spectrum of activities may probably be due to adjacent free hydroxyl groups.
METHODS: Protein activation and expression were analysed by western blotting, deoxyribonucleoside triphosphate levels by HPLC,
ribonucleotide reductase activity by 14C-cytidine incorporation into nascent DNA and cell-cycle distribution by FACS. Apoptosis was
measured by Hoechst 33258/propidium iodide double staining of nuclear chromatin and the formation of gaps into the
lymphendothelial barrier in a three-dimensional co-culture model consisting of MCF-7 tumour cell spheroids and human
lymphendothelial monolayers.
RESULTS: In HL-60 leukaemia cells, di-GA activated caspase 3 and dose-dependently induced apoptosis. It further inhibited cell-cycle
progression in the G1 phase by four different mechanisms: rapid downregulation of cyclin D1, induction of Chk2 with simultaneous
downregulation of Cdc25A, induction of the Cdk-inhibitor p21Cip/Waf and inhibition of ribonucleotide reductase activity resulting in
reduced dCTP and dTTP levels. Furthermore, di-GA inhibited the generation of lymphendothelial gaps by cancer cell spheroid-
secreted lipoxygenase metabolites. Lymphendothelial gaps, adjacent to tumour bulks, can be considered as gates facilitating metastatic
spread.
CONCLUSION: These data show that di-GA exhibits three distinct anticancer activities: induction of apoptosis, cell-cycle arrest and
disruption of cancer cell-induced lymphendothelial disintegration.
British Journal of Cancer (2010) 102, 1361–1370. doi:10.1038/sj.bjc.6605656 www.bjcancer.com
& 2010 Cancer Research UK
Keywords: digalloyl-resveratrol; anti-neoplastic; Cdc25A; ribonucleotide reductase; lymphendothelial retraction
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Digalloyl-resveratrol (di-GA) is a synthetic ester of the phytoalexin
resveratrol (3,40,5-trihydroxystilbene; RV) and the polyhydroxy
phenolic compound gallic acid (3,4,5-trihydroxybenzoic acid; GA)
(Figure 1). Gallic acid can be found in various natural products,
such as green tea, pineapples, bananas, apple peels, red and
white wine (Sun et al, 2002; De Beer et al, 2003; Wolfe et al,
2003). Resveratrol is a constituent of red wine and grapes. Both
compounds are proposed to contribute to the ‘French Paradox’,
a phenomenon of significantly lower (40%) heart infarction
incidence in the French population, when compared with other
European countries or the United States (Richard, 1987; Renaud
and De Lorgeril, 1992; Constant, 1997). Gallic acid and RV were
also described as excellent free radical scavengers (Inoue et al,
1994; Isuzugawa et al, 2001; Kawada et al, 2001; Salucci et al, 2002;
Sohi et al, 2003; Horvath et al, 2005) and as inducers of differen-
tiation and programmed cell death in a variety of tumour cell lines.
Other beneficial properties of GA-containing fruit extracts include
anti-diabetic and anti-angiogenic effects (Liu et al, 2005; Sridhar
et al, 2005). Gallic acid is also present at high concentrations in
gallnuts (name), which are proliferations of plant leaves that
become elicited by gall wasp exudates to build up a hatchery for
their larvae. Thus, the secretion of gall wasps stimulates plant cell
growth and overrules homeostasis of the affected leaf area – this is
similar to tumour outgrowth. In turn, the plant produces GA,
which seems to combat the improper growth signals and
re-establishes cell-cycle control. This could at least explain why
gallnuts are rich in GA and that gallnuts do not grow beyond a
certain size. This cytostatic property of GA – which is amplified in
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di-GA – seems to be one of the cancer-protective principles of a
variety of fruits and this could also be developed for adjuvant
therapy.
Gallnuts are not used in modern western medicine, but they
were mentioned in the first book of ‘De Materia Medica’ ascribed
to Pedanios Dioscurides (the ‘Vienna Dioscurides’, Austrian
National Library, which was written in the sixth century in
Konstantinopolis, East Roman Empire). Interestingly, this manu-
script claims that gallnuts ‘stop the growth of proliferating tissue’.
Other studies showed that RV and GA are effective inhibitors of
the enzyme ribonucleotide reductase (RR; EC1.17.4.1) (Fontecave
et al, 1998; Madlener et al, 2007). Ribonucleotide reductase is
significantly upregulated in malignant cells compared to non-
malignant cells. This enzyme catalyses the rate-limiting step of
de novo DNA synthesis, which is the reduction of ribonucleotides
into the corresponding deoxyribonucleoside triphosphates
(dNTPs). This qualifies RR as an excellent target for cancer
chemotherapy.
Apart from being a radical scavenger, the multifactorial effects
of GA encompass also the inhibition of cyclooxygenases (COXs)
and of lipoxygenases (LOXs). Tumours express high levels of
COX-2 and 12-LOX (Nie et al, 2003; Pidgeon et al, 2003; Nassar
et al, 2007), which metabolise arachidonic acid to prostanoids and
to hydroxyeicosatetraenoic acids (12(S)-HETE), respectively
(Marks et al, 2000). Certain HETEs function as inter- and
intracellular messengers and cause the repulsion of endothelial
cells thereby forming gaps in the endothelial cell layer (Ohigashi
et al, 1989; Nakamori et al, 1997; Uchide et al, 2007). Further, these
gaps may serve as entry ports for adjacent tumour cells into the
lymphatic system. Thus, we hypothesised that GA (and di-GA)
may inhibit lymphendothelial gap formation. Here we examine the
effects of di-GA on apoptosis, cell-cycle progression and lym-
phendothelial gap formation.
MATERIALS AND METHODS
Chemicals
Nordihydroguaiaretic acid (NDGA) was from Cayman Chemical
(Ann Arbor, MI, USA); and aspirin, mannitol, probucol, GA and
RV were from Sigma-Aldrich (Vienna, Austria). Catalase and
carboxy-PTIO were from Calbiochem-Merck Biosciences
(Nottingham, UK). Berberine chloride dihydrate (purity 98.92%)
was from Phytolab (Vestenbergsgreuth, Germany). Experimental
stock solutions (in DMSO) were prepared always fresh.
Mouse monoclonal anti-Cdc25A (F-6) Cat. No. 7389; anti-
PARP-1 (F-2) Cat. No. sc-8007; anti-cyclin D1 (M-20) Cat. No. sc-
718; anti-cyclin E (M20) Cat. No. sc-481 and anti-p21Cip/Waf (C-19)
Cat. No. sc-397 antibodies were from Santa Cruz Biotechnology
Inc. (Heidelberg, Germany). Polyclonal anti-phospho-Cdc25A
(Ser17) Cat. No. ab18321 antibody was from Abcam (Cambridge,
UK); and monoclonal anti-p34Cdc2 Cat. No. C3085 and anti-b-actin
(AC15) Cat. No. A5441 antibodies were from Sigma-Aldrich.
Rabbit monoclonal anti-cleaved caspase 3 (CPP32) clone C92-605
Cat. No. 58404 antibody was from Research Diagnostics Inc.
(Flanders, NJ, USA). Polyclonal anti-MEK 1/2 Cat. No. 9122; anti-
phospho-MEK 1/2 (Ser217/221) Cat. No. 9121 m; anti-phospho-
Chk2 (Thr68) Cat. No. 2661; anti-Chk2 Cat. No. 2662 and rabbit
monoclonal anti-p44/42 MAP Kinase (137F5) Cat. No. 4695;
anti-phospho-Cdc2 (Tyr15) Cat. No. 4539 and mouse monoclonal
anti-phospho-p44/42 MAPK (Thr202/Tyr204) (E10) Cat. No.
9106 antibodies were from Cell Signaling Technology Inc.
(Danvers, MA, USA). Anti-mouse IgG was from Dako (Vienna,
Austria). Anti-rabbit IgG and Amersham ECL – high-performance
chemiluminescence film – were from GE Healthcare (Vienna,
Austria).
Cell culture
HL-60 human promyelocytic cells were purchased from ATCC
(Wesel, Germany). Cells were grown in RPMI-1640 medium
supplemented with 10% heat-inactivated fetal calf serum, 1%
L-glutamine and 1% penicillin/streptomycin. MCF-7 cells were
grown in McCoy 5A medium containing 10% fetal calf serum
and 1% penicillin/streptomycin. Human normal lung fibro-
blasts (HLF) were a generous gift of the Cancer Research Institute
of the Medical University of Vienna and were grown in RPMI
medium containing 10% fetal calf serum and 1% penicillin/
streptomycin. All media, supplements and G418 were obtained
from Life Technologies (Lofer, Austria).
Human dermal microvascular endothelial cells (C-12260) were
purchased from PromoCell (Heidelberg, Germany). To obtain
a population of highly enriched lymphendothelial cells (LECs)
dermal microvascular endothelial cells were sorted with poly-
clonal rabbit anti-human podoplanin antibody and sheep anti-
rabbit dynabeads (M-280; Dynal 11203; Invitrogen, Lofer,
Austria). Subsequently, residual cells were sorted with anti-CD31
(Dynal 11128). Incubations were performed at 4 1C for 30min.
Such isolated LECs were stable transfected with telomerase
cDNA and then maintained in EGM2 Mv medium (EBM2-based
medium CC3156 and supplement CC4147; Lonza, Walkersville,
MD, USA) and G-418 (Schoppmann et al, 2004). All cell
types were kept in humidified atmosphere containing 5% CO2 at
37 1C.
Proliferation inhibition assay
HL-60 cells were seeded in T-25 tissue culture flasks at a
concentration of 1 105 per ml and incubated with increasing
concentrations of di-GA (2.5, 5, 7.5, 10 and 40 mM). Cell numbers
and IpC50 values were determined after 24 and 48 h using a CC-108
microcellcounter (Sysmex, Kobe, Japan).
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Figure 1 Chemical structures of (A) gallic acid (GA) and (B) digalloyl-
resveratrol (di-GA).
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Determination of deoxyribonucleoside triphosphates
The extraction of cellular dNTPs was performed according to a
method described previously (Garrett and Santi, 1979). HL-60 cells
(7 107) were incubated with 5, 10 and 40 mM di-GA for 24 h. Then,
1 108 were centrifuged at 1800 r.p.m. and resuspended in 100 ml
phosphate-buffered saline (PBS) and extracted with 10 ml trichloro-
acetic acid. The lysate was rested on ice and neutralised by adding
1.5 vol of freon containing 500 mM tri-n-octylamin. Afterwards the
lysate was centrifuged (15 000 r.p.m. for 4min) and the super-
natant was used for periodation (100 ml extract þ 30 ml 4M
methylamine (pH 7.5)þ 10 ml periodat). Aliquots (120 ml) of each
sample were analysed using a Merck ‘La Chrom’ HPLC-system
equipped with D-7000 interface, L-7100 pump, L-7200 autosampler
and L-7400 UV-detector. Detection time was set at 80min, the
detector operated on 280 nm for 40min and then switched to
260 nm for another 40min. Samples were eluted with a 3.2M
ammonium phosphate buffer, pH 3.6 (pH adjusted by addition of
3.2M H3PO4), containing 20mol l
1 acetonitrile using a
4.6 250mm Partisil 10 SAX column (Whatman Ltd., Kent, UK).
Separation was performed at constant ambient temperature and at
a flow rate of 2mlmin1. The concentrations of each dNTP of the
experimental samples were then calculated as percent of total area
under the control curves. Chemicals were from Sigma-Aldrich and
of highest available quality.
Hoechst 33258 and propidium iodide double staining
The vitality staining was performed according to a protocol
described before (Grusch et al, 2002). HL-60 cells (0.4 106 per
ml) were seeded in T-25 tissue culture flasks and exposed to
increasing concentrations of di-GA (2.5, 5, 7.5, 10 and 40 mM)
for 24 h. Hoechst 33258 and propidium iodide were purchased
from Sigma-Aldrich and added directly to the cells at final
concentrations of 5 and 2 mg/ml, respectively. After 60min of
incubation at 37 1C, we examined cells with a Zeiss Axiovert
fluorescence microscope and a DAPI filter (Carl Zeiss, Jena,
Germany). Cells were photographed and analysed by visual
examination (not by FACS). This method allows to distinguish
between early apoptosis, late apoptosis and necrosis. Cells were
judged according to their nuclear morphology and the disinte-
gration of their cell membranes, which is indicated by propidium
iodide uptake.
Cell-cycle distribution analysis
HL-60 cells (0.4 106 per ml) were seeded in T-25 tissue culture
flasks and incubated with 2.5, 5, 10 and 40 mM di-GA. After 24 h,
cells were harvested, washed with 5ml cold PBS, centrifuged
(600 r.p.m. for 5min) and resuspended and fixed in 3ml ethanol
(70%) at 4 1C for 30min. After two further washing steps with cold
PBS, RNAse A and propidium iodide were added to a final
concentration of 50 mgml1 each and incubated at 4 1C for 60min
before analysis on a FACSCalibur flow cytometer (BD Biosciences,
San Jose, CA, USA). The cell-cycle distribution was calculated with
ModFit LT software (Verity Software House, Topsham, ME, USA).
Determination of RR in situ activity
Exponentially growing HL-60 cells (5 105) were incubated with 1,
2.5 and 5 mM di-GA for 24 h at 37 1C in a humidified atmosphere
containing 5% CO2 to assess changes in RR in situ activity. Then,
cells were pulsed with 14C-cytidine (Sigma-Aldrich; 3 ml in a 5ml
cell suspension) at 37 1C for 30min, collected by centrifugation
(1200 r.p.m. for 5min), washed twice with PBS and processed to
extract total genomic DNA. Thereafter, the radioactivity, which
became incorporated into genomic DNA, was measured.
Western blotting
HL-60 cells (1.5 107 cells) were seeded into T-75 tissue culture
flasks and incubated with 10 mM di-GA for 0.5, 2, 4, 8 and 24 h.
Then, 1 106 cells were harvested (per experimental point),
washed twice with cold PBS, centrifuged at 1000 r.p.m. for 5min
and lysed in a buffer containing 150mM NaCl, 50mM Tris (pH 8.0),
1% Triton X-100, 1mM phenylmethylsulfonyl fluoride and protease
inhibitor cocktail (from a  100 stock; Sigma-Aldrich). The lysates
were centrifuged at 4 1C for 20min (12 000 r.p.m.) and super-
natants stored at 20 1C until further analysis. Equal amounts of
protein samples were separated by polyacrylamide gel electro-
phoresis and electroblotted onto PVDF membranes (Hybond, GE
Healthcare) at 4 1C overnight. Equal sample loading was controlled
by staining membranes with Poinceau S (Sigma-Aldrich). After
washing with PBS/0.5% Tween 20 (PBS/T) (pH 7.2) or TBS/0.1%
Tween 20 (TBS/T) (pH 7.6), membranes were blocked for 1 h in
blocking solution (5% non-fat dry milk in PBS/T or in TBS/T). The
membranes were incubated with the first antibody (in blocking
solution, dilution 1 : 500–1 : 1000) by gently rocking at 4 1C
overnight. Thereafter, the membranes were washed with PBS or
TBS and further incubated with the second antibody (peroxidase-
conjugated goat anti-rabbit IgG or anti-mouse IgG, dilution
1 : 2000–1 : 5000 in PBS/T or TBS/T) for 12 h. Chemoluminescence
was developed by the ECL detection kit and the exposure of
membranes to Amersham Hyperfilms (GE Healthcare).
MCF-7 spheroid generation
1.2 g of autoclaved methyl cellulose (M-0512; Sigma-Aldrich) was
resuspended in 100ml prewarmed McCoy 5A medium (Life
Technologies; 1.2% stock concentration), stirred until the solution
turned clear and centrifuged at 4000 r.p.m. (swing out rotor) for
2 h to pellet undesired debris. Then, 1 105 MCF-7 cells were
transferred to 15ml McCoy 5A medium containing 0.24% methyl
cellulose (final concentration). 150 ml (containing B1 103 cells)
was transferred to each well of a round bottom microtitre plate
(96-well) to allow spheroid formation. Cells were allowed to
aggregate and grow for 2 days, and then spheroids were sufficiently
dense for further manipulations. MCF-7 spheroids had an average
diameter of B300mm.
MCF-7 spheroid/LEC monolayer co-cultivation
LECs were seeded in EGM2 MV medium on 24-well plates and
allowed to grow for 2–3 days until confluence. Then, LECs were
stained with cytotracker green (concentration 2 mgml1 final
concentration, Molecular Probes-C2925, Invitrogen) at 37 1C for
90min and subsequently rinsed thoroughly. Thereafter, MCF-7
spheroids were washed in EGM2 MV medium to rid off methyl
cellulose, and 12 spheroids were carefully transferred using wide
bore yellow tips to each well containing LECs.
For those experiments in which inhibitors were used, the
indicated inhibitor concentrations (final concentrations) were
applied to the spheroids 30min prior addition of the spheroids
to the LEC layers.
Analysis of gap formation
LEC areas with spheroids on top were photographed using an FITC
filter, which was used to visualise cytotracker (green)-stained LECs
underneath the spheroids. Axiovert software (Carl Zeiss) facilitated
to measure the gap areas within the LEC layers.
Statistical calculations
Dose–response curves were calculated using the Prism 4.03
software package (GraphPad, San Diego, CA, USA) and statistical
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significance was determined by two-tailed paired t-test (signifi-
cance Po0.05).
RESULTS
Quite a few studies on GA and its derivatives, RV and RV
analogues were performed in human leukaemia cells (Saiko et al,
2008), because these cells are very sensitive to drugs and therefore
advantageous to test the efficacy of novel anticancer compounds.
HL-60 cells are particularly useful to discriminate the nuclear
morphology of necrotic and apoptotic cells (Grusch et al, 2002)
and hence, we used HL-60 cells to study di-GA facilitating the
comparability of our results with published data of other GA and
RV analogues.
Di-GA induces caspase 3 and apoptosis
The pro-apoptotic potential of naturally occurring GA was
compared to that of synthetic di-GA by incubating HL-60
promyelocytic leukaemia cells to both agents (Figure 2A and B).
Increasing concentrations of GA (10, 20, 40 and 80 mM) elicited 4,
10, 34 and 60% apoptosis, respectively. Because the di-GA
molecule contains two galloyl residues (as compared to just one
gallic acid molecule of GA) we expected that half of the di-GA
concentrations would induce similar apoptosis rates as the tested
GA concentrations. However, 5, 10 and 40 mM di-GA (to compare it
to 10, 20 and 80 mM GA, see above) triggered 12, 39 and 84%
apoptosis, respectively. In an earlier study, we showed that 25 and
50mM RV induced B18 and 45% apoptosis in HL-60 cells,
respectively (Horvath et al, 2006). Therefore, the apoptotic
efficiency of di-GA is the sum of the apoptotic properties of
2 GA plus RV. Apoptosis correlated with the activation of
caspase 3 and with the signature type cleavage of PARP into
an 85 kDa fragment (Figure 2C). Digalloyl-resveratrol did not
induce significant numbers of necrotic cells even at high
concentrations (data not shown). The data suggest that di-GA is
a potent inducer of apoptosis and significantly more effective than
GA alone.
Di-GA inhibits G1-S transition
HL-60 cells were exposed to increasing concentrations of GA and
di-GA and the cell numbers were measured after 24 and 48 h. The
percentages of proliferation inhibition were calculated at both time
points. Those concentrations that inhibited 50% proliferation
(IpC50) are shown in Table 1. Digalloyl-resveratrol inhibited
proliferation 7–10 times more efficiently than GA during the
tested time period. Inhibition of cell proliferation was due to a
dose-dependent cell-cycle block in G1 (Figure 3A).
Di-GA modulates mitogenic signalling and the expression
of cell-cycle regulators
We next examined the levels of the cell-cycle inhibitor p21Cip/Waf,
which is known to inhibit Cdk2 by blocking its interaction with
cyclin E (Jeon et al, 2007). p21Cip/Waf was induced within 4 h
(Figure 3B), which was independent of p53, because HL-60 cells
are p53 negative (Biroccio et al, 1999). Phosphorylation of Erk1
and MEK, which is indicative for their activation, preceded the
increase in p21Cip/Waf levels. This is consistent with previous
reports that MEK-Erk signalling upregulates p21Cip/Waf
(Facchinetti et al, 2004; Park et al, 2004; Perez-Pinera et al,
2006). Phosphorylation of Erk2 (the lower band occurring after 4
and 8 h) was simultaneous to p21Cip/Waf upregulation. Next, we
investigated whether the expression of the G1-specific cell-cycle
regulators Cdc25A, cyclin D1 and cyclin E was altered by di-GA
treatment (10 mM). Western blot analyses showed that cyclin D1
expression decreased after 2 h and remained suppressed, whereas
cyclin E expression persisted (Figure 3C). Cyclin D1 is required for
the activation of Cdk4 and Cdk6 (Lingfei et al, 1998; Alao, 2007),
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Figure 2 Induction of apoptosis by (A) GA and (B) di-GA in HL-60
cells. Cells were incubated with increasing concentrations of drugs for 24 h,
and then double stained with Hoechst 33258 and propidium iodide.
Afterwards cells were examined under the microscope with UV light
connected to a DAPI filter. Nuclei with a morphological phenotype
indicating apoptosis were counted and percentages of apoptotic cells were
calculated. Experiments were conducted in triplicate. Error bars indicate
s.e.m., asterisks significance (Po0.05). (C) Activation of caspase 3 and
cleavage of PARP on treatment with di-GA. Logarithmically growing HL-60
cells were incubated with 10mM di-GA for 0.5, 2, 4, 8 and 24 h. Afterwards
cells were lysed and protein expression was analysed by western blotting.
The anti-caspase 3 antibody recognises only the cleaved peptide indicating
its activation. Anti-PARP antibody recognises the full-length form (116 kDa)
and the signature-type cleaved product (85 kDa) that is generated by active
caspase 3. The antibody against b-actin was used to monitor equal sample
loading.
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which altogether is controlled by Cdc25A (Iavarone and Massague,
1997). Digalloyl-resveratrol strongly induced serine 17 (Ser17)
phosphorylation of Cdc25A after 4 h. Phosphorylation of Ser17-
Cdc25A was shown to stabilise this phosphatase at a high activity
status specifically in the M phase (Mailand et al, 2002), thereby
de-phosphorylating and activating its target Cdk1 (Cdc2). This is
mandatory for the transit through the G2-M phase (Karlsson-
Rosenthal and Millar, 2006). Hence, Cdc25A controls not only the
G1-S, but also the G2-M phase. Indeed, di-GA caused the
de-phosphorylation of Tyr15-Cdc2 indicating that cells entered
the mitotic phase. FACS analysis confirmed that 40 mM di-GA
allowed B90% of the cells to pass through S and M phase (likely
due to Cdc25A activity) but accumulated in the subsequent G1
phase because cyclin D1 was repressed. Finally, Cdc25A protein
level decreased after 24 h. This was paralleled by Chk2 activation
(indicated by its phosphorylation at Thr68), presumably due to
replicatory stress. Chk2 targets Cdc25A for proteolytic degra-
dation (Karlsson-Rosenthal and Millar, 2006). In summary, the
data suggest that di-GA inhibits cell proliferation by disturbing
orchestrated mitogenic signalling.
Di-GA inhibits RR
Gallic acid is a radical scavenger (Whang et al, 2005) and inhibits
RR through chelating the tyrosyl radical required for RR activity
(Madlener et al, 2007). Ribonucleotide reductase is the rate-
limiting enzyme for nucleotide metabolism necessary for DNA
synthesis during cell division.
Hence, RR activity was investigated by an assay that measures
the incorporation of 14C-cytidin into genomic DNA. Figure 4A
shows that 14C-cytidin incorporation into genomic DNA decreased
with increasing di-GA concentration. Further, RR activity was fully
blocked on treatment with 5 mM di-GA. At this concentration the
dCTP level (but not dTTP and dATP) dropped significantly
(Figure 4B). In HT29 colon carcinoma cells, a similar effect of
di-GA on RR activity, dCTP, dTTP and dATP levels was observed
(Bernhaus et al, 2009).
Table 1 Concentrations of GA and di-GA that inhibit proliferation of
HL-60 cells by 50%
IpC50 (24h) (lM) IpC50 (48h) (lM)
GA 21 24
Di-GA 4 2
Cell cycle distribution of
di-GA-trated HL-60 cells
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Figure 3 Effect of di-GA on the cell cycle of HL-60 cells. (A) Logarithmically growing HL-60 cells were incubated with increasing concentrations of di-GA
for 24 h and then subjected to FACS analysis. Experiments were conducted in triplicate. Error bars indicate s.e.m., asterisks significance (Po0.05). HL-60 cells
were incubated with 10mM di-GA for 0.5, 2, 4, 8 and 24 h, lysed, and the (B) expression of p21Cip/Waf, the phosphorylation of threonine202/tyrosine204-
Erk1/2 (p-Erk1/2) and serine217/221-MEK1/2 (p-MEK), and (C) phosphorylation of threonine68-Chk2 (p-Chk2), serine17-Cdc25A (p-Cdc25A), tyrosine15-
Cdc2 (p-Cdc2), and the protein levels of cyclin D1, E were analysed by western blotting. b-Actin served as loading control.
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Di-GA inhibits lymphendothelial gap formation induced
by co-cultivated tumour cell spheroids
Leukocytes trespass basal membranes and trans-migrate tissues
and endothelia as part of their normal physiological function and
are therefore, a priori ‘invasive’. Hence, HL-60 leukaemia cells
are inappropriate to study the pathological invasiveness of cancer
cells and the anti-invasive/anti-metastatic potential of di-GA.
In contrast, solid tumours acquire an invasive potential in course
of cancer progression and this particular cancer cell property has
to be studied and combated. We developed a novel bulk invasion
assay to establish an in vitro model resembling the pathologic
situation of ductal breast cancer cells invading the lymphatic
vasculature and to recapitulate the mechanism of metastasis
(Ohigashi et al, 1989; Nakamori et al, 1997; Uchide et al, 2007). For
this, telomerase immortalised human LECs were grown to
confluent monolayers and MCF-7 tumour spheroids (average
diameterB300 mm, containingB4000 cells) were placed on top to
mimic tumour intrusion into lymphatics. Lymphendothelial cells
were pre-labelled with cyto-tracker (green) immediately before
co-cultivation, to monitor presence or absence of LECs underneath
tumour spheroids (Figure 5A). Normal HLF spheroids served as
negative controls, because these primary cells with limited lifespan
(Hayflick limit) are non-malignant and do not invade blood or
lymphatic vasculature. After 4 h of co-cultivation, gaps formed
underneath 499% of the MCF-7 tumour spheroids (gap area was
on average B1.15 105mm2) whereas no or only small gaps were
formed underneath normal lung fibroblasts. The gap size area was
measured underneath at least 12 spheroids and in triplicate
experiments. These gaps resemble entry ports for cancer cell bulks
invading the lymphatic system, which is now widely accepted to be
a route for the spreading of certain cancers (Alitalo et al, 2005;
Oliver and Alitalo, 2005; Sipos et al, 2005).
Di-GA inhibited gap formation dose-dependently and maxi-
mally by460% (Figure 5B). We have evidence (time-laps movies;
data not shown) that gap formation is caused by LEC migration.
Berberine was reported to inhibit cell migration and invasion of
SCC-4 tongue squamous cancer cells (Ho et al, 2009) and HONE1
nasopharyngeal cancer cells (Tsang et al, 2009). The chemical
structure of berberine is reminiscent to parts of di-GA and for
control reasons we tested whether berberine had an effect on MCF-
7-induced LEC behaviour. Berberine dose-dependently inhibited
gap formation and this confirmed that the assay was functional
and responded according to prediction.
Primary cancers and also MCF-7 breast cancer cells express
elevated levels of LOXs, which metabolise arachidonic acid to
HETEs (Marks et al, 2000; Nie et al, 2003; Kudryavtsev et al, 2005).
The migration of endothelial cells was shown to be mediated by
LOXs generating 12(S)-HETE (Ohigashi et al, 1989; Nakamori et al,
1997; Uchide et al, 2007). 12(S)-HETE functions as inter- and
intracellular messenger and causes the retraction of endothelial
cells, thereby forming gaps into the confluent cell layer. The 12/
15-LOX inhibitors baicalein (100 mM) and NDGA (50 mM) reduced
the area of MCF-7 spheroid-induced gaps in the LEC monolayers
byB50 and 60%, respectively. Derivatives of GA are also known to
inhibit HETE generating LOXs, and prostanoids generating COXs
(Christow et al, 1991; Ha et al, 2004; Kim et al, 2006). However,
because aspirin had no effect on gap formation (Figure 5B) the
contribution of COXs can be excluded. We also took into account
that NDGA, baicalein, GA and di-GA are powerful radical scavengers
and antioxidants (Sohi et al, 2003; Floriano-Sanchez et al, 2006). In
case LEC gaps were induced by radicals, gap formation should be
inhibited by radical scavengers. To test this possibility, we analysed
the efficacy of four bona fide ROS scavengers. In particular, we used
mannitol, which scavenges the OHK radical; probucol, which is an
effective inhibitor of lipid peroxidation; catalase, which is an H2O2
catabolising enzyme; and carboxy-PTIO, which scavenges the NOK
radical. These scavengers did not prevent LEC gap formation.
Therefore, MCF-7-induced gap formation was independent of a
potential radical involvement.
Finally, we tested whether isolated GA and RV inhibited LEC gap
formation. Whereas 50 mM RV inhibited gap size by B25%, 80mM
GA was ineffective. Therefore, GA did not affect cell migration,
which was in contrast to a galloyl glucose derivate that inhibited
tube formation of human microvessel endothelial cells (Lee et al,
2004). Methyl gallate influences 5-LOX (Kim et al, 2006) and GA
may also inhibit this enzyme. However, 5-LOX did not contribute
to LEC gap formation, because 100 mM caffeic acid did not reduce
gap size (data not shown). This indicated that RV, but not GA, was
the inhibitory principle being improved by the higher complex
structure of di-GA.
In summary, di-GA dose-dependently inhibited LEC gap
formation with an efficiency similar to that of NDGA. The strong
anti-invasive property of di-GA is apparently due to the novel
chemical structure of the compound, but not due to the GA
residues, and only in part due to RV.
DISCUSSION
Gallic acid is a polyhydroxylated phenol previously known to
scavenge radicals, inhibit RR, COXs, LOXs, arrest cell cycle and
induce apoptosis (Ha et al, 2004; Faried et al, 2007; Hsu et al, 2007;
Madlener et al, 2007).
Here we tested a novel synthetic GA derivate, di-GA, assuming
that this compound may exhibit superior activity than GA itself.
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Figure 4 (A) Measurement of the in situ effect of di-GA on
ribonucleotide reductase (RR) activity. HL-60 cells were incubated with
1, 2.5 and 5mM di-GA for 24 h at 37 1C in a humidified atmosphere
containing 5% CO2 to assess changes in RR in situ activity. Then, cells were
pulsed with 14C-cytidine (Sigma-Aldrich; 3ml in a 5ml cell suspension) for
30min at 37 1C. Afterwards the cells were collected and the radioactivity
that became incorporated into genomic DNA was measured. (B) Effect of
di-GA on intracellular dNTP pools in HL-60 cells. HL-60 cells were
incubated with 5, 10 and 40 mM di-GA for 24 h. Then the cells were
prepared for HPLC analysis and the dNTP levels were determined
according to the protocol described in the ‘Materials and methods’ section.
Experiments were conducted in triplicate. Error bars indicate s.e.m.,
asterisks significance (Po0.05).
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In fact, the pro-apoptotic property of 10 mM di-GA exceeded that
of 20mM GA by four-fold. Thus, an additional pro-apoptotic
mechanism, apart from two galloyl residues, contributed to cell
death especially at low concentrations. This is of particular interest
because such concentrations can be achieved in humans. The
RV backbone, to which the galloyl residues are connected, may
be responsible for the additive effect, because RV was previously
reported to induce apoptosis in HL-60 cells (Horvath et al,
2006). The apoptotic activity of di-GA was much higher than the
reported RV activity (50 mM RV induced 50% apoptosis in HL-60),
but the apoptotic activity of the RV derivative, 3,30,4,40,5,
50-hexahydroxystilbene (M8) was even higher than that of di-GA
(Horvath et al, 2006). In contrast, another RV derivative with
anti-neoplastic properties, N-hydroxy-N0-(3,4,5-trimethoxyphenyl)-
3,4,5-trimethoxy-benzamidine (KITC), induced HL-60 apoptosis
less efficiently (Saiko et al, 2007). Digalloyl-resveratrol triggered
apoptosis through the caspase 3 pathway yet independent of
p53, because HL-60 cells are p53 deficient (Biroccio et al, 1999).
Because more than 50% of all cancer types harbour a defective p53
pathway, which is detrimental to successful therapeutic treatment,
compounds that exert anticancer activity independent of p53 are
of particular interest for clinical applications.
Another prominent anticancer property of therapeutic drugs is
to arrest the cell cycle. This can be achieved by blocking distinct
mechanisms such as cell-cycle regulators or enzymes involved in
DNA-replicative processes etc. Here we show that di-GA inhibited
3D Spheroids and LEC co-cultivation (4 h)
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Figure 5 Effect of di-GA on MCF-7 spheroid-induced gap formation in lymphendothelial cell monolayers. (A) LEC monolayers that were exposed to
MCF-7 spheroid (left side panels), MCF-7 spheroid treated with 40 mM di-GA (middle panels) and HLF spheroid (right side panels). Upper panels are phase-
contrast micrographs showing the respective spheroids, the panels below show the identical power fields using FITC filter and exhibit green stained LECs
underneath the respective spheroids. Bars in the lower right corners of upper panels indicate 100 mM. (B) MCF-7 tumor spheroids were preincubated with
solvent (control), or 5 and 50mM berberine; 5, 10, 25, 40 and 80 mM di-GA; 80mM GA; 50mM RV; 50mM NDGA; 100 mM baicalein; 200 mM aspirin; 25mM
mannitol; 600Uml1 catalase; 200 mM carboxy-PTIO and 100 mM probucol, and then placed on top of cytotracker stained LEC monolayers that were also
treated with respective agents for 4 h. Then, the size of the gaps that were formed in the LEC monolayers by MCF-7 spheroids (through repulsion of LECs)
was measured using an inverted microscope connected to an FITC filter and equipped with Axiovision 4.5 software (Carl Zeiss). As negative controls normal
human lung fibroblast (HLF) spheroids were used. Rho/rac (small GTPases regulating cell migration), LOX (lipoxygenase), COX (cyclooxygenases) and ROS
(reactive oxygen species) indicate which mechanisms and phenomena are inhibited by the respective agents. Experiments were conducted in triplicate, and
the underneath areas of at least 12 spheroids were analysed. Error bars indicate s.e.m., asterisks significance (Po0.05).
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cell proliferation 10-fold more efficiently than GA (Madlener et al,
2007). This again suggests that the RV backbone synergised with
the two galloyl residues. Similar to GA, di-GA also inhibited HL-60
cell cycle in G1 (Madlener et al, 2007). Resveratrol and its analogue
M8 were shown to inhibit the cell cycle in S phase (Ragione et al,
1998; Horvath et al, 2006) and, therefore, the G1-inhibitory effect
of the GA moieties was dominant over that of the RV backbone in
the di-GA molecule. Interestingly, also KITC inhibited the HL-60
cell cycle in G1 phase (Saiko et al, 2007). Digalloyl-resveratrol
caused cell-cycle arrest by four independent mechanisms:
(i) Di-GA downregulated cyclin D1 and thus presumably
inhibited Cdk4 and/or Cdk6. Cyclin D1 was identified as
the Prad 1 oncogene, which is overexpressed in many types of
cancer (Lingfei et al, 1998; Alao, 2007). Therefore, suppres-
sion of cyclin D1 is a relevant target to combat cancer.
(ii) Di-GA induced p21Cip/Waf and, therefore, affected Cdk2. Both
Cdk2- and Cdk4-activity are mandatory for G1-S transit. Hence,
blocking Cdk4 and Cdk2 inhibits cell division. p21Cip/Waf
upregulation was independent of p53, because HL-60 cells
are p53 deficient. Consistent with reports that p21Cip/Waf is also
induced by the MEK–Erk pathway (Facchinetti et al, 2004; Park
et al, 2004), we found that di-GA triggered Erk1(p44Thr202)-
phosphorylation within 30min and MEK1(Ser217)-phosphory-
lation within 2h. Further, Erk2(p42Tyr204)-phosphorylation
occurred at 4 h, which was simultaneous with p21Cip/Waf-
induction.
(iii) Di-GA stabilised Cdc25A by Ser17 phosphorylation and
forced cells through S and M phase. In consequence, B90%
of the cells accumulated in the following G1 phase due to
cyclin D1 suppression and p21Cip/Waf induction. This may
have resulted in replicative stress because after 24 h of di-GA
treatment Chk2 became activated, which was paralleled by
Cdc25A protein degradation. A similar effect was observed
on heat shock treatment, which also induces the ATM–Chk2
pathway resulting in the degradation of Cdc25A (Madlener
et al, 2009). In contrast, Agarwal et al (2006) observed an
almost immediate Cdc25ASer17 phosphorylation and Chk2
activation on treatment of DU145 cells with GA that was not
accompanied by degradation of Cdc25A.
(iv) Similar to GA, di-GA inhibited RR most probably by
chelating the tyrosyl radical that is required for RR activity
(Madlener et al, 2007). Resveratrol inhibits RR through a
similar mechanism (Fontecave et al, 1998). At 5 mM di-GA
inhibited 50% of dCTP synthesis, whereas it was reported
that 50 mM GA did not inhibit dCTP synthesis whatsoever
(Madlener et al, 2007). Digalloyl-resveratrol inhibited dCTP
synthesis also several-fold more efficiently than RV (Horvath
et al, 2005). This indicated that the galloyl residues
synergised with the RV backbone to inhibit DNA replication.
It has been shown that MCF-7 cells induce gap formation into
arterial endothelial cell layers by virtue of 12(S)-HETE secretion,
which is generated by LOXs metabolising arachidonic acid
(Kudryavtsev et al, 2005; Uchide et al, 2007). Gap formation was
due to LEC migration (retraction) but not due to apoptosis of
LECs, which was evidenced by microscopic time-laps movies (not
shown) and by berberine-mediated inhibition of migration (Ho
et al, 2009; Tsang et al, 2009). We extended this cell system using a
three-dimensional co-culture model consisting of MCF-7 spher-
oids and telomerase-immortalised primary human LECs (Schopp-
mann et al, 2004), because this closely resembles ductal breast
cancer bulks intruding the lymphatic vasculature. We showed that
MCF-7-triggered lymphendothelial gap formation could be re-
duced to 40% by NDGA, which is a potent inhibitor of 12/15-LOXs
but also a radical scavenger. Several gallate derivates are known to
inhibit LOXs (Christow et al, 1991; Ha et al, 2004; Kim et al, 2006),
to scavenge radicals (Whang et al, 2005) and to inhibit COX
(Madlener et al, 2007; Kim et al, 2006). However, neither radicals
nor COXs contributed to gap formation. Hence, baicalein- and
NDGA-mediated inhibition supports the notion that at least 50–
60% of gap formation was due to 12(S)-HETE generating LOX
activity. The property of di-GA that reduced LEC migration was
similar to that of NDGA. Also the tube formation of human
microvessel endothelial cells, which was inhibited by a galloyl
glucose derivate, was most likely due to the inhibition of cell
migration (Lee et al, 2004). Because 12/15-LOX contributes to
angiogenesis (Nie et al, 2000, 2006; Rose and Connolly, 2000) and
tumour metastasis (Liu et al, 1996; Jankun et al, 2006), di-GA may
prevent neo-vascularisation of tumours as well as infiltration of
cancer cells into the lymphatic vasculature. Another derivate,
galloyl glucose, blocked HT-1080 tumour invasion through gelatin
by inhibiting matrix metalloprotease-2 (MMP-2) and MMP-9 (Ata
et al, 1996). In our system, specific inhibition of MMP-2 and MMP-
9 with cell permeable small molecules exhibited only a weak effect
on MCF-7-mediated gap formation into LEC layers (data not
shown). Interestingly, 80 mM GA did not decrease lymphendothelial
gap formation whereas 50 mM RV inhibited gap formation by 25%
evidencing that the principal inhibitory activity was contributed by
RV and that the superior activity of di-GA was not the sum of RV
plus GA, but a new property of its own.
This is analogous to the observation that the RV derivate M8
exhibits not only improved but even new anti-neoplastic properties.
In particular, M8 inhibits ROCK1 expression in contrast to RV,
which even induces ROCK1 protein levels (Paulitschke et al, 2009).
ROCK1 supports migration, invasivity and lymph node metastasis
of melanoma cells. M8 inhibits melanoma lymph node metastasis in
an scid mouse model by B50% at a concentration that is compa-
rable to 50mM used in vitro (Paulitschke et al, 2009). Interestingly,
LEC gaps induced by melanoma spheroids could not be inhibited
by NDGA or baicalein suggesting that different cancer types invade
the lymphatic vasculature by a mechanism different of LOX. In
addition to the effects described above, RV and M8 are shown to
inhibit NF-kB (Holmes-McNary and Baldwin, 2000; Horvath et al,
2006). In preliminary investigations we found that specific
inhibition of NF-kB by small molecules significantly attenuated
LEC gap formation (data not shown). Whether di-GA affects
ROCK1 expression and/or NF-kB translocation remains to be
established. DMU-212 (3,4,5,40-tetramethoxystilbene) is another RV
derivate that exerts strong anti-neoplastic effects in breast
carcinoma cells by tubulin polymerisation, which is a mechanism
not induced by RV (Ma et al, 2008). Other approaches focus on RV
analogues with improved cellular uptake properties such as a
triacetate form of RV or vineatrol that both retain the anti-
neoplastic properties of RV (Colin et al, 2009).
In conclusion, we describe three distinct anticancer effects of
di-GA: the induction of apoptosis, the inhibition of cell division and
the inhibition of gap formation into lymphendothelial layers. Further,
we provide mechanistic explanations for the effect of di-GA on
apoptosis and cell cycle. For gap formation, we show the affection of
cell motility; however, an exact mechanism awaits elucidation.
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1. Introduction
Various compounds with hydroxyguanidine, thiosemicarba-
zide, and substituted benzohydroxamic acid functional groups
have shown promising antitumor activity [1–5]. Hydroxyguani-
dines and hydroxysemicarbazides were especially active against
human CCRF-CEM/0 and murine L1210 leukemia cells as well as
against human HT-29 colon cancer cells [1–4,6]. These agents
inhibited DNA synthesis as a consequence of inhibiting ribonucle-
otide reductase (RR; EC 1.17.4.1) activity.
RR is significantly upregulated in tumor cells in order to meet
the increased need for deoxyribonucleoside triphosphates (dNTPs)
of these rapidly proliferating cells for DNA synthesis [7]. The
enzyme is an a2b2 complex consisting of two subunits [8]. The
effector binding R1 subunit possesses an a2 homodimeric
structure with substrate and allosteric effective sites that control
enzyme activity and substrate specificity. The nonheme iron R2
subunit, a b2 homodimer, forms two dinuclear iron centers each
stabilizing a tyrosyl radical. The inhibition of the nonheme iron
subunit can be caused, for instance, by iron chelation or radical
scavenging of the tyrosyl radical [9]. Additionally, a p53-inducible
R2-homologue (p53R2) has been described recently [9]. Expres-
sion of the R2 and p53R2 subunits is induced byDNAdamage and it
has been reported that p53R2 supplies dNTPs for DNA repair in G0/
G1 cells in a p53-dependent manner [10]. Hydroxyurea (HU) is the
first RR inhibitor that has been used in clinical practice and is given
to treat chronic myeloid leukemia and many other neoplastic
diseases [11,12]. Difluorodeoxycytidine (Gemcitabine; dFdC) is
applied in chemotherapy regimens against non-small cell lung
cancer and pancreatic cancer [13,14].
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Ribonucleotide reductase (RR; EC 1.17.4.1) is responsible for the de novo conversion of ribonucleoside
diphosphates into deoxyribonucleoside diphosphates, which are essential for DNA replication. RR is
upregulated in tumor cells and therefore considered to be an excellent target for cancer chemotherapy.
ABNM-13 (N-hydroxy-2-(anthracene-2-yl-methylene)-hydrazinecarboximidamide), a novel N-hy-
droxy-N0-aminoguanidine has been designed to inhibit RR activity using 3D molecular space modeling
techniques. In this study, we evaluated its effect on human HL-60 promyelocytic leukemia cells. ABNM-
13 proved to be a potent inhibitor of RR which was displayed by significant alterations of
deoxyribonucleoside triphosphate (dNTP) pool balance and a highly significant decrease of incorporation
of radiolabeled cytidine into DNA of HL-60 cells. Diminished RR activity caused replication stress which
was consistent with activation of Chk1 and Chk2, resulting in downregulation/degradation of Cdc25A. In
contrast, Cdc25B was upregulated, leading to dephosphorylation and activation of Cdk1. The combined
disregulation of Cdc25A and Cdc25B was the most likely cause for ABNM-13 induced S-phase arrest.
Finally, we combined ABNM-13 with the first-line antileukemic agent arabinofuranosylcytosine (Ara-C)
and found that ABNM-13 synergistically potentiated the antineoplastic effects of Ara-C.
Due to these promising results, ABNM-13 deserves further preclinical and in vivo testing.
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HU is believed to destabilize R2 iron centers by scavenging the
tyrosyl radical which is essential for enzyme activity [9,15]. Several
newer iron chelating agents including tachypyridine [16–20] and a
number of thiosemicarbazones such as triapine [9,21] were shown
to interact with the iron-containing R2 subunit. These compounds
are currently under (pre)clinical development.
Modern drug design uses qualitative and quantitative struc-
ture–activity relationship (QSAR) studies as an approach to find
relationships between chemical structures or structure-related
properties and biological activities of distinct compounds. Based
on the prediction of the best QSARmodel, we synthesized 13 novel
compounds (ABNM-1 to ABNM-13) with potential RR inhibitory
capacities. Five of these agents were active in human HL-60
promyelocytic leukemia cells and ABNM-13 was chosen as lead
substance because of its pronounced growth inhibitory effects
whichwere up to 10-fold stronger than those of HU. The HL-60 cell
line is an excellent in vitromodel and has been extensively used by
our group and others, especially with regard to investigate RR
activity after treatment with various drugs. Additionally, growth
inhibition and cytotoxicity caused by ABNM-13 were also
investigated in human AsPC-1 pancreatic cancer cells. To study
themechanisms by which ABNM-13 influences cell cycle transit in
HL-60 cells, we examined the effects on RR and the cell cycle
regulators downstream of checkpoint kinase activation.
In general, anticancer drugs are more effective when used in
combination. The major advantage of drug combinations is the
achievement of additive or synergistic effects through intimidation
of distinctmolecular pathways and, accordingly, a decrease of drug
resistance. For example, administration of leucovorin increases the
binding of an active 5-fluorouracil metabolite to its target,
thymidylate synthase, thus increasing the antineoplastic effects
[22]. In addition, various RR inhibitors caused synergism together
with arabinofuranosylctosine (Ara-C), a first line antileukemia
drug affecting intracellular dCTP pools [23–27]. Following this
strategy, we combined ABNM-13 with Ara-C in order to test
potential additive or synergistic properties.
2. Materials and methods
2.1. Chemicals and supplies
ABNM 1-13 were synthesized and provided by the Department
of Pharmaceutical Sciences, Birla Institute of Technology, Mesra,
India. Structural formulas are shown in Fig. 1. Ara-C, HU and all
other chemicals and reagents were commercially available
(Sigma–Aldrich, Vienna, Austria) and of highest purity.
2.2. Cell culture
The human HL-60 promyelocytic leukemia and human AsPC-1
pancreatic adenocarcinoma cell lines were purchased from ATCC
(American Type Culture Collection, Manassas, VA, USA). Both lines
were grown in RPMI 1640 medium supplemented with 10% heat
inactivated fetal calf serum (FCS), 1% L-glutamine, and 1%
penicillin–streptomycin at 37 8C in a humidified atmosphere
containing 5% CO2 using a Heraeus cytoperm 2 incubator (Heraeus,
Vienna, Austria). AsPC-1 cells were grown in a monolayer culture
using 25 cm2 tissue culture flasks and were periodically detached
from the flask surface by 0.25% trypsin–ethylenediaminetetraa-
cetic acid (trypsin–EDTA) solution. All media and supplements
were obtained from Life Technologies (Paisley, Scotland, UK). Cell
counts were determined using a microcellcounter CC-110 (SYS-
MEX, Kobe, Japan). Cells growing in the logarithmic phase of
growth were used for all experiments described below.
2.3. Growth inhibition assay
HL-60 cells (0.1  106 per ml) were seeded in 25 cm2 Nunc
tissue culture flasks and incubated with increasing concentrations
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Fig. 1. Structural formula and biological activity of ABNM 1-13 in HL-60 cells. HL-60
cells (0.1  106 per ml) were incubated with increasing concentrations of drugs for
72 h. Cell counts and IC50 values (IC50 = 50% growth inhibition of tumor cells) were
determined using a microcellcounter CC-110. Viability of cells was determined by
trypan blue staining. Results were calculated as number of viable cells. Data are
means  standard errors of three determinations.
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of ABNM 1–13 or HU at 37 8C under cell culture conditions. Cell
counts and IC50 values (IC50 = 50% growth inhibition of tumor cells)
were determined after 24, 48, and 72 h using a microcellcounter
CC-110.
In another set of experiments, AsPC-1 cells were seeded in
25 cm2 Nunc tissue culture flasks and allowed to attach overnight.
Cells were then incubated with increasing concentrations of
ABNM-13 for 72 h. After that period, cells were detached from the
flask surface by 0.25% trypsin–ethylenediaminetetraacetic acid
(trypsin–EDTA) solution. After removal of trypsin–EDTA by
centrifugation and suspension of the pellet in RPMI 1640 medium,
cells were counted using a microcellcounter CC-110. Viability of
cells was determined by staining with trypan blue. Results were
calculated as number of viable cells.
2.4. Clonogenic assay
AsPC-1 cells (2  103 per well) were plated in 24-well plates
and allowed to attach overnight at 37 8C in a humidified
atmosphere containing 5% CO2. Then cells were incubated with
increasing concentrations of ABNM-13 for 6 days. Subsequently,
the medium was carefully removed from the wells and the plates
were stainedwith 0.5% crystal violet solution for 5 min. Colonies of
more than 50 cells were counted using an inverted microscope at
40-fold magnification.
2.5. MTT chemosensitivity assay
AsPC-1 or HL-60 cells (5  103 per well) were seeded in 96-well
microtiter plates in supplemented RPMI 1640 medium. AsPC-1
cells were allowed to attach overnight. Cells were then incubated
with various concentrations of ABNM-13 for 96 h at 37 8C under
cell culture conditions. After that period, the reduction of the
yellow tetrazolium compound 3-(4,5-dimethylthiazo-2-yl)-2,5-
diphenyl tetrazoliumbromide (MTT) by the mitochondrial dehy-
drogenases of viable cells to a purple formazan product was
determined using an assay kit from Promega1 according to the
supplier’s manual. The change in absorbance at 550 nm was
tracked on a Wallac 1420 Victor 2 multilabel plate reader
(PerkinElmer Life and Analytical Sciences). Drug effect was
quantified as the percentage of control absorbance of reduced
dye at this wavelength.
2.6. Simultaneous growth inhibition assay using ABNM-13 and Ara-C
HL-60 cells (0.1  106 per ml) were simultaneously incubated
with various concentrations of ABNM-13 (12.5, 15, 17.5, and
20 mM) and Ara-C (10, 15, and 20 nM) for 72 h. After that period,
cells were counted using a microcellcounter CC-110.
2.7. Sequential growth inhibition assay using ABNM-13 and Ara-C
HL-60 cells (0.1  106 per ml) were first incubated with
different concentrations of ABNM-13 (2.5, 5, 7.5, and 10 mM) for
24 h. Then ABNM-13 was washed out and cells were further
exposed to various concentrations of Ara-C (10, 15, and 20 nM) for
another 48 h. After that period, cells were counted using a
microcellcounter CC-110.
2.8. Cell cycle distribution analysis
Cells (0.4  106 per ml) were seeded in 25 cm2 Nunc tissue
culture flasks and incubated with increasing concentrations of
drugs at 37 8C under cell culture conditions. After 24 h, cells were
harvested and suspended in 5 ml cold PBS, centrifuged, resus-
pended and fixed in 3 ml cold ethanol (70%) for 30 min at 4 8C. After
twowashing steps in cold PBS RNAse A and propidium iodide were
added to a final concentration of 50 mg/ml each and incubated at
4 8C for 60 min before measurement. Cells were analyzed on a
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA)
and cell cycle distribution was calculated with ModFit LT software
(Verity Software House, Topsham, ME, USA).
2.9. Western blotting
After incubation with 15 mM ABNM-13 and/or 15 nM Ara-C,
HL-60 cells (2  106 per ml) were harvested, washed twice with
ice-cold PBS (pH 7.2) and lysed in a buffer containing 150 mMNaCl,
50 mM Tris-buffered saline (Tris pH 8.0), 1% Triton X-100, 2.5%
100 mM phenylmethylsulfonylfluoride (PMSF) and 2.5% protease
inhibitor cocktail (PIC; from a 100 stock). The lysate was
centrifuged at 12,000 rpm for 20 min at 4 8C, and the supernatant
was stored at 20 8C until further analysis. Equal amounts of
protein samples were separated by polyacrylamide gel electro-
phoresis (PAGE) and electroblotted onto PVDF membranes
(Hybond, Amersham) overnight at 4 8C. Equal sample loading
was controlled by staining membranes with Ponceau S. After
washingwith PBS/Tween-20 (PBS/T) pH7.2 or Tris/Tween-20 (TBS/
T) pH 7.6,membraneswere blocked for 60 min in blocking solution
(5% non-fat dry milk in PBS containing 0.5% Tween-20 or in TBS
containing 0.1% Tween-20). Thenmembraneswere incubatedwith
the first antibody (in blocking solution, dilution 1:500 to 1:1000)
by gently rocking at 4 8C, overnight. Subsequently, the membranes
were washed with PBS or TBS and further incubated with the
second antibody (peroxidase-conjugated goat anti-rabbit IgG, anti-
mouse IgG, or donkey anti-goat IgG – dilution 1:2000 to 1:5000 in
PBS/T or TBS/T) at room temperature for 60 min. Chemilumines-
cence was developed by the ECL detection kit (Amersham,
Buckinghamshire, UK) and then membranes were exposed to
Amersham Hyperfilms.
Equal numbers of cells were lysed for each sample, protein
content was measured by the Bradford method, and PVDF
membranes were checked by Ponceau S staining. Equal sample
loadingwas controlled byb-actin expressionwhich appeared to be
stable when inspected in short term exposures to X-ray films. Each
Western blot experiment was performed at least twice, and
specific experimental points were done more often as they served
as internal controls.
Antibodies directed against p(Ser1981)-ATM, p(Ser317)-Chk1,
Chk1, p(Thr68)-Chk2, Chk2, p(Tyr15)-Cdc2, cleaved Caspase-3
(Asp175) and anti-rabbit IgG were from Cell Signaling (Danvers,
MA, USA), against p(Ser75)-Cdc25A from Abcam (Cambridge, MA,
USA), against p(Ser177)-Cdc25A from Abgent (San Diego, CA, USA),
against R1 (T-16), R2 (I-15), p53R2 (N-16), Cdc25A (F-6), Cdc25B (C-
20), Cdc25C (C-20), Cdc2 p34 (17), and donkey anti-goat IgG from
Santa Cruz (Santa Cruz, CA, USA), against ph(Ser139)-gH2AX from
Merck (Darmstadt, Germany), againstb-actin fromSigma (St. Louis,
MO, USA), and anti-mouse IgGwas fromDako (Glostrup, Denmark).
2.10. Incorporation of 14C-labeled cytidine into DNA (DNA synthesis
assay)
To analyze the effect of ABNM-13 treatment on the activity of
DNA synthesis, an assay was performed as described previously
[28]. Radiolabeled 14C-cytidine has to be reduced by RR in order to
be incorporated into the DNA of HL-60 cells following incubation
with ABNM-13 and/or Ara-C. HL-60 cells (0.4  106 cells per ml)
were incubated with various concentrations of ABNM-13 for 24 h.
After that, cells were counted and pulsed with 14C-cytidine
(0.3125mCi, 5 nM) for 30 min at 37 8C. In another set of
experiments, cells were treated with ABNM-13 and/or Ara-C for
30 min and simultaneously pulsed with 14C-cytidine (0.3125mCi,
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5 nM). Afterwards, cells were collected by centrifugation and
washed with PBS. Total DNA from 5  106 cells was purified by
phenol–chloroform–isoamyl alcohol extraction and specific
radioactivity of the samples was determined using a Wallac
1414 liquid scintillation counter (PerkinElmer, Boston, MA)
whose read out was normalized by a Hitachi U-2000 Double
Beam Spectrophotometer to ensure equal amounts and purity of
DNA.
2.11. Determination of deoxyribonucleoside triphosphates (dNTPs)
Cells were seeded in 175 cm2 tissue culture flasks
(5  107 per flask) and incubated with increasing concentrations
of ABNM-13 for 24 h. The cells were then centrifuged at 1800  g
for 5 min, resuspended in 100 ml of PBS, and extracted with 10 ml
of trichloracetic acid (90%). The lysate was allowed to rest on ice
for 30 min and neutralized by the addition of 1.5 volumes of
freon containing 0.5 mol/l tri-n-octylamine. Concentrations of
dNTPs were then determined using the method described by
Garrett and Santi [29]. Aliquots (100 ml) of the samples were
analyzed using a Merck ‘‘La Chrom’’ high-performance liquid
chromatography (HPLC) system (Merck, Darmstadt, Germany)
equipped with D-7000 interface, L-7100 pump, L-7200 auto-
sampler, and L-7400 UV detector. Detection time was set at
80 min, with the detector operating on 280 nm for 40 min and
then switched to 260 nm for another 40 min. Samples were
eluted with a 3.2 M ammonium phosphate buffer (pH 3.6,
adjusted by the addition of 3.2 mM H3PO4) containing 20 M
acetonitrile using a 4.6  250 mm PARTISIL 10 SAX column
(Whatman Ltd., Kent, UK). Separation was performed at constant
ambient temperature and a flow rate of 2 ml per min. The
concentration of each dNTP was calculated as percentage of the
total area under the curve for each sample.
2.12. Hoechst dye 33258 and propidium iodide double staining
The Hoechst staining was performed according to the method
described by our group [30]. HL-60 cells (0.2  106 per ml) were
seeded in 25 cm2 Nunc tissue culture flasks and exposed to
increasing concentrations of ABNM-13 for 24 and 48 h. Hoechst
33258 (HO, Sigma, St. Louis, MO, USA) and propidium iodide (PI,
Sigma, St. Louis, MO, USA) were added directly to the cells to final
concentrations of 5mg/ml and 2 mg/ml, respectively, followed by
60 min of incubation at 37 8C. Cells were examined on a Nikon
Eclipse TE-300 Inverted Epi-Fluorescence Microscope (Nikon,
Tokyo, Japan) equipped with a Nikon DS-5M-L1 Digital Sight
Camera System including appropriate filters for Hoechst 33258
and PI. Thismethod allows distinguishing between early apoptosis,
late apoptosis, and necrosis and is therefore superior to TUNEL
assay which fails to discriminate among apoptosis and necrosis
[31,32] and does not provide any morphological information. In
addition, the HO/PI staining is more sensitive than a customary
FACS based Annexin V binding assay [32–34]. The Hoechst dye
stains the nuclei of all cells and thus allows monitoring cellular
changes associated with apoptosis, such as chromatin condensa-
tion and nuclear fragmentation. In contrast, PI is excluded from
viable and early apoptotic cells; consequently, PI uptake indicates
loss of membrane integrity being characteristic of late apoptotic
and necrotic cells. In combinationwith fluorescencemicroscopy to
evaluate the morphologies of nuclei, the selective uptake of the
two dyes enables studying the induction of apoptosis in intact
cultures and to distinguish it from non-apoptotic cell death by
means of necrosis. The latter is characterized by nuclear PI uptake
without chromatin condensation or nuclear fragmentation [35].
Cells were judged according to their morphology and the
integrity of their cell membranes, counted under the microscope
and the number of apoptotic cells was given as percentage value.
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Fig. 2. (a and b) Growth inhibition of HL-60 cells after incubation with ABNM-13 or HU. HL-60 cells (0.1  106 per ml) were incubated with increasing concentrations of
ABNM-13 or HU. Cell counts and IC50 values (IC50 = 50% growth inhibition of tumor cells) were determined using amicrocellcounter CC-110. Viability of cells was determined
by trypan blue staining. Results were calculated as number of viable cells. Data are means  standard errors of three determinations. (c) Inhibition of colony formation of AsPC-1
cells after incubation with ABNM-13. AsPC-1 cells (2  103 per well) were plated in 24-well plates and allowed to attach overnight at 37 8C in a humidified atmosphere containing
5% CO2. After 24 h, the cells were incubated with increasing concentrations of ABNM-13 for 6 days. Subsequently, the mediumwas carefully removed from the wells and the plates
were stained with 0.5% crystal violet solution for 5 min. Colonies of more than 50 cells were counted using an inverted microscope at 40-fold magnification. Data are
means  standard errors of three determinations.
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2.13. Statistical calculations
Dose–response curves were calculated using the Prism 5.01
software package (GraphPad, San Diego, CA, USA) and significant
differences between controls and each drug concentration applied
were determined by unpaired t-test. The calculations of dose–
response curves and combination effectswere performed using the
‘‘Calcusyn’’ software designed by Chou and Talalay (Biosoft,
Ferguson, MO) [36]. The analytical method of Chou and Talalay
[36,37] describes the interaction among drugs in a given
combination. A combination index (CI) of <0.9 indicates syner-
gism, a CI of 0.9–1.1 indicates additive effects, and a CI of >1.1
indicates antagonism.
3. Results
3.1. Effect of ABNM 1-13 on the growth of HL-60 and AsPC-1 cells
HL-60 cells (0.1  106 per ml) were seeded in 25 cm2 Nunc
tissue culture flasks and incubated with increasing concentrations
of ABNM 1-13. After 72 h, the cell number of viable leukemia cells
was determined. ABNM-4, ABNM-8, ABNM-9, ABNM-12, and
ABNM-13 inhibited the growth of HL-60 cells with IC50 values
(IC50 = 50% growth inhibition of tumor cells) of 95  2.2, 67  1.3,
60  1.0, 62  2.0, and 11  1.1 mM, respectively. The IC50 values of
all other compounds remained beyond 100 mM (Fig. 1). In another set
of experiments, AsPC-1 cells (0.2  106 per ml) were seeded in
25 cm2 Nunc tissue culture flasks and allowed to attach overnight.
After 72 h, cells were detached and counted using a microcellcounter
CC-110. ABNM-13 inhibited the growth of AsPC-1 cells with an IC50 of
76  4 mM.
3.2. Effect of ABNM-13 on the growth of HL-60 cells – alone and in
combination with Ara-C
HL-60 cells were seeded at a concentration of 0.1  106 per ml
and incubated with increasing concentrations of ABNM-13. After
24, 48, and 72 h, the cell number of viable leukemia cells was
determined. ABNM-13 inhibited the growth of HL-60 cells with
IC50 values (IC50 = 50% growth inhibition of tumor cells) of 15  0.3
and 11  1.1 mM, respectively (Fig. 2a). Exposure to ABNM-13 for
24 h resulted in a cell count of 67  0.6% (33% growth inhibition).
Treatment with HU, a RR inhibitor currently used in the clinic for 48
and 72 h resulted in IC50 values of 143  0.2 and 88  0.2 mM,
respectively (Fig. 2b). These findings are consistent with those
obtained by Szekeres et al. who determined an IC50 of 73 mM after
96 h of incubation [38].
To investigate the effect of ABNM-13 in combination with Ara-
C, HL-60 cells were seeded at a concentration of 0.1  106 per ml
and simultaneously or sequentially incubated with increasing
Table 1
Synergistic combination effects of ABNM-13 and Ara-C in HL-60 cells employing a sequential growth inhibition assay.
Compound Concentration (mM/nM) Cell number SD (% of control) Predicted valuea Combination indexb
ABNM-13 (A) 2.5 88.7 0.78
(mM) 5.0 61.8 0.16
7.5 50.9 0.78
10.0 32.6 0.31
Ara-C (B) 10 72.4 0.94
(nM) 15 71.83.61
20 59.33.45
ABNM-13 2.5
+ Ara-C 10 49.24.55 64.2 0.607c
ABNM-13 2.5
+Ara-C 15 25.24.87 63.7 0.305c
ABNM-13 2.5
+Ara-C 20 39.82.35 52.6 0.607c
ABNM-13 5
+Ara-C 10 15.57.85 44.7 0.329c
ABNM-13 5
+Ara-C 15 20.05.65 44.4 0.418c
ABNM-13 5
+Ara-C 20 32.11.10 36.6 0.692c
ABNM-13 7.5
+Ara-C 10 17.35.02 36.9 0.514c
ABNM-13 7.5
+Ara-C 15 26.4 0.00 36.6 0.740c
ABNM-13 7.5
+Ara-C 20 23.21.41 30.2 0.695c
ABNM-13 10
+Ara-C 10 17.22.04 23.6 0.670c
ABNM-13 10
+Ara-C 15 16.81.73 23.4 0.676c
ABNM-13 10
+Ara-C 20 17.92.67 19.3 0.727c
Cells were sequentially incubated with (1) ABNM-13 for 24h and (2) Ara-C for 48h, and then the cell number was determined. Data are means of two
determinations standard deviations (SD).
a Predicted value: (%A%B)/100.
b Combination indices according to the equation of Chou and Talalay [36].
c Synergistic combination effect.
P. Saiko et al. / Biochemical Pharmacology 81 (2011) 50–5954
105
concentrations of drugs (ABNM-13 first for 24 h and then Ara-C for
48 h as described in the Section 2). All 12 drug combinations
yielded additive effects when ABNM-13 and Ara-C were applied
simultaneously (data not shown). Moreover, all 12 combinations
led to highly synergistic effects when applied sequentially (cells
were first incubatedwith 2.5, 5, 7.5, and 10 mMABNM-13 followed
by the addition of 5, 10, and 20 nM Ara-C, respectively) (Table 1).
3.3. Effect of ABNM-13 on the growth of AsPC-1 cell colonies
AsPC-1 cells were seeded at a concentration of 2  103 per well
and incubated with increasing concentrations of ABNM-13.
Colonies were counted after 6 days of treatment. ABNM-13
inhibited the growth of AsPC-1 cell colonies with an IC50 value of
11.5  1.4 mM (Fig. 2c) being almost identical to the IC50 seen in HL-
60 cells (11  1.1 mM).
3.4. MTT chemosensitivity assay
AsPC-1 or HL-60 cells (5  103 per well) were seeded in 96-well
microtiter plates and exposed to increasing concentrations of
ABNM-13 as described in Section 2. After 96 h of incubation,
ABNM-13 reduced the absorbance (viability) of AsPC-1 and HL-60
cells with IC50 values of 40  3.4 and 9  1.7 mM, respectively.
3.5. Inhibition of incorporation of 14C-cytidine into DNA of HL-60 cells
(DNA synthesis assay) and dNTP alterations after treatment with
ABNM-13 and/or Ara-C
Incorporation of 14C-cytidine into nascent DNA was mea-
sured in HL-60 cells after incubation with increasing concen-
trations of ABNM-13. Exposure to 10, 20, and 40 mM ABNM-13
for 24 h significantly decreased 14C-cytidine incorporation to
52  13.9%, 17  6.1%, and 4  2.8%, respectively (Fig. 3a). Consti-
tutive RR activity maintains balanced dNTP pools, whereas RR
inhibition tilts this balance. In line with this, ABNM-13 treatment
caused also an imbalance of dNTPs in HL-60 cells after 24 h, which
was determined by HPLC analysis. Incubation of cells with 40 mM
ABNM-13 resulted in a significant depletion of intracellular dGTP
pools to 36  15.7%. Treatment with 10, 20, and 40 mM ABNM-13
significantly increased dTTP pools to 134  8.0%, 200  22.7%, and
237  21.3% of control values, respectively. Regarding dCTP and
dATP pools, treatment with ABNM-13 led to insignificant changes
(Fig. 3b).
To analyze the immediacy of DNA synthesis inhibition, HL-60
cells were exposed to 15 nM Ara-C, 15mM ABNM-13, and the
simultaneous combination of both compounds for only 30 min.
Even this short incubation period reduced the incorporation of 14C-
cytidine to 93  33.8%, 27  6.3%, and 4  5.7% of controls, respec-
tively (Fig. 3c).
3.6. Expression of RR subunits R1, R2, and p53R2 after treatment with
ABNM-13 and/or Ara-C
To monitor the effect of RR inhibitors on the expression of RR
subunits, HL-60 cells were incubated with 15 nM Ara-C and/or
15mMABNM-13 for 0.5, 2, 4, 8, and 24 h and subjected toWestern
blot analysis. The protein level of the constitutively expressed R1
subunit remained unchanged during the whole time course. R2
levels showed an increase after 8 and 24 h, and p53R2 levels were
elevated after 24 h of incubation (Fig. 3d). Both R2 and p53R2 are S-
phase specific.
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Fig. 3. (a) Inhibition of incorporation of 14C-cytidine into DNA of HL-60 cells after treatmentwith ABNM-13 for 24 h (DNA synthesis assay). HL-60 cells (0.4  106 cells per ml)
were incubated with increasing concentrations of ABNM-13 for 24 h. After the incubation period, cells were counted and pulsed with 14C-cytidine (0.3125 mCi, 5 nM) for
30 min at 37 8C. Then cells were collected by centrifugation and washed with PBS. Total DNA was extracted from 5  106 cells and specific radioactivity of the samples was
determined using aWallac 1414 liquid scintillation counter (PerkinElmer, Boston,MA). Data aremeans  standard errors of three determinations. Values significantly (p < 0.05)
different from control are marked with an asterisk (*). Highly significant (p < 0.01) differences are marked with two asterisks (**). (b) Concentration of dNTP pools in HL-60 cells
upon treatment with ABNM-13. HL-60 cells (0.4  106 cells per ml) were incubated with 10, 20, and 40 mM ABNM-13 for 24 h. Afterwards, 5  107 cells were separated for the
extraction of dNTPs. The concentration of dNTPs was calculated as percent of total area under the curve for each sample. Data are means  standard errors of three determinations.
Values significantly (p < 0.05) different from control are marked with an asterisk (*). (c) Inhibition of incorporation of 14C-cytidine into DNA of HL-60 cells after treatment with
ABNM-13 and/or Ara-C for 30 min (DNA synthesis assay). HL-60 cells (0.4  106 cells per ml) were incubated with 15 mMABNM-13 and/or 15 nMAra-C and simultaneously pulsed
with 14C-cytidine (0.3125 mCi, 5 nM) for 30 min at 37 8C. Then cells were collected by centrifugation and washed with PBS. Total DNAwas extracted from 5  106 cells and specific
radioactivity of the samples was determined using aWallac 1414 liquid scintillation counter (PerkinElmer, Boston, MA). Data are means  standard errors of three determinations.
Highly significant (p < 0.01) differences aremarkedwith two asterisks (**). (d) Expression levels of RR subunits R1, R2 and p53R2 in HL-60 cells upon treatment with ABNM-13 and/
or Ara-C. After incubation with 15 mMABNM-13 and/or 15 nM Ara-C for 0.5, 2, 4, 8, and 24 h, HL-60 cells (2  106 per ml) were harvested, washed twice with ice-cold PBS (pH 7.2)
and lysed in a buffer containing 150 mMNaCl, 50 mMTris-buffered saline (Tris pH 8.0), 1% Triton X-100, 1 mMphenylmethylsulfonylfluoride (PMSF) and protease inhibitor cocktail
(PIC; from a 100 stock). The lysate was centrifuged at 12,000 rpm for 20 min at 4 8C, and the supernatant was subjected to Western blot analysis.
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3.7. Cell cycle distribution in HL-60 cells after treatment with ABNM-
13 and/or Ara-C
HL-60 cells were simultaneously incubatedwith 15 mMABNM-
13 and/or 15 nM Ara-C for 24 h. Treatment of HL-60 cells with
15 mMABNM-13 caused cell cycle arrest in S-phase, increasing this
cell population from 34  0.4% to 62  0.0%, whereas G0–G1 phase
cells decreased from 46  0.1% to 21  0.1%. 15 nM Ara-C likewise
caused an accumulation of 69  1.6% HL-60 cells in S-phase and a
concomitant decrease of G0–G1 cells to 12  0.8%. Simultaneous
incubation of HL-60 cells with 15 mMABNM-13 and 15 nM Ara-C led
to an even more pronounced growth arrest in the S-phase, increasing
this cell population from 34  0.4% to 94  0.5% while decreasing
cells in the G0–G1 phase from 46  0.5% to 6  0.5% (Fig. 4a–c). No
subG1 peaks could be observed by FACS at the time points measured.
3.8. Expression of checkpoint and cell cycle regulating proteins after
treatment with ABNM-13 and/or Ara-C
To investigate whether S-phase inhibition caused activation of
cell cycle checkpoint kinases, HL-60 cells were simultaneously
treated with 15 nM Ara-C and/or 15mM ABNM-13 for 0.5, 2, 4, 8,
and 24 h and subjected to Western blot analysis (Fig. 4d and e).
Chk1 was phosphorylated at the activating Ser317 site within
30 min (Ara-C), 2 h (ABNM-13), and 30 min (Ara-C/ABNM-13).
Chk2 was phosphorylated at the activating Thr68 site within 24 h
(Ara-C), 30 min (ABNM-13), and 30 min (ABNM-13/Ara-C). Chk1
protein levels remained unchanged, whereas Chk2 protein levels
increased transiently, in particular when using the combination of
ABNM-13 and Ara-C (Fig. 4d). In addition, ABNM-13 caused
phosphorylation at Ser75 and Ser177 of the dual-specificity
phosphatase Cdc25A, which are target sites of Chk1 and Chk2,
respectively, resulting in its downregulation after 8 and 24 h. On
the other hand, ABNM-13 upregulated Cdc25B protein levels after
24 h (Ara-C after 8 and 24 h), resulting in the dephosphorylation of
Tyr15 of Cdk1 after 24 h, which is indicative for its activation
(Fig. 4e). Ara-C treatment did not cause dephosphorylation of Cdk1.
Cdc25C levels remained unchanged throughout the time course.
3.9. Induction of apoptosis in HL-60 cells by ABNM-13 and/or Ara-C
HL-60 cells were exposed to 12.5, 15, 17.5, and 20 mM ABNM-
13 and/or 15 nM Ara-C for 24 and 48 h and double stained with
Hoechst 33258 and propidium iodide to analyzewhether apoptotic
cell death was induced. The nuclear morphology of 16  0.9% and
22  2.4% HL-60 cells showed early or late apoptosis stages upon
treatment with 15 mM ABNM-13 for 24 and 48 h, respectively
(Fig. 5a). Incubation with 15 nM Ara-C or the combination of 15 mM
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Fig. 4. (a–c) Cell cycle distribution in HL-60 cells after incubationwith ABNM-13 and/or Ara-C. HL-60 cells (0.4  106 per ml) were seeded in 25 cm2Nunc tissue culture flasks
and simultaneously incubatedwith 15mMABNM-13 and/or 15 nMAra-C at 37 8C for 24 h under cell culture conditions. Cells were analyzed on a FACSCalibur flow cytometer
(BD Biosciences, San Jose, CA, USA) and cell cycle distributionwas calculatedwithModFit LT software (Verity Software House, Topsham,ME, USA). Data aremeans  standard
errors of three determinations. (d) Expression levels of p(Ser 317)Chk1, Chk1, p(Thr 68)Chk2, Chk2, p(Ser 75)Cdc25A, p(Ser 177)Cdc25A, and Cdc25A after incubationwith ABNM-13
and/or Ara-C. After incubation with 15 mMABNM-13 and/or 15 nM Ara-C for 0.5, 2, 4, 8, and 24 h, HL-60 cells (2  106 per ml) were harvested, washed twice with ice-cold PBS (pH
7.2) and lysed in a buffer containing 150 mM NaCl, 50 mM Tris-buffered saline (Tris pH 8.0), 1% Triton X-100, 1 mM phenylmethylsulfonylfluoride (PMSF) and protease inhibitor
cocktail (PIC; from a 100 stock). The lysate was centrifuged at 12,000 rpm for 20 min at 4 8C, and the supernatant was subjected to Western blot analysis. (e) Expression levels of
Cdc25B, Cdc25C, p(Tyr 15)Cdk1, and Cdk1 after incubation with ABNM-13 and/or Ara-C. After incubation with 15 mMABNM-13 and/or 15 nM Ara-C for 0.5, 2, 4, 8, and 24 h, HL-60
cells (2  106 per ml) were harvested, washed twice with ice-cold PBS (pH 7.2) and lysed in a buffer containing 150 mMNaCl, 50 mM Tris-buffered saline (Tris pH 8.0), 1% Triton X-
100, 1 mM phenylmethylsulfonylfluoride (PMSF) and protease inhibitor cocktail (PIC; from a 100 stock). The lysate was centrifuged at 12,000  rpm for 20 min at 4 8C, and the
supernatant was subjected to Western blot analysis.
P. Saiko et al. / Biochemical Pharmacology 81 (2011) 50–5956
107
ABNM-13 and 15 nM Ara-C for 24 h resulted in only 8.2  0.5% and
13  2.7% apoptotic cells, respectively. Even the exposure of cells to
15 nMAra-C or the combination of 15 mMABNM-13 and 15 nMAra-C
for 48 h led to no more than 10  0.6% and 28  4.8% apoptotic cells,
respectively, suggesting that cell death is at best additive but not
synergistic after simultaneous application of both compounds
(Fig. 5b). The induction of apoptosis was further substantiated by
the cleavage and therefore activation of caspase-3 after 8 and 24 h of
treatment with 15 mM ABNM-13 or the combination of 15 mM
ABNM-13 and 15 nM Ara-C which in turn led to increased protein
levels of gH2AX after 24 h (Fig. 5c). In contrast, 15 nM Ara-C induced
activated caspase-3 and gH2AX levels only marginally. Constitutive
phospho-ATM levels were not enhanced upon treatment with ABNM-
13 and/or Ara-C. Examples of the cellular morphology are provided in
Fig. 5d.
4. Discussion
3Dmolecular spacemodeling techniqueswere used to design in
silico structures specifically to inhibit the activity of ribonucleotide
reductase (RR), which is the rate-limiting enzyme of de novo DNA
synthesis. From a panel of 13 compounds, we found that ABNM-13
is the most active agent with regard to growth inhibition of HL-60
cells.
The analysis of the in situ RR activity evidenced that ABNM-13 is
a powerful RR inhibitor even after a short incubation time and at
low concentrations. In addition, ABNM-13 caused alterations of
deoxyribonucleoside triphosphate (dNTP) pool balance: dGTP
pools were significantly depleted while dTTP pools were elevated.
By misbalancing the concentration of precursors for de novo DNA
synthesis, the latter is blocked in proliferating cells. Cell cycle
[(Fig._5)TD$FIG]
Fig. 5. (a and b) Induction of apoptosis inHL-60 cells after incubationwith ABNM-13 and/or Ara-C. HL-60 cells (0.2  106 per ml) were exposed to increasing concentrations of
ABNM-13 for 24 and 48 h (a) or treated with 15mMABNM-13 and/or 15 nM Ara-C for 24 and 48 h (b). Hoechst 33258 (HO, Sigma, St. Louis, MO, USA) and propidium iodide
(PI, Sigma, St. Louis, MO, USA) were added directly to the cells to final concentrations of 5mg/ml and 2mg/ml, respectively. After 60 min of incubation at 37 8C, cells were
counted under a fluorescence microscope and the number of apoptotic cells was given as percentage value. Data are means  standard errors of three determinations. (c)
Expression levels of cleaved caspase-3 and gH2AX after incubationwith ABNM-13 and/or Ara-C. After incubationwith 15 mMABNM-13 and/or 15 nMAra-C for 0.5, 2, 4, 8, and 24 h,
HL-60 cells (2  106 per ml) were harvested, washed twice with ice-cold PBS (pH 7.2) and lysed in a buffer containing 150 mM NaCl, 50 mM Tris-buffered saline (Tris pH 8.0), 1%
Triton X-100, 1 mM phenylmethylsulfonylfluoride (PMSF) and protease inhibitor cocktail (PIC; from a 100 stock). The lysate was centrifuged at 12,000 rpm for 20 min at 4 8C, and
the supernatant was subjected toWestern blot analysis. (d) Examples of the cellular morphology. After incubation with increasing concentrations of ABNM-13 for 48 h, HL-60 cells
were double stained with Hoechst dye 33258 plus propidium iodide. In comparison to untreated controls, the cell morphology of HL-60 cells after treatment showed nuclear
condensation and apoptotic bodies (early apoptosis) or loss of membrane integrity (late apoptosis).
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perturbations, growth arrest and induction of apoptosis are the
consequences, as it was observed in the course of ABNM-13
treatment.
The prime effect of ABNM-13was a strong S-phase arrest which
is consistent with the role of RR as the rate limiting enzyme for S-
phase transit and the fact that inhibition of RR leads to inhibition of
cells in S-phase [39]. It has been suggested that cells in which RR
was inhibited by HU may enter the early S-phase at a normal rate
and accumulate there until they undergo apoptosis [40,41]. The
protein level of the constitutively expressed R1 subunit of RR
remained unchanged. In contrast, the S-phase specific R2 subunit
and also the p53R2 subunit of the enzyme were elevated although
HL-60 cells are p53 deficient, indicating a compensatory up-
regulation through which the cells try to rebalance their dNTP
production. However, these findings are in line with the
observations made by Yanomoto et al. [42] who demonstrated
that basal levels of p53R2 are expressed regardless of the cellular
p53 status and of Zhang et al. [43] who showed that up-regulation
of the R2 protein levels occurs in response to DNA damage and
involves up-regulation and activation of Chk1.
DNA damage or disrupted dNTP balance and incomplete DNA
synthesis activate cell cycle checkpoints to prevent DNA synthesis
and cell cycle progression [44–46] and to provide time for repair
before thedamagegetspassedon todaughter cells or toallow for the
reconstitution of the dNTP pools. These regulatory pathways govern
the order and timing of cell cycle transitions to ensure completion of
one cellular event prior to commencement of another. Before
mitosis, cells have to pass G1–S, intra-S, and G2–M cell cycle
checkpoints, which are controlled by their key regulators, ATR and
ATM protein kinases, through activation of their downstream
effector kinasesChk1andChk2, respectively [46,47]. ActivatedChk1
and Chk2 phosphorylate the Cdc25A phosphatase at Ser75 and
Ser177, respectively, and target it for proteasomal degradation.
Cdc25A is an oncogene and required for cell cycle transit. Treatment
with ABNM-13 activated both Chk1 and Chk2, the latter being
phosphorylated within as little as 30 min.
Both Cdc25B and Cdc25C induce mitosis by activating Cdk1/
cyclin B [48], and Cdc25B has been implicated as the initial
phosphatase to activate Cdk1/cyclin B [49]. Activated Cdk1/cyclin
B then phosphorylates and activates Cdc25C, which in turn keeps
Cdk1/cyclin B active, creating a positive feedback loop that drives
the cell through mitosis [50]. Cdc25B protein levels were
upregulated by ABNM-13, leading to dephosphorylation and
activation of Cdk1. Cdc25C levels remained unchanged. In contrast,
Ara-C induced Cdk1 protein expression, and co-treatment with
Ara-C and ABNM-13 resulted in both an increase of Cdk1 levels and
subsequent increase of its activity. Undue overexpression of
Cdc25B, i.e. when Cdc25A is unavailable, and consequent
dephosphorylation of Cdk1/cyclin B, as observed in this study,
was shown to induce cell cycle arrest by abrogating entry into
mitosis [51]. Furthermore, Cdk2, as being regulated by Cdc25A, is
required for S-phase progression [52]. Therefore, the combined
effect of Cdc25A degradation and Cdc25B overexpression most
likely caused the almost complete S-phase arrest induced by
ABNM-13 alone and together with Ara-C (Fig. 6). Apoptosis upon
treatment with ABNM-13 occurred in only 22% of cells (after 48 h),
indicating that cell cycle inhibition rather than induction of
programmed cell death seems to be the primary antineoplastic
effect of ABNM-13. We therefore believe that a portion of treated
cells was growing much slower than untreated controls, but did
not undergo necrosis or apoptosis. The latter was further
determined by the expression of cleaved caspase-3 (after 8 h)
which in turn led to elevation of gH2AX protein levels (after 24 h),
suggesting that treatment with ABNM-13 was not the primary
cause for DNA double strand breaks but the consequence of
caspase-3 induced DNAse activation. This was supported by the
fact that constitutive phospho-ATM levels were not elevated,
either. Cell death viamitotic catastrophe (i.e. the formation of giant
cells with two or more nuclei) being promoted by Chk2 inhibition
[53,54] could not be observed at any time point.
Combination treatment is expected to produce fortified
antitumor effects, if the pharmacokinetic and pharmacological
properties are different from each other. Accordingly ABNM-13,
which disregulated dTTP and dGTP pools and Ara-C, which is
known to affect dCTP pools [55–57] inhibited cell proliferation
synergistically. Using a sequential combination of ABNM-13 and
Ara-C, all 12 concentrations applied yielded highly synergistic
antineoplastic effects.
Taken together, we demonstrate that the novel RR inhibitor
ABNM-13 exerts pronounced anticancer activity both as single
agent and as enhancer of another antitumor drug such as Ara-C.
Due to these promising results, ABNM-13 may support conven-
tional chemotherapy of human malignancies and therefore
deserves further preclinical and in vivo testing.
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Abstract
Resveratrol is a naturally occurring anticancer compound present in grapes and wine with antiproliferative
properties against breast cancer cells and xenografts. Our objective was to investigate the metabolic alterations
that characterize the effects of resveratrol in the human breast cancer cell lines MCF-7 and MDA-MB-231 using
high-throughput liquid chromatography-based mass spectrometry. In both cell lines, growth inhibition was dose
dependent and accompanied by substantial metabolic changes. For all 21 amino acids analyzed levels increased
more than 100-fold at a resveratrol dose of 100 mM with far lower concentrations in MDA-MB-231 compared to
MCF-7 cells. Among the biogenic amines and modiﬁed amino acids (n¼ 16) resveratrol increased the synthesis
of serotonin, kynurenine, and spermindine in both cell lines up to 61-fold indicating that resveratrol strongly
interacts with cellular biogenic amine metabolism. Among the eicosanoids and oxidized polyunsaturated fatty
acids (n¼ 17) a pronounced increase in arachidonic acid and its metabolite 12S-HETE was observed in MDA-
MB-231 and to a lesser extent in MCF-7 cells, indicating release from cell membrane phospholipids upon
activation of phospholipase A2 and subsequent metabolism by 12-lipoxygenase. In conclusion, metabolomic
analysis elucidated several small molecules as markers for the response of breast cancer cells to resveratrol.
Introduction
Breast cancer is a major cause of cancer death in wo-men worldwide. Evidence from epidemiological and ex-
perimental studies indicates that certain natural constituents of
diet may act as chemopreventive agents and inhibit mammary
carcinogenesis. One such compound is resveratrol (3,40,5-
trihydroxy-trans-stilbene), which is produced by several plants,
berries, and fruits, and ismainly found in the skin of grapes and
red wine. The antiproliferative property of resveratrol has been
demonstrated in vitro against hormone-dependent and hor-
mone-independent breast cancer cells and is due to the induc-
tion of apoptosis via downregulation of NF-kappa B and Bcl-2
(Bove et al., 2002; Garvin et al., 2006; Nakagawa et al., 2001;
Pozo-Guisado et al., 2002). Also, resveratrol signiﬁcantly de-
creases extracellular vascular endothelial growth factor (VEGF)
and effectively inhibits ribonucleotide reductase, which cata-
lyzes the rate-limiting step of the de novo DNA synthesis and is
highly upregulated in rapidly proliferating tumor cells (Fonte-
cave et al., 2002; Horvath et al., 2005). Resveratrol has also been
shown to arrest cells in the S and G2 phases of the cell cycle
(Ragione et al., 1998). Moreover, resveratrol is active in the in-
hibition of cyclooxygenases (COX-1, COX-2) (Murias et al.,
2004), which partly explains why this compound also reduces
the occurrence of colon and breast cancer (Anderson et al.,
2003). In addition to these in vitrodata, experiments have shown
signiﬁcantly less tumor growth in human breast cancer xeno-
grafts in vivo, supporting the use of this polyphenol as a po-
tential chemotherapeutic agent (Nakagawa et al., 2001).
Although gene and protein expression in breast cancer cells
after resveratrol treatment have been extensively proﬁled,
there are no data about the metabolic alterations caused by
this compound. In contrast to genetics and proteomics, the
identiﬁcation and quantiﬁcation of speciﬁc metabolites in
tumor cells provide high-resolution biochemical snapshots
depicting the functional endpoints of the physiologic state of
an organism, including the effects of drug disposure (Deber-
ardinis et al., 2008; Weinberger and Graber 2005).
Studies conducted on laboratory animals and humans have
reported a very low oral bioavailability of resveratrol based
1Department of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria.
2Biocrates Life Sciences AG, Innsbruck, Austria.
3Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
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on extensive metabolism in gut and liver to several glucuro-
nides and sulfates. In human breast cancer cell lines, however,
resveratrol is exclusively metabolized to trans-resveratrol-3-
O-sulfate. Surprisingly, in this setting the concentrations of
resveratrol glucuronides were below the detection limits
(Murias et al., 2008). Furthermore, recent data from our
lab also demonstrate that trans-resveratrol-3-O-sulfate was
about threefold less cytotoxic against the hormone-dependent
MCF-7 and the hormone-independent MDA-MB-231 human
breast cancer cell lines with IC50 values of about 200 mM, in-
dicating that sulfation of resveratrol has only aminor effect on
cell growth inhibition (Miksits et al. 2010). Therefore, we used
these cell lines to investigate possible alterations in the cellular
concentrations of amino acids, biogenic amines, eicosanoids,
and polyunsaturated fatty acids after resveratrol application
using a targeted metabolomic approach. This information is
important as some small molecules analyzed in this study
may act as markers for the anticancer activity of resveratrol.
Materials and Methods
Materials
Resveratrol (3,40,5-trihydroxy-trans-stilbene, 99% GC) and
dimethyl sulfoxide (DMSO) were obtained from Sigma-
Aldrich (Munich, Germany). All other chemicals and solvents
were commercially available, of analytical grade, and used
without further puriﬁcation.
Cell culture
MCF-7 and MDA-MB-231 breast cancer cells were pur-
chased from the American Type Culture Collection (ATCC,
Rockville, MD, USA). Both cell lines were grown in phenolred-
free RPMI 1640 tissue culture medium including L-glutamine
(PAN Biotech, Aldenbach, Germany), supplemented with 10%
heat-inactivated fetal bovine serum (FBS) and 1% penicillin-
streptomycin (Gibco InvitrogenCorp., Grand Island,NY,USA)
under standard conditions at 378C in a humidiﬁed atmosphere
containing 5% CO2 and 95% air. Twenty-four hours before
treatment, cells were transferred to a RPMI 1640 medium
supplemented with 2.5% charcoal-stripped FBS (PAN Biotech,
Aidenbach, Germany) and 1% penicillin–streptomycin. Cells
were placed into 15-cm plates and allowed to attach overnight.
Resveratrol was dissolved in DMSO and diluted with medium
(ﬁnal DMSO concentration <0.1%) to 5–100mM. Experiments
under each set of conditionswere carried out in triplicate. Blank
experiments contained DMSO in the medium in place of re-
sveratrol. After 72 h, media were aspirated by suction and ali-
quots (100mL) were analyzed by LC-MS/MS. In parallel, cells
were scraped off, washed three times with phosphate-buffered
saline, and lysed in ethanol/phosphate buffer (85/15v/v) by
repeating (three times) shock freezing in liquid nitrogen, and
thawing. After centrifugation at 10,000g for 5min, 10 or 20mL
of the supernatant (cytoplasm) was subjected to the LC-MS/
MS quantiﬁcation assays.
Cell growth inhibition
The effect of resveratrol (0–100 mM) on the in vitro growth of
MCF-7 and MDA-MB-231 cells was evaluated after 72 h of
resveratrol application under identical conditions (see above)
using the CellTiter-Glo Luminescent Cell Viability Assay
(Promega, Madison, WI, USA) and a Victor microplate
reader (Perkin-Elmer, Waltham, MA, USA) according to the
manufacturer’s instructions.
Targeted metabolomics
Using a high-throughput liquid chromatography-based
mass spectrometry platform for targeted metabolomics, 54
analytes were quantiﬁed in cell pellets and in medium at
Biocrates Life Sciences AG, Austria. Multiple reaction moni-
toring detection was performed using a 4000 Q TRAP tandem
mass spectrometry instrument (Applied Biosystems, Bedford,
MA, USA) to obtain concentration data, which were ﬁnally
exported for statistical analysis. Metabolomics datawere used
as received from Biocrates. No data correction or removal of
data points was applied. The experimental metabolomics
measurement technique was carried out as previously de-
scribed (Gieger et al., 2008).
Statistical analysis
Unless otherwise indicated, values are expressed as mean
SD of three individual experiments. Statistical differences from
control values were evaluated using the Students’ paired t-test
at a signiﬁcance level of p< 0.05 using the Prism program
(version 5.0, GraphPad Software Inc., San Diego, CA, USA).
Results
Amino Acids
Resveratrol signiﬁcantly reduced cell viability in the cancer
cell lines MCF-7 and MDA-MB-231, yielding IC50 values of
68.3 2.6 and 67.6 4.1mM, respectively (data not shown). Cell
growth inhibition was accompanied by substantial metabolic
changes,whichwere dose dependent but different between both
cell lines. After 72h of cell growth in the presence of resveratrol,
the concentrations in themedium of all 21 analyzed amino acids
(19 proteinogenic, 2 nonproteinogenic) were substantially in-
creased compared to resveratrol-free controls. ForMDA-MB-231
cells, this effect was less pronounced than for theMCF-7 cell line
(data not shown). In the presence of resveratrol, the maximum
changes seen between resveratrol-treated cells and controlswere
21-fold for serine in MCF-7 cell culture and 63-fold for methio-
nine in MDA-MB-231 cells (Table 1). Signiﬁcant increases in the
synthesis of all amino acids under resveratrol treatmentwas also
observed in the cytoplasm ofMDA-MB-231 cells (up to 18-fold),
whereas the concentrations of many amino acids, most notably
aspartic acid, glutamine, glycine, and ornithine in MCF-7 cells
were decreased (0.42 to 0.56-fold) (Table 1).
Biogenic Amines and Modified Amino Acids
Metabolic changes in response to resveratrol were also seen
for biogenic amines and modiﬁed amino acids (n¼ 16). As
already observed for amino acids, much higher concentra-
tions were seen in the medium of MCF-7 cells than in the
MDA-MB-231 cell line. In cytoplasm, however, concentra-
tions in both cell lines were very low or below the detection
limit (Table 1). Most important, resveratrol signiﬁcantly in-
creased the synthesis of serotonin, kynurenine, spermidine,
and spermine by up to ﬁvefold in MCF-7 and up to 61-fold in
MDA-MB 231 compared with controls (Fig. 1), indicating that
resveratrol strongly interacts with cellular biogenic amine
metabolism. Furthermore, resveratrol induced the oxidation
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Table 1. Influence of Resveratrol (100mM) on the Metabolite Concentrations in Cells
and Medium of MCF-7 and MDA-MB-231 Cells Given as n-Fold Changes to the Control
MCF-7 MDA-MB-231
Metabolite Cells Medium Cells Medium
Amino acids
Alanine 0.81 2.16 7.51 18.51
Arginine 0.82 2.53 5.55 6.25
Asparagine 0.75 5.34 9.50 15.08
Aspartic acid 0.42 5.35 4.33 5.56
Citrulline 1.33 3.08 n.d. 4.51
Glutamine 0.49 1.85 7.01 5.28
Glutamic acid 1.02 3.71 5.25 11.47
Glycine 0.56 3.58 9.71 14.61
Histidine 0.99 1.87 13.50 6.22
Isoleucine 1.66 4.03 18.02 37.7
Leucine 1.31 4.01 16.32 55.25
Lysine 1.06 2.59 6.33 5.53
Methionine 1.51 3.20 14.99 63.44
Ornithine 0.51 2.21 5.03 6.40
Phenylalanine 1.12 1.87 9.47 9.89
Proline 0.90 1.55 5.69 4.46
Serine 0.83 21.08 5.37 18.78
Threonine 0.86 2.15 8.34 5.51
Tryptophan 1.57 2.09 7.04 41.26
Tyrosine 0.99 2.01 12.87 9.21
Valine 1.34 2.81 18.08 29.70
Biogene amines and modified amino acids
ADMA (Asymmetric dimethylarginine) n.d. 1.09 n.d. 3.52
SDMA (Symmetric dimethylarginine) 1.0 1.0 n.d. 3.14
Creatinine n.d. 1.51 n.d. 3.53
Histamine n.d. 1.08 n.d. 4.33
Kynurenine n.d. 1.54 n.d. 4.01
Methionine-sulfoxide n.d. 1.71 n.d. 5.24
Nitrotyrosine n.d. n.d. n.d. 4.98
Hydroxykynurenine n.d. 1.62 n.d. 7.45
Hydroxyproline n.d. n.d. n.d. n.d.
PEA (Phenylethylamine) n.d. n.d. n.d. n.d.
Putrescine 0.27 1.20 n.d. 4.60
Sarcosine 0.67 3.21 n.d. 2.91
Serotonin n.d. 5.20 n.d. 3.66
Spermidine 1.78 5.25 n.d. 39.90
Spermine 1.46 2.46 3.12 61.31
Taurine 0.61 11.28 5.75 14.38
Eicosanoids and oxidized polyunsaturated fatty acids
12S-HETE (12(S)-Hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid) n.d. 5.98 n.d. 5.14
15S-HETE (15(S)-Hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid) n.d. n.d. n.d. n.d.
5S-HpETE (5(S)-Hydroperoxy-6E,(Z,11Z,14Z-eicosatetraenoic acid) n.d. n.d. n.d. n.d.
14(15)-EpETE (()14,15-Epoxy-5Z,8Z,11Z,17Z-eicosatetraenoic acid) n.d. n.d. n.d n.d.
15S-EpETE (15(S)-Hydroperoxy-5Z,8Z,11Z,13E-eicosatetraenoic acid) n.d. n.d. n.d. n.d.
9-HODE (()9-Hydroxy-10E,12Z-octadecadienoic acid) 2.86 1.84 0.83 2.33
13S-HODE (13-Hydroxy-9Z,11E-octadecadienoic acid) 2.64 2.11 2.11 1.35
Arachidonic acid 1.03 2.90 1.18 84.03
Docosahexaenoic acid 1.88 2.22 3.16 9.51
Leukotriene B4 n.d. 10.82 n.d. n.d.
Leukotriene D4 n.d. n.d. n.d. n.d.
Prostaglandin D2 n.d. n.d. n.d. n.d.
Prostaglandin E2 n.d. 0.35 n.d. 0.07
Prostaglandin F2a n.d. 0.67 n.d. 1.08
6-keto-Prostaglandin F1a n.d. n.d. n.d. n.d.
8-iso-Prostaglandin F2a n.d. n.d. n.d. n.d.
Thromboxane B2 n.d. n.d. n.d. n.d.
Values in bold indicate signiﬁcant changes (p< 0.05).
n.d., not detectable.
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of methionine to methionine sulfoxide by 1.7- and 5.24-fold in
MCF-7 and MDA-MB-231 cells, respectively (Table 1). Phe-
nylalanine and phenylethylamine (PEA) concentrations were
below the detection limits in both cell lines.
Eicosanoids and Oxidized Polyunsaturated Fatty Acids
Among the 17 analytes quantiﬁed, a marked increase in
extracellular arachidonic acid and its metabolite 12S-HETE
(12(S)-hydroxy-5Z,8Z,10,E14Z-eicosatetraenoic acid) was ob-
served (Fig. 1). Concentrations of the linoleic acidsmetabolites
13S-HODE [13(S)-hydroxy- 9Z, 11E-octadecadienoic acid]
and 9-HODE [()9-hydroxy-10E,12Z-octadecadienoic acid]
were also increased by resveratrol. Remarkably, extracellular
arachidonic acid concentrations rose 84-fold in MDA-MB-231
cells cultures, but only 2.9-fold in MCF-7 cells compared to
control (Fig. 1). Also, resveratrol signiﬁcantly reduced pros-
taglandin E2 (PGE2) levels in the medium of MDA-MB-231
FIG. 1. Induction of serotonin (A), kynurenine (B), spermidine (C), spermine (D), arachidonic acid (E), and 12S-HETE (F) in
the human breast cancer cell lines MCF-7 and MDA-MB-231 after incubation with resveratrol (0–100 mM) for 72 h. Data
represent the mean SD of triplicate determinations.
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cells (>99%), whereas the reduction in MCF-7 cells was less
pronounced (65%) (Table 1). Several other oxidized polyun-
saturated fatty acids and prostaglandins as well as leucotriene
D4 and thromboxane B2 were below the detection limit.
Discussion
In the present study, we investigated themetabolic changes
in two human breast cancer cell lines after resveratrol appli-
cation (5–100 mM). These concentrations were chosen based
on daily intake of resveratrol as beverage (red wine) or as
dietary supplement (5–100mg/day). By quantifying 54 ana-
lytes, we found that resveratrol signiﬁcantly induced the
synthesis of 21 amino acids with far higher concentrations in
MCF-7 than inMDA-MB-231 cells. In both cell lines, all amino
acids were substantially released from the cytoplasm into the
medium, which is often caused by cell swelling and the oc-
currence of reactive oxygen species (Lambert, 2007). Resver-
atrol also profoundly modulated the polyamine biosynthesis
in both cell lines. Tryptophan, serotonin, and kynurenine in-
creased signiﬁcantly in the presence of resveratrol, indicating
that enzymatic conversion of tryptophan to the bioactive
metabolite serotonin through tryptophanhydroxylase and to
kynurenine through tryptophan-2,3-dioxygenase and mono-
oxygenase was stimulated. Kynurenine was further metabo-
lized to hydroxykynurenine3-hydroxy-kynurenine with
much higher concentrations in the medium of MDA-MB-231
cells than in the MCF-7 cell line (Fig. 1).
Treatment of both breast cancer cell lines with resveratrol
also stimulated the synthesis of putrescine and spermidine
indicating activation of ornithine decarboxylase and spermi-
dine synthase, respectively. Interestingly, synthesis of sper-
mine from spermidine was stimulated in MDA-MB-231 cells
but inhibited in MCF-7 cells. Because putrescine, spermidine
and spermine are essential for a variety of cellular processes
related to signal transduction, resveratrol-induced growth
and differentiation changes in polyamine metabolism may be
directly linked to cell vitality (Takao et al., 2006). Conversion
of putrescine to the metabolically active polyamines spermi-
dine and spermine occurs early during cell proliferation. It is
mediated by S-adenosylmethionine decarboxylase (SADMC),
the rate-limiting enzymes of polyamine biosynthesis. Similar
to ornithine decarboxylase (ODC), SADMC activity is in-
creased in proliferating cells (Milovic et al, 2000). In human
colon adenocarcinoma CaCo-2 cells, resveratrol, and the an-
alog (Z)-3,5,40-trimethoxystilbene have been shown to reduce
ODC and SADMC activities by depletion of the polyamines
putrescine and spermidine, exerting their cytotoxic effects by
depleting the intracellular pool of polyamines (Schneider
et al., 2003; Wolter et al., 2003). In contrast to colon cancer
cells, resveratrol stimulated putrescine and spermidine syn-
thesis in MCF-7 and MDA-MB-231 cells, indicating that cell
growth inhibition may rather be caused by high polyamine
concentrations, which have also been to induce cell death
(Takao et al., 2006).
Our study also showed a pronounced increase in extra-
cellular arachidonic acid and its metabolite 12S-HETE at high
resveratrol concentrations, indicating the release of arachi-
donic acid from cell membrane phospholipids upon activa-
tion of phospholipase A2. Arachidonic acid is subsequently
converted to 12S-HETE through the action of 12-lipox-
ygenase. Increased levels of 12S-HETEmay therefore indicate
oxidative stress in tumor cells under resveratrol treatment
(Nazarewicz et al, 2007). Furthermore, resveratrol also re-
duced prostaglandin E2 (PGE2) levels, thus conﬁrming that
this polyphenol is an inhibitor of cyclooxygenase 2 (Murias
et al. 2004). In conclusion, we revealed several small mole-
cules as novel markers for the anticancer activity of resvera-
trol. Further investigations are required to better understand
the resveratrol-inducedmetabolic differences between hormone-
sensitive and hormone-insensitive cell lines.
Acknowledgments
This study was supported by grants of the Jubila¨umsfonds
der O¨sterreichischen Nationalbank (12600 to W.J.) and FWF
(P21083-B11 to W.J.).
Author Disclosure Statement
No competing ﬁnancial interests exist.
References
Anderson, W.F., Umar, A., and Hawk, E.T. (2003). Cycloox-
genase inhibition in cancer prevention and treatment. Expert
Opin Pharmacother 4, 2193–2204.
Bove, K., Lincoln, D.W., and Tsan, M.F. (2002). Effect of re-
sveratrol on growth of 4T1 breast cancer cells in vitro and
in vivo. Biochem Biophys Res Commun 291, 1001–1005.
Deberardinis, R.J., Sayed, N., Ditsworth, D., and Thompson, C.B.
(2008). Brick by brick: metabolism and tumor cell growth.
Curr Opin Genet Dev 18, 54–61.
Fontecave, M., Lepoivre, M., Elleingand, E., Gerez, C., and
Guittet, O. (1998). Resveratrol, a remarkable inhibitor of ri-
bonucleotide reductase. FEBS Lett 421, 277–279.
Garvin, S., Ollinger, K., and Dabrosin, C. (2006). Resveratrol
induces apoptosis and inhibits angiogenesis in human breast
cancer xenografts in vivo. Cancer Lett 231, 113–122.
Gieger, C., Geistlinger, L., Altmaier, E., Hrabe de Angelis, M.,
Kronenberg, F., Meitinger, T., et al. (2008). Genetics meets
metabolomics: a genome-wide association study of metabolite
proﬁles in human serum. PLoS Genet 4, e1000282.
Horvath, Z., Saiko, P., Madlener, S., Hoechtl, T., Bauer, W., Er-
ker, T., et al. (2005). Synergistic action of resveratrol, an in-
gredient of wine, with Ara-C and tiazofurin in HL-60 human
promyelocytic leukemia cells. Exp Hematol 33, 329–335.
Lambert, I.H. (2007). Activation and inactivation of the volume-
sensitive taurine leak pathway in NIH3T3 ﬁbroblasts and Ehr-
lich Lettre ascites cells. Am J Physiol Cell Physiol 293, 390–400.
Milovic, V., Stein, J.E.,Odera, G., Gilani, S., and Murphy, G.M.
(2000). Low-dose deoxycholic acid stimulates putresine up-
take in colon cancer cells (Caco-2). Cancer Lett 154, 195–200.
Miksits, M., Wlcek, K., Svoboda, M., Kunert, O., Haslinger, E.,
Thalhammer, T., et al. (2010). Antitumor activity of resveratrol
and its sulfated metabolites against human breast cacner cells.
Planta Medica 75, 1–4.
Murias, M., Handler, N., Erker, T., Pleban, K., Ecker, G., Saiko,
P., et al. (2004). Resveratrol analogues as selective cycloox-
ygenase-2 inhibitors: synthesis and structure–activity rela-
tionship. Bioorg Med Chem 12, 5571–5578.
Murias, M., Miksits, M., Aust, S., Spatzenegger, M., Thalham-
mer, T., et al. (2008). Metabolism of resveratrol in breast cacner
cell lines: impact of sulfotransferase 1A1 expression on cell
growth inhibition. Cancer Lett 261, 172–182.
Nakagawa, H., Kiyozuka, Y., Uemura, Y., Senzaki, H., Shikata,
N, Hioki, K., et al. (2001). Resveratrol inhibits human breast
METABOLOMIC ANALYSIS IN BREAST CANCER CELLS 13
117
cancer cell growth and may mitigate the effect of linoleic acid,
a potent breast cancer cell stimulator. J Cancer Res Clin Oncol
127, 258–264.
Nazarewicz, R., Zenebe, W.J., Parihar, A., Parihar, M.S., Vaccaro,
M., Rink, C., et al. (2007). 12(S)-hydroperoxyeicosatetraenoic
acid (12-HETE) increases mitochondrial nitric oxide by in-
creasing intramitochondrial calcium. Arch Biochem Biophys
468, 114–120.
Pozo-Guisado, E., Alvarez-Barrientos, A., Mulero-Navarro, S.,
Santiago-Josefat, B., and Fernandez-Salguero, P.M. (2002). The
antiproliferative activity of resveratrol results in apoptosis in
MCF-7 but not in MDA-MB-231 human breast cancer cells:
cell-speciﬁc alteration of the cell cycle. Biochem Pharmacol 64,
1375–1386.
Ragione, F.D., Cucciolla, V., Boriello, A., Pietra, V.D., Racioppi,
L., Soldati, G., et al. (1998). Resveratrol arrests the cell division
cycle at S/G2 phase transition. Biochem Biophys Res Com-
mun 250, 53–58.
Schneider, Y., Chabert, P., Stutzmann, J., Coelho, D., Fouger-
ousse, A., Gosse, F., et al. (2003). Resveratrol analog (Z)-3,5,40-
trimethoxystilbene is a potent anti-mitotic drug inhibiting
tubulin polymerization. Int J Cancer 107, 189–196.
Takao, K., Rickhag, M., Hegardt, C., Oredsson, S., and Persson,
L. (2006). Induction of apoptotic cell death by putrescine. Int J
Biochem Cell Biol 38, 621–628.
Weinberger, K.M., and Graber, A. (2005). Using comprehensive
metabolomics to identify novel biomarkers. Screen Trends
Drug Discov 6, 42–45.
Wolter, F., Turchanova, L., and Stein, J. (2003). Resveratrol-
induced modiﬁcation of polyamine metabolism is accompa-
nied by induction of c-Fos. Carcinogenesis 24, 469–474.
Address correspondence to:
Prof. Walter Ja¨ger
Department of Clinical Pharmacy and Diagnostics
University of Vienna
A-1090 Vienna, Austria
E-mail: walter.jaeger@univie.ac.at
14 JA¨GER ET AL.
118
  
 
 
 
NF-κB mediates the 12(S)-HETE-induced endothelial to 
mesenchymal transition of lymphendothelial cells during the 
intravasation of breast carcinoma cells. 
 
 
Vonach C., Viola K., Giessrigl B., Huttary N., Raab I., Kalt R., Krieger S., 
Vo T.P., Madlener S., Bauer S., Marian B., Hämmerle M., Kretschy N., 
Teichmann M., Hantusch B., Stary S., Unger C., Seelinger M., Eger A., 
Mader R., Jäger W., Schmidt W., Grusch M., Dolznig H., Mikulits W. and 
Krupitza G. 
 
 
Br. J. Cancer 105: 263-271, 2011. 
119
 120
NF-kB mediates the 12(S)-HETE-induced endothelial to
mesenchymal transition of lymphendothelial cells during
the intravasation of breast carcinoma cells
C Vonach1,2, K Viola1,2, B Giessrigl1, N Huttary1, I Raab1, R Kalt1, S Krieger1, TPN Vo1, S Madlener1, S Bauer1,
B Marian2, M Ha¨mmerle1, N Kretschy1, M Teichmann1, B Hantusch1, S Stary1, C Unger1, M Seelinger1, A Eger3,
R Mader2, W Ja¨ger4, W Schmidt5, M Grusch2, H Dolznig1,6, W Mikulits2 and G Krupitza*,1
1Institute of Clinical Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; 2Department of Medicine I, Institute of
Cancer Research, Medical University of Vienna, Vienna, Austria; 3University of Applied Science, Krems, Austria; 4Department of Clinical Pharmacy and
Diagnostics, University of Vienna, Vienna, Austria; 5Neuromuscular Research Department, Center for Anatomy and Cell Biology, Medical University of
Vienna, Vienna, Austria; 6Institute of Medical Genetics, Medical University of Vienna, Vienna, Austria
BACKGROUND: The intravasation of breast cancer into the lymphendothelium is an early step of metastasis. Little is known about the
mechanisms of bulky cancer invasion into lymph ducts.
METHODS: To particularly address this issue, we developed a 3-dimensional co-culture model involving MCF-7 breast cancer cell
spheroids and telomerase-immortalised human lymphendothelial cell (LEC) monolayers, which resembles intravasation in vivo and
correlated the malignant phenotype with specific protein expression of LECs.
RESULTS: We show that tumour spheroids generate ‘circular chemorepellent-induced defects’ (CCID) in LEC monolayers through
retraction of LECs, which was induced by 12(S)-hydroxyeicosatetraenoic acid (HETE) secreted by MCF-7 spheroids. This 12(S)-
HETE-regulated retraction of LECs during intravasation particularly allowed us to investigate the key regulators involved in the motility
and plasticity of LECs. In all, 12(S)-HETE induced pro-metastatic protein expression patterns and showed NF-kB-dependent up-
regulation of the mesenchymal marker protein S100A4 and of transcriptional repressor ZEB1 concomittant with down-regulation of
the endothelial adherence junction component VE-cadherin. This was in accordance withB50% attenuation of CCID formation by
treatment of cells with 10mM Bay11-7082. Notably, 12(S)-HETE-induced VE-cadherin repression was regulated by either NF-kB or
by ZEB1 since ZEB1 siRNA knockdown abrogated not only 12(S)-HETE-mediated VE-cadherin repression but inhibited VE-cadherin
expression in general.
INTERPRETATION: These data suggest an endothelial to mesenchymal transition-like process of LECs, which induces single cell motility
during endothelial transmigration of breast carcinoma cells. In conclusion, this study demonstrates that the 12(S)-HETE-induced
intravasation of MCF-7 spheroids through LECs require an NF-kB-dependent process of LECs triggering the disintegration of
cell–cell contacts, migration, and the generation of CCID.
British Journal of Cancer (2011) 105, 263–271. doi:10.1038/bjc.2011.194 www.bjcancer.com
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Breast cancer is the most common malignancy causing the highest
death rate among women. Noteworthy, patients are not threatened
by the primary tumour, but by metastases that destroy the function
of infested organs. Breast cancer is believed to spread mainly
through the lymphatic vasculature and as soon as carcinoma cell
emboli are detectable in intrametastatic lymphatic vessels of
sentinel lymph nodes (intrametastatic carcinosis), the postsentinel
lymph nodes also fill up with cancer cells (Kerjaschki et al, 2011).
The number of metastasised lymph nodes is a clinical predictor for
the development of distant organ metastases and patient outcome
(Carlson et al, 2009). Hence, understanding early steps of tumour
cell intravasation into the lymphatic vasculature is important for
the development of tailored anti-metastatic treatment concepts.
Ductal breast cancer accesses the lymphatics in bulks generating
gaps in the lymphendothelial cell (LEC) wall that serve as entry
gates for the tumour. Therefore, we aimed to investigate the
mechanisms of breast cancer cells that generate gaps – and as we
now call them – ‘circular chemorepellent-induced defects’ (CCID)
into LEC monolayers to identify potential target molecules for
therapy. In a 3-dimensional (3D) co-culture model in vitro, we
recently demonstrated that human MCF-7 breast cancer spheroids
induced the formation of CCID into LEC monolayers right
underneath the spheroids through centrifugal LEC migration
(Madlener et al, 2010), a process closely resembling the situation in
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human patients. Tumour cells (MCF-7) secrete 12(S)-hydroxy-
eicosatetraenoic acid (HETE) (Uchide et al, 2007), which is
produced by lipoxygenase-15 (ALOX15) in MCF-7 cells. Our recent
study identified this arachidonic acid metabolite as one of the
major factors in the process of CCID formation (Kerjaschki et al,
2011). Notably, 12(S)-HETE was described as the ‘endothelial
retraction factor’ (Honn et al, 1994). The NF-kB promotes
endothelial cell migration (Flister et al, 2010) and in preliminary
experiments, we found that NF-kB inhibition reduced CCID
formation. As the migration of LECs is an early and relevant
event in mammary tumour cell intravasation and metastasis, we
investigated the mechanism of 12(S)-HETE and the role of NF-kB
on LEC motility.
MATERIALS AND METHODS
Chemicals
The I-kBa phosphorylation inhibitor (E)-3-[(4-methylphenylsulfo-
nyl]-2-propenenitrile (Bay11-7082) was from Biomol (Hamburg,
Germany) and 12(S)-HETE was purchased from Cayman Chemical
(Ann Arbor, MI, USA).
Monoclonal antibody against CD144 (VE-cadherin) (PN
IM1597) was from Beckman Coulter (Fullerton, CA, USA). The
polyclonal rabbit anti-paxillin antibody (H-114) (SC-5574), the
monoclonal mouse a-tubulin (DM1A) antibody, and rabbit
polyclonal anti-ZEB1 (H-102) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
Monoclonal mouse antibody phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204) (E10), monoclonal rabbit p44/42 MAPK (Erk1/2)
(137F5) antibody, polyclonal rabbit antibody phospho-myosin light
chain 2 (MLC2) (Ser19), polyclonal rabbit MLC2 antibody, mono-
clonal mouse antibody phospho-Akt (Ser473) (587F11), polyclonal
rabbit Akt antibody, monoclonal rabbit antibody ROCK-1 (C8F7),
polyclonal rabbit ILK1 antibody, and polyclonal rabbit MYPT1
antibody were from Cell Signaling (Danvers, MA, USA). Monoclonal
mouse anti-b-actin (clone AC-15) and monoclonal mouse anti-
acetylated-tubulin (clone 6-11B-1) were from Sigma-Aldrich (Munich,
Germany). The polyclonal rabbit IgG anti-phospho-MYPT1 (Thr696)
was purchased from Upstate (Lake Placid, NY, USA). The polyclonal
rabbit phospho-specific actin (Tyr-53) antibody was from extra-
cellular matrix (ECM) Biosciences (Versailles, KY, USA). Rabbit anti-
S100A4 was purchased from Sigma (St Louis, MO, USA). Polyclonal
goat ARP2/3 subunit 1B antibody was purchased from Abcam
(Cambridge, MA, USA). Polyclonal rabbit anti-mouse and anti-rabbit
IgGs were from Dako (Glostrup, Denmark). Alexa-Fluor 488 (green)
goat-anti-rabbit and Alexa-Fluor 594 (red) goat-anti-mouse labelled
antibodies were purchased from Molecular Probes, Invitrogen
(Karlsruhe, Germany).
Cell culture
Human MCF-7 breast cancer cells were grown in MEM medium
supplemented with 10% fetal calf serum (FCS), 1% penicillin/
streptomycin, 1% NEAA (Invitrogen) at 371C in a humidified
atmosphere containing 5% CO2. Telomerase-immortalised human
LECs were grown in EGM2 MV (Clonetics, Allendale, NJ, USA) at
371C in a humidified atmosphere containing 5% CO2.
For gap formation assays, LECs were stained with cytotracker
green purchased from Invitrogen.
3D co-cultivation of MCF-7 cancer cells with LECs
Mock cells (MCF-7) were transferred to 30ml MEM medium
containing 6ml of a 1.6% methylcellulose solution (0.3% final
concentration; Cat. No.: M-512, 4000 centipoises; Sigma,
Karlsruhe, Germany). A total of 150ml of this cell suspension
were transferred to each well of a 96-well plate (Greiner Bio-one,
Cellstar 650185, Kremsmu¨nster, Austria) to allow spheroid
formation within the following 2 days. Then, MCF-7 spheroids
were washed in phosphate-buffered saline (PBS) and transferred to
cytotracker-stained LEC monolayers that were seeded into 24-well
plates (Costar 3524, Sigma-Aldrich) in 2ml EGM2 MV medium.
CCID assay
The MCF-7 cell spheroids (3000 cells/spheroid) were transferred to
the 24-well plate containing LEC monolayers. After 4 h of
incubating the MCF-7 spheroids-LEC monolayer co-cultures, the
gap sizes in the LEC monolayer underneath the MCF-7 spheroids
were photographed using an Axiovert (Zeiss, Jena, Germany)
fluorescence microscope to visualise cytotracker(green)-stained
LECs underneath the spheroids. Gap areas were calculated with the
Axiovision Re. 4.5 software (Carl Zeiss, Jena, Germany). The
MCF-7 spheroids were treated with solvent (DMSO) as negative
control. Each experiment was performed in triplicate and for each
condition, the gap size of 12 and more spheroids was measured.
Confocal microscopy and immunofluoresce analysis
Lab-Tek II chambered coverglasses (Nalgen Nunc International,
Wiesbaden, Germany) were coated with 10 mgml–1 fibronectin for
1 h at room temperature. Lymphendothelial cells were seeded in
1ml EGM 2MV onto chambered coverslips and allowed to grow
for 2 days followed by co-cultivation with MCF-7 spheroids on LEC
monolayers. After 4 h of incubation, cells were washed with ice-
cold PBS and fixed in 4% paraformaldehyde for 15min at room
temperature. Cells were immunostained with various antibodies
and analysed by confocal microscopy. For this, cells were washed
with PBS and permeabilised with 0.1% Triton X-100 in PBS for
30min at room temperature, followed by washing with PBS and
blocking for 1 h with 10% goat serum diluted in BSA. Thereafter,
the cells were incubated with the primary antibody against
VE-cadherin diluted 1 : 50 for 1 h at room temperature and washed
with PBS. Cells were further incubated with a fluorescence labelled
second antibody diluted 1 : 1000 for 1 h at room temperature in the
dark and washed with PBS. Cells were counterstained with DAPI
(dilution 1 : 50 0000) at room temperature.
Western blotting
Lymphendothelial cells were seeded in 6 cm dishes and treated
with the indicated compounds (10mM Bay11-7082 and or 1 mM
12(S)-HETE). Cells were washed twice with ice-cold PBS and lysed
in buffer containing 150mM NaCl, 50mM Tris pH 8.0, 0,1% Triton
X-100, 1mM phenylmethylsulfonylfluorid and protease inhibitor
cocktail. Afterwards, the lysate was centrifuged at 12 000 r.p.m. for
20min at 41C and the supernatant was stored at 201C until
further analysis. Equal amounts of protein samples were separated
by SDS polyacrylamide gel electrophoresis and electro-transferred
onto Hybond PVDF membranes at 100V for 1 h at 41C. To control
equal sample loading, membranes were stained with Ponceau S.
After washing with PBS/T (PBS/Tween 20; pH: 7.2) or TBS/T (Tris-
buffered saline/Tween 20; pH: 7.6), membranes were immersed in
blocking solution (5% non-fat dry milk in TBS containing 0.1%
Tween or in PBS containing 0.5% Tween 20) at room temperature
for 1 h. Membranes were washed and incubated with the first
antibody (in blocking solution; dilution 1 : 500–1 : 1000) by gently
rocking at 41C overnight or at room temperature for 1 h.
Thereafter, the membranes were washed with PBS/T or TBS/T
and incubated with the second antibody (peroxidase-conjugated
goat-anti-rabbit IgG or anti-mouse IgG; dilution 1 : 2000) at room
temperature for 1 h. Chemiluminescence was detected by ECL
detection kit (Thermo Scientific, Portsmouth, NH, USA) and the
membranes were exposed to Amersham Hyperfilms (GE-Healthcare,
Amersham, Buckinghamshire, UK).
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Transient siRNA transfection
Lymphendothelial cells were grown in 6-well plates to 70%
confluence in EGM 2MV medium. Cells were subsequently
transfected using RNAiFect (Qiagen, Hamburg, Germany). siRNA
(ZEB1 silencer select pre-designed siRNA ID: s13883, and ID:
s13885, and scrambled RNA Ambion; Applied Biosystems, Austin,
TX, USA) was diluted in culture medium containing FCS and
antibiotics (final volume 100ml) to a final concentration of 100 nM.
A total of 15 ml of RNAiFect transfection reagent was added to the
diluted siRNA and incubated for 15min at room temperature.
Then the mixture was added to cells and incubated for 8 h at 371C.
Thereafter, the medium was changed and the cells were incubated
further 48 h. ZEB1 expression was analysed by western blotting.
Statistical analysis
Dose–response curves were analysed using Prism 4 software (San
Diego, CA, USA) and significance was determined by paired
Student’s t-test. Significant differences between experimental
groups were *Po0.05.
RESULTS
12(S)-HETE induces protein expression in LECs associated
with motility
Breast cancer cells (MCF-7) secrete 12(S)-HETE (Uchide et al,
2007), which has been shown to induce the motility of endothelial
cells (Honn et al, 1994). The time-dependent formation of CCIDs
was caused by MCF-7 spheroids in the underneath growing LEC
monolayer (Figures 1A and B). We could demonstrate by time lap
microscopy that MCF-7 spheroid-induced CCID formation was the
result of rapid cell retraction rather than a cell clearence through
apoptosis (Kerjaschki et al, 2011). Confocal laser scanning
microscopy revealed that cell retraction correlated with the
increased phosphorylation of myosin light chain phospho-
transferase (MYPT1, synonym: PPP1R12A) threonine-696 and of
MLC2 serine-19 in underneath growing LECs at the rim of CCIDs
(Figure 1C; upper right corner each, which was covered by the
MCF-7 spheroid), indicating a mobile LEC phenotype. To simplify
the 3D co-culture model consisting of MCF-7 spheroids and LEC
monolayer, in which the role of ALOX15, ALOX12, and 12(S)-
HETE was investigated in detail (Madlener et al, 2010; Kerjaschki
et al, 2011) and to analyse protein expression/activation, LECs
were treated with 1 mM synthetic 12(S)-HETE. Indeed, purified
12(S)-HETE increased the phosphorylation of MYPT1 in LECs
within 1 h (Figure 2A), confirming our recent data (Kerjaschki
et al, 2011). Furthermore, MLC2 showed increased phosphoryla-
tion, which substantiated the fact that 12(S)-HETE induced the
motility of LECs.
Akt is an important component in pro-survival pathways but
also significantly involved in pro-migratory signalling (Burgering
and Coffer, 1995; Franke et al, 1997). Treatment with 12(S)-HETE
transiently increased the level of phosphorylated Akt within 30min
(Figure 2A).
Arp2/3 activity correlates with mesenchymal-type migration,
whereas ROCK-1 is associated with amoeboid migration
(Paulitschke et al, 2010) and both co-regulate the actin cytoske-
leton (Xu et al, 2009; To et al, 2010). 12(S)-HETE stimulated a
marginal increase of ROCK-1 and Arp2/3 expression; however, the
constitutive phosphorylation of actin at the Tyr53 activation site
remained unchanged (Figure 2B).
Paxillin is a focal adhesion phosphoprotein contributing to the
contact between the endothelial cell and the ECM, and its up-
regulation associates with a mobile cell phenotype (Huang et al,
2003; Webb et al, 2004). Treatment of LECs with 12(S)-HETE
caused an increase of paxillin after 2 h (Figure 2C) and a transient
up-regulation of the pro-metastatic Ca2þ signal transducer
S100A4, both suggesting a mesenchymal and mobile phenotype
(Zeisberg and Neilson, 2009). S100A4 expression was reported to
correlate with tubulin polymerisation (Lakshmi et al, 1993), which
is indicated by increased acetylation of a-tubulin (Piperno and
Fuller, 1985). In all, 12(S)-HETE slightly increased tubulin
acetylation (Figure 2C) concomittant with S100A4 up-regulation
and this was accompanied by dephosphorylation (inactivation) of
Erk1/2 (Figure 2D). Active Erk and paxillin mediate disadhesion, a
process required for a directionally migrating cell phenotype
(Webb et al, 2004). The reason for 12(S)-HETE-mediated Erk
inactivation upon treatment remains obscure. It might indicate
that the migratory stimulus was not an attracting one, but a
repelling one, or that 12(S)-HETE-induced LEC adhesion dis-
assemby is independent of Erk. Yet, from the total of the data we
conclude that 12(S)-HETE induced a mesenchymal and mobile
LEC phenotype mandatory for metastatic intravasation.
12(S)-HETE transiently inhibits VE-cadherin expression
and induces endothelial disassembly
For cell–cell cohesion, VE-cadherin is necessary and hence, for
vascular integrity. Therefore, VE-cadherin is a marker for an
endothelial, immobile phenotype that withstands metastatic cell
intravasation. Conversely, metastatic cells have to interefere with
VE-cadherin function to facilitate the migration of LECs. In fact,
treatment of LECs with 12(S)-HETE transiently down-regulated
VE-cadherin expression (Figure 3A).
To investigate the effect of MCF-7 spheroids on VE-cadherin
expression of underneath LECs, we analysed VE-cadherin dis-
tribution by confocal immunofluorescence microscopy. Lymph-
endothelial cells at distance of MCF-7 spheroids showed intact
VE-cadherin structures (Figure 3B). At the margin of CCID, LECs
showed disintegrated and reduced VE-cadherin at cell boundaries,
suggesting disassembly of endothelial organisation (Figure 3C).
The MCF-7 cells constantly produce 12(S)-HETE and, therefore,
the down-regulation of VE-cadherin of underneath growing
LECs was observed even after 4 h of co-culture and was not only
transiently suppressed as seen upon synthetic 12(S)-HETE
treatment.
These data implicate that LEC motility might be caused by the
loss of cell–cell contacts through down-regulation of VE-cadherin
and suggest an endothelial to mesenchymal transition (EMT)-like
process, both by the spheroid as well as by 12(S)-HETE.
ZEB1 contributes to 12(S)-HETE-induced VE-cadherin
repression
E-cadherin is negatively regulated by the transcription factor and
proto-oncogene ZEB1 (Eger et al, 2005; Chua et al, 2007; Peinado
et al, 2007). Therefore, we examined whether VE-cadherin was also
regulated by ZEB1. In fact, 12(S)-HETE rapidly induced ZEB1 that
was accompanied by VE-cadherin repression (Figure 4). Since it
was so far unknown whether ZEB1 also (co)regulates VE-cadherin,
we investigated by siRNA approach whether knockdown of ZEB1
causes loss of VE-cadherin regulation by 12(S)-HETE. Two
different and validated siRNAs were transiently transfected into
LECs to specifically knockdown the expression of ZEB1. This
resulted in the loss of VE-cadherin regulation upon 12(S)-HETE
stimulation (Figure 4). Unexpectedly, blocking ZEB1 expression
down-regulated constitutive VE-cadherin expression, which
implicated that VE-cadherin was not directly regulated by ZEB1.
Inhibition of NF-jB blocks MCF-7-induced gap formation
of LEC
The inhibition of NF-kB translocation with Bay11-7082 blocked
MCF-7 spheroid-induced gap formation of LECs in a
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Figure 1 CCID formation by cell migration. (A) Time lap experiment show the same microscopic power field after 0–5 h co-culture of LECs (upper
panel; cytotracker green, FITC filter) and MCF-7 spheroids (lower panel; phase contrast); The images show the progression of CCID formation over time.
No apoptotic features were observed. Scale bars: 200 mm. (B) The gradual increase of CCID areas over time was measured underneath five MCF-7
spheroids or human normal lung fibroblast spheroids (HLF) after the indicated time points using Axiovision software (Zeiss). Error bars indicate s.e.m.
(C) LECs were grown on coverslips until confluence when MCF-7 spheroids were transferred on top of LECs and co-incubated for 4 h at 371C to allow
CCID formation. LECs were stained with respective antibodies. Confocal laser scanning microscopy of immunocytochemically stained LECs at the
rim of CCID (upper right diagon each, which was the part covered by the MCF-7 spheroid) show elevated levels of phosphorylation (green; FITC filter)
of MYPT threonine-696 (left panel) and MLC2 serine-19 (right panel), indicating increased cell mobility. Nuclei are stained with DAPI (blue). Scale bars:
45mm.
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dose-dependent fashion. A total of 10 mM Bay11-7082 reduced
CCID areas by 50–60% and 15 mM prevented CCID formation
almost completely (Figure 5A). Bay11-7082 is an irreversible
inhibitor of I-kBa phosphorylation and this allowed a specific
experimental design that facilitated to discriminate whether NF-kB
activity of MCF-7 cells or of LECs contributed to CCID formation
of LECs. Therefore, LEC monolayers or MCF-7 spheroids were
each pretreated with Bay11-7082 for 30min followed by a thorough
washing procedure to prevent contaminating spill overs to the
respective other cell type. Subsequently, MCF-7 spheroids were
placed on the LEC monolayer (Figure 5B). Similar levels of
inhibition were achieved when the drug was applied either on
MCF-7 spheroids or on LECs, indicating that NF-kB contributed to
gap formation by at least two mechanisms. Here, we focussed only
on the role of NF-kB in LECs, regulating the change of endothelial
plasticity associated with motility, and studied the expression of
VE-cadherin and S100A4 by Western blot analysis. For this, LECs
were pretreated with Bay11-7082 and then exposed to 12(S)-HETE.
Bay11-7082 caused the up-regulation of VE-cadherin and the
down-regulation of ZEB1 as well as of the mesenchymal marker
protein S100A4 (Figures 6A and B). Immunocytochemistry
confirmed that LECs expressed high levels of the mobility marker
S100A4 (green) underneath MCF-7 spheroids (Figure 6C), which
were down-regulated in the presence of Bay11-7082 (Figure 6D).
Bay11-7082 prevented the suppression of VE-cadherin (red)
underneath spheroids, although the VE-cadherin patterns ap-
peared disintegrated and unconnected to adjacent cell borders
(nuclei are in blue). These data suggest the involvement of NF-kB
in the acquisition of a mesenchymal-like phenotype of LECs, which
induces single cell motility necessary for intravasation of breast
carcinoma cells into the endothelium.
DISCUSSION
The progression of tumours to metastatic outgrowth is the fatal
process of most cancer entities. Metastasis includes multiple steps
such as intravasation of bulky tumours or dissociated single cells
into the vasculature, transport through vessels, extravasation,
invasion of tumour cells in target tissues, and manifestation of
secondary tumours (Geiger and Peeper, 2009). Therefore, the
direct interaction of tumour cells with vascular endothelial cells
(Kramer and Nicolson, 1979) is one of the earliest events that
facilitates intra- and extravasation into and from the blood or
lymphatic vasculature (Honn et al, 1987). The break through of
tumour emboli into intrametastatic lymphatic vessels of sentinel
lymph nodes (Hirakawa et al, 2009) is the preceding step for the
subsequent colonisation of lymph nodes along efferent axes with
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Figure 2 Modulation of protein expression and posttranslational modifications in LECs. LEC monolayers were incubated with 1mM synthetic 12(S)-HETE
and analysed by western blotting after 0.2, 0.5, 1.0, 2.0, and 4.0 h. Equal sample loading was controlled by Ponceau S staining, b-actin (A, B, D), or a-tubulin
(C) expression. Co, untreated LECs.
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carcinoma cells. Notably, this event is indicative for a bad
prognosis of ductal breast cancer (Kerjaschki et al, 2011). Hence,
it is important to understand the mechanisms of tumour/lymph-
endothelial interactions. Here, we used a 3D-co-culture system to
mimic an early step of trespassing breast cancer cells through the
lymphatic vasculature. The generation of CCID into LEC mono-
layers recapitulated the situation in the sentinel and postsentinel
lymph nodes in ductal breast cancer lymph metastasis in humans.
Metastasis was shown to depend on the expression and activity of
ALOXs that produce 12(S)-HETE as in case of MCF-7 spheroids
(Uchide et al, 2007; Kerjaschki et al, 2011). In all, 12(S)-HETE
induces endothelial cell retraction (Honn et al, 1994) and
stimulates tumour cell spreading on the ECM (Timar et al,
1992). Several studies have shown the involvement of ALOXs in
tumour differentiation and progression (Chen et al, 1994; Jiang
et al, 2006; Nithipatikom et al, 2006) and increased levels of
ALOX12 were observed in breast cancer (Jiang et al, 2006). We
identified that LEC migration was the crucial step for CCID
(Kerjaschki et al, 2011) and, therefore, LECs were treated with the
pro-migratory factor 12(S)-HETE to analyse protein expression
that causes or correlates with a mobile cell phenotype. Since 12(S)-
HETE is a labile compound that is rapidly metabolised/degraded,
the effects observed on protein expression were immediate (0.2–
0.5 h) and transient. This was in contrast to the effects on LECs
underneath spheroids, which were long lasting (4 h) due to the
permanent supply of 12(S)-HETE by MCF-7 cells as de novo
generated molecules.
Here, we demonstrated that MYPT1 and MLC2 became
phosphorylated at the rim of MCF-7 spheroid-induced CCID in
LECs. MYPT1 is the regulatory/targeting subunit of the myosin
phosphatase, which regulates the interaction of actin and myosin
in response to signalling through the GTPase Rho (Feng et al,
1999). Phosphorylation leads to the inhibition of MYPT1,
cytoskeletal reorganisation and is associated with motility
(Birukova et al, 2004a, b). In addition, the phosphorylation of
MLC2 at Thr18 and Ser19 (Ikebe and Hartshorne, 1985), which is
correlated with myosin ATPase activity and contraction of
myosine microfilament bundles (Tan et al, 1992), became induced
in LECs upon 12(S)-HETE treatment, and also ROCK-1 became
slightly up-regulated. ROCK is known to phosphorylate MLC2 at
12(S)-HETE
LECM
CF
-7
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VE-cadherin
-Actin
0.2 0.5 2 4 8
Figure 3 Analysis of VE-cadherin expression in LECs. (A) LECs were treated with 1 mM 12(S)-HETE for 0.2, 0.5, 2, 4, and 8 h. Then, cells were harvested
and protein lysates were analysed by western blotting. MCF-7 cells were used as negative control. Equal sample loading was controlled by Ponceau S staining
and b-actin analysis. Confocal immunofluorescence images of LECs next to a spheroid (B) and underneath an MCF-7 spheroid (C). LECs were grown on
coverslips until confluence when MCF-7 spheroids were transferred on top of LECs and co-incubated for 4 h at 371C to allow CCID formation. LECs were
stained with anti-VE-cadherin antibody (red) and DAPI (blue). (B) Distant to a spheroid, VE-cadherin structures appear well developed, whereas (C) VE-
cadherin interactions are disrupted underneath an MCF-7 spheroid. Scale bar: 15 mM. The colour reproduction of this figure is available at the British Journal of
Cancer journal online.
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Figure 4 Effect of ZEB1 suppression on VE-cadherin regulation by
12(S)-HETE. LECs were transiently transfected with two different siRNAs
against ZEB1 (þ : siRNA1; þ 0 : siRNA2), or with scrambled siRNA. LECs
were subsequently treated with 1mM 12(S)-HETE and analysed by western
blotting using antibodies against ZEB1 and VE-cadherin. Equal sample
loading was controlled by b-actin expression.
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Figure 5 Quantitative analysis of formation and inhibition of CCID in LEC monolayers by MCF-7 spheroids formation. LECs were seeded into 24-well
plates and allowed to grow for 2 days until confluence when LECs were stained with cytotracker green. (A) MCF-7spheroids, which were treated with
different concentrations (solvent, 1, 5, 10, 15, and 25 mM) of Bay11-7082 for 0.5 h at 371C, were transferred on top of LECs. (B) Either LECs or MCF-7
spheroids were treated with the Bay11-7082 for 0.5 h, which was entirely washed off before both cell types were co-cultivated. The 3D-MCF-7 spheroids/
LEC monolayer co-cultures were incubated for 4 h at 371C. The size of CCIDs, which were formed by MCF-7 spheroids in the LEC monolayer in this time
period, was measured using a Zeiss Axiovert microscope and Axiovision software. In the solvent treated controls, the CCID sizes in LEC monolayers were
set 100%. For each condition, the gap area of at least 12 spheroids was measured. Error bars indicate standard error of the mean. Asterisks show significant
differences in the inhibition of CCID formation compared with control (*Po0.05).
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Figure 6 Analysis of mesenchymal marker expression in LECs after intervention with NF-kB signalling. LECs were pretreated with 10mM of the I-kBa
phosphorylation inhibitor Bay11-7082 for 0.5 h and then stimulated with 1mM 12(S)-HETE for 0.2 h. Cells were harvested and analysed by western blotting
using (A) anti-ZEB1 and anti-VE-cadherin antibodies. MCF-7 cells were used as negative control. (B) Blots were analysed with anti-S100A4 antibody. Equal
sample loading was controlled by Ponceau S staining and b-actin analysis. Confocal immunofluorescence images of LECs at the rim of CCID (C) induced by
an MCF-7 spheroid; (D) and from a similar position after treatment with 10mM Bay11-7082. LECs were grown on coverslips until confluence when MCF-7
spheroids were transferred on top of LECs and co-incubated for 4 h at 371C to allow CCID formation. LECs were stained with anti-S400A4 antibody
(green), anti-VE-cadherin antibody (red), and DAPI (blue). (C) S100A4 is well expressed and VE-cadherin interactions are disrupted. (D) Upon Bay11-7082
treatment, VE-cadherin structures again appear well developed (although unconnected to VE-cadherin structures of neighbouring cells), whereas S100A4
expression is decreased. Scale bar: 15mM.
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Ser19 regulating the assembly of stress fibres (Totsukawa et al,
2000) and causes focal adhesions generating an amoeboid
movement (Sahai and Marshall, 2003). Moreover, Arp2/3, which
levels were also marginally elevated by 12(S)-HETE, regulates
mesenchymal invasion (Paulitschke et al, 2010).
The mobile state of induced LECs was furthermore confirmed by
the increased expression of paxillin and protein S100A4. Paxillin
(focal adhesion phosphoprotein) is necessary for cell–ECM
contact, and its increased expression could already be associated
in vivo and in vitro with enhanced endothelial cell motility (Lu
et al, 2006; Deakin and Turner, 2008). S100A4 is a calcium-binding
protein that interacts with intracellular target proteins (Mandinova
et al, 1998) and is a marker for a mesenchymal phenotype and
mesenchymal transition of epithelial cells, which encompasses cell
mobility (Zeisberg and Neilson, 2009). In epithelial tumours,
activation of the embryonic epithelial–mesenchymal transition
programme is important for the dissemination and invasion of
cancer cells (Yilmaz et al, 2007). S100A4 has been associated with
migratory and invasive properties and is able to induce metastasis
in rodent models of breast cancer (Rudland et al, 2000).
Noteworthy, the levels of S100A4 mRNA are higher in breast
carcinomas than in benign breast tumour specimens (Wang et al,
2000). S100A4 acts as an angiogenic factor by stimulating the
motility and invasiveness of endothelial cells (Takenaga et al, 1994;
Ambartsumian et al, 2001; Jenkinson et al, 2004; Schmidt-Hansen
et al, 2004). Therefore, S100A4 has a role in both – cancer cells and
endothelial cells – to increase malignancy.
Single cell motility can only be realised when cell–cell contacts
of the continuous monolayer are disrupted and this was in fact
accomplished through both MCF-7 spheroid- and 12(S)-HETE-
mediated down-regulation of VE-cadherin. This was consistent
with the fact that loss of VE-cadherin is associated with a mobile
phenotype. VE-cadherin is expressed specifically in endothelial
cells and is important for the maintenance and control of
endothelial cell contacts. Hence, VE-cadherin is a marker for a
differentiated endothelium and an immobile cellular phenotype.
Cadherins (E-, P-, N-, M-, and VE-cadherin) are cell adhesion
molecules, which organise contacts via Ca2þ -dependent interac-
tions and bind directly to b-catenin, which is required for cohesive
function (Vestweber, 2008). Loss of E-cadherin is a key initiating
event in EMT (Thiery, 2002). It enables the first step of metastasis
– local invasion and dissemination of cancer cells from the
primary tumour. ZEB1 is a transcriptional repressor of E-cadherin
(Schmalhofer et al, 2009) and, therefore, high ZEB1 expression
correlates with loss of E-cadherin and an increased migratory and
invasive potential and induces EMT (Arumugam et al, 2009). Here,
we could demonstrate that ZEB1 also regulated 12(S)-HETE-
mediated VE-cadherin repression. However, the relation of ZEB1
with VE-cadherin regulation remained unclear. Our results
propose that 12(S)-HETE induces an EMT-like phenotype of
LECs. This interpretation is problematic, because LECs are of
mesenchymal origin yet with an epitheloid phenotype and
function.
NF-kB activation was reported to be associated with tumour cell
proliferation, survival, angiogenesis, and invasion (Brown et al,
2008). Irreversible inhibition of I-kBa with Bay11-7082 (Pierce
et al, 1997) inhibited MCF-7 spheroid-induced CCID formation of
LECs in a dose-dependent manner and at low concentration. Since
Bay11-7082 caused a decrease of ZEB1 expression and induction of
VE-cadherin expression, NF-kB activation is associated with
induction of ZEB1 expression (Chua et al, 2007). The mode of
12(S)-HETE-induced activation of NF-kB in LECs remains to be
established, as we did not observe an increase in E-selectin mRNA
levels upon 12(S)-HETE treatment (data not shown). Interestingly,
the extracellular addition of S100A4 activates NF-kB through
induction of phosphorylation and subsequent degradation of
I-kBa (Boye et al, 2008). We found that 12(S)-HETE-induced
S100A4 and Bay11-7082 inhibited S100A4 expression. However,
since S100A4 up-regulation occurred after NF-kB-dependent ZEB1
induction, an autocrine activation loop can be excluded. Our study
provides biochemical data suggesting that 12(S)-HETE induced a
migratory phenotype in LECs (Paulitschke et al, 2010) that was
already microscopically observed during the formation of large
CCIDs in the LEC monolayer underneath MCF-7 spheroids
(Madlener et al, 2010; Kerjaschki et al, 2011). The mechanisms
of breast cancer cell intravasation require NF-kB activity that is
necessary for LEC motility and the here discovered alterations of
LEC structural dynamics allow insights into metastatic mecha-
nisms and the search for anti-metastatic compounds.
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1. ABSTRACT 
 
Natural products continue to represent the main 
source for therapeutics, and ethnopharmacological 
remedies from high biodiversity regions are a rich source 
for the development of novel drugs. Hence, in our attempt 
to find new anti-neoplastic activities we focused on ethno-
medicinal plants of the Maya, who live in the world’s third 
richest area in vascular plant species. Pluchea odorata 
(Asteraceae) is traditionally used for the treatment of 
various inflammatory disorders and recently, the in vitro 
anti-cancer activities of different extracts of this plant were 
described. Here, we present the results of bioassay-guided 
fractionations of the dichloromethane extract of P. odorata 
that aimed to enrich the active principles. The separation 
resulted in fractions which showed the dissociation of two 
distinct anti-neoplastic mechanisms; firstly, a genotoxic 
effect that was accompanied by tubulin polymerization, cell 
cycle arrest, and apoptosis (fraction F2/11), and secondly, 
an effect that interfered with the orchestrated expression of 
Cyclin D1, Cdc25A, and Cdc2 and that also led to cell 
cycle arrest and apoptosis (fraction F3/4). Thus, the 
elimination of generally toxic properties and beyond that 
the development of active principles of P. odorata, which 
disturb cancer cell cycle progression, are of interest for 
potential future therapeutic concepts against proliferative 
diseases. 
2. INTRODUCTION  
 
The majority of medicinal drugs used in western medicine 
are derived from natural products (1, 2). A success story in 
natural product drug discovery is paclitaxel (Taxol), which 
is derived from the bark of the Pacific Yew, Taxus 
brevifolia Nutt. (Taxaceae). The antitumor activity of Taxol 
is based on its ability to stabilize microtubules in tumor 
cells, triggering mitotic arrest and cell death (3-5). Several 
Native American tribes have used Taxus species for the 
treatment of non-cancerous diseases (6). Ethno-
pharmacological remedies, particularly from high 
biodiversity regions such as rainforests, can be a rich 
source for the development of novel drugs (7) and 
therefore, we investigate traditional healing plants of the 
Maya who live in a region which is the world’s third richest 
in vascular plant species (8). Over the centuries and 
millennia, the Maya developed an advanced pharmaceutical 
knowledge that is still practiced today. In the attempt to 
find plants with anti-neoplastic activities we select those 
traditionally used against severe inflammations, because 
there are several similar signaling pathways, which are 
commonly up-regulated in both, in inflammatory 
conditions and in cancer (9). Maya healers prepare 
decoctions of the Asteraceae Pluchea odorata (L.) Cass. 
(Itza-Maya vernacular name: "Chal Che"), to treat coughs, 
cold, neuritis, and arthritis and also swelling, bruises, 
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Table 1. Fractionation of the Pluchea odorata CH2Cl2 crude extract by VLC 
F1-Fractions Mobile phase (1000 ml)  Yield (g) 
F1/1 PE  0.21 
F1/2 CHCl3  1.36 
F1/3 CHCl3 : MeOH (9:1)  1.46 
F1/4 CHCl3 : MeOH (7:3)  0.45 
F1/5 CHCl3 : MeOH (5:5)  0.09 
F1/6 CHCl3 : MeOH (3:7)  0.14 
F1/7 CHCl3 : MeOH (1:9)  0.09 
F1/8 MeOH : H2O (7:3)  0.08 
F1/9 MeOH : H2O (1:1)  0.05 
F1/10 H2O  0.02 
Fractionation of the Pluchea odorata CH2Cl2 crude extract by VLC. The CH2Cl2 extract was chromatographed on a silica gel 
column using the indicated solvents as mobile phase, which resulted in 10 fractions (F1/1 – F1/10).  
 
Table 2. Fractionation of the Pluchea odorata F1/3 extract by column chromatography (CC-I) 
Yield w/o chlorophyll F2-Fractions Mobile phase Yield (mg) 
(mg) (%) 
F2/1 32.5   
F2/2 30.5   
F2/3 12.2   
F2/4 54.2   
F2/5 
CHCl3 
(500 ml) 
17.8   
F2/6 26.4   
F2/7 67.2   
F2/8 24.8   
F2/9 48.5   
F2/10 32.9   
F2/11 
CHCl3:MeOH:H2O (95:1.5:0.1) 
(600 ml) 
113.2 25.7 22.7 
F2/12 90.7 16.3 17.9 
F2/13 170.6 41.2 24.2 
F2/14 88.6 27.9 31.5 
F2/15 26.3 2.4 9.1 
F2/16 148.5 21.6 14.5 
F2/17 
CHCl3:MeOH:H2O (90:3.5:0.2) 
(562 ml) 
44.1   
F2/18 64.9   
F2/19 184.6   
F2/20 
CHCl3:MeOH:H2O (85:8.0:0.5) 
(2000 ml) 
268.0   
F2/21 MeOH:H2O (95:5.0) (500 ml) 213.0   
Fractionation of the Pluchea odorata F1/3 extract by column chromatography (CC-I). The extract was applied on a silica gel 
column and eluted with the indicated solvents and 21 main fractions (F2/1 – F2/21) were obtained. Chlorophyll was removed 
from fractions F2/11-16 and the fraction-yield (mg, %) before and after chlorophyll separation was calculated. 
 
inflammations, and tumors (10). Recently, the anti-cancer 
activity of extracts of this medicinal herb was described 
(11). Here, we focused on the dichloromethane extract of P. 
odorata and performed bioassay-guided fractionations to 
separate and enrich different bioactive principles. 
 
3. MATERIALS AND METHODS 
 
3.1. Plant material  
Pluchea odorata (L.) Cass. was collected in 
Guatemala, Departamento Peten, near the north-western 
shore of Lago Peten Itza, San Jose, within an area of four 
year old secondary vegetation ~1 km north of the road from 
San Jose to La Nueva San Jose (16°59'30" N, 89°54'00" 
W). Voucher specimens (leg. G. Krupitza & R. O. Frisch, 
Nr. 1-2009, 08. 04. 2009, Herbarium W) were archived at 
the Museum of Natural History, Vienna, Austria. The fresh 
plant material (the aerial plant parts, leaves, caulis and 
florescence) of P. odorata was stored deep-frozen until 
lyophilization and subsequent extraction.  
 
3.2. Extraction and fractionation 
Aerial plant parts of P. odorata were lyophilised, 
ground and 192 g were taken for extraction using an 
accelerated solvent extractor (ASE) (ASE® 200, Dionex, 
California, USA). The first cycle was performed with PE in 
order to partly eliminate chlorophyll and lipids. Then, the 
same plant material was extracted x 3 with CH2Cl2. The 
extraction was performed with a pressure of 150 bar and at 
40°C. The CH2Cl2 extract was evaporated under reduced 
pressure to yield 4.0 g dried extract. The crude CH2Cl2 extract 
was subjected to vacuum liquid chromatography (VLC) on a 
silica gel column, eluting with a stepwise gradient from PE to 
H2O (Table 1) to provide ten main fractions (F1/1 – F1/10) 
which were collected based on similar TLC profiles. Fraction 
F1/3 (1.46 g) was further chromatographed on a silica gel 
column (CC-I) using a stepwise gradient from CHCl3 to 
MeOH : H2O for elution (Table 2) and led to the collection of 
21 main fractions (F2/1 – F2/21). Chlorophyll was separated 
from fractions F2/11 – F2/16 by redissolving the dried 
fractions in CH2Cl2 (1 g fraction / 150 ml CH2Cl2) and adding 
an equal volume of MeOH : H2O (1 : 1). Then CH2Cl2 was 
evaporated under reduced pressure to precipitate chlorophyll in 
the MeOH : H2O phase. Chlorophyll was removed by 
filtration and the chlorophyll-free MeOH : H2O layer was 
dried under reduced pressure. After the removal of 
chlorophyll, fraction F2/13 (30 mg) was purified on a silica 
gel column (CC-II) eluting with CHCl3 : MeOH in different 
ratios (Table 3). Fractions with similar TLC profiles were 
pooled to give five main fractions (F3/1 – F3/5).  
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Table 3. Fractionation of the Pluchea odorata F2/13 
extract by column chromatography (CC-II) 
F3-Fractions Mobile phase Yield 
(mg) 
F3/1 3.41 
F3/2 13.03 
F3/3 
CHCl3 : MeOH (95:0.5)  
(700 ml) 
7.87 
F3/4 CHCl3 : MeOH (95:0.5)  
(300 ml) 
3.58 
F3/5 CHCl3 : MeOH (90:0.5)  
(300 ml) 
21.32 
Fractionation of the Pluchea odorata F2/13 extract by 
column chromatography (CC-II). The extract was 
chromatographed on a silica gel column using the indicated 
solvents as mobile phase; the separation resulted in 5 main 
fractions (F3/1 – F3/5). 
 
3.3. Cell Culture 
HL-60 promyelocytic leukaemia cells were 
purchased from ATCC and grown in RPMI 1640 medium 
and humidified atmosphere containing 5% CO2 at 37°C. 
The medium was supplemented with 10 % heat-inactivated 
fetal calf serum (FCS), 1 % Glutamax and 1 % Penicillin-
Streptomycin. The medium and supplements were obtained 
from Life Technologies (Carlsbad, CA, USA). 
 
3.4. Proliferation inhibition analysis 
HL-60 cells were seeded in T-25 tissue culture 
flasks or in 24-well plates at a concentration of 1 x 105 
cells/ml and incubated with increasing concentrations of 
plant extracts or fractions. Cell counts and IC50 values were 
determined within 24 h using a KX-21 N microcell counter 
(Sysmex Corporation, Kobe, Japan). All experiments were 
performed in triplicate. Cell proliferation rates were 
calculated as described (11-13). 
 
3.5. Cell death analysis 
In order to determine the type of cell death, HL-
60 cells were seeded in 24-well plates at a concentration of 
1 x 105 cells/ml and grown for 24 h. Then cells were treated 
with the indicated concentrations of the extract and 
fractions for 8 h and 24 h. Hoechst 33258 and propidium 
iodide were added to the cells at final concentrations of 5 
and 2 µg/ml, respectively. After 1 h of incubation at 37°C, 
cells were examined on a Zeiss Axiovert fluorescence 
microscope equipped with a DAPI filter. Cells were 
photographed and analyzed by visual examination to 
distinguish between apoptosis and necrosis (14-16). For 
this, cells were judged according to their morphology and 
the integrity of the plasma membrane on the basis of 
propidium iodide exclusion. Experiments were performed 
in triplicate. 
 
3.6. Western blot analysis 
HL-60 cells were seeded in T-75 tissue culture 
flasks at a concentration of 1 x 106 cells/ml and incubated 
with 3 µg/ml fractions (F2/11, F2/13, F3/4, respectively) 
for 0.5 h, 2 h, 4 h, 8 h and 24 h. At each time point, 2 x 106 
cells were harvested, placed on ice, centrifuged (1000 rpm, 
4 ºC, 4 min), washed twice with cold PBS (pH 7.2), and 
lysed in 150 µl buffer containing 150 mM NaCl, 50 mM 
Tris pH 8.0, 1 % Triton X-100, 1mM 
phenylmethylsulfonylfluorid (PMSF) and Protease 
Inhibitor Cocktail (Sigma, Schnelldorf, Germany). Debris 
was removed by centrifugation (12,000 rpm, 4 ºC, 20 min) 
and equal amounts of total protein were electrophoretically 
separated by SDS polyacrylamide gels (10 %) and then 
transferred to PVDF membranes (Hybond P, Amersham, 
Buckinghamshire, UK) at 100 V and 4ºC for 1 h. To 
confirm equal sample loading, membranes were stained 
with Ponceau S (17-19). Customary blotting protocol was 
employed; primary antibodies were diluted 1:500 in blocking 
solution and incubated with the membrane at 4 ºC, overnight 
and the secondary antibodies were diluted 1:2000. Blots were 
analyzed using an enhanced chemoluminescence technique 
(ECL detection kit) and detected by exposure of the 
membranes to Amersham HyperfilmTM (both Amersham, 
Buckinghamshire, UK). The antibody against Phospho-
Cdc25A (S75) was from Abcam (Cambridge, MA, USA) and 
against phospho-Cdc25A (S177) from Abgent (San Diego, 
CA, USA). Anti-gamma-H2AX (pSer139) was purchased 
from Calbiochem (San Diego, CA, USA) and the antibodies 
against cleaved caspase-3 (Asp175), Chk2, phospho-Chk2 and 
phospho-Cdc2 (Tyr15) from Cell Signaling (Danvers, MA, 
USA). The antibodies against Cdc2 p34 (17), Cdc25A (F-6), 
Cyclin D1 (M-20), PARP-1 (F-2) and alpha-tubulin (DM1A) 
were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, 
USA) and the antibodies against beta-actin (clone 6-11B-1) 
and acetylated alpha-tubulin (clone 6-11B-1) were from Sigma 
(St. Louis, MO, USA). The secondary antibodies peroxidase-
conjugated anti-rabbit IgG and anti-mouse IgG were 
purchased from Dako (Glostrup, Denmark). 
 
3.7. Statistical analysis  
The apoptosis and proliferation experiments were 
analyzed by t-test using GraphPad Prism version 4 
(GraphPad Prim Sofware, Inc., San Diego, CA, USA). 
 
4. RESULTS AND DISCUSSION 
 
4.1. Anti-proliferative activity of Pluchea odorata 
CH2Cl2 crude extract and F1 (VLC) fractions 
The activity of the obtained CH2Cl2 crude extract, 
which was 2.1 % of the dried plant material input (196 g), 
was tested in HL-60 leukemia cells. Cells were incubated 
with increasing concentrations of crude extract (1-15 
µg/ml) and the number of cells was counted twice within a 
time span of 24 h in order to calculate the proliferation 
rates. The CH2Cl2 crude extract significantly decreased the 
proliferation rate of HL-60 cells; the concentration which 
inhibited cell proliferation by 50 % (IC50) was ~10 µg/ml 
(Figure 1). Subsequently, the crude extract was fractionated 
by VLC resulting in fraction F1/1 – F1/10 (Table 1). All 
fractions were tested at concentrations of 10µg/ml. The 
results showed that fraction F1/3, which represented 36.5 % 
of the CH2Cl2 extract input (4.0 g), inhibited proliferation 
by ~ 60 %, whereas the other fractions had no effect on cell 
growth (data not shown). Therefore, the gain of activity 
was not significant and VLC was an insufficient procedure 
to enrich the active principles. Based on these results, 
subsequent fractionation of F1/3 by CC-I followed. 
 
4.2. Anti-proliferative activity of F2 (CC-I) fractions 
derived from F1/3 
Fraction F1/3 was further subjected to CC-I to 
provide 21 main fractions (Table 2). The anti-proliferative
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Figure 1. Anti-proliferative effects of Pluchea odorata 
CH2Cl2 crude extract. HL60 cells were seeded into T-25 
flasks (1 x 105  cells/ml), grown for 24 hours, and treated 
with solvent (0.5 % EtOH) or  the specified concentrations 
of CH2Cl2 extract. After 24 hours the proliferation was 
calculated as percentage of control. Values are mean ± 
SEM of experiments performed in triplicate. *p<0.05 as 
compared to untreated control. 
 
activity of the fractions (10 µg/ml) was determined in HL-
60 cells (Figure 2a). Fractions F2/11 – F2/16 showed 
effective growth inhibitory activity; fractions F2/11, F2/12, 
F2/13 and F2/15 inhibited cell growth up to nearly 100 %, 
F2/16 up to 95 % and F2/14 up to 80 %. Hence, CC-I 
facilitated the enrichment of the bioactive properties. The 
TLC profile of the active fractions F2/11 – F2/16 indicated 
the presence of chlorophyll (data not shown). In order to 
exclude the possibility that chlorophyll contributed to the 
anti-proliferative effect, fractions F2/11 – F2/16 were 
subjected to separation of chlorophyll and then re-evaluated 
for activity. The results indicated that the anti-proliferative 
activity was preserved in the chlorophyll-free fractions 
(Figure 2b). Moreover, the effect of fraction F2/14 was 
increased after the removal of chlorophyll.  
 
4.3. Anti-proliferative activity of F3 (CC-II) fractions 
derived from F2/13 
Since CC-I fractionation was successful in 
enriching the anti-proliferative activity, we then selected 
one of the most active chlorophyll-free fractions for further 
fractionation. Fraction F2/13 contained the least restrictive 
amount of material, which was 2.8 % of the F1/3 input 
(1.46 g). Hence, fraction F2/13 was subjected to a second 
step CC separation (CC-II). Based on similarities of the 
TLC profile, five main fractions (F3/1 – F3/5) were 
obtained (Table 3). In order to determine the anti-
proliferative effect, HL-60 cells were treated with the 
indicated concentrations of fractions (Figure 3). The results 
suggested fraction F3/4 to be the most potent of the F3 
fractions. Fraction F3/4 inhibited proliferation with a 
calculated IC50 of ~0.4 µg/ml; therefore, the increase of the 
activity compared to the crude extract was ~25-fold.  
Additional separations of F3 fractions with 
reversed phase solid phase extraction resulted in decreased 
bio-activities (data not shown). Therefore, these fractions 
seemed to separate different active principles that were 
additive in F3/4. This evidences that controlled multi-
compound preparations of plant extracts, such as F3/4 or 
i.e. Avemar (20), can be more effective than isolated single 
compounds. The attempt to identify these active principles 
would have exceeded the frame of this investigation. 
 
4.4. Western blot analysis of cell cycle and checkpoint 
regulators 
 Fractions F2/11, F2/13 and F3/4 showed the 
highest anti-proliferative activity. Hence, their effect on the 
expression of cell cycle regulatory proteins was analyzed 
by Western blotting, because protagonists such as the 
proto-oncogenes Cyclin D1 and Cdc25A, which are both 
up-regulated in hyper-proliferative diseases, are goals for 
new anti-neoplastic therapies (21, 22). The lowest common 
concentration of fractions F2/11, F2/13 and F3/4, which 
completely inhibited HL-60 cell proliferation, was 3 µg/ml 
and therefore, the following analyses were performed with 
this concentration. Fraction F2/11 suppressed Cyclin D1 
expression after 24 h, whereas F2/13 reduced the Cyclin D1 
level after 8 h and its derivative fraction F3/4 already after 
30 minutes (Figure 4). Temporally the D-family of cyclins 
appears in early G1 of the cell cycle (23-25) and Cyclin D1 
is required for the activation of Cdk4 and Cdk6 (21, 26) 
and it is also known as the Prad1 proto-oncogene (27). 
 
The intra-S-phase checkpoint prevents the 
duplication of damaged or broken DNA which would 
eventually lead to genomic instability. This checkpoint is 
i.e. regulated by ATM/ATR-Chk2-Chk1-Cdc25A (28). 
Depending on the type of DNA damage (genotoxic stress), 
ATM or ATR phosphorylates Chk2 or Chk1, which in turn 
phosphorylates Cdc25A (29, 30). Thereby, Cdc25A 
becomes inactivated and causes the inhibition of Cdk2 and 
Cdc2 (31). Here we demonstrate that Chk2 was 
phosphorylated at the activating Thr68 site upon treatment 
with all three tested fractions. F2/11 caused a rapid and 
transient phosphorylation of Chk2 within 2 h, which 
returned to constitutive levels after 24 h. In contrast, 
fraction F2/13 induced phosphorylation of Chk2 after 24 h 
and fraction F3/4 after 8 h which sustained for 24 h. 
Therefore, activation of Chk2 by F3/4 was not transient and 
was caused by a different trigger than by F2/11. Chk2 
protein levels remained unchanged upon incubation with 
F2/13 and F3/4, but the level decreased upon incubation 
with F2/11 after 24 h (Figure 4). The analysis of Chk2 
phosphorylation- and protein levels supported the notion 
that different active principles are contained in F2/11 
compared to F2/13 and its derivative F3/4. The activation 
of Chk2 by F2/11 was the earliest effect observed in this 
protein expression study, whereas it was the latest event 
upon treatment with F2/13 and F3/4. The rapid Chk2 
induction indicated that F2/11 caused DNA damage, which 
was supported by the fact that the phosphorylation of 
H2AX (gamma-H2AX) was induced even before Chk2-
activation (Figure 6) and that the subsequent alterations of 
gene expression and cellular responses were most likely the 
consequences of this property. The induction of gamma-
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Figure 2. Anti-proliferative effects of Pluchea odorata fractions F2/1 – F2/21. HL60 cells were seeded into 24-well plates (1 x 
105  cells/ml) and grown for 24 hours, and incubated with solvent (0.5 % DMSO) or (a) 10 µg/ml fraction F2/1 – F2/21 and (b) 
the specified concentrations of chlorophyll-free fraction F2/11 – F2/16. After 24 hours the proliferation was calculated as 
percentage of control. Values are mean ± SEM of experiments performed in triplicate. *p<0.05 as compared to untreated control. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Anti-proliferative effects of Pluchea odorata fractions F3/1 – F3/5. Cells were seeded into 24-well plates (1 x 105  
cells/ml), grown for 24 hours, and incubated with solvent (0.5 % DMSO) or with the specified concentrations of fractions F3/1 – 
F3/5 for 24 hours. Cell proliferation was calculated as percentage of control. Values are mean ± SEM of experiments performed 
in triplicate. *p<0.05 as compared to untreated control. 
 
H2AX is among the earliest indicators of DNA 
strand breaks (32). In contrast, the activation of Chk2 by 
F3/4 and F2/13 (Figure 4) correlated with the 
comparatively late activation of caspase 3, respectively 
(Figure 6) that causes the degradation of DNA as one of 
several downstream effects. Cdc25A is a direct target of 
Chk2 and Chk1 and activation of Chk2 can cause the 
phosphorylation of Ser177 of Cdc25A, Chk1 the 
phosphorylation of Ser75 of Cdc25A, and both 
phosphorylations inactivate Cdc25A (33, 34). F2/11 caused 
an intense phosphorylation of (Ser177)Cdc25A within 4 h 
and shortly after the activation of Chk2 (Figure 4). Also 
(Ser75)Cdc25A became phosphorylated, but this was not 
due to Chk1 because this kinase did not become activated 
(data not shown). As a consequence, the phosphorylation 
level of (Tyr15)Cdc2 increased, because inactivated 
Cdc25A phosphatase did not resume to constitutively de-
phosphorylate this Cdc2 site (35). Thus, the kinase activity
137
Separation of anti-neoplastic principles from Pluchea odorata 
 
 
Figure 4. Influence of fraction F2/11, F2/13 and F3/4 on cell cycle and checkpoint regulators. Cells were cultivated in T-75 
tissue culture flasks (1 x 105  cells/ml), grown for 24 hours, and incubated with 3µg/ml fraction F2/11, F2/13 and F3/4 for the 
specified periods of time. Then, isolated protein samples were subjected to 10 % SDS-PAGE separation and subsequent Western 
blot analysis using the indicated antibodies. Equal sample loading was controlled by Poinceau S staining and ?-actin analysis. 
 
 
 
 
 
 
 
 
Figure 5. Induction of apoptosis by Pluchea odorata CH2Cl2 crude extract and fractions F2/11, F2/13, F2/14, F2/15 and F3/4. 
HL60 cells were seeded into 24-well plates (1 x 105  cells/ml) for 24 hours and treated with solvent (0.5% EtOH or DMSO) or the 
indicated concentrations of CH2Cl2 crude extract and fractions F2/11, F2/13, F2/14, F2/15 and F3/4. After 24 hours cells were 
double stained with Hoechst 33258 and propidium iodide and examined under the microscope with UV light connected to a 
DAPI filter. Cells with morphological changes indicative for apoptosis were counted and the percentage of cell death was 
calculated. Values are mean ± SEM of experiments performed in triplicate. *p<0.05 as compared to untreated control.
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Figure 6. Effect of fraction F2/11, F2/13 and F3/4 on apoptosis-related proteins. Cells were cultivated in T-75 tissue culture 
flasks (1 x 105  cells/ml), grown for 24 hours, and incubated with 3µg/ml fraction F2/11, F2/13 and F3/4 for the specified periods 
of time. Then, isolated protein samples were subjected to 10 % SDS-PAGE separation and subsequent Western blot analysis 
using the indicated antibodies. Equal sample loading was controlled by Poinceau S staining and ?-actin analysis. 
 
of Wee1 prevailed, which gave rise to a transient accumulation 
of (Tyr15)Cdc2 phosphorylation upon treatment with F2/11 
(36). 
 
In contrast, F2/13 caused the de-phosphorylation of 
(Ser177)Cdc25A and hence, its activation (37). This was 
reflected by the de-phosphorylation of (Tyr15)Cdc2 after 8 h. 
Cdc2 is mandatory for orchestrated G2-M transit. Cdc25A and 
Cdc25C de-phosphorylate Cdc2, which causes the activation 
of its kinase domain (30). Cdc2 protein levels were much more 
stable in cells treated with F2/13 than in those treated with 
F2/11. In fact, Cdc2 was undetectable upon treatment with 
F2/11 after 24 h, such as Cyclin D1, and this was most likely 
causal for cessation of cell proliferation. 
 
F3/4 caused a very transient phosphorylation of 
(Ser177)Cdc25A and a weak but more sustained 
phosphorylation of (Ser75)Cdc25A, which correlated with the 
degradation of this protein after 24 h, and with a slight increase 
of (Tyr15)Cdc2 phosphorylation levels (Figure 4). We 
investigated, whether the stress response protein p38/MAPK 
may have caused phosphorylation of (Ser75)Cdc25A (38). 
However, constitutive p38 phosphorylation levels were even 
reduced upon treatment with F3/4 (data not shown). After 24 h 
the lack of detectable (Tyr15)Cdc2 phosphorylation suggested 
that this cell cycle protagonist was fully activated. Therefore, 
suppression of Cyclin D1 together with the activation of Cdc2, 
as it was observed upon treatment with F3/4 and F 2/13, 
caused conflicting signals regarding an orchestrated cell cycle 
progression. 
 
4.5. Fractions F2/11, F2/13 and F3/4 induce apoptosis 
 Since fractions F2/11, F2/13, and its derivative 
F3/4 were the most potent inhibitors of proliferation, they 
were also studied regarding their pro-apoptotic activities. 
We analyzed apoptosis with a highly sensitive method that 
identifies very early hallmark phenotypes long before the 
metabolism collapses and cells actually die (14-16).  
 
 HL-60 cells were incubated with the indicated 
concentrations of the respective fractions (F2/11, F2/13, 
F2/14, F2/15, F3/4), and with 35 µg/ml of P. odorata 
CH2Cl2 crude extract for 24 h, to investigate cell death 
induction. For the CH2Cl2 crude extract ,the calculated 
concentration which induced 50 % apoptosis (AIC50) was 
~25µM (Figure 5). Fraction F2/11 and F3/4 were the 
most potent fractions, inducing 100 % apoptosis. 
Interestingly, F2/13, which was the precursor of F3/4, 
induced only 40 % apoptosis, similar to F2/15, and F2/14 
was ineffective at the tested concentration. To unravel 
which of the two fractions was more potent, further 
dilutions to 1.5 µg/ml, 0.8 µg/ml, and 0.4 µg/ml enabled 
to calculate the AIC50 after 24 h, which was ~1.4 µg/ml 
for fraction F2/11 and ~0.6 µg/ml for fraction F3/4. In 
addition, fraction F2/11 und F3/4 were analyzed after 8 h 
of treatment and the results indicated  F3/4 to be twice as 
active as F2/11 (Table 4). Therefore, in fraction F3/4 the 
pro-apoptotic activity was 45-fold enriched compared to 
the crude CH2Cl2 extract (Figure 5). 
 
Since in F3/4 the anti-proliferative and pro-
apoptotic activities accumulated, we tested, whether an 
anti-migratory/metastatic property was contained as well 
and assessed F3/4 in a novel anti-metastasis assay based on 
the formation of gaps in lymphendothelial cell monolayers 
generated by MCF-7 breast cancer cell spheroids (39). 
However, F3/4 did not prevent the formation of gaps (data 
not shown). 
139
Separation of anti-neoplastic principles from Pluchea odorata 
Table 4. Induction of apoptosis by Pluchea odorata 
fractions F2/11, F2/13 and F3/4. 
Fractions3 µg/ml Apoptosis 8h treatment 
F2/11 ~20 % 
F2/13 ~5 % 
F3/4 ~40 % 
Induction of apoptosis by Pluchea odorata fractions F2/11, 
F2/13 and F3/4. HL60 cells were seeded into 24-well plates 
(1 x 105  cells/ml) for 24 hours and treated with solvent 
(0.5% DMSO) or 3 µg/ml fractions F2/11, F2/13 and F3/4. 
After 8 hours cells were double stained with Hoechst 33258 
and propidium iodide and examined under the microscope 
with UV light connected to a DAPI filter. Cells with 
morphological changes indicative for apoptosis were 
counted and the percentage of cell death was calculated. 
Values are mean ± SEM of experiments performed in 
triplicate. *p<0.05 as compared to untreated control. 
 
4.6. Western blot analysis of apoptosis related proteins 
 When HL-60 cells were treated with 3 µg/ml of 
the indicated fractions, the cleavage of caspase 3 to a 19 
kDa and a 12 kDa fragment was observed, which is a 
prerequisite for its activation that was confirmed by 
signature type cleavage of the downstream target PARP 
(40). F2/11 caused the induction of gamma-H2AX within 
30 minutes (Figure 6) followed by the rapid activation of 
Chk2 (Figure 4), thereby indicating genotoxicity and the 
presence of a DNA targeting component in F2/11. In 
contrast, F2/13 induced gamma-H2AX after 24 h and F3/4 
after 8 h, which correlated with caspase 3 activity (Figure 
6). In this case, the induction of gamma-H2AX, and also 
the activation of Chk2 (Figure 4), were most likely the 
consequence of the activation of Caspase-Activated-
DNAse (CAD) through caspase 3 (41).  
 
Fractions F2/11, F2/13, and F3/4 induced the 
acetylation of alpha-tubulin and therefore, the stabilization 
of microtubule (42-44). This was reminiscent of the 
mechanism of taxol that causes mitotic arrest (3, 4). Tilting 
the fine-tuned equilibrium of polymerized/de-polymerized 
microtubule is incompatible with normal cell division and 
this causes cell cycle arrest and apoptosis (5), and 
therefore, tubulin-targeting drugs are validated anti-cancer 
therapeutics (45). The effect of fraction F2/11 differed from 
those of fractions F2/13 and F3/4 in that the acetylation of 
tubulin was rapid and severe upon treatment with F2/11, 
whereas fraction F2/13 induced tubulin acetylation only 
after 24 h and less pronounced. F3/4 induced tubulin 
acetylation already after 8 h which correlated with the 
enrichment of bio-activity compared to F2/13 (Figure 6). 
Therefore, we could separate two very distinct anti-
neoplastic properties in fractions that were derived from the 
P. odorata CH2Cl2 crude extract. Firstly, a genotoxic 
property in fraction F2/11, which also triggered strong 
tubulin polymerization and which was certainly causal for 
both, cell cycle arrest and apoptosis. Secondly, an even 
stronger pro-apoptotic property in F3/4, which had more 
impact on the expression of the oncogenes Cyclin D1 and 
Cdc25A. The conflicting signals generated by cyclin D1 
suppression and Cdc2 activation would specifically affect 
constantly cycling cancer cells. This was confirmed in 
experiments utilizing slowly cycling normal human lung 
fibroblasts, which were affected significantly less by 
fraction F3/4 than by fraction F2/11 (data not shown). 
 
Previous studies on the genus Pluchea showed 
that the methanol extracts of P. odorata exhibited activity 
against Giardia lamblia trophozoites (46), and in the 
methanol extract of P. indica plucheol A and B, which are 
unique to species of Pluchea, were discovered (47). From the 
chloroform extract of P. arabia, godotol A and B were 
isolated, which exert weak anti-bacterial activity (48). In 
addition, in the chloroform extract of the aerial parts of P. 
sagittalis, the eudesmane-type sesquiterpenoids cuauthemone 
was found, which has anti-feedant activity (49), and 
cuauthemone, pluchin, plucheinol, among other eudesmane-
type sesquiterpenoids, were isolated from P. chingaio (50). 
Cuauthemone was furthermore found in P. odorata (51), and 
thus, cuauthemone is a likely constituent of the 
dichloromethane extract, which was shown to exert anti-
inflammatory activity (11, 52). Flavonoids are well known for 
their anti-oxidant, anti-inflammatory, and anti-neoplastic 
effects and quercetin and isorhamnetin have been found in the 
leaves of P. lanceolata (53). It is however unlikely, that polar 
flavonoids were contained in the here described 
dichloromethane extract of P. odorata. In a broad search for 
eudesmane-type sesquiterpenoids in the Asteraceae family 
only eudesmane ketones were found in P. odorata (54, 55). 
Whether cuauthemone or other eudesmane ketones may 
have contributed to the anti-neolpastic effects of the here 
studied fractions of the P. odorata dichloromethane extract 
remains to be established. The TLC profile after detection 
with anisaldehyde sulphuric acid reagent proposes the 
presence of sesquiterpenes in the active fractions. 
 
 This study evidenced that the traditional Maya 
healing plant P. odorata used for the treatment of severe 
and chronic inflammations, has also anti-neoplastic 
potential. The separation of a genotoxic property in F2/11 
from a cell cycle-interfering property in F3/4 is a relevant 
step to rid off extract components that may cause 
unspecific and therefore, undesired therapeutic side effects.  
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 Abstract 
BACKGROUND: Many cancers spread through lymphatic routes and mechanistic insights of  
tumour intravasation into the lymphatic vasculature and targets for intervention are limited. 
The major emphasis of research focuses currently on the molecular biology of tumour cells, 
whereas still little is known regarding the contribution of lymphatics.  
METHODS: Breast cancer cell spheroids attached to lymphendothelial cell (LEC) 
monolayers enable to study the process of intravasation by measuring the areas of "circular 
chemorepellent-induced defects" (CCID), which can be considered as gates for bulky tumour 
transmigration. Pro-metastatic mechanisms of tumour and lymphendothelial cells and anti-
intravasative properties of compounds were studied by the CCID bio-assay and through 
simplification of the assay by replacing cancer spheroids with the CCID-triggering compound 
12(S)- hydroxyeicosatetraenoic acid (HETE). Here we analysed xanthohumol, a prenylated 
hop-derived flavonoid contained in beer, to learn more about its activity spectrum regarding 
the modulation of CCIDs.  
RESULTS: The formation of CCIDs was mediated by NF-κB dependent i) binding of LECs 
to MCF-7 spheroids, which correlated with ICAM-1 expression of LECs and ii) LEC 
migration, which correlated with the expression of the prometastatic factor S100A4. Also the 
expression of semaphorine 3F, a well documented cell repellent, depended on NF-κB in 
MCF-7 cells. Simultaneous inhibition of NF-κB with Bay11-7082 and of ALOX15 with 
baicalein, which was previously shown to attenuate CCIDs, prevented CCID formation 
synergistically. Furthermore, xanthohumol was a strong inhibitor of MCF-7-triggered CCID 
formation, whereas MDA-MB231-triggered CCIDs were much less affected. This correlated 
with the potential of xanthohumol to inhibit the activity of CYP1A1 in these cell lines. 
CONCLUSIONS: The CCID bio-assay, which was recently validated in mouse xenograft 
assays and human patient samples, was used to elucidate NF-κB-dependent processes in 
ALOX15-induced tumour intravasation through the lymphatic barrier.  
In this setting, well described compounds such as i.e. Bay11-7082 and baicalein, or less 
known molecules, i.e. xanthohumol, can be studied regarding their anti-intravasative 
properties. Compounds identified by this functional assay represent excellent candidates as 
anti-metastatic agents for cancer therapy. 
  
Key words: lymphatic endothelium; migration; tumour spheroid intravasation; NFkappaB; 
xanthohumol; CCID 
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 Introduction 
Mostly, metastatic outgrowth demands an early step of intravasation of primary tumour cells 
into the blood- and lymphatic vasculature, whereby breast cancer cells seem to more 
commonly frequent the lymphatic route. Therefore, the number of axillar lymph nodes that 
are colonised by tumour cells is a reliable clinical predictor for patient outcome (Carlson et 
al. 2009). We found that post-sentinel lymph node colonisation and organ invasion correlate 
with intravasation of tumour cell clusters into lymphatics of sentinel lymph node metastases 
(“intrametastatic lymphatic carcinosis”; Kerjaschki et al. 2011). If intrametastatic lymphatic 
carcinosis of the sentinel lymph node does not take place, post-sentinel lymph nodes remain 
metastasis free. Therefore, this step is considered as critical for breast cancer cell spread. 
Lymph node intravasation involves partly the expression of the lipoxygenases ALOX12 and 
ALOX15 and their metabolite 12(S)- hydroxyeicosatetraenoic acid (HETE), which is secreted 
i.e. by MCF-7 cells (Uchide et al. 2007). In vitro 12(S)-HETE causes the retraction of 
lymphatic endothelial cells (LECs) thereby causing "circular chemorepellent-induced defects" 
(CCID) in LEC walls. CCIDs are entry gates through which breast cancer cells intravasate 
(transmigrate) into the lymphatic vasculature. Immunodeficient mice orthotopically 
xenografted with ALOX15-proficient or ALOX15-deficient breast cancer cells provided in 
vivo pathophysiological evidence of this mechanism. The relevant protagonists, ALOX12, 
ALOX15 and 12(S)-HETE, were also detected in paraffin sections of human metastatic 
lymph nodes and the expression of ALOX15 correlated inversely with metastasis free survival 
of the patients (Kerjaschki et al. 2011). The process of intravasation through lymphatics is 
only partly triggered by 12(S)-HETE and effectors that act in parallel and/or downstream are 
unkown. Therefore, the elucidation of the mechanistic details, which are causal for CCID 
formation, is important. The transcription factor NF-κB plays a role in murine lung alveolar 
carcinoma metastasis, pulmonary metastasis of murine osteosarcomas, and lung metastasis of 
invasive breast cancer MDA-MB-468 cells orthotopically xenografted in BALB/c nude mice 
(Andela et al. 2000, Nishimura et al. 2010, Srivastava et al. 2010,). In a recent study we 
demonstrated that VE-cadherin expression increased upon inhibition of NF-κB, which 
stabilised the integrity of LEC monolayers (Vonach et al. 2011). Therefore, besides 
ALOX12/15, also NF-κB activity was involved in the corruption of lymph vessel integrity 
and in CCID formation. In the present study we investigated the contribution of NF-κB to the 
attachment of MCF-7 spheroids to LECs and to LEC mobility. Furthermore, we tested the 
applicability of the CCID bio-assay and studied the effect of the phyto-flavonoid and bona 
fide NF-κB inhibitor xanthohumol (Gao et al. 2009) a major active component in hop cones 
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 (Magalhães et al. 2009). Xanthohumol is a constitutent of beer (Stevens and Page 2004) and 
was reported to possess strong anti-neoplastic properties (Monteghirfo et al. 2008). 
 
 
Materials and Methods  
 
Chemicals: The I-ĸBα phosphorylation inhibitor (E)-3-[(4-methylphenylsulfonyl]-2-
propenenitrile (Bay11-7082) and baicalein (EI-106) were purchased from Biomol (Hamburg, 
Germany), 12(S)-HETE from Cayman Chemical (Ann Arbor, MI, USA). Wogonin Cat was 
purchased from Calbiochem (Darmstadt, Germany), xanthohumol from Naturalchemics 
(Homburg, Germany).  Mouse monoclonal anti-CD54 (ICAM-1) antibody was from 
Immunotech (Marseille, France) and polyclonal rabbit anti-paxillin (H-114) (SC-5574) from 
Santa Cruz Biotechnology (Heidelberg, Germany). Polyclonal rabbit anti-semaphorin 3F 
antibody was from Chemicon (Tenecula, CA, USA), and monoclonal mouse anti-phospho-
p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10), monoclonal rabbit anti-p44/42 MAPK 
(Erk1/2) (137F5), polyclonal rabbit anti-phospho-Myosin Light Chain 2 (Ser19), polyclonal 
rabbit anti-Myosin Light Chain 2, and polyclonal rabbit anti-MYPT1 were from Cell 
Signaling (Danvers, MA, USA). Monoclonal mouse anti-β-actin (clone AC-15) and 
polyclonal rabbit anti-S100A4 were from Sigma-Aldrich (Munich, Germany), polyclonal 
rabbit anti-phospho-MYPT1 (Thr696) from Upstate (Lake Placid, NY, USA). Monoclonal 
mouse anti-CD31 (JC70A), polyclonal rabbit anti-mouse and anti-rabbit IgGs were from 
Dako (Glostrup, Denmark).  
 
Cell culture: Human MCF-7 and MDA-MB231 breast cancer cells were purchased from the 
American Type Culture Collection (ATCC, Rockville, MD, USA) and grown in MEM 
medium supplemented with 10% fetal calf serum (FCS), 1% penicillin/streptomycin (PS), 1% 
NEAA (Invitrogen, Karlsruhe, Germany). Telomerase immortalized human lymphendothelial 
cells (LECs) were grown in EGM2 MV (Clonetics CC-4147,  Allendale, NJ, USA), all at 
37°C in a humidified atmosphere containing 5% CO2. For CCID formation assays, LECs 
were stained with cytotracker green purchased from Invitrogen (Karlsruhe, Germany). Human 
umbilical vein endothelial cells (HUVECs) were isolated and cultured in M199 medium 
supplemented with 20% FCS, antibiotics, endothelial cell growth supplement and heparin as 
previously described (Zhang et al. 1998). 
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 3-D co-cultivation of breast cancer spheroids with LEC monolayers: MCF-7 or MDA-
MB231 cells were transferred to 30 ml MEM medium containing 6 ml of a 1.6% 
methylcellulose solution (0.3% final concentration; Cat. No.: M-512, 4000 centipoises; 
Sigma-Aldrich, Munich, Germany). 150 µl of this cell suspension were transferred to each 
well of a 96 well plate (Greiner Bio-one, Cellstar 650185, Kremsmünster, Austria) to allow 
spheroid formation within 48 h. Then, MCF-7 spheroids were washed in PBS and transferred 
to cytotracker-stained LEC monolayers  that were seeded into 24-well plates (Costar 3524, 
Sigma-Aldrich, Munich, Germany) in 2 ml EGM2 MV medium. 
 
CCID assay: MCF-7 cell spheroids (3000 cells/spheroid) were transferred to 24-well plates 
containing LEC monolayers. After four hours of incubation, the CCID areas in the LEC 
monolayers underneath the MCF-7 spheroids were photographed using an Axiovert (Zeiss, 
Jena, Germany) fluorescence microscope to visualise cytotracker(green)-stained LECs 
underneath the spheroids. CCID areas were calculated with the Axiovision Re. 4.5 software 
(Zeiss, Jena, Germany). MCF-7 spheroids were treated with solvent (DMSO) as negative 
control. Each experiment was performed in triplicate and for each condition, the CCID size of 
12 or more spheroids (unless otherwise specified) was measured. 
 
Western blotting: LECs were seeded in 6 cm dishes and treated with the indicated 
compounds (10 µM Bay11-7082 and or 1 µM 12(S)-HETE). Cells were washed twice with 
ice cold PBS and lysed in buffer containing 150 mM NaCl, 50 mM Tris pH 8.0, 0.1% Triton-
X100, 1 mM phenylmethylsulfonylfluorid (PMSF) and protease inhibitor cocktail (PIC). 
Afterwards, the lysate was centrifuged at 12000 rpm for 20 min at 4°C and the supernatant 
stored at -20°C until further analysis. Equal amounts of protein were separated by SDS 
polyacrylamide gel electrophoresis and electro-transferred onto Hybond PVDF-membranes at 
100V for 1 h at 4°C. To control equal sample loading, membranes were stained with Ponceau 
S (Sigma-Aldrich, Munich, Germany). After washing with PBS/T (PBS/Tween 20; pH: 7.2) 
or TBS/T (Tris Buffered Saline/Tween 20; pH: 7.6), membranes were immersed in blocking 
solution (5% non-fat dry milk in TBS containing 0.1% Tween or in PBS containing 0.5% 
Tween 20) at room temperature for 1 h. Membranes were washed and incubated with primary 
antibodies (in blocking solution; dilution 1:500 – 1:1000) by gently rocking at 4°C overnight 
or at room temperature for 1 h. Thereafter, the membranes were washed with PBS/T or 
TBS/T and incubated with secondary antibodies (peroxidase-conjugated goat anti-rabbit IgG 
or anti-mouse IgG; dilution 1:2000) at room temperature for 1 h. Chemiluminescence was 
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 detected by ECL detection Kit (Thermo Scientific, Portsmouth, USA), and the membranes 
were exposed to Amersham Hyperfilms (GE-Healthcare, Buckinghamshire, UK).  
 
SELE (CD62E, E-selectin, ELAM)-induction assay: Each well of a 96-well plate was 
coated with gelatine by applying 200 µl of 1.0% gelatine for 10 minutes at room temperature. 
Outer wells (A1-A12, H1-H12, 1-H1 and A12-H12) contained only 200 µl/well medium and 
served as an evaporation barrier. 1 × 104 HUVECs were seeded in each of the other wells in 
200 µl medium and grown for 48 hours to optimal confluence. Increasing concentrations of 
xanthohumol were then added to the HUVEC-containing wells in triplicates, and the cells 
were incubated for 30 min, after which 10 ng/ml TNFα was added per well to stimulate 
NFκB, and thus SELE. After a further four hours incubation, the levels of SELE in each of 
the HUVEC-containing wells were determined by enzyme-linked activity assays (ELISAs) as 
described below. 
Cell-surface ELISA SELE: Cells were washed once with PBS and fixed with 100 µl/well 25% 
glutaraldehyde (40µl in 10ml PBS, Sigma-Aldrich (Munich, Germany), stored at –20°C in 
aliquots) for 15 min at room temperature. Then, cells were washed 3 x with 200 µl per well 
PBS/0.05% Tween 20, blocked with 200 µl/well 5% BSA/PBS for 1 hour, and washed again 
3 x with 200 µl per well PBS/0.05% Tween 20. Then, anti-SELE-antibody (clone BBA-1, 
R&D Systems, Minneapolis, MN, USA) diluted 1:5000 in 0.1% BSA/PBS (100µl per well) 
was added for 1 hour at room temperature and washed thereafter 5 x with 200 µ per well 
PBS/0.05% Tween 20. Subsequently, goat anti mouse-HRP antibody (Sigma-Aldrich, 
Munich, Germany) diluted 1:10000 in 0.1% BSA/PBS (100µl per well) was applied and the 
cells were incubated for a further hour in the dark at room temperature and, after decanting, 
washed five times with 200 µl per well PBS/0.05 % Tween 20.  The HRP-activity of the cells 
in each of the wells was estimated using Fast-OPD (o-phenylenediamine dihydrochloride) 
(Sigma-Aldrich, Munich, Germany) assay as described (Gridling et al. 2009) and absorbance 
was measured at OD492nm in a vertical spectrophotometer. 
 
Cytotoxicity testing: For the SELE expression assay the toxicity of xanthhohumol was 
assessed in HUVECs by Calcein AM cytotoxicity assays in 96-well microtitre plates 
(Madlener et al. 2009). 20 µL portions of each of the xanthohumol concentrations were 
added in triplicate to the cells, which were then incubated at 37oC in an atmosphere 
containing 5 % CO2 for 4 hours, after which Calcein AM solution (Molecular Probes, 
Invitrogen, Karlsruhe, Germany) was added for 1 hour according to the manufacturer’s 
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 instructions. The fluorescence of viable cells was quantified using a Fluoroskan Ascent 
instrument (Labsystems, Finland) reader and on the basis of triplicate experiments the 
cytotoxic concentrations were calculated.  
 
Ethoxyresorufin-O-deethylase (EROD) assay selective for CYP1A1 activity: MDA-MB-
231 and MCF-7 breast cancer cells were grown in phenol red-free RPMI 1640 tissue culture 
medium (PAN Biotech, Aldenbach, Germany), supplemented with 10% FCS and 1% PS 
(Invitrogen, Karlsruhe, Germany) under standard conditions at 37°C in a humidified 
atmosphere containing 5% CO2 and 95% air. Twenty-four hours before treatment, the cells 
were transferred to RPMI 1640 medium (Invitrogen, Karlsruhe, Germany) supplemented with 
2.5% charcoal-stripped FCS (PAN Biotech, Aldenbach, Germany) and 1% PS. Test 
compounds were dissolved in DMSO and diluted with medium (final DMSO concentration < 
0.1%) to 5-25 µM. Experiments under each set of condition were carried out in triplicate. 
Blanks contained DMSO in the medium of the test compounds. After 18 h of incubation, 
ethoxyresorufin (final concentration 5.0 µM, Sigma-Aldrich, Munich, Germany) was added 
and 0.4 ml aliquots of the medium were sampled after 200 min. Subsequently, the formation 
of resorufin was analyzed by spectrofluorometry (PerkinElmer LS50B, Waltham, MA, USA) 
with an excitation wavelength of 530 nm and an emission wavelength of 585 nm. 
 
Real-time PCR: LECs were seeded in 12 well plates, then they were pre-treated with 10 µM 
Bay11-7082 for 30 min and thereafter stimulated with 1.0 µM 12(S)-HETE or with TNFα 
(20ng/ml). Total RNA was isolated using the RNeasy Mini Kit 50 and QIAshredder 50 
(QIAGEN, Hamburg, Germany). 1.0 µg of total RNA was reverse transcribed with 
Superscript First Strand Synthesis System (Invitrogen, Karlsruhe, Germany), the resulting 
cDNA was amplified using TaqMan Universal PCR Master mix (No AmpErase UNG; PartNo 
4324018; Applied Biosystems, Vienna, Austria) with the E-selectin Primer (TaqMan Gene 
Expression Assays Part No 4331182; Applied Biosystems, Vienna, Austria). PCR products 
were analysed on the Abi Prism 7000 sequence detection system. Duplicate samples were 
analyzed in parallel. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as internal 
control. Relative transcript expression was calculated using the ∆∆CT method. 
 
Statistical analysis: Dose-response curves were analysed using Prism 4 software (La Jolla, 
CA, USA) and significance was determined by paired Student’s t-test. Significant differences 
between experimental groups were * p<0,05. 
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 Results 
 
NF-κB inhibition interferes with MCF-7 spheroid-induced CCID formation in 
lymphendothelial monolayers 
MCF-7 spheroids placed on LEC monolayers were treated with the NF-κB inhibitor Bay11-
7082 and this dose-dependently suppressed LEC-CCID formation (Fig 1a). It is known that 
Bay11-7082 irreversibly stabilizes I-κBα and prevents NF-κB activation (Pierce et al. 1997), 
which facilitated to study how NF-κB in MCF-7 cancer cells and in LECs independently 
contributes to tumor cell intravasation into the lymphatic vasculature. The individual 
pretreatment of either MCF-7 spheroids or LEC monolayers with Bay11-7082 blocked CCID 
formation and this evidenced, that NF-κB of MCF-7 as well as that of LECs played a role for 
CCIDs (Fig 1b). ALOX12/15 and its metabolite 12(S)-HETE, which is shedded by MCF-7 
spheroids (Uchide et al. 2007), was shown to be a trigger factor of CCID (Kerjaschki et al. 
2011,Vonach et al. 2011, Madlener et al. 2010). Since the pretreatment of MCF-7 spheroids 
with Bay11-7082 had a stronger inhibitory effect on CCIDs than the pretreatment of LECs 
this suggests that a second major CCID-forming mechanism, which was different from 
ALOX12/15, controls MCF-7 cell intravasation into the lymphatic vasculature. SEMA3F was 
shown to repel endothelial and breast cancer cells (Bielenberg et al. 2004, Nasarre et al. 
2005). MCF-7 cells expressed SEMA3F NF-κB dependently (Fig.1 c) and this can explain 
why the treatment of MCF-7 spheroids with Bay11-7082 inhibited CCIDs.  
 
Inhibition of LEC migration by Bay11-7082 
The treatment of LECs with 10 µM Bay11-7082 inhibited the MCF-7 spheroid-triggered 
CCID formation and this correlated with the inhibition of the mobility- and EMT- marker 
S100A, and the phosphorylation of Erk, but not with the activating phosphorylation of 
threonine-696 of MYPT (Fig. 2a). Therefore, MYPT activation was independent of NF-κB, 
evidencing that also other mechanisms contribute to LEC plasticity. 
In earlier studies we could demonstrate that adherence among LECs was facilitated by VE-
cadherin. The exposure of LECs to MCF-7 spheroids or to 12(S)-HETE downregulated VE-
cadherin expression causing the disruption of the intercellular VE-cadherin bonds, which was 
demonstrated by Western blotting and confocal immunofluorescence of VE-cadherin 
(Kerjaschki et al. 2011, Vonach et al. 2011). Here we show that, in consequence to MCF-7 
spheroid-mediated downregulation of VE-cadherin, the projected cell surface area of Bay11-
7082 treated LECs appeared on average smaller compared to untreated controls, due to the 
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 loss of contacts to the neighboring cells and concommittant rounding up (Fig. 2b). It further 
led to an increase of the peri-cellular areas, and alltogether to an affection of the intact LEC 
monolayer. However, the peri-cellular space between the cells did not increase because the 
migration of LECs was inhibited. 
 
NFkB-dependent expression of adhesion molecules on LECs 
15 µM Bay11-7082 caused the gradual loss of MCF-7 spheroid adhesion to the LEC 
monolayer (by ~30 %) and the treatment with 25 µM Bay11-7082 completely prevented the 
attachment of MCF-7 spheroids to LECs and CCID formation (Fig.1a). Therefore, NF-κB-
dependent expression of adhesion molecules could account for the stable contact of MCF-7 
spheroids to LECs. CD31, E-selectin (SELE), and intracellular adhesion molecule 1 (ICAM-
1) are known to be expressed in endothelial cells. They contribute to adhesion to other cell 
types through counter-receptors i.e. αvβ3 integrin (vitronectin receptor), CD44, and αLβ2 
integrin (LFA-1), respectively, which were all reported to be expressed in MCF-7 cells 
(Deryungina et al. 2000, Budinsky et al. 1997). 12(S)-HETE induced the expression of 
ICAM-1 and CD31 in LECs, but only ICAM-1 induction was inhibited by 15 µM Bay11-
7082 (Fig. 3a,b). Therefore, ICAM-1 may have contributed to NF-κB dependent adhesion of 
MCF-7 spheroids to LEC monolayers. SELE was neither constitutively expressed in LECs 
nor induced by 12(S)-HETE (Fig 3c). In summary, we describe two NF-κB regulated 
mechanisms, which were required for the formation of CCIDs in LEC monolayers: 1) LEC 
motility, and 2) the adherence of LECs to MCF-7 spheroids.  
 
Simultaneous blocking of NF-kB and lipoxygenase activities synergistically inhibits 
CCID 
Consistent with the role of ALOX12/15 in the formation of CCIDs was the fact that 
ALOX12/15 inhibitor baicalein (100 µM), or the closely related compound wogonin (75 µM), 
attenuated LEC-CCID formation by 40-50 % (Fig. 4a). Simultaneous treatment with baicalein 
plus Bay11-7082 inhibited CCIDs synergistically (Fig. 4b). This inhibition was controlled in 
several ways: 1) By the CCID-inducing activity of ALOX15, which was restricted to MCF-7 
cells because in 12(S)-HETE-stimulated LECs the expression of S100A4 and the 
phosphorylation patterns of MYPT1, MLC2, and Erk1/2, remained unchanged in presence of 
baicalein (Fig. 4c). 2) By the CCID-inducing activity of NF-κB, which controlled the mobility 
and the adhesion of LECs to MCF-7 spheroids (Fig. 1-3). The contribution of NF-κB 
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 dependent SEMA3F expression of MCF-7 cells to the formation of CCIDs needs to be further 
analysed. 
 
Xanthohumol attenuates LEC-CCID formation  
Since we established the CCID bio-assay, which faithfully resembles intravasation of breast 
cancer emboli into intrametastatic lymphatics (Kerjaschki et al. 2011), the mechanisms of 
the underlying cellular processes as well as the anti-metastatic effects of pharmaceutic and 
natural compounds can be investigated. To challenge the assay we studied the prenylated 
flavonoid xanthohumol (2,4´,4-trihydroxy-6´-methoxy3´-prenylchalcone), because it was 
reported to possess health beneficial and anti-carcinogenic properties and to inhibit NF-κB 
activation in benign and malignant BHP-1 and PC3 prostate epithelial cells (Colgate et al. 
2007). Xanthohumol, which is well tolerated by humans, is a component of the Chinese 
medicinal plant Sophora flavescens Ait. and of hop cones (Humulus lupulus L.), and is present 
in beer and hop cone tea (Stevens and Page 2004, Stevens et al. 1999), and more 
concentrated also in enriched beverage formulations.  
CCIDs triggered by MCF-7 spheroids were dose-dependently inhibited with an IC-50 (the 
concentration of xanthohumol inhibiting 50% of the CCID-formation effect) of ~5 µM (Fig. 
5a, 5b), whereas the IC-50 of xanthohumol for MDA-MB231 spheroid-triggered CCIDs was 
~100 µM. Notably, the NF-κB inhibitor Bay11-7082 was active in a similar range (~10 µM) 
in both cell lines (Fig.5c). Therefore, we tested whether xanthohumol can inhibit NF-κB 
activity in endothelial cells. In HUVECs TNFα induced SELE expression (Table 1),  which is 
indicative for NF-κB activity. However, xanthohumol reduced SELE expression  only 
insignificantly suggesting that the flavonoid did not inhibit NF-κB activity in this in vitro 
model.  
Xanthohumol has been shown to be metabolised by Cytochrome P450 (CYP; Guo et al. 
2006) and CYP activity contributes to CCID (in preparation) and promotes metastasis 
(Jiang et al. 2007). Proadifen (2-Diethylaminoethyl 2,2-diphenylpentanoate; SKF 525-A), an 
inhibitor of the CYP family which is used as a local anaesthetic, significantly attenuates 
CCIDs (in preparation). In fact, xanthohumol as well as proadifen, significantly inhibited 
CYP1A1 activity in MCF-7 cells (5 µM) (Fig. 6a), as assessed by ethoxyresorufin-O-
deethylase (EROD) catalytic assay. At higher concentration (25µM) xanthohumol inhibited 
CYP1A1 also in MDA-MB231 cells, yet less efficiently.  
12(S)-HETE, which is secreted by MCF-7 (Uchide et al. 2007), but not by MDA-MB231 
cells, contributes to ~50 % CCID formation triggered by MCF-7 spheroids (Kerjaschki et al. 
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 2011). Therefore, LECs were directly treated with 12(S)-HETE to study the effect of 
xanthohumol on protein expression that is related to cell motility. Xanthohumol treatment 
dephosphorylated (inactivated) MLC2 and downregulated S100A4 and paxillin expression, 
and it reversed 12(S)-HETE-modulated suppression of Erk1/2 phosphorylation (Fig. 6b). 
Only a part of these effects was also observed upon Bay11-7082 treatment (Fig. 2g).  
Therefore, we describe a new property of xanthohumol, which inhibited the migration of 
LECs and suppressed marker proteins typical for an endothelial-mesenchymal transition type 
of cell plasticity. This correlated with the inhibition of CYP1A1 activity and with ALOX15 
expression in breast cancer cells. Both, CYP and ALOX12/15 metabolise arachidonic acid 
and are contributing to CCID formation induced by MCF-7 spheroids. 
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 Discussion 
 
In this investigation we mimicked the interactive process of breast cancer cell intravasation 
into the lymphatic vasculature using a 3D co-culture system consisting of MCF-7 cancer cell 
spheroids (Madlener et al. 2010) and telomerase-immortalised human LEC monolayers 
(Schoppmann et al. 2004). Intravasation of tumor cells depends on cell attachment and on 
the motility of tumor cells and endothelial cells alike, whereby LEC movement has not been 
studied in this respect. We recently elucidated one prime intravasation mechanism of MCF-7 
breast cancer spheroids and reported that 12(S)-HETE, which is secreted by MCF-7 cells 
(Uchide et al. 2007), causes LECs to respond with the formation of CCIDs (Vonach et al. 
2011, Kerjaschki et al. 2011).  Under physiologic conditions, 12(S)-HETE is mainly 
produced by platelets, leukocytes, smooth muscle, epithelium, neuron, and fibroblast cells 
(Spector et al. 1988) and induces retraction of microvascular endothelial cells (Uchide et al. 
2007, Honn et al. 1994). Under pathophysiologic conditions, 12(S)-HETE increases tumour 
cell adhesion to exposed ECM (Honn et al. 1989). Here, we investigated the 12(S)-HETE 
triggered effects in LECs and tried to elucidate how downstream signaling was mediated. 
Since the  deregulation of  NF-κB is associated with cancer development (Folmer et al. 2009) 
promoting oncogenesis through the transcriptional activation of genes associated with cell 
proliferation, angiogenesis and metastasis (Orlowski and Baldwin 2002), we focussed on the 
role of NF-κB on CCID formation. The interaction of MCF-7 spheroids with LECs was 
necessary for CCIDs and this was corrupted by Bay11-7082 concentrations >15 µM and 
correlated with the NF-κB-dependent downregulation of ICAM-1 in LECs. ICAM-1 is a 
member of the immunoglobulin gene superfamily and an inducible counter receptor for 
several leukocyte β2 integrins (Rosenstein et al. 1991), i.e. αLβ2 integrin (synonym: LFA-1), 
which is expressed in MCF-7 cells (Budinsky et al. 1997). 
Mobility is mediated in microvascular endothelial cells through enhanced phosphorylation 
(activation) of proteins comigrating with myosin light chain, actin and vimentin (Tang et al. 
1993). It was showed that 12(S)-HETE treatment results in an increase in the filamentous 
polymeric F-actin content in the cytoskeleton, and enhanced phosphorylation of myosin light 
chain (Rice et al. 1998). MCF-7 spheroids and 12(S)-HETE induced also the migration of 
LECs and blood endothelial cells (Kerjaschki et al. 2011, Uchide et al. 2007, Honn et al. 
1994) and here we describe the mobility components that become activated by 12(S)-HETE.  
S100A4, an angiogenic factor and a marker for a mesenchymal phenotype (Zeisberg and 
Neilson 2009), stimulates the mesenchymal motility and invasiveness of endothelial cells 
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 (Takenaga et al. 1994, Jenkinson et al. 2004, Ambartsumian et al. 2001, Schmidt-Hansen 
et al. 2004). S100A4 was enhanced upon 12(S)-HETE treatment of LECs and thus, 12(S)-
HETE-induced a mobile, mostly mesenchymal, phenotype in LECs. The expression of 
S100A4 correlated with the formation of CCIDs in the LEC monolayer underneath MCF-7 
spheroids, which was found in earlier studies (Vonach et al. 2011, Kerjaschki et al. 2011; 
Madlener et al. 2010). This is furthermore consistent with a significant reduction of CCID 
sizes in the LEC monolayer underneath Bay11-7082 treated MCF-7 spheroids, which 
indicates reduced LEC motility. Besides S100A4, the mobility markers MYPT1, MLC2 and 
paxillin were also shown to be induced in LECs growing underneath MCF-7 spheroids or by 
synthetic 12(S)-HETE (Vonach et al. 2011), but Bay11-7082 could reverse only S100A4 
induction, indicating additional mechanisms of cell mobility regulation. 
In conclusion, this part of the study revealed that NF-κB controls not only the adhesion of 
MCF-7 spheroids to LECs, but also the movement of LECs and therefore the formation of 
CCIDs. In principle, it is also possible that NF-κB executed its effect only by one but not two 
mechanisms i.e. by facilitating the adherence of MCF-7 spheroids to LECs, infering that this 
contact through ICAM-1 was at the same time the trigger factor for LEC migration. However, 
it was shown that 12(S)-HETE stimulates NF-ĸB activation and NF-ĸB dependent ICAM-1 
expression through RhoA and PKCα (Bolick et al. 2005). This indicates that RhoA is an 
upstream regulator of ICAM-1 and Rho/Rac family GTPases are also prominent regulators of 
cell migration. Therefore ICAM-1 expression and LEC motility are most likely parallel but 
not serial events.  
Co-treatment of the 3D cell system with Bay11-7082 together with the ALOX12/15 inhibitor 
baicalein synergised in the prevention of CCID formation. These results underscore the 
potential of combination therapies for the management of metastasising cancer and provide 
evidence that several distinct mechanisms contribute to tumour intravasation. The LOX 
inhibitor baicalein showed no effects in LECs and this is in agreement with the observation 
that inhibition of CCID by baicalein affected only the ALOX12/15 and 12(S)-HETE 
metabolism in MCF-7 cells, but not in MDA-MB321 cells, which do not express ALOX12/15 
(Kerjaschki et al. 2011). 
               In search of new anti-neoplastic drugs natural products like xanthohumol are of 
particular interest, because of their availabilty, tolerability, and multi-target properties that 
may synergize to achieve the anticipated effects. The root of Sophora flavescens Ait., which 
contains Isoxanthohumol and other anti-neoplastic compounds, is used in traditional Chinese 
medicine to treat viral hepatitis and cancer. Xanthohumol possesses antiproliferative activities 
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 in several cancer lines such as human breast cancer (MCF-7), colon cancer (HT-29) and 
ovarian cancer (A-2780) cells (Miranda et al. 1999), and significantly induces apoptosis in 
HCT 116 colon cancer cells by downregulation of Bcl-2 and activation of the caspase cascade 
(Pan et al. 2005). Xanthohumol was shown to repress both, NF-κB and Akt pathways in 
endothelial cells, and interfered with the angiogenic process, including inhibition of growth, 
and of endothelial cell migration (Albini et al. 2006). This is in agreement with our data 
because the 12(S)-HETE-induced expression of paxillin (focal adhesion phosphoprotein), was 
inhibited by xanthohumol. Paxillin is associated in vivo and in vitro with enhanced endothelial 
cell motility and necessary for cell-ECM contact (Huang et al. 2003, Zaidel-Bar et a. 2003). 
Furthermore, 12(S)-HETE activated MLC2 and MYPT1 and induced S100A4 expression, 
which are markers for cell mobility. Whereas Bay11-7082 blocked only S100A4 induction, 
xanthohumol prevented that of S100A4, MLC2 and paxillin. This suggests that xanthohumol 
exhibits a wider spectrum of effects that may synergise in the inhibition of CCIDs i.e by 
inhibition of paxillin and MLC2 (both are unaffected by Bay11-7082). This could be the 
reason, why xanthohumol is much less toxic than Bay11-7082, which powerfully and most 
and for all, inhibits a central mechanism necessary for cell survival.  
Xanthohumol has been shown to possess antioxidant (Hartkorn et al. 2009) as well as 
radical-inducing properties (Strathmann et al. 2010). Radicals however, are not involved in 
CCID formation (Madlener et al. 2010, Kerjaschki et al. 2011).  
CYP is an arachidonic acid metabolising enzyme. It was shown to be involved also in the 
metabolism of isoxanthohumol (Guo et al. 2006) and xanthohumol interfered with CYP1A1 
activity. Other arachidonic acid metabolising enzymes are ALOXs and COX1/2, but the 
known role of xanthohumol in the inhibition of COX1/2 (Gerhäuser et al. 2002) did not 
contribute to the inhibition of CCID formation, because this is independent of COX1/2 
(Kerjaschki et al. 2011, Madlener et al. 2010).  
The inhibition of ALOX15 in MCF-7 spheroids by xanthohumol is conceivable, and the 
inefficiency of xanthohumol to inhibit CCIDs that were induced by MDA-MB231 spheroids 
could have been due to the fact that MDA-MB231 cells are ALOX12/15 deficient 
(Kerjaschki et al. 2011). Note in this context that also baicalein did not inhibit MDA-
MB231-spheroid induced CCID formation (Fig. 5c). This shows that CCID formation was 
exclusively mediated by the ALOX15 activity of MCF-7 spheroids but not by the 
ALOX12/15 activity of LECs.  
Furthermore,  MCF-7 cells in contrast to MDA-MB231 breast cancer cells are estrogen-
receptor (ER) positive (Roomi et al. 2005) and previous studies have shown that 
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 xanthohumol blocks the effects of estrogens. The flavonoid binds to the ER and it was 
postulated that this property may prevent breast cancer (Gerhäuser et al. 2002). It is 
however, unlikely that binding to estrogen receptor was the reason why xanthohumol 
inhibited CCID formation induced by MCF-7 cell spheroids, because some colon cancer 
spheroids induce gaps by the same mechanisms as MCF-7 cells (Kerjaschki et al. 2011), yet 
colon cancer cells do not express ER receptors. With MCF-7 spheroids, both, Bay11-7082 
and xanthohumol exhibit their CCID-inhibitory properties at rather low concentrations (IC50 
~5-10 µM), whereas with MDA-MB231 spheroids the efficiency of xanthohumol was 
dramatically reduced (IC50 ~ 100µM). The weak inhibitory effect of xanthohumol in MDA-
MB231 spheroids regarding CCID formation indicates again that Bay11-7082 and 
xanthohumol target different mechanisms. Our data suggest novel targets for anti-
carcinogenic effects of xanthohumol. Whether inhibition of ALOX12/15 in MCF-7 cells is 
part of the CCID-inhibitory effect of xanthohumol is going to be addressed in future studies.  
Summing up, we show that the CCID assay is a reliable tool to study new compounds that can 
inhibit the intravasation of tumour emboli into lymphatics and to elucidate the respective 
mechanisms. Furthermore, we provide evidence of a new anti-metastatic property of 
xanthohumol that could be exploited for the treatment of breast cancer. 
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Table 1 
 
Selectin E (SELE) expression in TNFα -induced HUVECs 
 
Analysis 
 
Control 
 
TNFα 
 
TNFα & 
1 µM X 
 
TNFα & 
10 µM X 
 
TNFα & 
30 µM X 
 
Inflammatory 
reaction 
SELE 
(OD) 
0.053 
SD 0.002 
0.130 
SD 0.01 
0.115 
SD 019 
0.121 
SD 0.024 
0.112 
SD 0.022 
       
Cytotoxicity CalceinAM 
(OD) 
46.4 
SD 2.7 
44.5 
SD 6.4 
44.6 
SD 3.9 
43.8 
SD 5.3 
38.5 
SD 8.0 
 
1 x 10
4
 HUVECs /well were seeded into 96-well plates and grown to confluence. Indicated 
concentrations of xanthohumol (X) were added 1 h prior to application of 10 ng/ml TNFα for 
another 4 h. Then cells were fixed and SELE levels analysed by ELISA. In parallel, extracts 
were analysed by CalceinAM assay to monitor non-specific extract toxicity.  
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Viola et al. Figure legends 
 
 
Figure 1: Inhibition of CCIDs by Bay11-7082 
a) MCF-7 spheroids were placed on LEC monolayers and co-cultivated for 4 h either with 
medium alone and solvent  (DMSO; Co), or with increasing concentrations Bay11-7082 (1-25 
µM) and then the areas of CCIDs were measured. b) MCF-7 spheroids and LEC monolayers 
(MCF-7&LEC), or MCF-7 spheroids alone, or LEC monolayers alone were pretreated for 30 
min with 15 µM Bay11-7082, then the inhibitor was thoroughly removed and the pretreated 
cell types were co-cultivated with the respective untreated partner cell line (either untreated 
LECs or MCF-7, respectively) for 4h, and then CCID areas were measured.  
The CCIDs underneath 12 spheroids were analysed for each condition. Experiments were 
done in triplicate, error bars indicate SEM and asterisks significance (p<0.05). 
c) MCF-7 cells were grown as monolayer and treated with 15 µM Bay11-7082 for the 
indicated times (0, 0.2h, 0.5h, 1h, 2h). Then cells were lysed, proteins separated by SDS gel 
electrophoresis and subjected to Western blotting using anti-semaphorine 3F (SEMA3F) 
antibody. Staining with Ponceau S and immunoblotting with anti-β-actin antibody controlled 
equal sample loading. 
 
 
Figure 2: Inhibition of LEC migration by Bay11-7082 
a) LECs were grown to confluence and then pretreated with 10 µM Bay11-7082 or solvent 
(DMSO) for 0.5 h and then LECs were stimulated with 1 µM 12(S)-HETE for 1 h. Then cells 
were lysed, protein separated by SDS gel electrophoresis and subjected to Western blotting 
using the indicated antibodies. Staining with Ponceau S and immunoblotting with anti-β-actin 
antibody controlled equal sample loading. b) Upper panel: LEC monolayers were pretreated 
with 10 µM Bay11-7082 for 0.5 h and then untreated MCF-7 spheroids were placed onto the 
LEC monolayers and the size of LECs underneath the spheroid was measured after 4 h of co-
incubation. Average LEC size (length): 36.25 µm (n=15). Lower panel: This is the reciprocal 
experiment in which MCF-7 spheroids were pretrated with 10 µM Bay11-7082 for 0.5 h and 
then placed onto untreated LEC monolayers and the size of LECs underneath the spheroid 
was measured after 4 h of co-incubation. Average LEC size (length): 53.25 µm (n=15). 
Pictures were taken using a Zeiss Axiovert microscope and Axiovision software to measure 
cell sizes. LECs were stained with cell tracker (green).   
 
 
Figure 3: Analysis of adhesion protein expression upon 12(S)-HETE and Bay11-7082 
treatment 
LECs growing in 6-well plates were treated with 1 µM 12(S)-HETE for 0.2, 0.5, 2, 4 and 8 h 
(a, b, left panels), or LECs were pre-treated with 15 µM Bay11-7082 or solvent (DMSO) for 
0.5 h and then stimulated with 1 µM 12(S)-HETE for 0.5 h (a, b, right panels). Then, cells 
were harvested and protein lysates were analysed by Western blotting using antibodies against 
(a) CD31 and (b) ICAM-1. Equal sample loading was controlled by β-actin expression. 
c) Analysis of E-selectin expression. LECs were grown in 12 well plates and pre-treated with 
Bay11-7082 for 0.5 h and thereafter stimulated with 20 ng/ml TNF-α or solvent (Co) for 0.5 
h, or with 1 µM 12(S)-HETE for the indicated times. PCR products were analysed on the Abi 
Prism 7000 sequence detection system. Duplicate samples were analyzed. GAPDH served as 
internal control. Relative expression numbers were calculated using the ∆∆CT method. 
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Figure 4: a) Inhibition of CCIDs by wogonin and baicalein 
MCF-7 spheroids were placed on LEC monolayers and co-cultivated for 4 h either with 
solvent  (DMSO; Co) or with increasing concentrations of wogonin (5-75 µM) or 100 µM 
baicalein and then the areas of CCIDs were measured.  
b) Synergistic inhibition of CCIDs by baicalein and Bay11-7082 
MCF-7 spheroids and LEC co-cultures were treated with 10 µM Bay11-7082 and/or 100 µM 
baicalein for 4 h.Then the CCID areas underneath at least 12 spheroids (per condition) were 
measured using a Zeiss Axiovert microscope and Axiovision software. Error bars indicate 
SEM, asterisks significe compared to control (p<0.05). 
c) Analysis of LEC protein expression upon treatment with baicalein 
LECs were grown to confluence and then pretreated with 100 µM baicalein or solvent 
(DMSO) for 0.5 h and then LECs were stimulated with 1 µM 12(S)-HETE for 1 h. Cells  were 
lysed, proteins separated by SDS gel electrophoresis, and subjected to Western blotting using 
the indicated antibodies. Staining with Ponceau S and immunoblotting with anti-β-actin 
antibody controlled equal sample loading. 
 
 
Figure 5: Inhibition of CCIDs by xanthohumol 
a) MCF-7 spheroids were placed on LEC monolayers and co-cultivated either with solvent 
(DMSO; Co) or with 10 µM xanthohumol for 4 h and then the areas of CCIDs were 
photographed. Left panel: microscopic power field of a CCID underneath a MCF-7 spheroid 
of an untreated co-culture and right side: of a co-culture treated with 25 µM xanthohumol. 
Scale bars: 700 µm 
b) MCF-7  spheroids and c) MDA-MB231 spheroids were placed on LEC monolayers and co-
cultivated either with solvent (DMSO; Co) or with the indicated concentrations of 
xanthohumol, or 100 µM baicalein, or 10 µM Bay11-7082 for 4 h and then the areas of 
CCIDs were measured using a Zeiss Axiovert microscope and Axiovision software. Error bars 
indicate SEM, asterisks significance compared to control (p<0.05). 
 
 
Figure 6:  
a) Inhibition of CYP1A1 activity in breast cancer cells by xanthohumol and proadifen  
MCF-7 and MDA-MB231 cells were kept under steroid-free conditions and treated with 
proadifen (5 µM; P), or xanthohumol (5 µM, 25 µM; X), or solvent (DMSO; Co). Then, 5 µM 
ethoxyresorufin was added and after 200 min the formation of resorufin was analysed, which 
is specific for CYP1A1 activity. Experiments were done in triplicate, error bars indicate SEM 
and asterisks significance (p<0.05). 
b) Analysis of migratory markers in LECs upon treatment with xanthohumol 
LECs were grown to confluence and then pretreated with 25 µM xanthohumol or solvent 
(DMSO) for 0.5 h and then LECs were stimulated with 1 µM 12(S)-HETE for 1 h. Cells  were 
lysed, proteins separated by SDS gel electrophoresis, and subjected to Western blotting using 
the indicated antibodies. Staining with Ponceau S and immunoblotting with anti-β-actin 
antibody controlled equal sample loading. 
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 Abstract 
 
Introduction: Several studies demonstrated that anti-inflammatory remedies exhibit excellent 
anti-neoplastic properties. An extract of the Asteracea Pluchea odorata, which is used for 
wound healing and against inflammatory conditions, was fractionated and properties 
correlating to anti-neoplastic- and wound healing effects were separated. 
Methods: Up to six fractionation steps using silica gel, sephadex columns and distinct solvent 
systems were used and eluted fractions were analysed by thin layer chromatography, 
apoptosis- and proliferation assays. The expression of oncogenes and proteins regulating cell 
migration was investigated by immuno-blotting after treating HL60 cells with the most active 
fractions. 
Results: Sequential fractionations enriched anti-neoplastic activities which suppressed 
oncogene expression of i.e. JunB, c-Jun, c-Myc, and Stat3. Furthermore, a fraction (F4.6.3) 
inducing-, or keeping-up expression of the mobility markers MYPT, ROCK1 and paxillin 
could be separated from another fraction (F5.3.3.7), which inhibited these markers.  
Conclusions: Wound healing builds up scar- or specific tissue and hence, compounds 
enhancing cell migration support this process. In contrast, successful anti-neoplastic therapy 
combats tumour progression and thus, suppression of cell migration is mandatory.  
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 Introduction 
 
Drug discovery is a constant need for bio-medical research and clinical progress. Particularly 
mega-bio-diversity areas such as the tropical rainforests of Central America are very 
promising for the discovery of new pharmaceutical lead compounds. Therefore, we chose an 
ethno-medical approach to drug discovery and focussed on traditional remedies of the Maya 
to pre-select plants with proven health effects.  
Traditional medicine plants are often used for hundreds of years (Fabricant and Farnsworth 
2001), which is the reason why no or only little toxic effects in humans can be expected. 
Especially in Africa and Central and South America traditional medicine is advised by a 
shamans, curanderos or herbalists who often keep the use of the healing plants as a secret 
(Rastogi and Dhawan 1982). Although these plants are used since ages little is known about 
the “Pinciples of Activity” and/or the targeted cellular mechanisms and hence, these remedies 
have a great potential for drug development. We aimed for the separation and isolation of 
distinct properties of the Maya healing plant Pluchea odorata which are relevant for 
anticancer treatment. P. odorata grows in the USA, Mexico, Belize, Guatemala, Panama, 
Cayman Islands, Guadeloupe, Jamaica, Puerto Rico, St. Lucia, Venezuela and Ecuador 
(Germplasm Resources Information Network, United States Department of Agriculture, 9 
November 2004, http://www.ars-grin.gov/cgi-bin/npgs/html/taxon  p.104497) and is still used 
by the Maya to treat common cold, fever, flu, head colds, headache, hypertension, neuralgia, 
ophthalmia, palsy, pneumonia, snake bite, swellings, inflammation, and bruises of the skin 
(Arvigo and Balick 1998). The medical solution is prepared by boiling two handfuls of 
leaves in one gallon of water and then it is frequently applied on the affected area until the 
inflammation subsides (Balick and Lee 2005). Further the plant is described as being 
antidote, astringent, diaphoretic, and haemostatic (Johnson 1999), as well as traditionally 
used by mothers after giving birth to decrease the risk for infections and conveyance of tissue 
recovery (Arvigo and Balick 1998). Gridling et al. (2009) and Bauer et al. (2011) describe 
a strong anti-neoplastic effect of the dichloromethane extract in HL60 and MCF-7 cells and 
an anti-inflammatory response in HUVECs.  
Pharmaceutical drugs are prepared under standardised conditions and usually contain just one 
Active Principle. In contrast, ethno-pharmacologic remedies are mixtures of a vast number of 
compounds, which are in many cases unknown, and vary in their composition and activity 
depending on the growth area and the time of collection. This makes them difficult for 
application and trading. Moreover, plant extracts can also contain compounds that are 
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 systemically toxic or counteract the desired effect of the Active Principle(s). On the other 
hand, some of the different compounds in a plant extract can synergise. The present work will 
give examples of this phenomenon. A common reason to terminate a priori successful 
therapies of all kinds of cancer and other diseases is the acquisition of drug resistance. 
However, it has not been reported so far that complex plant mixtures induce treatment 
resistances in patients, most likely because several distinct Active Principles target various 
intra- and inter-cellular signalling pathways simultaneously thereby preventing that the 
organism develops an “escape mechanism”. Thus, the development of complex extracts 
should be considered as a strategy to treat cancer. Standardisation procedures for such 
mixtures must be individually developed to provide therapeutics which are effective and safe 
and do not exhibit from batch to batch variations. The fractionation and accompanying testing 
in bio-assays and by appropriate analyses are a feasible concept for standardisation and 
remedies emerging along such procedures can be approved by national agencies (i.e. Avemar, 
WO 2004014406  (A1): “Use of a fermented wheat germ extract as anti-inflammatory agent” 
by Hidvegi and Resetar).  
Here we describe a fractionation approach of the dichloromethane extract of P. odorata, 
which was constantly controlled regarding its activity by bio-assays and analyses that can be 
standardised. This resulted in fractions causing distinct cellular responses indicative for 
wound healing or anti-neoplastic properties. 
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 Material and Methods 
 
Plant material 
The aerial parts (leaves, caulis, florescence) of Pluchea odorata (L.) Cass. was collected in 
Guatemala, Departamento Petén, near the north-western shore of Lago Petén Itzá, San José, 
within an area of four year old secondary vegetation ~1 km north of the road from San José to 
La Nueva San José (16°59'30" N, 89°54'00" W). Voucher specimens (leg. G. Krupitza & R. 
O. Frisch, Nr. 1-2009, 08. 04. 2009, Herbarium W) were archived at the Museum of Natural 
History, Vienna, Austria. 6 kg of air dried plant material have been extracted with 
dichloromethane by Björn Feistel (Finzelberg GmbH & Co.KG, Andernach, Germany), and 
the extract stored in an exiccator in the dark at 4
o
C until use. 
 
Plant extraction and fractionation 
Plant extracion with dichloromethane was essentially as described earlier (Gridling et al. 
2009, Bauer et al. 2011).  
   Vacuum Liquid Chromatography (VLC) was used for the separation of large amounts of 
extract. 36 g crude dichloromethane extract was re-dissolved in dichloromethane, mixed with 
70 g silica gel and evaporated to dryness and ground in a mortar to obtain a homogenous 
powder. A 12 x 40 cm column was packed with 900 g silica gel, on top the silica gel-
containing extract, and covered with sea sand to ballast the sample. The mobile phase was 
passed through by application of vacuum. Table 1 shows the mobile phases used. After 
checking the collected fractions by TLC, those with similar bands were recombined. 
Table 1 Mobile phases used for VLC of the dichloromethane extract 
Mobile phase Relation Volume (l) 
Petroleum ether  4 
Petroleum ether: chloroform 9 : 1 5 
Chloroform  12 
Chloroform: methanol  9 : 1 9 
Chloroform: methanol  7 : 3 9 
Chloroform: methanol 5 : 5 9 
Chloroform: methanol  3 : 7 9 
Chloroform: methanol  1 : 9 9 
Methanol  9 
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    VLC-fractionation of F1: 10 g of F1 were dissolved in dichloromethane, mixed with 20 g 
silica gel, evaporated to dryness, refined in a mortar and applied on top a 5 x 60 cm silica gel 
column. Compounds were eluted with the mobile phases shown in table 2 by applying 
vacuum. Collected fractions were checked by TLC and similar fractions were recombined. 
Table 2 Mobile phases used for VLC of F1 
Mobile phase Relation Volume (l) 
Dichloromethane: hexan 8 : 2 2 
Dichloromethane  2 
Dichloromethane: ethyl acetate 8 : 2 1 
Dichloromethane: ethyl acetate 6 : 4 1 
Dichloromethane: ethyl acetate 4 : 6 1 
Dichloromethane: ethyl acetate 2 : 8 1 
Ethyl acetate  1 
Ethyl acetate: methanol  8 : 2 1 
Ethyl acetate: methanol 6 : 4 1 
   Column chromatography (CC)-fractionation of F2.6: Fractions with less than 2 g CC were 
eluted without vacuum. 1.6 g F2.6 were dissolved in dichloromethane, mixed with 3 g silica 
gel, evaporated to dryness, placed on top a 5 x 50 cm silcia gel column and eluted with mobile 
phases shown in table 3. The collected fractions were checked by TLC and those with similar 
band patterns were recombined.  
Table 3 Mobile phases used for CC of F2.6 
Mobile phase Relation Volume (l) 
Dichloromethane 100 % 1 
Dichloromethane: ethyl acetate 80 : 20 2 
Dichloromethane: ethyl acetate 60 : 40 1 
Dichloromethane: ethyl acetate  40 : 60 1 
Dichloromethane: ethyl acetate  20 : 80 1 
Ethyl acetate 100 % 1 
   CC-fractionation of F3.3 and F3.6: 1.14 g of F3.3 or 0.32 g of F3.6 were dissolved in 
dichloromethane and methanol (90:3.5) and applied on top a 3.5 x 40 cm sephadex column 
which was conditioned with methanol (2.5 x 40 cm for 3.6). Then, the loaded column was 
covered with some more sephadex to protect the sample. Methanol was used as mobile phase. 
Fractions were collected, checked by TLC and those with similar band patterns were 
recombined. 
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    CC-fractionation of F4.3.3: 1.08 g F3.3 was dissolved in dichloromethane, placed on top of 
a 2 x 30 cm silica gel column and covered with silica gel. Mobile phases were used as 
illustrated in table 4. Fractions were checked by TLC and those with similar band patterns 
were recombined. 
Table 4 Mobile phases used for CC of F4.3.3 
Mobile phase  Relation Volume (ml) 
Dichloromethane 100 % 500 
Dichloromethane: ethyl acetate 90 : 10 500 
Dichloromethane: ethyl acetate 80 : 20 500 
Dichloromethane: ethyl acetate 60 : 40 500 
Dichloromethane: ethyl acetate 40 : 60 500 
Dichloromethane: ethyl acetate 20 : 80 500 
Ethyl acetate 100 % 500 
   CC-fractionation of F5.3.3.7: 145.64 mg F5.3.3.7 was dissolved dichloromethane and 
applied on a  dichloromethane-conditioned 80 x 1.5 cm silica gel column and fractionated 
with one litre solvent (chloroform: methanol: water, 95:1.5:0.1). Fractions were collected in 
tubes, ten drops per minute, and every 30 minutes the tubes were changed. Afterwards the 
column was washed with 300 ml methanol. Fractions were checked by TLC and those with 
similar band patterns were recombined.  
   CC-fractionation of F4.6.3: 20 mg F4.6.3 (very oily) was dissolved in dichloromethane, 
mixed with silica gel and applied on top a 2.5 x 15 cm dichloromethane conditioned silica gel 
column. Successful elution was achieved with dichloromethane:ethylacetate (50:50). 
Fractions were checked by TLC and those with similar band patterns were recombined. 
 
Thin layer chromatography (TLC)  
TLC was used for detecting the best solvent combination for VLC or CC or as a finger print 
of new fractions. Stationary phase and mobile phases are described in table 5. The mobile 
phase varied between six solvent systems. Plates were detected under UV254, UV366 and 
visible light, before and after spraying with anisaldehyd sulphuric acid reagent (ASR). ASR 
consisted of 0.5 ml anisaldehyd, 10 ml glacial acetic acid, 85 ml methanol and 5 ml H2SO4 
(sulfuric acid). The sprayed plate was heated at 100 °C for five minutes and then compounds 
were detected at UV and visible light. Unless otherwise stated 8 µl extract or fraction were 
applied to the plate.  
Table 1 Stationary phase, mobile phases and detection methods used for TLC 
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 Stationary phase  silica gel plates 60 F254 (Merck, Darmstadt, Germany) 
Mobile phase 
  
 TLC system 1: chloroform: methanol: water 90:22:3.5 
 TLC system 2: chloroform: methanol: water  90:3.5:0.2 
 TLC system 3: chloroform: methanol: water  70:30:10 
 TLC system 4: dichloromethane: ethyl acetate 80:20 
 TLC system 5: dichloromethane: ethyl acetate 85:15 
 TLC system 6: chloroform: methanol: water  70:22:3.5 
Detection 
 
 UV254, UV366, visible light 
 Anisaldehyd sulphuric acid reagent (ASR) 
 
Cell culture 
HL-60 (human promyelocytic leukaemia cell) cells were purchased from American Type 
Culture Collection (ATCC). The cells were grown in RPMI 1640 medium which was 
supplemented with 10 % heat-inactivated fetal calf serum (FCS), 1 % Glutamax and 1 % 
Penicillin-Streptomycin. Both, medium and supplements were obtained from Life 
Technologies (Carlsbad, CA, USA). The cells were kept in humidified atmosphere at 37 °C 
containing 5 % CO2.  
 
Proliferation assay 
Proliferation assays were performed to analyse the inhibition of proliferation of HL-60 cells 
treated with extract or fractions of P. odorata. Extract and fractions were dissolved in ethanol 
(final concentration was 0.2 %). HL-60 cells were seeded in 24-well plates at a concentration 
of 1 x 10
5
 cells per ml RPMI medium allowing logarithmic growth within the time of 
treatment with plant extract or fractions. The control was treated with solvent. After 24 and 48 
hours the number of cells was determined using the Sysmex Cell Counter (Sysmex Corp., 
Kobe, Japan). Experiments were done in triplicate. Percentage of cell division progression 
compared to the untreated control was calculated by applying the following formula:  
 
 
Apoptosis assay 
Determination of cell death by Hoechst 33258 (HO) and propidium iodide (PI) double 
staining (both Sigma, St. Louis, MO) allows identifying the amount and the type of cell death 
188
 (early or late apoptosis or necrosis). Therefore HL-60 cells were seeded in a 24-well plate at a 
concentration of 1 x 10
5
 cells per ml RPMI medium. Cells were treated with fractions or 
extract of P. odorata. The cells were incubated for 8, 24, 48 and/or 72 hours, depending on 
the experiment. At each time point 100 µl cell suspension of each well were transferred into 
separate wells of a 96-well plate and Hoechst 33285 and propidium iodide were added at final 
concentrations of 5 µg/ml and 2 µg/ml, respectively. After one hour of incubation at 37 °C, 
stained cells were examined and photographed with an Axiovert fluorescence microscope 
(Zeiss, Jena, Germany) equipped with a DAPI filter. Type and number of cell deaths were 
evaluated by visual examination of the photographs according to the morphological 
characteristics revealed by HOPI staining. Experiments were done in triplicate.  
 
Western Blotting 
Preparation of lysates: HL60 cells were seeded in a tissue culture flask at a concentration of 1 
x 10
6
 cells per ml RPMI medium. P. odorata fractions F1, F4.6.3 and F5.3.6.7 were analysed 
by western blots. HL60 cells were either incubated with 40 µg/ml F1 or with 10 µg/ml of one 
of the other two P. odorata fractions for the indicated times. At each time point, 4 x 10
6
 cells 
were harvested, placed on ice and centrifuged (1000 rpm, 4 °C, 4 min). Then, the supernatant 
(medium) was discarded and the pellet was washed twice with cold phosphate buffered saline 
(PBS, pH 7.2), and centrifuged (1000 rpm, 4 °C, 4 min). The cell pellet was lysed in a buffer 
containing 150 mM NaCl, 50 mM Tris (pH 8.0), 1 % Triton-X-100, 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and 1 mM protease inhibitor cocktail (PIC) (Sigma, 
Schnelldorf, Germany). Afterwards the lysate was centrifuged at 12000 rpm for 20 min at 
4 °C. Supernatant was transferred into a 1.5 ml tube and stored at -20 °C for further analyses. 
Gel electrophoresis (SDS-PAGE) and blotting: Equal amounts of protein samples (lysate) 
were mixed with sodium dodecyl sulfate (SDS) sample buffer (1:1) and loaded onto a 10 % 
polyacrylamide gel. Proteins were separated by polyacrylamide gel electrophoresis (PAGE) at 
120 Volt for approximately one hour. To make proteins accessible to antibody detection, they 
were electrotransferred from the gel onto a polyvinylidene difluoride (PVDF) Hybond 
membrane (Amersham, Buckinghamshire, UK) at 95 Volt for 80 minutes. Membranes were 
allowed to dry for 30 minutes to provide fixing of the proteins on the membrane. Methanol 
was used moist the membranes. Equal sample loading was checked by staining the membrane 
with Ponceau S (Sigma, Schnelldorf, Germany).  
Protein detection: After washing with PBS or TBS (Tris buffered saline, pH 7.6), membranes 
were blocked in PBS- or TBS-milk (5 % non-fat dry milk in PBS containing 0.5 % Tween 20 
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 or TBS containing 0.1 % Tween 20) for one hour at room temperature. Then membranes were 
washed with PBS/T (PBS containing 0.5 % Tween 20) or TBS/T (TBS containing 0.1 % 
Tween 20), changing the washing solution four to five times every five minutes. Then every 
membrane was incubated with a primary antibody (1:500) in blocking solution (according to 
the data sheet TBS-, PBS- milk or TBS-, PBS- BSA), at 4 °C over night gently shaking. 
Subsequently the membrane was again washed with PBS/T or TBS/T, and incubated with the 
second antibody (peroxidase-conjugated goat anti-rabbit IgG or anti-mouse IgG) diluted 
1:2000 for one hour at room temperature. After washing the membranes chemiluminescence 
was developed with enhanced chemiluminescence (ECL) plus detection kit (Amersham, UK) 
(two seconds to ten minutes) and membranes were exposed to the Lumi-Imager TM F1 
(Roche) for increasing times.  
 
Antibodies 
Monoclonal mouse ascites fluid anti-acetylated α-tubulin (6-11B-1), and β actin (AC-15) 
antibodies were from Sigma (St. Louis, MO, USA). Monoclonal mouse α-tubulin (DM1A), β-
tubulin (H-235), Cdc25A (F-6), and polyclonal rabbit paxillin (H-114), ROCK-1 (C8F7), c-
Jun (H-79), Jun b (210) were from Santa Cruz Biotechnology, Inc.(Santa Cruz, CA, USA). 
Monoclonal rabbit cleaved caspase 8 (Asp391) (18C8) and phospho-Stat3 (Tyr705)(D3A7) 
antibodies and polyclonal rabbit cleaved caspase 3 (Asp175), human specific cleaved caspase 
9 (Asp330), phospho-Chk2 (Thr68), Chk2, phospho-myosin light chain 2 (MLC2-Ser19), 
myosin light chain 2, Stat3, and MYPT1 were from Cell Signaling (Danvers, MA, USA).  
Polyclonal rabbit phospho-Cdc25A (Ser177) antibody was from Abgent (San Diego, CA, 
USA), polyclonal rabbit Phospho-MYPT1 (Thr696) from Upstate (NY, USA), mouse 
monoclonal γH2AX (pSer139) (DR 1017) from Calbiochem (San Diego, CA, USA), and 
mouse monoclonal c-Myc Ab-2 (9E10.3) from Thermo Fisher Scientific, Inc. 
(xxxxxxxxxxxxxxxxxxxxxx). The secondary antibodies peroxidase-conjugated anti-rabbit 
IgG and anti-mouse IgG were purchased from Dako (Glostrup, Denmark). 
 
Statistical Analysis 
For statistical analyses Excel 2003 software and Prism 5 software package (GraphPad, San 
Diego, CA, USA) were used. The values were expressed as mean ± standard deviation and the 
Student’s T-test was applied to compare differences between control samples and treatment 
groups. Statistical significance level was set to p < 0.05. 
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 Results and Discussion 
 
The dichloromethane extract of P. odorata exhibits strong anti-neoplastic activity (Fig. 1a).  
Therefore, we fractionated this extract and constantly monitored the activities by bio-assays 
measuring apoptosis- and/or proliferation rates to get closer to the Active Principles. In the 
first round the crude extract was split in three distinct fractions of which fraction F1 exhibited 
the strongest anti-proliferative and pro-apoptotic activity (Fig 1b, c). 40 µg F1/ml induced 
caspase 3 and decreased β-actin- and α-tubulin levels and therefore, also reduced acetylation 
levels of α-tubulin were detected within 4 h of treatment (Fig.1d). This suggested that the 
overall protein decrease was due to the early activation of caspase 3 and subsequent cell 
death.  
 
Fig 1a                                            Fig 1b 
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Fig 1c                                                                     Fig 1d                                             
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 Legend figure 1: Anti-proliferative effect of a) dichloromethane crude extract, b) fraction F1 in HL60 
cells; 1 x 10
5
 cells/ml were seeded into 24-well plate, incubated with 5, 15 and 40 µg/ml extract or 
fraction F1 and the percentage of proliferation was calculated relative to solvent treated control within 
a 24 h period; c) Induction of apoptosis by F1, F2 and F3; Cells were grown as described and 
incubated with 15 and 40 µg/ml of each fraction for 72 h. Then, cells were double stained with 
Hoechst 33258 and propidium iodide and examined under the microscope with UV light connected to 
a DAPI filter. Nuclei with morphological changes which indicated cell death were counted and the 
percentages of dead cells were calculated. Experiments were performed in triplicate. Asterisks indicate 
significance compared to untreated control (p<0.05) and error bars indicate ±SD. d) 1 x 10
6
 cells/ml 
were incubated with 40 µg/ml F1 and harvested after 0.5, 2, 4, 8 and 24 h of treatment, lysed and total 
protein applied to SDS-PAGE. Western blot analysis was conducted with the indicated antibodies. 
Equal sample loading was confirmed by Ponceau S staining and β-actin analysis. 
 
 
F1 was further processed yielding fractions F2.1-F2.9. F2.6 was nearly as active F2.7 (Fig 
2a), but contained ~10 times more fraction material (1.9g versus 0.2g, respectively). 
Therefore F2.6 was further processed yielding fractions F3.1-F3.10 (Fig 2b, 2c).  
 
Fig 2a 
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Fig 2b                                                                    Fig 2c 
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Legend figure 2: a) Induction of apoptosis of HL60 cells by F2.1-F2.9 
1 x 105 cells/ml were seeded in 24-well plates and incubated with 10 µg/ml of each fraction for 72 h. 
Then, cells were double stained with Hoechst 33258 and propidium iodide and examined under the 
microscope with UV light connected to a DAPI filter. Nuclei with morphological changes which 
indicated cell death were counted and the percentages of dead cells were calculated. Significance was 
calculated in comparison to F2.2. b) Anti-proliferative effect of F3.3 and F3.6; 1 x 105 cells/ml were 
seeded into 24-well plate, incubated with 2 and 10 µg/ml of each fraction and the percentage of 
proliferation was calculated relative to solvent treated control within a 24 h period. Experiments were 
performed in triplicate. Asterisks indicate significance compared to untreated control (p<0.05) and 
error bars indicate ±SD. c) thin layer chromatography (TLC) of F2.6 (0) and F3.1-F3-10 (1-10); 
Mobile phase: TLC system 2; Detection: visible light with ASR. 
 
 
10 µg/ml of F3.4-F3.6 exhibited potent anti-proliferative properties in HL60 cells suppressing 
cell growth by 100 %. The TLC analysis showed that both, F3.3 and F3.6, contained a distinct 
main compound, and therefore, F3.3 and F3.6 were further fractionated. Also F3.2 was 
processed however this yielded only several low-activity fractions (data not shown).  
   i) The sub-fractionation of F3.3 by sephadex produced three main fractions with similar 
TLC patterns and these were also similar to the one shown in figure 2c. Therefore, they were 
recombined (and termed F.4.3.3) and re-fractionated on a silica gel column yielding the 
potent anti-proliferative and pro-apoptotic fraction F5.3.3.7 (Fig. 3a, 3b). Further 
fractionation of F5.3.3.7 caused the decomposition of the strong cytotoxic activity into many 
low active fractions (F6.3.3.7.1-F6.3.3.7.12; Fig 3c), which in sum approximated the activity 
of the precursor. 
 
Fig 3a 
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 Fig. 3b    
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Fig 3c 
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Legend figure 3: a) Anti-proliferative effect of F5.3.3.1-F5.3.3.12 in HL60 cells; 1 x 10
5
 cells/ml were 
seeded into 24-well plates, incubated with 5 and 10 µg/ml of each fraction and the percentage of 
proliferation was calculated relative to solvent treated control within a 24 h period. b) Induction of 
apoptosis by F5.3.3.7 and c) by F6.3.3.7.1-F6.3.3.7.12 in HL60 cells; 1 x 10
5
 cells/ml were seeded in 
24-well plates and incubated with b) 5 and 10 µg/ml of F5.5.3.7 for 24 and 48 h and c) with 2 and 5 
µg/ml of each fraction for 24 h. Then, cells were double stained with Hoechst 33258 and propidium 
iodide and examined under the microscope with UV light connected to a DAPI filter. Nuclei with 
morphological changes which indicated cell death were counted and the percentages of dead cells 
were calculated. Experiments were performed in triplicate. Asterisks indicate significance compared to 
untreated control (p<0.05) and error bars indicate ±SD. 
 
 
   ii) The sub-processing of F3.6 yielded fraction F4.6.3 as the most pro-apoptotic one which 
was very oily (Fig 4a). Upon further fractionation the activity of F4.6.3 also decomposed into 
several low-activity fractions (F5.6.3.1-F5.6.3.6; Fig 4b).  
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 Fig 4a   
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Fig 4b 
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Legend figure 4:  a) Induction of apoptosis; 1 x 10
5
 HL60 cells/ml were seeded in 24-well plates and 
incubated with 2 and/or 10 µg/ml of F4.6.3 for 8, 24 and 48 h or b) 2 and 5 µg/ml of F5.6.3.1-F5.6.3.6 
for 24 h. Then, cells were double stained with Hoechst 33258 and propidium iodide and examined 
under the microscope with UV light connected to a DAPI filter. Nuclei with morphological changes 
which indicated cell death were counted and the percentages of dead cells were calculated. 
Experiments were performed in triplicate. Asterisks indicate significance compared to untreated 
control (p<0.05) and error bars indicate ±SD. 
 
 
Therefore, we went back to F5.3.3.7 and F4.6.3 and continued analyses with these two 
distinct high activity fractions. The TLC patterns of F5.3.3.7 and F4.6.3 were clearly different 
of each other evidencing that they contain different compounds (Fig 5a). To characterise the 
two distinct fraction types post-translational modifications and expression levels of proteins, 
which are relevant for apoptosis and cell cycle arrest, were investigated. F5.3.3.7 slightly 
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 induced Chk2 phosphorylation and hence, its activation, whereas F4.6.3 did not (Fig 5b). 
Chk2 was shown to phosphorylate Cdc25A at Ser177 and tags it for proteasomal degradation 
(Madlener et al 2009, Karlsson-Rosenthal and Millar 2006). However, treatment of HL60 
cells with F5.3.3.7 caused the de-phosphorylation of Ser177 and protein stabilisation. Also 
F4.6.3 stabilised Cdc25A despite Ser177 phosphorylation. This implicated that Cdc25A was 
not regulated by Chk2 activity in this scenario. Moreover Cdc25A stabilisation suggested an 
increase in cell cycle activity (Blomberg and Hoffmann 1999). Nevertheless, cell 
proliferation was inhibited. 
 
Fig 5a 
 
 
 
 
 
Fig 5b                                                                     Fig 5c 
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Fig 5d                                                                             Fig 5e 
 
 
   
   
Legend figure 5:  a) Thin layer chromatography (TLC) of F 4.6.3 (left panel) and F5.3.3.7 (right 
panel); Mobile phase: TLC system 2; Detection: UV254. 
Analysis of b) Cell cycle and checkpoint regulators, c) apoptosis related proteins, d) oncogenes, e) 
proteins required for mobility; 1 x 106 HL60 cells/ml were incubated with 10 µg/ml F4.6.3 and 
F5.3.3.7, respectively and harvested after 0.5, 2, 4, 8 and 24 h of treatment. Cells were lysed and 
obtained proteins samples applied to SDS-PAGE. Western blot analysis was performed with the 
indicated antibodies. Equal sample loading was confirmed by Ponceau S staining and β-actin analysis. 
 
 
   In search of molecular causes for reduced proliferation, we found that the fractionation steps 
enriched a spindle toxin or an indirect microfilament-targeting activity). This was reflected by 
induced α-tubulin acetylation, which is an indicator of the polymerisation status of tubulin 
microfilaments (Piperno et al. 1987, Hubbert et al. 2002), within 2 h of treatment with 
F5.3.3.7 and F4.6.3 (Fig. 5c). Thereafter, caspase 3 became activated. Also the 
phosphorylation of H2AX occurred after treatment with both fractions indicating DNA 
damage presumably due to caspase 3-induced DNAse activity of DNA fragmentation factor 
(DFF; Liu et al. 1997), because caspase 3 activation and H2AX phosphorylation appeared 
simultaneously (Paull et al., 2000). Evidently, the molecular onset of apoptosis occurred 
faster than the orchestrated expression of the investigated cell cycle regulators. Interestingly, 
the activation of caspase 3 concurred with the activation of caspase 8, but not with activation 
of caspase 9, indicating that the extrinsic apoptosis pathway became activated and not the 
intrinsic one. The signature-type processing of caspase 3 into the active fragment was more 
prominent by F1 than by F5.3.3.7 and F4.6.3. This was most likely due to the four times 
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 higher F1 concentration used (40 µg/ml), which caused also the degradation of α-tubulin and 
β-actin as consequence of swift onset of cell death.  
The low or absent activation of Chk2 (respectively) suggested that a genotoxic activity, which 
was formerly present in the crude extract (Gridling et al. 2009) and in other subfractions 
(Bauer et al. 2011), was eliminated throughout the described fractionations. Avoiding 
genotoxicity can be beneficial, because it reduces DNA damage and subsequent mutations 
that may cause secondary malignancies. Cdc25A, a classified oncogene (Kiyokawa and Ray 
2008, Ray and Kiyokawa 2008) was up-regulated by both fraction types and therefore, we 
investigated also the expression of other oncogenes, which are related to tumour growth and 
progression. F4.6.3 had a substantial effect on the repression of c-Myc and only a minor effect 
on c-Jun. Even more effective, F5.3.3.7 suppressed also the phosphorylation of Tyr705 of 
Stat3 and thus inhibited its function, which is known to play a role in tumour progression 
(Devarajan and Huang 2009). This fraction further repressed JunB and c-Jun and c-Myc 
more effectively than F4.6.3. 
   Since P. odorata is used also as a wound healing remedy, this property also involves tissue 
regeneration and the regulation of a process called “epthelial to mesenchymal transition” 
(EMT, van Zijl et al. 2011, Thiery et al. 2009). The most prominent feature of EMT is the 
acquisition of a mobile phenotype (Kalluri and Weinberg 2009, Vonach et al. 2011). If 
transient and tightly regulated EMT is beneficial for the organism because it contributes to 
acute inflammation and tissue repair (Lu et al. 2006, Grivennikov et al. 2010, Lopez-Novoa 
and Nieto 2009). In contrast, the chronic status occurrence of EMT causes pathologies such 
as progression of cancer (Wu and Zhou 2009). The mobility of cancer cells is a prerequisite 
for the intra- and extra-vasation of the vasculature, tissue invasion and metastatic spread 
(Krupitza et al. 1996, van Zijl et al. 2011) and it is mediated by proteins that allow cell 
plasticity and movement. Therefore, the alteration of motility-related gene products in 
cancerous cells, such as paxillin (Schaller 2001, Deakin and Turner 2008), ROCK1 (Sahai 
and Marshall 2003), MLC2 for the formation of stress fibres (Totsukawa et al. 2000) and 
MYPT (Vetterkind et al. 2010), are indicators for increased mobility and hence, cancer 
progression. Also leukaemia cells such as differentiated HL60 attach to the ECM and vascular 
cells and transmigrate through vessel walls, invade tissues (Liu et al 2009, Wang et al. 2010, 
Raman et al. 2010) and add to the progression of the disease. Hence, HL60 cells possess a 
repertoire of proteins facilitating cell movement although they normally grow in suspension. 
Treatment with F5.3.3.7 caused ROCK1 repression below constitutive and detectable levels, 
which was not the case with F4.6.3 (Fig. 5d). Also MYPT expression decreased upon 
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 treatment with F5.3.3.7. Paxillin became up-regulated by F4.6.3 treatment and marginally by 
F5.3.3.7 and this was also the case for the phosphorylation of MLC2. Since P. odorata is 
successfully used for tissue recovery and healing of skin bruises the increased mobility of 
cells (fibroblasts, epithelial cells, macrophages etc) is required to close the tissue disruption. 
This very property however, is detrimental throughout cancer treatment and elimination of 
this activity might be beneficial for this purpose. Therefore, future research has to address the 
question whether F5.3.3.7 is advantageous for cancer cell treatment, whereas F4.6.3 exhibits 
advanced wound healing properties. 
 
 
Conclusions 
 
A spindle-damaging activity became enriched by fractionations, which was reflected by 
increased α-tubulin acetylation followed by the activation of caspases 8 and 3 and the typical 
nuclear morphology of apoptosis. The impact on apoptosis and the orchestration of apoptosis 
regulator activation were similar for both fractions. In comparison to earlier work genotoxic 
components activating Chk2 were eliminated.  
Importantly, F4.6.3 induced mobility markers, whereas F5.3.3.7 inhibited the expression of 
mobility markers or did not interfere with their constitutive expression. This property 
implicates an inhibitory effect of F5.3.3.7 on tumour progression which was also reflected by 
the down-regulation of the Jun family of oncogenes and the suppression of Stat3 activity. 
These findings can provide a basis for the development of remedies 1) supporting wound 
healing in case of F.6.3 or 2) interfering with tumour progression in case of F5.3.37. 
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Abstract 
 
Introduction: Different studies describe the anti-inflammatory effects of Scrophularia species, 
a medicinal plant widely used in folk medicine since ancient times. As knowledge regarding 
the anti-neoplastic properties of this species is rather limited, we investigated the influence of 
methanolic extracts of different Scrophularia species on cell proliferation, cell death, and 
tumour cell intravasation through the lymphendothelial barrier. 
Methods: HL-60 leukaemia cells were treated with methanolic extracts of different 
Scrophularia species leading to strong growth inhibition and high cell death rates. The 
expression of cell cycle regulators, oncogenes and cell death inducers was checked by 
Western blot analysis. Furthermore the effect of S. lucida was studied in a NF-κB reporter 
assay, and in a novel assay measuring “circular chemorepellent-induced defects” (CCID) in 
lymphendothelial monolayers that were induced by MCF-7 breast cancer spheroids. 
Results: Methanol extracts of Scrophularia species exhibited strong anti-proliferative 
properties. S. floribunda extract inhibited G2/M- and later on S-phase and S.lucida inhibited 
S-phase and in both cases this was associated with the down-regulation of c-Myc expression. 
Extracts of S. floribunda and S. lucida led to necrosis and apoptosis, respectively. 
Furthermore, S. lucida, but not S. floribunda, effectively attenuated tumor cell intravasation 
through lymphendothelial cell monolayers, which correlated with the inhibition of NF-κB. 
Conclusions: S. lucida exhibited promising anti-neoplastic effects and this was most likely 
due to the down-regulation of various cell cycle regulators, proto-oncogenes and NF-κB and 
the activation of caspase 3. 
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Introduction 
 
While only ~1% of the estimated 300 000 different species of higher plants have a history in 
food use, up to 10-15% have extensive documentation for application in traditional medicine 
(1). Natural products have played a significant role in human healthcare for thousands of 
years, especially in the treatment of infectious diseases (2). Even today, more than 60% of all 
drugs used are either natural products or directly derived thereof and are used to treat even 
diseases such as cancer. Among these are very important agents like vinblastine, vincristine, 
the camptothecin derivatives, topotecan and irinotecan, etoposide, derived from 
epidopodophyllotoxin, and paclitaxel (3, 4, 5). 
Ethno-medicine does not only explore written sources i.e. Traditional Chinese Medicine or 
Ayurveda, but in particular also gives strong attention to the many kinds of folk medicine that 
was practiced in all parts of the world for centuries.  
A very rich plant diversity is found in Turkey, because the Taurus peninsula has seas on three 
sides and various climatic zones and topographies. The flora of Turkey is rich in medicinal 
and aromatic plants that have been used to treat different diseases in Turkish and antique folk 
medicine (6, 7). Since ancient times, different Scrophularia species have been used as 
remedies for some medical treatments, including scabies, eczema, psoriasis, inflammatory 
diseases and tumors (8). There are more than 220 genera of the Scrophulariaceae family in 
which the genus Scrophularia is known for the rich presence of sugar esters and iridoid 
glycosides (9, 10), and a few publications describe the anti-inflammatory properties of 
different Scrophularia species (11, 12). Oleanonic and ursolonic acids extracted from the root 
of S. ningpoensis Hemsl were found to be cytotoxic against a series of human cancer cell lines 
(MCF7, K562 and A549) (10).  
We have investigated the anti-proliferative and pro-apoptotic potency of the methanol extracts 
of five different Scrophularia species (two endemic to Turkey: S. libanotica and S. pinardii) 
and elucidated the corresponding pathways of those two species that showed the strongest 
antineoplastic effect. Furthermore, we discovered a property in S. lucida, which correlates 
with the inhibition of lymph node metastasis of breast cancer cells. 
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Methods 
 
Plant material: Scrophularia floribunda, S. lucida, S. peregrina, S. pinardii and S. libanotica 
subsp. libanotica var. mesogitana were collected in the south-west of Turkey at a height 
around 250 m in Aydin and Marmaris, respectively. Flowering times of these plants were 
identified from books for specifying the collection time. Plants were recognized in the field 
survey by various plant parts (flower, leaf, stamen, colouring of petals and etc.) and by 
comparing with previously prepared herbarium samples. Taxonomic determinations were 
made by Dr. Özkan Eren using the serial “Flora of Turkey and the East Aegean Islands” 
(Davis, 1965-1988). Voucher specimens (voucher numbers: S. floribunda AYDN 432; S. 
lucida AYDN 433), in duplicates were deposited in the herbarium of the Department of 
Biology, Adnan Menderes University. 
 
Sample preparation: Plants were freeze dried, subsequently milled and extracted with 
methanol at the ratio of 1:10. Extraction was carried out on a shaker at room temperature 
overnight. After filtration, methanol was evaporated with a rotary evaporator and extract 
weight was determined (table 1). For the experiments, the extracts were dissolved in ethanol. 
For the proliferation- and apoptosis assays the following concentrations as calculated for dried 
plant material were used: 500 µg/ml, 1 mg/ml, 4 mg/ml and 10 mg/ml. To exclude an effect of 
ethanol on cell proliferation and apoptosis, controls were treated with same concentrations of 
ethanol as used for sample treatment (in general 0.2 % EtOH) (13,14). 
 
Species Wet weight (g) Dry weight (g) 
Extract weight 
(g) 
S. floribunda 349 87 17 
S. lucida 295 87 14 
S. peregrine 243 55 11.6 
S. pinardii 383 88 17 
S. libanotica 280 88 12.5 
 
Table 1 Extract yields after sample preparation 
 
Detannification: For removal of tannins 5 g of the total methanol extract of S. floribunda and 
S. lucida, respectively, were dissolved in 60 ml of a methanol/water mixture (10:1). After 
triple solvent extraction with 60 ml petroleum ether for withdrawal of chlorophyll, waxes and 
fats, the methanol fraction was diluted with 60 ml of water and subsequently this aqueous 
solution was extracted three times with 120 ml chloroform. To gain the detannified extract, 
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the collected chloroform fraction was washed three times with 360 ml sodium chloride 
solution (1%) and after drying with sodium sulphate, the chloroform was evaporated with a 
rotary evaporator. S. floribunda and S. lucida total methanol extract yielded 0.24 g and 0.11 g 
per g, respectively.  
 
Cell culture: HL-60 promyeloic leukaemia cells were purchased from ATCC. Cells were 
grown in RPMI 1640 medium supplemented with 10 % heat inactivated fetal calf serum 
(FCS), 1 % L-glutamine and 1 % penicilline/streptomycin. Human MCF-7 breast cancer cells 
were cultivated in MEM medium supplemented with 10% FCS, 1 % penicillin/streptomycin, 
1 % NEAA. Telomerase immortalized human lymphendothelial cells (LECs) were grown in 
EGM2 MV (Clonetics CC-4147, Allendale, NJ, USA). For CCID formation assays, LECs 
were stained with cytotracker green. HEK293-NFκB-Luc cells were cultivated in high 
glucose DMEM containing phenol red, supplemented with 10% FCS, 1% 
penicillin/streptomycin and 1% L-glutamine. GFP transfection of HEK293-NFκB-Luc cells 
using lipofectamin2000 was carried out in medium without penicillin/streptomycin.  
All cells were grown at 37°C in a humidified atmosphere containing 5% CO2. If not 
mentioned otherwise, all media and supplements were obtained from Invitrogen Life 
Technologies (Karlsruhe, Germany).  
 
3-D co-cultivation of MCF-7 cancer cells with LECs: MCF-7 mock cells were transferred 
to 30 ml MEM medium containing 6 ml of a 1.6 % methylcellulose solution (0.3 % final 
concentration; Cat. No.: M-512, 4000 centipoises; Sigma, Munich, Germany). 150 µl of this 
cell suspension were transferred to each well of a 96 well plate (Greiner Bio-one, Cellstar 
650185, Kremsmünster, Austria) to allow spheroid formation within the following two days. 
Then, MCF-7 spheroids were washed in PBS and transferred to cytotracker-stained LEC 
monolayers that were seeded into 24 well plates (Costar 3524, Sigma, Munich, Germany) in 2 
ml EGM2 MV medium (15, 16). 
 
Circular chemorepellent induced defect (CCID) assay: MCF-7 cell spheroids (3000 
cells/spheroid) were transferred to the 24 well plate containing LEC monolayers. After four 
hours of incubating the MCF-7 spheroids-LEC monolayer co-cultures, the CCID sizes in the 
LEC monolayer underneath the MCF-7 spheroids were photographed using an Axiovert 
(Zeiss, Jena, Germany) fluorescence microscope to visualise cytotracker (green)-stained LECs 
underneath the spheroids (17). Gap areas were calculated with the Axiovision Re. 4.5 
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software (Carl Zeiss, Jena, Germany). MCF-7 spheroids were treated with solvent (ethanol) as 
negative control. The gap sizes of at least 12 spheroids per experiment were measured. 
 
Reagents and antibodies: Hoechst 33258 and propidium iodide were purchased from Sigma 
(Munich, Germany). Amersham ECLPlus Western Blotting Detection System was from GE 
Healthcare (Buckinghamshire, UK). 
Antibodies: Mouse monoclonal (ascites fluid) anti-acetylated tubulin clone 6-11B1 Cat# 
AT6793 and mouse monoclonal (ascites fluid) anti-β-actin clone AC-15 Cat# A5441 were 
from Sigma (Munich, Germany). Anti α-tubulin (TU-02) Cat# sc-8035, PARP-1 (F-2) Cat# sc 
8007, anti cyclin D1 (M-20) Cat# sc-718, p21 (C-19) Cat# sc-397, cdc25a (F-6) Cat# sc-7389, 
cdc25b (C-20) Cat# sc-326, cdc25c (C-20) Cat# sc-327, c-jun (C-20) Cat# sc-1694 and jun-B 
(210) Cat+# sc-73 were from Santa Cruz Biotechnologies Inc. (Santa Cruz, CA, USA) 
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Cat# 9106, p44/42 MAPK (Erk1/2) 
(137F5) Cat# 4695, phospho-p38 MAPK (Thr180/Tyr182) (12F8) Yat# 4631, p38 MAPK Cat# 
9212, cleaved caspase 3 (Asp175) Cat# 9661, phospho-Wee1 (Ser642) (D47G5) Cat# 4910, 
Wee1 Cat# 4936, phospho-chk2 (Thr68) Cat# 2661, chk2 Cat# 2662, Myosin Light Chain 1 
Cat# 3672 and phospho-Myosin Light Chain 2 (Ser19) Cat# 3671  were purchased from Cell 
Signalling (Danvers, MA, USA). Anti c-myc antibody Ab-2 (9E10.3) was from Neomarkers 
(Fremont, CA, USA) and rabbit polyclonal phospho detect anti-H2AX (pSer139) Cat# dr-1017 
from Calbiochem (Merck, Darmstadt, Germany). Anti mouse and anti rabbit IgG were from 
Dako (Glostrup, Denmark). 
 
Proliferation inhibition analysis: HL-60 cells were seeded in T-25 Nunc tissue culture 
flasks at a concentration of 1x105/ml and incubated with increasing concentrations of plant 
extracts (corresponding to 500 µg/ml, 1 mg/ml, 4 mg/ml and 10 mg/ml of the dried plant). 
Cell counts and IC50 values were determined at 24, 48 and 72 hours using a Casy TTC cell 
counter (Roche, Basel, Switzerland), respectively.  
The percent of cell divisions compared to the untreated control were calculated as follows: 
((C72h + drug – C24h + drug)/(C72h - drug – C24h – drug)) x 100 = % cell division, where C72h + drug is the 
cell number after 72 h of extract treatment, C24h + drug is the cell number after 24 h of extract 
treatment, C72h - drug  and C24h – drug are the cell numbers after 72 and 24 h without extract 
treatment (18,19). 
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Cell death analysis: The Hoechst propidium iodide double staining was performed according 
to the method described by Grusch et al. (20, 21). HL-60 cells (1x105) were seeded in T-25 
Nunc tissue culture flasks and exposed to 20 µg/ml detannified extract (corresponding to 0.42 
mg/ml of dried S. floribunda and 1.10 mg/ml of dried S. lucida) for 24 and 48 h. Hoechst 
33258 and propidium iodide (Sigma, Munich, Germany) were added directly to the cells at 
final concentrations of 5 and 2 µg/ml, respectively. After 60 min of incubation at 37°C cells 
were examined on a Zeiss Axiovert fluorescence microscope (Zeiss, Jena, Germany) equipped 
with a DAPI filter. Cells were photographed and analysed by visual examination to 
distinguish between apoptosis and necrosis (22). Cells were judged according to their 
morphology and the integrity of their cell membranes by propidium iodide staining. 
 
FACS analysis: HL-60 cells (1x106 per ml) were seeded in T-25 Nunc tissue culture flasks 
and incubated with 20 µg/ml detannified extract (corresponding to 0.42 mg/ml of dried S. 
floribunda and 1.10 mg/ml of dried S. lucida) for 8 and 24 h, respectively. Then, cells were 
washed with 5 ml cold PBS, centrifuged (800 rpm for 5 min), and resuspended and fixed in 3 
ml cold ethanol (70%) for 30 min at 4˚C. After two further washing steps with cold PBS, 
RNAse A and propidium iodide were added to a final concentration of 50 µg/ml each and 
incubated at 4˚C for 60 min before measurement (23, 24). Cells were analysed on a 
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) and cell cycle 
distribution was calculated with ModFit LT software (Verity Software House, Topsham, ME, 
USA). 
 
NF-κB Luciferase Assay: 10x106 HEK293-NFκB-Luc cells (Panomics, Fremont, USA) were 
seeded in 20 ml full growth DMEM medium in a 15 cm dish. Next day, cells were transfected 
with the cDNA of green fluorescence protein (GFP). A total of 30 µl Lipofectamin 2000 
(Invitrogen, Karlsruhe, Germany) and 7.5 µg DNA were mixed in 2 ml transfection medium 
and incubated for 20 min at room temperature followed by adding this mixture to the cells. 
After incubation for 6 hours in humidified atmosphere containing 5% CO2, 4x10
4 cells per 
well were seeded in serum- and phenol red-free DMEM in a 96 transparent well plate. On the 
next day cells were treated with detannified S. lucida extract (corresponding to 0.5 mg/ml, 2 
mg/ml and 4 mg/ml of the dried plant) and 15 µM Bay 11-7082 (Sigma Aldrich Cat# B5556) 
as a specific inhibitor of NFκB (control). One hour after treatment cells were stimulated with 
2 ng/ml human recombinant TNF-α for additional 4 hours. Luminescence of the firefly 
luciferase and fluorescence of the GFP were quantified on a GeniusPro plate reader (Tecan, 
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Grödig, Austria). The luciferase signal derived from the NF-κB reporter was normalized by 
the GFP-derived fluorescence to account for differences in the cell number or transfection 
efficiency. 
 
Western Blotting: HL-60 cells (0.5 x 106) were seeded into T-75 Nunc tissue culture flasks 
and incubated with 20 µg/ml detannified extract (corresponding to 0.4 mg/ml of dried S. 
floribunda and 1.1 mg/ml of dried S. lucida) for 0.5, 2, 4, 8 and 24 h, respectively. At each 
time point 2 x 106 cells were harvested, washed twice with cold PBS, centrifuged (175 x g) 
for 5 min and lysed in a buffer containing 150 nM NaCl, 50 mM Tris, 1 % Triton-X-100, 1 
mM phenylmethylsulfonylfluride (PMSF) and 2.5 % PIC (Cat#P8849 Sigma, Munich, 
Germany). After centrifugation (12 000 x g) for 20 min at 4°C the supernatant was stored at -
20°C until further analysis. Equal amounts of protein samples were separated by 
polyacrylamide gel electrophoresis and electrotransferred onto PVDV-membranes (Hybond-
P, Amersham) at 4°C overnight. Staining membranes with Ponceau S controlled equal sample 
loading. After washing with Tris buffered saline (TBS) ph 7.6, membranes were blocked for 1 
h in 5 % non-fat dry milk in TBS containing 0.1% Tween-20. Membranes were incubated 
with the first antibody (in blocking solution, dilution 1:500-1:1000) by gently rocking 
overnight at 4°C, washed with TBS containing 0.1% Tween-20 and further incubated with the 
second antibody (peroxidase-conjugated swine anti-rabbit IgG or rabbit anti-mouse IgG, 
dilution 1:2000-1:5000 in blocking solution) for 1 h. Chemoluminescence  was developed by 
the ECL plus detection kit (GE Healthcare, Buckinghamshire, UK) and detected using a 
Lumi-Imageer F1 Workstation (Roche, Basel, Switzerland). 
 
Statistics: All experiments were performed in triplicate and analysed by t-test (GraphPad 
Prism 5.0 program, GraphPad (San Diego, CA, USA). 
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Results 
 
Anti-proliferative activity 
The methanol extracts of the tested Scrophularia species inhibited cell growth of HL-60 
promyeloic leukaemia cells, whereof S. floribunda and S. lucida showed the strongest 
inhibition with IC50 values of 0.54 mg/ml and 0.41 mg/ml, respectively (calculated for dried 
plant material; table 2, figure 1). Methanol extracts contain tannins, which may have caused 
this effect non-specifically. Therefore, the extracts of those plants exhibiting the strongest 
activities were purified to remove chlorophyll and fatty ingredients in a first step and then 
tannins and other polar substances in a second step. The obtained detannified extracts (dt) 
were tested again regarding their anti-proliferative activity and they still showed 
approximately the same strong growth inhibition (IC50 values of 0.3 mg/ml and 0.4 mg/ml for 
S. floribunda dt and S. lucida dt, respectively, figure 2). To compare the two Scrophularia 
species regarding their potency, 20 µg/ml of the detannified extracts (corresponding to 1.1 
mg/ml S. lucida and 0.4 mg/ml S. floribunda, respectively) were used for all further 
experiments. 
 
Methanol extract IC50 (mg/ml) 
S. floribunda 0.5 
S. lucida 0.4 
S. peregrina 3.7 
S. pinardii 0.9 
S. libanotica 0.9 
 
Table 2 IC50 values in HL-60 cells after 72h of treatment with the total methanol extracts of indicated 
Scrophularia species 
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Figure 1 Proliferation inhibition upon treatment with total methanol extracts for 72 h. HL-60 cells (1x105 
cells/ml) were seeded in T-25 tissue culture flasks and were incubated with total methanolic extracts 
corresponding to 0.5 mg/ml, 1 mg/ml, 4 mg/ml and 10 mg/ml of the dried plant. Experiments were performed in 
triplicate. To avoid unspecific effects caused by the solvent, ethanol concentration was the same in all samples 
(0.2%). Asterisks indicate significance compared to untreated control (p<0.05) and error bars indicate ±SD.  
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Figure 2 Proliferation inhibition upon treatment with the detannified extracts (corresponding to 0.4, 0.5, 1.0 and 
1.1 mg dried plant / ml medium) for 72 h. For S. floribunda or S. lucida 20 µg dtMeOH extract corresponded to 
0.4 or 1.1 mg dried plant weight, respectively. Experiments were performed in triplicate. To avoid unspecific 
effects caused by the solvent, ethanol concentration was the same in all samples (0.2%). Asterisks indicate 
significance compared to untreated control (p<0.05) and error bars indicate ±SD.  
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Cell cycle distribution 
To investigate the cell cycle distribution, logarithmically growing HL-60 cells were exposed 
to 20 µg/ml detannified methanol extract of S. lucida and S. floribunda for 8 an 24 h, 
respectively. Both extracts caused a rapid reduction of G1 cells (figure 3). S. floribunda 
treatment induced a strong G2/M arrest after 8 h and a significant accumulation of cells in the 
S-phase after 24 h. In contrast S. lucida did not elicit a G2/M arrest, but a strong accumulation 
in the S-phase after 8 h and a distinct sub-G1 peak indicating loss of DNA typical for 
apoptosis. 
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Figure 3 Effects of Scrophularia extracts on cell cycle distribution; HL-60 cells (1x106 per ml) were seeded in 
T-25 tissue culture flasks and incubated with 20 µg/ml detannified extract (corresponding to 0.4 mg/ml of dried 
S. floribunda and 1.1 mg/ml of dried S. lucida) for 8 and 24 h. Experiments were performed in triplicate. To 
avoid unspecific effects caused by the solvent, ethanol concentration was the same in all samples (0.2%). 
Asterisks indicate significance compared to untreated control (p<0.05) and error bars indicate ±SD. 
 
 
 
Potential mechanisms arresting cell proliferation 
To investigate the underlying mechanisms responsible for the strong proliferation inhibition 
we analysed the expression profiles of different positive and negative cell cycle regulators 
(figure 4, figure 5). S. floribunda clearly increased the p21 level after 4 h, while S. lucida 
extract inhibited p21 expression within 4 h. Although p21 is a prominent transcriptional target 
of p53 another pathway must have triggered the p21 increase since HL-60 cells are p53 
deficient (25). As also the activation of the MEK-Erk pathway was shown to up-regulate p21 
(26, 27), we checked the phosphorylation status of Erk1/2. S. floribunda showed a slight 
increase of the phosphorylation status of Erk1/2 at the 4 h time point going along with the p21 
up regulation.  In contrast S. lucida strongly phosphorylated Erk1/2 already after 2 h, followed 
by a decrease after 8 h and a drop below control level after 24 h. Therefore, p21 must have 
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been regulated independent of Erk1/2. However, both extracts lead to Erk phosphorylation for 
an unusually long time, which is known in other contexts to be activated only for some 10-20 
min (28).  
Another prominent inducer of cell cycle arrest and apoptosis is cellular stress. p38 MAPK 
presents an important member in a signalling cascade controlling its responses to cellular 
stress.  Phosphorylation of p38 at Thr180 and Tyr182 leads to its activation and binding to 
Jnk or Max modulates transcription (29, 30). Both extracts were capable to activate p38 
within 2 h indicating that cellular stress was another important factor that may have caused 
growth arrest. 
 
 
 
Figure 4 Western blot analysis of different proteins of the MAPK pathway. 1 x 106 HL-60 cells/ml were 
incubated with 20 µg/ml detannified extract and harvested after 0.5, 2, 4, 8 and 24 h of treatment. Cells were 
lysed and obtained protein samples applied to SDS-PAGE. Western blot analysis was performed with the 
indicated antibodies. Equal sample loading was confirmed by Ponceau S staining and β-actin analysis. 
 
 
The activation of Chk2 by S. floribunda (figure 5) was in time with the phosphorylation of 
Erk1/2 and the induction of p21. The inhibition of the cell cycle was due to the inactivation of 
Cdc2, which was reflected by the increased phosphorylation of Tyr15. Interestingly, Tyr15-
Cdc2 phosphorylation correlated with over-expression of Wee1, which specifically 
phosphorylates this site, but not with Cdc25A and Cdc25C, because these phosphatases 
responsible for the de-phosphorylation of Tyr15-Cdc2 became up-regulated. This was in 
sharp contrast to the effects on cell cycle regulators elicited by S. lucida extract, because Chk2 
was induced much earlier and this correlated with the degradation of the Cdc25 family, which 
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is in accordance with the reported mechanisms of cell cycle inhibition upon DNA check point 
activation (31, 32). It was expected that this would result in hyper-phosphorylation and 
inactivation of the effector-kinase Cdc2, but the contrary was the case due to inhibition and 
down-regulation of Wee1. Therefore, the phosphorylation status of Cdc2 primarily correlates 
with Wee1 but not with Cdc25A and Cdc25C. Also Cdc25B became down-regulated by S. 
lucida but was expressed unchanged upon treatment with S. floribunda. This evidenced that S. 
floribunda and S. lucida contained distinct “Active Principles”. Although potential 
mechanisms as to how the extract of S. floribunda inhibits cell division could be outlined, it 
was still unclear how the extract of S. lucida arrested cell proliferation.  
 
 
 
 
Figure 5 Western blot analysis of cell cycle and checkpoint regulators. 1 x 106 HL-60 cells/ml were incubated 
with 20 µg/ml detannified extract and harvested after 0.5, 2, 4, 8 and 24 h of treatment. Cells were lysed and 
obtained protein samples applied to SDS-PAGE. Western blot analysis was performed with the indicated 
antibodies. Equal sample loading was confirmed by Ponceau S staining and β-actin analysis. 
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Downregulation of oncogenes 
Hence, we investigated the expression of proto-oncogenes, which are involved in tumour cell 
proliferation. C-Myc, a member of the Myc family of oncogenes, is essential for promoting 
cell growth by regulating the transcription of target genes required for proliferation and c-Myc 
was shown to be over-expressed in a wide spectrum of tumors (33). As an over-expression 
leads to constitutive signals that promote proliferation and angiogenesis of the tumor (34), we 
checked the expression levels of the c-Myc protein to investigate whether the two 
Scrophularia extracts were capable to down regulate that oncogene. In fact, treatment of HL-
60 cells with the two extracts resulted in c-Myc protein decrease, in particular with S. lucida 
that showed a dramatic down regulation within 2 hours (figure 6). Together with Fos family 
members, Jun family members form the group of AP-1 proteins which, after dimerisation, 
bind to responsive elements in the promoter regions of different target genes (35). AP-1 
heterodimers are important regulators of genes playing a major role in proliferation, 
differentiation, invasion and metastasis (36). Therefore, we also checked the expression status 
of c-Jun, JunB and Fos after incubation with the two Scrophularia extracts. While Fos was 
slightly up regulated by both extracts, and S. floribunda did not affect Jun and JunB, S. lucida 
showed a strong down regulation of these two oncogenes after 24 hours. 
 
 
 
Figure 6 Western blot analysis of different oncogenes. 1 x 106 HL-60 cells/ml were incubated with 20 µg/ml 
detannified extract and harvested after 0.5, 2, 4, 8 and 24 h of treatment. Cells were lysed and obtained proteins 
samples applied to SDS-PAGE. Western blot analysis was performed with the indicated antibodies. Equal 
sample loading was confirmed by Ponceau S staining and β-actin analysis. 
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Cell death induction 
Treatment of HL-60 cells with the detannified S. lucida and S. floribunda extract resulted in 
high cell death rates (figure 7). While incubation with detannified extract of S. lucida 
corresponding to 1 mg/ml of the dried plant induced up to 70 % of apoptosis after 48 h, HL-
60 cells treated with S. floribunda extract showed a para-typical apoptosis phenotype with 
almost instantaneous incorporation of propidium iodide indicating necrosis, which was 
substantiated in respective western blots (see below).  
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Figure 7 Induction of cell death of HL-60 cells treated with detannified Scrophularia extracts. 1x105 HL-60 
cells/ml were seeded in 24-well plates and incubated with 0.5 mg/ml and 1 mg/ml extract corresponding to dried 
plant and 20 µg/ml to pure extract (corresponding to 1.1 mg/ml S. lucida and 0.4 mg/ml S. floribunda, 
respectively). Then, cells were double stained with Hoechst 33258 and propidium iodide and examined under the 
microscope with UV light connected to a DAPI filter. Nuclei with morphological changes which indicated cell 
death were counted and the percentages of dead cells were calculated. Experiments were performed in triplicate. 
Asterisks indicate significance compared to untreated control (p<0.05) and error bars indicate ±SD. 
 
 
Cell death mechanisms  
FACS analyses (figure 3) and HOPI staining (figure 7) indicated that S. lucida induced 
apoptosis but not necrosis, while the extract of S. floribunda did not show a sub G1 peak. As 
both compounds led to cell death, we further investigated the two extracts regarding the 
mechanisms involved. Caspase 3 plays a critical role in the execution of the apoptotic 
program and is one of the key enzymes for the cleavage of the 113 kDa nuclear enzyme poly-
(ADP-ribose) polymerase (PARP) that is cleaved in fragments of 89 and 24 kDa during 
apoptosis (37, 38). 
S. lucida caused the specific cleavage of Caspase 3 to the active 17 kDa and the proteolytic 
cleavage of the death substrate PARP into the large 89 kDa fragment demonstrating that 
caspase 3 was functional and responsible for the pro-apoptotic property of S. lucida methanol 
extract (figure 8). In contrast, S. floribunda did not show caspase 3 activation and signature 
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type PARP cleavage. Instead of the 89 kDa cleavage product we found a smaller 55 kDa 
fragment. It was demonstrated that also necrotic cell death of HL-60 cells goes along with 
degradation of PARP, but different from that observed during apoptosis (39, 40). Gobeil et al. 
(41) revealed that necrotic treatment of Jurkat T cells did not cause caspase activation and 
provoked the appearance of multiple PARP cleavage products mediated by lysosomal 
proteases. The main fragment was at 55 kDa, which was also found here after treatment of Hl-
60 cells with S. floribunda extract and which correlated with the necrotic phenotype observed 
by HO/PI double staining (20, 21, 42). 
    To investigate whether genotoxicity of the two extracts was responsible for cell death, we 
analysed the phosphorylation status of the histone H2AX (γ-H2AX), because this core histone 
variant becomes rapidly phosphorylated in response to DNA double strand breaks. 
Interestingly both extracts, S. lucida and as well S. floribunda, caused severe phosphorylation 
of H2AX after 2 and 4 h incubation, respectively.  
    Tubulin is the major constituent of microtubuli, which facilitates chromosome disjunction 
during mitosis, and therefore, affecting the tubulin structures is incompatible with functional 
cell division (43). Alterations of the fine tuned balance of microtubuli polymerisation/de-
polymerisation, such as by taxol are reflected by the acetylation status of α-tubulin (44). Both 
methanol extracts increased the acetylation of α-tubulin demonstrating that cytotoxicity can 
be attributed to tubulin polymerization.  
 
 
Figure 8 Western blot analysis of apoptosis related proteins. 1 x 106 HL-60 cells/ml were incubated with 
20 µg/ml detannified extract and harvested after 0.5, 2, 4, 8 and 24 h of treatment. Cells were lysed and obtained 
protein samples applied to SDS-PAGE. Western blot analysis was performed with the indicated antibodies. 
Equal sample loading was confirmed by Ponceau S staining and α-tubulin analysis. 
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Inhibition of lymphendothelial gap formation induced by co-cultivated tumour cell 
spheroids 
Tissue invasion and metastasis is one of the hallmarks of cancer described by Hanahan and 
Weinberg (45, 46) and for most tumor types patients are not threatened by the primary 
tumour but by metastases that destroy the function of infested organs. We tested the extracts 
of both plants in a recently developed three-dimensional cell culture assay measuring the area 
of circular chemorepellent-induced defects CCIDs in the lymphendothelial cell (LEC) barrier 
(figure 9) which are induced by exudates (i.e. 12(S)-hydoxyeicosatetraenoic acid) of MCF-7 
cancer cell spheroids. CCIDs can be considered as entry gates for tumor cells and are directly 
responsible for lymph node- and distant metastases (15, 16, 17). The extract of S. floribunda 
did not prevent CCID formation but affected the viability of LECs and because of the toxic 
effect of 1 mg/ml MeOH extract to LECs, the precise effect on CCID formation could not be 
evaluated. Both extracts of S. lucida (MeOH and detannified dtMeOH) significantly inhibited 
CCID formation in LECs up to 40%. The total MeOH extract showed extremely high 
fluorescence that disappeared after detannification. 
 
 
 
 
 
 
                                                   
 
 
223
 18 
    d 
           Inhibition of MCF-7 spheroid-induced
                         LEC-CCID formation by
                         S. lucida MeOH extracts
C
on
tr
ol
S.
 lu
ci
da
 4
 m
g/
m
l
S.
 lu
ci
da
 4
 m
g/
m
l d
t
0
50
100
150
*
*
%
 C
C
ID
 a
re
a
 
Figure 9 Effect of different Scrophularia extracts on MCF-7 spheroid induced gap formation in 
lymphendothelial cell monolayers. Upper panel: MCF-7 tumor cell spheroids; lower panel: same microscopical 
frame showing LECs underneath MCF-7 spheroids. The 3D co-cultures were treated either with a) solvent 
(ethanol) or with dtMeOH extracts of b) S. lucida or c) S. floribunda corresponding to 4 mg dried plant weight 
/ml medium. When the 3D co-cultures were treated with S. lucida extract the generated CCIDs in LECs 
underneath the MCF-7 spheroids were d) on average ~40 % smaller than those in controls. dt: detannified MeOH 
extract; scale bars: 150 µm 
 
 
NF-κB inhibition by S. lucida extract 
Besides exudates like 12-S-HETE mentioned above, also NF-κB activation was reported to be 
associated with tumor cell proliferation, survival, angiogenesis and invasion (47, 48). We 
could show that the inhibition of NF-κB translocation with Bay11-7082, an irreversible 
inhibitor of I-κBα phosphorylation, blocked MCF-7 spheroid-induced gap formation of LECs 
in a dose-dependent fashion (16). To check whether the significant inhibition of CCID 
formation in LECs caused by S. lucida extracts may be induced through inhibition of NF-κB 
activity, we tested the detannified extract in a NF-κB luciferase reporter gene assay. Cells 
were stimulated with 2 ng/ml TNF-α, and luciferase activity was measured after incubation 
with the selective NF-κB inhibitor Bay11-7082 and different concentrations of S. lucida 
(corresponding 0.5 g/ml, 2 g/ml and 4 g/ml of the dried plant) and compared with a TNF-
α/ethanol treated control. As expected, 15 µM of Bay11-7082 (as positive control) inhibited 
NF-κB activity by nearly 70%. S. lucida also decreased the expression of the reporter gene 
dose-dependently (figure 10). 
 
224
 19 
NF-κB Luciferase Assay
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Figure 10 Effect of S. lucida extract on the NF-κB transactivation activity. 10x106 HEK293-NFκB-Luc cells 
were transfected with the cDNA of green fluorescence protein (GFP). After incubation for 6 hours, 4x104 cells 
per well were seeded in serum- and phenol red-free DMEM in a 96 transparent well plate. On the next day cells 
were treated with detannified S. lucida extract (corresponding to 0.5, 2 and 4 mg dried plant /ml medium), 15 
µM Bay 11-7082 as a specific inhibitor of NF-κB, or solvent (ethanol). One hour after treatment cells were 
stimulated with 2 ng/ml human recombinant TNF-α for additional 4 hours. Luminescence of the firefly luciferase 
and fluorescence of the GFP were quantified on a GeniusPro plate reader. The luciferase signal derived from the 
NF-κB reporter was normalized by the GFP-derived fluorescence to account for differences in cell number or 
transfection efficiency. Experiments were performed in triplicate. Asterisks indicate significance compared to 
untreated control (p<0.05) and error bars indicate ±SD. 
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Discussion 
 
Different species of the Scrophularia family are used since ancient times as remedies for 
some medical conditions including inflammatory diseases and tumors (8, 10). While most 
publications focus on the anti-inflammatory properties (11, 12), this work demonstrates for 
the first time the anti-proliferative and pro-apoptotic properties of different Scrophularia 
species, and beyond that we show that S. lucida inhibits LEC-CCID formation by co-
cultivated MCF-7 cancer cell spheroids (14, 17) and inhibited NF-κB activity. Recently we 
could demonstrate that NF-κB activity contributed to LEC-CCID formation through inhibition 
of VE-cadherin expression and loss of intra-specific LEC adhesion (16, 49). 
As of the different tested methanolic Scrophularia extracts S. lucida and S. floribunda showed 
the strongest anti-proliferative properties, these two extracts were chosen to check the 
underlying mechanisms. Treating HL-60 cells with the detannified S. floribunda extract 
resulted in a strong G2/M arrest after 8 hours. This increase of the cell number in G2/M 
correlated with the phosphorylation status of Cdc2, which is indicative for its inhibition. In 
contrast, 8 hour treatment with S. lucida showed a strong accumulation in the S-phase and 
after 24 hours there was a severe G2/M decrease (correlating with Cdc2 activation). The 
subsequent increase of the subG1 peak suggests that the cells are directly running into death 
from G2/M. Interestingly, the Cdc2 phosphorylation status did not correlate with the 
expression levels of Cdc25 phosphatases neither after treatment with the extract of S. 
floribunda nor with that of S. lucida, but it correlated with the expression of Wee1. Therefore, 
Scrophularia extracts most likely regulated Cdc2 activity through Wee1 and not Cdc25, 
demonstrating that Wee1 activity dominates over Cdc25 activity. However, tilting fine tuned 
Cdc25 activities and expression may trigger cell cycle arrest and finally apoptosis although 
Cdc2 is active.  
The accumulation of HL-60 cells in S-phase after 8 hour treatment with S. lucida might be 
caused through degradation of c-myc oncogene. c-Myc is associated with a wide range of 
cancers and is an essential regulator of G1/S transition (50, 51). While in normal cells 
inhibition of c-myc usually results in a G0/G1 cell cycle arrest (52, 53), tumor cells exhibit 
significant heterogeneity with regard to the positioning of cell cycle arrest in response to c-
Myc depletion (54). Cannell et al. (55) showed that in response to DNA damage c-myc is 
translationally repressed by the induction of miR-34c microRNA and that this induction is 
induced by p38 MAPK/MK2 signalling resulting in S-phase arrest. As c-myc is over-
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expressed primarily in cancer cells, its down-regulation may inhibit proliferating cancer cells 
specifically (56, 57). 
Another important property of a good anti cancer remedy is its ability to kill cancer cells and 
beside their anti-proliferative properties both extracts led to cell death in HL-60 cells. Strong 
phosphorylation of the histone H2AX demonstrates that both extracts are genotoxic. 
Treatment of HL-60 cells with S. lucida resulted in high apoptosis rate after 48 hours, driven 
through caspase 3 activation and subsequent cleavage of PARP into the active 89 kDa 
fragment. In contrast, S. floribunda showed severe necrosis and neither caspase 3 activation 
nor signature type cleavage of PARP. The main fragment was at 55 kDa and is described as 
necrotic PARP cleavage product (41). This extremely toxic effect was also observed in the 
CCID assay, where S. floribunda killed the LECs already after 4 hours. Due to this generally 
toxic effect also against normal cells S. floribunda has to be dismissed as an anti-cancer 
remedy. 
     As mentioned above, most publications highlight anti-inflammatory properties of 
Scrophularia species. Giner et al. (11) investigated the activity of four glycoterpenoids (two 
saponins, verbascosaponin A and verbascosaponin, and two iridoids, scropolioside A and 
scrovalentinoside) isolated from S. auriculata ssp. pseudoauriculata in different models of 
acute and chronic inflammation and demonstrated the anti-inflammatory activity in mice 
against different endema inducers. In another publication (12) five phenylpropanoid 
glycosides isolated from the roots of S. scordonia L. have been evaluated as potential 
inhibitors of some macrophage functions involved in the inflammatory process. They were 
shown to perform inhibitory effects on enzymes of the arachidonate cascade (COX-1, COX-2) 
and significant reduction of LPS-induced TNF-α production without relevant effects on the 
ALOX5 pathway. Treating LEC monolayers with 1 µM synthetic 12(S)-HETE, a metabolite 
of arachidonic acid generated by ALOX12/15, caused the phosphorylation of MLC2 (16) 
indicating that 12(S)-HETE induced the motility of LECs thereby provoking an early step of 
metastasis (15, 17). This observation is also consistent with an inflammatory process, which is 
accompanied by the acquisition of a mobile phenotype of the affected cells reflecting 
“epithelial to mesenchymal transition” (EMT; 58). Interestingly, the extract of S. lucida 
activated the mobility marker MLC2 (data not shown). It was expected that MLC2 would 
become inhibited, because of the markedly attenuated formation of CCIDs. Therefore, other 
activities suppressing LEC migration must have prevailed over MLC2 activation and the NF-
κB inhibitory property of S. lucida is a likely candidate for this effect. As Scrophularia 
species have been used as remedies for different skin diseases, including scabies, eczema and 
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psoriasis (8) the partly pro-migratory property inducing MLC2 phosphorylation could be an 
explanation for this wound healing effect, which depends on the plasticity of cells.  
Furthermore, an ethanol extract prepared from the aerial parts of S. striata Boiss significantly 
and dose-dependently inhibited matrix metalloproteinases (MMPs) activity (59). According to 
the critical role of MMPs in tumor invasion, metastasis and neovascularisation, the inhibition 
of the degradation of components of the extracellular matrix is a promising approach for the 
prevention of cancer progression. In order to develop distal metastasis a tumor cell has to 
encompass different steps: local infiltration into the adjacent tissue, intravasation, survival 
within the circulatory system, extravasation and subsequent proliferation leading to 
colonization (58, 60). Inhibiting the first steps of this multi step process must be a major goal 
of cancer therapy. We could demonstrate that S. lucida exhibited significant inhibition of 
CCID formation and MMP2 and MMP9 play a significant role in this particular assay (15).  
 
 
 
Conclusion 
 
Here we could show that the species S. lucida, which is a genus widely used as folk remedy, 
exhibits severe anti-proliferative and killing effects on cancer cells and strong anti-invasive 
properties. The fractionation of the methanol extract will be a mandatory future approach to 
identify the compounds responsible for the anti-proliferative and anti-metastatic properties. 
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 Abstract 
 
Introduction: Digalloylresveratrol (DIG) is a newly synthesized compound aimed to combine 
the biological effects of the plant polyphenolics gallic acid and resveratrol, which are both 
radical scavengers exhibiting anticancer activity. In this study, we investigated the effects of 
DIG in the human AsPC-1 and BxPC-3 pancreatic adenocarcinoma cell lines. 
 
Methods: The colony formation of cells was determined by clonogenic assay, the induction 
of apoptosis was evaluated by a specific Hoechst dye 33258 and propidium iodide double 
staining, cell cycle distribution was analyzed by FACS, and RR in situ activity was quantified 
by incorporation of 
14
C-cytidine into nascent DNA. Alterations of deoxyribonucleoside 
triphosphate (dNTP) pools were measured by HPLC, and protein expression was investigated 
by western blotting. 
 
Results: DIG dose-dependently inhibited the formation of tumor cell colonies and caused an 
accumulation of cells in the S phase. The incorporation of 
14
C-cytidine into nascent DNA was 
significantly inhibited at all DIG concentrations employed, being equivalent to an in situ 
inhibition of RR and this was consistent with the observed S phase arrest. Furthermore, 
Erk1/2 became inactivated and moderated p38 phosphorylation indicating a mild replication 
stress. DIG led to a significant depletion of the dATP pool in AsPC-1 cells, activated ATM and 
Chk2, and induced the phosphorylation and degradation of the proto-oncogene Cdc25A, 
whereas DIG-induced phosphorylation of Akt compromised apoptosis. 
 
240
 Conclusion: DIG strongly inhibits colony formation, cell cycle progression, and RR in situ 
activity in AsPC-1 and BxPC-3 cells. Due to these promising results, further preclinical and in 
vivo investigations are warranted. 
 
Key words: Digalloylresveratrol, ribonucleotide reductase, pancreatic cancer, AsPC-1 cells, 
BxPC-3 cells. 
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 Introduction 
 
Pancreatic cancer is an aggressive malignancy with poor prognosis, suffering from the lack of 
early diagnosis and appropriate treatment options. The 5-year survival rate remains beyond 
5%, with the median survival period being less than 6 months [1]. Pancreatic cancer 
accounts for 6% of all cancer deaths, and is the fourth leading cause of cancer death in the 
United States [2-3]. The introduction of potentially curative resection has led to improved 
survival, but patients eventually relapse from local recurrence and metastasis, which renders 
pancreatic cancer an incurable disease given the currently available treatment modalities. 
Accordingly, more effective therapeutic strategies are needed for an ameliorated control of 
unresectable and/or metastatic disease. 
Naturally occurring compounds with putative cancer chemopreventive properties, such as 
the phytoalexin resveratrol (3,4',5-trihydroxy-trans-stilbene; RV) or the virostatic and 
antimycotic agent gallic acid (3,4,5-trihydroxybenzoic acid; GA), guide the design of novel 
agents with improved pharmacologic potential. RV has initially been identified as the main 
ingredient of (red) wine being responsible for the so-called French paradox [4]. The latter is 
the fact that the heart infarction rate in France is at least 40% lower than in all other 
European countries and the United States, despite a diet rich in saturated fat [5]. As part of 
the tannin molecule, GA is also present in (red) wine and has been proposed to contribute to 
the French paradox [6]. 
During the past years, numerous studies revealed the distinct free radical-scavenging activity 
of RV and GA and their anticancer effects [7-9]. RV and GA were shown to induce 
differentiation and programmed cell death in a wide variety of tumor cell lines [10] and to 
effectively inhibit the enzyme ribonucleotide reductase (RR; EC 1.17.4.1) [8, 11]. RR catalyzes 
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 the rate-limiting step of de novo DNA synthesis, which is the reduction of ribonucleotide 
diphosphates into the corresponding deoxyribonucleotide diphosphates. RR is significantly 
upregulated in tumor cells and in order to meet the increased need for deoxyribonucleoside 
triphosphates (dNTPs) for DNA synthesis [12] and is therefore considered an excellent target 
for cancer chemotherapy. Difluorodeoxycytidine (Gemcitabine; dFdC) is a commonly used RR 
inhibitor that has been the mainstay of systemic treatment of pancreatic cancer for more 
than a decade but with only limited therapeutic efficacy [1, 13-14]. 
The enzyme is an α2β2 complex consisting of two subunits [15]. The effector binding R1 
subunit possesses an α2 homodimeric structure with substrate and allosteric effective sites 
that control enzyme activity and substrate specificity. The nonheme iron R2 subunit, a β2 
homodimer, forms two dinuclear iron centers each stabilizing a tyrosyl radical. The inhibition 
of the nonheme iron subunit can be caused, for instance, by iron chelation or radical 
scavenging of the tyrosyl radical [16]. Additionally, a p53-inducible R2-homologue (p53R2) 
has been described recently [16]. Expression of the R2 and p53R2 subunits is induced by 
DNA damage and it has been reported that p53R2 supplies dNTPs for DNA repair in G0/G1 
cells in a p53-dependent manner [17]. 
Based on the promising cytotoxic effects of the single compounds, we recently synthesized 
an ester of one molecule RV and two molecules GA, digalloylresveratrol (DIG). To date, we 
have already shown that an equimolar combination of RV and GA (ratio 1:2) inhibited the 
growth of human HT-29 colon cancer cells to a lesser extent than DIG. The latter also 
diminished RR activity in this cell line [18]. In human HL-60 promyelocytic leukemia cells, 
treatment with DIG led to induction of apoptosis, cell cycle arrest, attenuation of RR activity, 
and inhibition of lymphendothelial gap formation in vitro [19]. 
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 We therefore hypothesized that DIG may be also effective in solid malignancies showing an 
even worse prognosis, such as pancreatic cancer. Following this strategy, we investigated the 
biochemical effects of DIG in the AsPC-1 and BxPC-3 human pancreatic adenocarcinoma cell 
lines in order to identify possible beneficial effects that might lead to further preclinical and 
in vivo studies. 
DIG was examined for its cytotoxicity employing clonogenic assays. The induction of 
apoptosis was quantified using a Hoechst/propidium iodide double staining method and cell 
cycle distribution effects were evaluated by FACS. Expression levels of cell cycle regulating 
proteins were determined by western blotting: We investigated the phosphorylation of 
ATM, Chk2, p38, and Akt kinases as well as the phosphorylation of Cdc25A phosphatase. The 
question of whether DIG inhibits the in situ activity of RR and/or affects the steady state of 
deoxynucleosidetriphosphate pools (dNTPs), which are the products of RR metabolism, was 
addressed by incorporation of radio-labeled 
14
C-cytidine into nascent DNA of tumor cells and 
by employing a specific HPLC method, respectively. In addition, the radical scavenging 
potential of DIG was measured by DPPH assay because the tyrosyl radical harbored in the R2 
subunit of RR serves as an additional target for inhibiting the enzyme. 
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 Methods 
 
Chemicals and supplies 
Digalloylresveratrol (DIG) was synthesized and provided by Laila Impex R&D Center, Jawahar 
Autonagar, Vijayawada, 520 007 India. Resveratrol (3,4,5-trihydroxy-trans-stilbene; RV), 
gallic acid (3,4,5-trihydroxybenzoic acid; GA), and solvent DMSO were obtained from Sigma-
Aldrich GmbH, Vienna, Austria. Structural formulas of DIG, GA, and RV including 
nomenclature, molecular weight, and molecular formula are given in figure 1. All other 
chemicals and reagents were commercially available and of highest purity. 
 
Cell culture 
Human AsPC-1 and BxPC-3 pancreatic adenocarcinoma cells were purchased from ATCC 
(American Type Culture Collection, Manassas, VA, USA) and were grown in RPMI 1640 
Medium with GLUTAMAX supplemented with 10% heat inactivated fetal calf serum (FCS), 1% 
Sodium Pyruvate, and 1% Penicillin-streptomycin. Both cell lines were maintained at 37°C in 
a humidified atmosphere containing 5% CO2 using a Heraeus cytoperm 2 incubator (Heraeus, 
Vienna, Austria). Cells were grown in a monolayer culture using 25cm
2
 tissue culture flasks 
and were periodically detached from the flask surface by 0.25% trypsin-
ethylenediaminetetraacetic acid (trypsin-EDTA) solution. All media and supplements were 
obtained from Life Technologies (Paisley, Scotland, UK). Cell counts were determined using a 
microcellcounter CC-110 (SYSMEX, Kobe, Japan). Cells being in the logarithmic phase of 
growth were used for all experiments described below. 
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 Clonogenic assay 
Cells (1x10
3
 per well) were plated in 24-well plates and allowed to attach overnight at 37°C 
in a humidified atmosphere containing 5% CO2. Then cells were incubated with increasing 
concentrations of DIG for 6 days. Subsequently, the medium was carefully removed from the 
wells and the plates were stained with 0.5% crystal violet solution for 5 minutes. Colonies of 
more than 50 cells were counted using an inverted microscope at 40-fold magnification. 
 
Hoechst dye 33258 and propidium iodide double staining 
The Hoechst staining was performed according to the method described by our group [20]. 
Cells (0.2x10
6
 per ml) were seeded in 25cm
2
 Nunc tissue culture flasks and exposed to 
increasing concentrations of DIG for 72 hours. Hoechst 33258 (HO, Sigma, St. Louis, MO, 
USA) and propidium iodide (PI, Sigma, St. Louis, MO, USA) were added directly to the cells to 
final concentrations of 5 µg/ml and 2 µg/ml, respectively, followed by 60 minutes of 
incubation at 37°C. Cells were examined on a Nikon Eclipse TE-300 Inverted Epi-Fluorescence 
Microscope (Nikon, Tokyo, Japan) equipped with a Nikon DS-5M-L1 Digital Sight Camera 
System including appropriate filters for Hoechst 33258 and PI. This method allows 
distinguishing between early apoptosis, late apoptosis, and necrosis and is therefore 
superior to TUNEL assay that fails to discriminate among apoptosis and necrosis [21-22] and 
does not provide any morphological information. In addition, the HO/PI staining is more 
sensitive than a customary FACS based Annexin V binding assay [22-24]. The Hoechst dye 
stains the nuclei of all cells and thus allows monitoring cellular changes associated with 
apoptosis, such as chromatin condensation and nuclear fragmentation. In contrast, PI is 
excluded from viable and early apoptotic cells; consequently, PI uptake indicates loss of 
membrane integrity being characteristic of late apoptotic and necrotic cells. In combination 
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 with fluorescence microscopy to evaluate the morphologies of nuclei, the selective uptake of 
the two dyes enables studying the apoptosis induction of intact cultures and distinguishing it 
from non-apoptotic cell death by means of necrosis. The latter is characterized by nuclear PI 
uptake without chromatin condensation or nuclear fragmentation [25]. Cells were judged 
according to their morphology and the integrity of their cell membranes, counted under the 
microscope and the number of apoptotic cells was given as percentage value. 
 
DPPH radical scavenging activity assay 
The radical scavenging activity of DIG was determined using the free radical 2,2-diphenyl-1-
picrylhydrazyl (DPPH). In its radical form, DPPH absorbs at 515nm but upon reduction by an 
antioxidant or radical species, its absorption decreases. The reaction was started by the 
addition of DIG, RV, GA, or an equimolar combination of RV and GA (10µl; 1–100µM final 
concentration) to 3.0ml of 0.1mM DPPH in methanol. The bleaching of DPPH was followed 
using an HP 8453 diode array spectrometer equipped with a magnetically stirred quartz cell. 
Absorbance was recorded for up to 15 min, although steady states of reaction were reached 
within 5 min in most cases. The reference cuvette contained up to 0.1mM DPPH in 3.0ml of 
methanol. The DPPH radical scavenging activity obtained for each compound was compared 
with that of ascorbic acid and α-Tocopherol. 
 
Cell cycle distribution analysis 
Cells (0.4x10
6
 per ml) were seeded in 25cm
2
 Nunc tissue culture flasks and incubated with 
increasing concentrations of DIG at 37°C under cell culture conditions. After 48 hours, cells 
were harvested and suspended in 5 ml cold PBS, centrifuged, resuspended and fixed in 3 ml 
cold ethanol (70%) for 30 minutes at 4°C. After two washing steps in cold PBS RNAse A and 
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 propidium iodide were added to a final concentration of 50 µg/ml each and incubated at 4°C 
for 60 minutes before measurement. Cells were analyzed on a FACSCalibur flow cytometer 
(BD Biosciences, San Jose, CA, USA) and cell cycle distribution was calculated with ModFit LT 
software (Verity Software House, Topsham, ME, USA). 
 
Incorporation of 
14
C-labeled cytidine into DNA 
To analyze the effect of DIG treatment on the in situ activity of RR, an assay was performed 
as described previously [26]. Radiolabeled 
14
C-cytidine has to be reduced by RR in order to 
be incorporated into the DNA of cells following incubation with DIG. Cells (0.4x10
6 
cells per 
ml) were incubated with various concentrations of DIG for 24 hours. Subsequently, cells 
were counted and pulsed with 
14
C-cytidine (0.3125 µCi, 5 nM) for 30 minutes at 37°C. 
Afterwards, cells were collected by centrifugation and washed with PBS. Total DNA from 
5x10
6
 cells was purified by phenol-chloroform-isoamyl alcohol extraction and specific 
radioactivity of the samples was determined using a Wallac 1414 liquid scintillation counter 
(PerkinElmer, Boston, MA) whose read out was normalized by a Hitachi U-2000 Double 
Beam Spectrophotometer to ensure equal amounts and purity of DNA. 
 
Determination of deoxyribonucleoside triphosphates (dNTPs) 
AsPC-1 cells were seeded in 175 cm
2
 tissue culture flasks (5x10
7
 per flask) and then 
incubated with increasing concentrations of DIG for 24 hours. The cells were then 
centrifuged at 1800 g for 5 min, resuspended in 100 µl of PBS, and extracted with 10 µl of 
trichloracetic acid (90%). The lysate was allowed to rest on ice for 30 min and neutralized by 
the addition of 1.5 volumes of freon containing 0.5 mol/l tri-n-octylamine. Concentrations of 
dNTPs were then determined using the method described by Garrett and Santi [27]. Aliquots 
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 (100 µl) of the samples were analyzed using a Merck ‘‘La Chrom’’ high-performance liquid 
chromatography (HPLC) system (Merck, Darmstadt, Germany) equipped with D-7000 
interface, L-7100 pump, L-7200 autosampler, and L-7400 UV detector. Detection time was 
set at 80 min, with the detector operating on 280 nm for 40 min and then switched to 260 
nm for another 40 min. Samples were eluted with a 3.2 M ammonium phosphate buffer (pH 
3.6, adjusted by the addition of 3.2 mM H3PO4) containing 20 M acetonitrile using a 4.6x250 
mm PARTISIL 10 SAX column (Whatman Ltd., Kent, UK). Separation was performed at 
constant ambient temperature and a flow rate of 2 ml per minute. The concentration of 
each dNTP was calculated as percentage of the total area under the curve for each sample. 
 
Western blotting 
After incubation with 40µM DIG, AsPC-1 cells (2x10
6
 per ml) were harvested, washed twice 
with ice-cold PBS (pH 7.2) and lysed in a buffer containing 150 mM NaCl, 50 mM Tris-
buffered saline (Tris pH 8.0), 1% Triton X-100, 2.5% 100mM phenylmethylsulfonylfluoride 
(PMSF) and 2.5% protease inhibitor cocktail (PIC; from a 100x stock). The lysate was 
centrifuged at 12000 rpm for 20 minutes at 4°C, and the supernatant was stored at -20°C 
until further analysis. Equal amounts of protein samples were separated by polyacrylamide 
gel electrophoresis (PAGE) and electroblotted onto PVDF membranes (Hybond, Amersham) 
overnight at 4°C. Equal sample loading was controlled by staining membranes with Ponceau 
S. After washing with PBS/Tween-20 (PBS/T) pH 7.2 or Tris/Tween-20 (TBS/T) pH 7.6, 
membranes were blocked for 60 minutes in blocking solution (5% non-fat dry milk in PBS 
containing 0.5% Tween-20 or in TBS containing 0.1% Tween-20). Then membranes were 
incubated with the first antibody (in blocking solution, dilution 1:500 to 1:1000) by gently 
rocking at 4°C, overnight. Subsequently, the membranes were washed with PBS or TBS and 
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 further incubated with the second antibody (peroxidase-conjugated goat anti-rabbit IgG, 
anti-mouse IgG, or donkey anti-goat IgG – dilution 1:2000 to 1:5000 in PBS/T or TBS/T) at 
room temperature for 60 minutes. Chemoluminescence was developed by the ECL detection 
kit (Amersham, Buckinghamshire, UK) and then membranes were exposed to Amersham 
Hyperfilms. Equal numbers of cells were lysed for each sample and PVDF membranes were 
checked by Ponceau S staining. Equal sample loading was controlled by β-actin expression, 
which appeared to be stable when inspected in short term exposures to x-ray films. Each 
western blot experiment was performed at least twice, and specific experimental points 
were done more often as they served as internal controls. 
Antibodies directed against p(Ser1981)-ATM, p(Thr68)-Chk2, Chk2, cleaved Caspase-3 
(Asp175), p(Thr202/Tyr204)-Erk1/2, Erk1/2, p(Thr180/Tyr182)-p38MAPK, p38MAPK, 
p(Ser473)-Akt, Akt, and goat anti-rabbit IgG were from Cell Signaling (Danvers, MA, USA), 
against p(Ser177)-Cdc25A from Abgent (San Diego, CA, USA), against R2 (I-15), Cdc25A (F-6), 
and donkey anti-goat IgG from Santa Cruz (Santa Cruz, CA, USA), against β-actin from Sigma 
(St. Louis, MO, USA), and goat anti-mouse IgG was from Dako (Glostrup, Denmark). 
 
Statistical calculations 
Dose-response curves were calculated using the Prism 5.01 software package (GraphPad, 
San Diego, CA, USA) and significant differences between controls and each drug 
concentration applied were determined by unpaired t-test. All p-values beyond 0.05 were 
considered significant and marked with an asterisk (*). 
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 Results 
 
Effect of DIG on the colony formation of AsPC-1 and BxPC-3 cells 
Logarithmically growing cells were incubated with various concentrations of drugs for 6 
days. After that time, cell colonies were counted as described in the methods section. In 
AsPC-1 cells, incubation with DIG, GA, and RV led to IC50 values (50% inhibition of colonies) 
of 21.5, 21, and 18µM, respectively. DIG, GA, and RV inhibited the growth of BxPC-3 cell 
colonies with IC50 values of 8.5, 41, and 13 µM, respectively (table 1). 
 
Induction of apoptosis in AsPC-1 and BxPC-3 cells by DIG 
Pancreatic cancer cells were exposed to increasing concentrations of DIG for 72 hours and 
double stained with Hoechst 33258 and propidium iodide to analyze whether apoptotic cell 
death was induced. However, the number of apoptotic cells did not significantly differ from 
untreated controls, which is in line with the results of similar studies performed by our group 
[18] and others [28]. 
Upon treatment with 30µM DIG, 8.5% of AsPC-1 cells underwent apoptosis (figure 2a). 
Accordingly, western blot analysis after incubation of AsPC-1 cells with 40µM DIG showed 
that caspase 3 protein levels remained unchanged (data not shown). Interestingly, Akt 
kinase became highly phosphorylated at Ser473 within 2 hours, which was shown to provide 
a survival advantage by inhibiting apoptosis (figure 2b). For technical reasons (rapid 
agglomeration) apoptosis induction could not be evaluated in BxPC-3 cells. 
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 Cell cycle distribution in AsPC-1 and BXPC-3 cells after treatment with DIG 
Cells were incubated with different concentrations of DIG for 48 hours. Treatment of both 
AsPC-1 and BxPC-3 cells led to an arrest in the S Phase. In AsPC-1 cells, 80µM DIG increased 
this cell population from 36.7% to 53.3%, whereas G2-M phase cells decreased from 11.4% 
to 0%. In BxPC-3 cells, exposure to 40µM DIG elevated this cell population from 11.6% to 
29.1% while depleting cells in the G0-G1 phase from 85.6% to 68.5% (figures 3a-b). In both 
cell lines, no subG1 peaks could be observed by FACS at the time points measured. 
 
Inhibition of incorporation of 
14
C-cytidine into DNA of AsPC-1 and BxPC-3 cells after 
treatment with DIG 
The incorporation of 
14
C-cytidine into nascent DNA (to determine RR in situ activity) was 
measured in AsPC-1 and BxPC-3 cells after incubation with increasing concentrations of DIG 
for 24 hours. After exposure of AsPC-1 cells to 20, 25, 30, and 35µM DIG for 24 hours, the 
incorporation of 
14
C-cytidine was significantly reduced to 7%, 5%, 5%, and 4% of untreated 
controls, respectively. BxPC-3 cells were treated with 5, 10, 15 and 20µM DIG, which 
significantly decreased the incorporation of 
14
C-cytidine to values beyond 5% at every 
concentration applied (figures 4a-b). 
 
dNTP alterations after treatment with DIG 
Constitutive RR activity maintains balanced dNTP pools, whereas RR inhibition tilts this 
balance. In line with this, DIG treatment caused an imbalance of dNTPs in AsPC-1 cells after 
24 hours, which was determined by HPLC analysis as described in the methods section. 
Incubation of cells with 20 µM DIG resulted in a significant depletion of intracellular dATP 
pools to 31% when compared to controls. In contrast, treatment with 30 µM DIG increased 
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 dTTP pools to 130% of control values. Regarding the dCTP pools, treatment with DIG led to 
only marginal changes. All dGTP pools remained beyond the detectability of the method 
(figure 5). 
 
Antioxidant activity of DIG, RV, and GA 
The in vitro free radical-scavenging activity of DIG, RV, GA, and equimolar combinations of 
RV and GA was determined employing a DPPH-assay. After incubation for 10 min DIG, RV, 
and GA inhibited 50% of DPPH activity with IC50 values of 1.83, 98.3, and 3.12µM, 
respectively. Although the radical-scavenging activity of RV was notably rather weak when 
compared with GA, this finding is in agreement with the literature [29-31]. The combination 
of RV and GA inhibited 50% of DPPH activity at 4.82µM, thus indicating that the antioxidant 
potential of DIG is superior to an equimolar application of the single agents by about 2.5-
fold. Tocopherol and ascorbic acid were used as reference compounds resulting in IC50 
values of 6.98µM and 9.63µM, respectively (table 2). 
 
Expression of RR subunit R2 after treatment with DIG 
To monitor the effect of RR inhibitors on the expression of RR subunit R2, AsPC-1 cells were 
incubated with 40µM DIG for 0.5, 2, 4, 8, and 24 hours and subjected to western blot 
analysis. The protein level of the inducible R2 subunit remained unchanged during the time 
course being consistent with the fact that the activity of the enzyme can be attenuated 
without influencing the protein levels of its subunits [32] (data not shown). 
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 Expression of checkpoint and cell cycle regulating proteins after treatment of AsPC-1 cells 
with DIG 
To investigate whether stalling of the replication fork caused activation of cell cycle 
checkpoint kinases, AsPC-1 cells were treated with 40µM DIG for 0.5, 2, 4, 8, and 24 hours 
and subjected to western blot analysis. Treatment with DIG resulted in phosphorylation at 
Ser1981 of ATM kinase within 2 hours. ATM is activated upon DNA damage and in turn 
caused phosphorylation of Chk2 at the activating Thr68 site. Furthermore, DIG 
phosphorylated Ser177 of Cdc25A, which is a target of Chk2, finally resulting in 
reduction/degradation of Cdc25A after 24 hours (figure 6). 
 
Expression of mitogen-activated protein (MAP) kinases after treatment of AsPC-1 cells 
with DIG 
AsPC-1 cells were incubated with 40µM DIG for 0.5, 2, 4, 8, and 24 hours and subjected to 
western blotting to determine the effect on MAP kinases. Phosphorylation of Erk1/2 was 
reduced within 2 hours. However, DIG showed an induction of p38 kinase phosphorylation 
indicating a stress response (figure 7). 
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 Discussion 
 
Gallic acid (GA) and resveratrol (RV) are naturally occurring polyphenolics previously 
reported to scavenge free radicals, to inhibit ribonucleotide reductase (RR), and to induce 
cell cycle arrest and apoptosis [8, 11, 33-35]. Pancreatic cancer is a very aggressive, 
malignant neoplasm with poor prognosis correlating to short overall survival. In this study, 
we tested a novel synthetic ester of GA and RV, digalloylresveratrol (DIG) in the AsPC-1 and 
BxPC-3 pancreatic cancer cell lines, assuming that this compound may exhibit stronger 
activity than GA or RV itself. 
It has already been demonstrated that growth inhibition of human HT-29 colon cancer cells 
after treatment with DIG surpasses incubation with an equimolar combination of RV and GA 
[18]. In human HL-60 promyelocytic leukemia cells, the inhibition of cell proliferation of DIG 
exceeded that of GA by 10-fold [11]. These results support the conclusion that the RV 
backbone, to which the galloyl-residues are connected, is responsible for the improved 
effects seen with DIG [19]. 
Employing clonogenic assays, we show that DIG inhibited the colony formation of BxPC-3 
cells with an IC50 of 8.5 µM being superior to treatment with GA or RV resulting in IC50 values 
of 41 µM and 13 µM, respectively. Unexpectedly, in AsPC-1 cells, DIG yielded an IC50 of 21.5 
µM thus not exceeding the inhibition of colony formation caused by GA (21 µM) and RV (18 
µM). Different cellular morphology and pharmacology might be the reason for these 
findings. Cui et al recently reported that the sensitivity of various pancreatic cancer cell lines 
to RV is different [36], which could also be an explanation for our observations since RV 
serves as backbone in the DIG molecule. Furthermore, the same group also demonstrated 
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 that RV exerts less pronounced growth inhibition activity in AsPC-1 cells than in BxPC-3 cells 
[36] suggesting that in pancreatic cancer cell lines, RV might be the active principle of DIG. 
The analysis of the in situ RR activity evidenced that DIG is a powerful RR inhibitor even at 
low concentrations. In addition, DIG caused alterations of deoxyribonucleoside triphosphate 
(dNTP) pool balance: dATP pools were significantly depleted while dTTP pools were 
elevated. A similar depletion of dATP pool sizes could previously be observed with 
Gemcitabine [37-38], a mechanism mainly contributing to the antitumor properties of this 
clinically established anticancer drug. By misbalancing the concentration of precursors for de 
novo DNA synthesis, the latter is blocked in proliferating cells. Growth arrest and cell cycle 
perturbations are the consequences, as it was monitored in the course of DIG treatment. 
The prime effect of DIG was an S-phase arrest, which is consistent with the role of RR as the 
rate limiting enzyme for S-phase transit and the fact that inhibition of RR leads to 
accumulation of cells in S-phase [39]. DNA damage or disrupted dNTP balance and 
incomplete DNA synthesis activate cell cycle checkpoints to prevent DNA synthesis and cell 
cycle progression [40-42] and to provide time for repair before the damage gets passed on 
to daughter cells or to allow for the reconstitution of the dNTP pools. These regulatory 
pathways govern the order and timing of cell cycle transitions to ensure completion of one 
cellular event prior to commencement of another. Before mitosis, cells have to pass G1-S, 
intra-S, and G2-M cell cycle checkpoints, which are controlled by their key regulators, ATR 
and ATM protein kinases, through activation of their downstream effector kinases Chk1 and 
Chk2, respectively [42-43]. Exposure of AsPC-1 cells to DIG resulted in phosphorylation of 
ATM at Ser1981 and in turn caused phosphorylation of Chk2. These observations are in line 
with the fact that ATM activation is not limited to an ionizing radiation-induced response 
[44], but seemingly plays an important role in response to DNA damage caused by 
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 chemotherapeutic agents as well. Activated Chk2 phosphorylates the Cdc25A phosphatase 
at Ser177 targeting it for proteasomal degradation as it was observed in AsPC-1 cells upon 
DIG treatment. Cdc25A is a proto-oncogene [45] required for cell cycle transit [46], and its 
overexpression often correlates with more aggressive diseases and poor prognosis [45]. A 
similar effect was observed on short 42°C heat shock treatment, which also induced the 
ATM-Chk2 pathway, resulting in subsequent degradation of Cdc25A in human HEK293 
embryonic kidney cells [47]. 
Apart from the ATM-Chk2 pathway, various groups have reported an involvement of 
mitogen activated protein kinases (MAPK) activation in attenuating cells in the S phase of 
the cell cycle [44, 48-49]. MAP kinases are important mediators between cell surface 
receptors and transcription factors transducing signals triggered by i.e. physical and chemical 
stress (e.g. after exposure to chemotherapeutic agents) and regulate numerous cellular 
processes such as proliferation and programmed cell death [50]. Western blot analysis 
revealed that DIG eventually blocked Erk1/2 phosphorylation thereby inhibiting cell division 
driven by extracellular mitogens. This was paralleled by phosphorylation of p38 reflecting 
increased cellular stress. 
Another prominent anticancer attribute of chemotherapeutics is the induction of apoptosis. 
DIG exhibited strong pro-apoptotic properties in HL-60 cells and triggered apoptosis by the 
caspase 3 pathway [19]. Caspases are a family of cysteases being involved in regulating the 
activation of apoptotic signal transmission that cleave protein substrates after their Asp 
residues [36]. In contrast, apoptosis upon DIG treatment occurred in only 8.5% of AsPC-1 
cells, indicating that cell cycle inhibition rather than induction of programmed cell death 
seems to be the primary antineoplastic effect of DIG. Consistently, the expression level of 
caspase 3 protein in AsPC-1 cells remained unchanged throughout the time course (data not 
257
 shown), whereas Akt became phosphorylated. Akt plays a critical role in inhibiting caspase 
activation and apoptosis thus promoting cell survival [51]. This protein kinase is activated by 
phospholipid binding and activation loop phosphoryl ation at Thr308 by PDK1 [52] and by 
phosphorylation within the carboxy terminus at Ser473 by PDK2. Phosphorylation at Ser473 
is accomplished by mammalian target of rapamycin (mTOR) in a rapamycin-insensitive 
complex with rictor and Sin1 [53-54] or by DNA-PK [55]. DNA-PK becomes activated upon 
DNA damage and cellular stress [56-57] and this, most likely, caused the phosphorylation at 
Ser473 rendering AsPC-1 cells resistant to apoptosis. Reportedly, increased Akt signaling is 
accompanied by a poor clinical outcome in many tumor types including pancreatic cancer 
[58]. 
GA was shown to inhibit RR by scavenging the tyrosyl radical being essential for the activity 
of the enzyme [11], and RV diminished RR activity through a similar mechanism [59]. The in 
vitro radical-scavenging activity of DIG exceeded that of an equimolar combination of RV and 
GA by about 2.5-fold, suggesting that the RV backbone synergizes with the GA molecules 
resulting in a more pronounced inhibition of the DPPH radical. Since the measurement of 
14
C-cytidine incorporation revealed a significant inhibition of RR in situ activity in both AsPC-
1 and BxPC-3 cells, we strongly believe that DIG also attenuates RR activity by tyrosyl radical 
scavenging. 
Taken together, DIG shows remarkable in vitro radical-scavenging properties, significantly 
inhibits RR in situ activity, and induces cell cycle arrest. We demonstrate that the novel RR 
inhibitor DIG exerts pronounced antitumor activity in human pancreatic cancer cell lines and 
therefore deserves further preclinical and in vivo testing. 
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 Table 1 
Effect of DIG, GA, and RV on the colony formation of human AsPC-1 and BxPC-3 pancreatic 
cancer cells (IC50 values) 
 
Compound AsPC-1 BxPC-3 
DIG 21.5µM 8.5µM 
GA 21.0µM 41.0µM 
RV 18.0µM 13.3µM 
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 Table 2 
DPPH activity after incubation with DIG, GA, RV, 1 Mol RV + 2 Mol GA, Ascorbic acid, and 
Tocopherol for 15 minutes 
 
Compound IC50 (µM) 
DIG 1.8 
GA 3.1 
RV 95.0 
RV + GA (1+2) 4.7 
Ascorbic acid 9.5 
Tocopherol 7.0 
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 Figure legends 
 
Figure 1. Structural formulas of DIG, GA, and RV including nomenclature and molecular 
weight (MW). 
 
Figure 2a. Induction of apoptosis in AsPC-1 cells after incubation with DIG. Cells (0.2x10
6
 
per ml) were exposed to increasing concentrations of DIG for 72 hours. Hoechst 33258 (HO, 
Sigma, St. Louis, MO, USA) and propidium iodide (PI, Sigma, St. Louis, MO, USA) were added 
directly to the cells to final concentrations of 5 µg/ml and 2 µg/ml, respectively. After 60 
minutes of incubation at 37°C, cells were counted under a fluorescence microscope and the 
number of apoptotic cells was given as percentage value. Data are means ± standard errors 
of three determinations. 
 
Figure 2b. Expression levels of p(Ser473)Akt and Akt after incubation with DIG. After 
incubation with 40µM DIG for 0.5, 2, 4, 8, and 24 hours, AsPC-1 cells (2x10
6
 per ml) were 
harvested, washed twice with ice-cold PBS (pH 7.2) and lysed in a buffer containing 150 mM 
NaCl, 50 mM Tris-buffered saline (Tris pH 8.0), 1% Triton X-100, 1 mM 
phenylmethylsulfonylfluoride (PMSF) and protease inhibitor cocktail (PIC; from a 100x 
stock). The lysate was centrifuged at 12000 rpm for 20 minutes at 4°C, and the supernatant 
was subjected to western blot analysis. 
 
Figure 3. Cell cycle distribution in AsPC-1 (a) and BxPC-3 (b) cells after incubation with DIG. 
Cells (0.4x10
6
 per ml) were seeded in 25cm
2
 Nunc tissue culture flasks and incubated with 
increasing concentrations of DIG for 48 hours under cell culture conditions. Cells were 
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 analyzed on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) and cell cycle 
distribution was calculated with ModFit LT software (Verity Software House, Topsham, ME, 
USA). Data are means ± standard errors of three determinations. 
 
Figure 4. Inhibition of incorporation of 
14
C-cytidine into DNA of AsPC-1 (a) and BxPC-3 (b) 
cells after treatment with DIG. Cells (0.4x10
6 
cells per ml) were incubated with increasing 
concentrations of DIG for 24 hours. After the incubation period, cells were counted and 
pulsed with 
14
C-cytidine (0.3125 µCi, 5 nM) for 30 minutes at 37°C. Then cells were collected 
by centrifugation and washed with PBS. Total DNA was extracted from 5x10
6
 cells and 
specific radioactivity of the samples was determined using a Wallac 1414 liquid scintillation 
counter (PerkinElmer, Boston, MA). Data are means ± standard errors of three 
determinations. Values significantly (p<0.05) different from control are marked with an 
asterisk (*). 
 
Figure 5. Concentration of dNTP pools in AsPC-1 cells upon treatment with DIG. Cells 
(0.4x10
6 
cells per ml) were incubated with 20, 30, and 40 µM DIG for 24 hours. Afterwards, 
5x10
7
 cells were separated for the extraction of dNTPs. The concentration of dNTPs was 
calculated as percent of total area under the curve for each sample. Data are means ± 
standard errors of three determinations. Values significantly (p<0.05) different from control 
are marked with an asterisk (*). 
 
Figure 6. Expression levels of p(Ser1981)ATM, p(Thr68)Chk2, Chk2, p(Ser75)Cdc25A, 
p(Ser177)Cdc25A, and Cdc25A after incubation with DIG. After incubation with 40µM DIG 
for 0.5, 2, 4, 8, and 24 hours, AsPC-1 cells (2x10
6
 per ml) were harvested, washed twice with 
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 ice-cold PBS (pH 7.2) and lysed in a buffer containing 150 mM NaCl, 50 mM Tris-buffered 
saline (Tris pH 8.0), 1% Triton X-100, 1 mM phenylmethylsulfonylfluoride (PMSF) and 
protease inhibitor cocktail (PIC; from a 100x stock). The lysate was centrifuged at 12000 rpm 
for 20 minutes at 4°C, and the supernatant was subjected to western blot analysis. 
 
Figure 7. Expression levels of p(Thr202/Tyr204)Erk1/2, Erk1/2, p(Thr180/Tyr182)p38MAPK, 
and p38MAPK after incubation with DIG. After incubation with 40µM DIG for 0.5, 2, 4, 8, 
and 24 hours, AsPC-1 cells (2x10
6
 per ml) were harvested, washed twice with ice-cold PBS 
(pH 7.2) and lysed in a buffer containing 150 mM NaCl, 50 mM Tris-buffered saline (Tris pH 
8.0), 1% Triton X-100, 1 mM phenylmethylsulfonylfluoride (PMSF) and protease inhibitor 
cocktail (PIC; from a 100x stock). The lysate was centrifuged at 12000 rpm for 20 minutes at 
4°C, and the supernatant was subjected to western blot analysis. 
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 Figure 1. 
Structural formulas of DIG, GA, and RV including nomenclature and molecular weight 
(MW) 
 
DIG (3,5-O-digalloyl-resveratrol)
MW = 532.47
Gallic acid (3,4,5-trihydroxybenzoic acid)
MW = 170.12
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MW = 228.25
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 Figure 2. 
(a) Induction of apoptosis in AsPC-1 cells after incubation with DIG for 72 hours. 
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(b) Expression levels of p(Ser473)Akt and Akt after incubation of AsPC-1 cells with DIG. 
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 Figure 3. 
Effect of DIG on the cell cycle distribution of AsPC-1 (a) and BxPC-3 (b) cells 
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 Figure 4. 
In situ measurement of ribonucleotide reductase activity in AsPC-1 (a) and BxPC-3 (b) cells 
after treatment with DIG for 24 hours 
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 Figure 5. 
Concentration of dNTP pools in AsPC-1 cells after treatment with DIG for 24 hours 
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 Figure 6. 
Expression of checkpoint and cell cycle regulating proteins after treatment of AsPC-1 cells 
with DIG 
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 Figure 7. 
Expression of mitogen-activated protein (MAP) kinases after treatment of AsPC-1 cells 
with DIG 
 
 
 
 
274
  
 
 
 
Hsp90 stabilises Cdc25A and counteracts heat shock 
mediated Cdc25A degradation and cell cycle attenuation in 
pancreas carcinoma cells. 
 
 
Giessrigl B., Krieger S., Huttary N., Saiko P., Alami M., Maciuk A., 
Gollinger M., Mazal P., Szekeres T., Jäger W. and Krupitza G. 
 
 
Hum Mol Genet., submitted. 
275
 276
 Hsp90 stabilises Cdc25A and counteracts heat shock mediated Cdc25A degradation and 
cell cycle attenuation in pancreas carcinoma cells 
 
Benedikt Giessrigl
1,2
, Sigurd Krieger
1
, Nicole Huttary
1
, Philipp Saiko
3
, Mouad Alami
4
, 
Alexandre Maciuk
5
, Michaela Gollinger
1
, Peter Mazal
1
, Thomas Szekeres
3
, Walter Jäger
2
, 
Georg Krupitza
1
 
 
1 
Institute of Clinical Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-
1090 Vienna, Austria  
2
Department of Clinical Pharmacy and Diagnostics, Faculty of Life Sciences, University of 
Vienna, Althanstrasse 14, A-1090 Vienna, Austria 
3
Department of Medical and Chemical Laboratory Diagnostics, Medical University of 
Vienna, General Hospital of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria 
4 
Laboratory of Therapeutic Chemistry, UMR CNRS 8076 BioCIS, Faculty of Pharmacy, 
University Paris-South 11 
5
Laboratoire de Pharmacognosie - UMR CNRS 8076 BioCIS, Faculty of Pharmacy, 
University Paris-South 11 
 
 
 
Short title: Heat shock and inhibition of Hsp90 destabilises Ccd25A and arrests the cell cycle 
 
 
Key words: Hsp90, Cdc25A stability, cell cycle, heat shock 
 
 
Correspondence: 
Georg Krupitza, Institute of Clinical Pathology, Medical University of Vienna, Waehringer 
Guertel 18-20, A-1090, Vienna, Austria 
e-mail: georg.krupitza@meduniwien.ac.at,  
 
 
 
 
277
 Abstract 
 
Pancreas cancer cells escape most treatment options. Heat shock protein (Hsp)90 is frequently 
over-expressed in pancreas carcinomas and protects a number cell cycle regulators such as the 
proto-oncogene Cdc25A. We show that inhibition of Hsp90 with geldanamycine (GD) 
destabilises Cdc25A independent of Chk1/2 whereas the standard drug for pancreas 
carcinoma treatment, gemcitabine (GEM), causes Cdc25A degradation through activation of 
Chk2. Both agents applied together additively inhibit the expression of Cdc25A and 
proliferation of pancreas carcinoma cells thereby demonstrating that both Cdc25A-
destabilising/degrading pathways are separated. The role of Hsp90 as stabiliser of Cdc25A in 
pancreas carcinoma cells is further supported by two novel synthetic inhibitors 4-TCNA and 
7-TCNA and specific Hsp90AB1 (Hsp90β) shRNA. The here presented data open a treatment 
option for cancers, which are hardly responding to drugs, such as pancreas carcinomas or 
cancers with acquired resistances. We conclude that targeting i.e. Hsp90 is a hypothesis 
driven and tailored approach for drug intervention. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
278
 Introduction 
 
Pancreatic cancer is the tenth most common type of cancer in western countries and ranks 
fourth in cancer mortality statistics and in spite of intensive research and significant 
improvement in the survival of pancreatic cancer patients (Mihaljevic et al., 2010, Fahrig et 
al. 2006, Heinrich et al. 2011) this cancer entity is still amongst the most malignant ones. 
Because of the lack of early detection, the absence of symptoms and effective screening tests, 
high rate of relapse and limited effective therapies, prognosis is very poor with a 5 year 
survival rate of less than 5% and a 1 year survival rate of less than 20% (Evans et al., 2001). 
Due to metastasis more than 80% of these carcinomas are not resectable (Niederhuber et al., 
1995) and therefore systemic chemotherapy plays an important role in the treatment of this 
extremely aggressive cancer with the goal to provide symptomatic relief and prolong survival. 
Besides 5-fluorouracil, gemcitabine (GEM) was identified as the two main treatment options 
(Huguet et al., 2009) but in particular metastatic pancreatic cancer is highly chemoresistant 
and response rates of single agent therapies are less than 20% (Evans et al., 2001). Because 
of this lack of effective therapy, research for new capable treatment options represents an 
important challenge. Heat shock proteins (Hsps) represent a highly conserved set of proteins 
that have a pivotal role in cell cycle progression and cell death (apoptosis) as well as in 
maintaining cellular homeostasis under stress (Khalil et al., 2011). Various insults like 
hypoxia, ischemia, exposure to UV light or chemicals, nutritional deficiencies or other stress 
rapidly induce their expression (Cotto and Morimoto, 1999; Lindquist and Craig, 1998) 
and Hsp90A (further on termed Hsp90) over-expression was shown among others e.g. for 
pancreatic, breast and lung cancer and for leukemia (Khalil et al., 2011). 
In a recent study we could show that heat shock (HS) induces Cdc25A degradation and that 
Hsp90 stabilises Cdc25A in HeLa and HEK293 cells (Madlener et al., 2009). The cell cycle 
promoting phosphatase Cdc25A is an oncogene and indispensable for embryonic 
development (Nilsson and Hoffmann, 2000) and can substitute for Cdc25B and Cdc25C. 
Therefore, Cdc25A is mandatory for cell cycle progression and the fact that HS, in presence 
of the Hsp90 inhibitor geldanamycine (GD, which is currently investigated in clinical trials), 
destabilises Cdc25A in HEK293 and HeLa cells tempted us to test whether this is also the 
case in pancreas carcinoma cells. As there is still no cure for this cancer entity and 
gemcitabine (GEM) therapy has more of a palliative than life-extending effect, we 
investigated whether Hsp90 inhibition combination with high-fever-range HS might affect 
pancreas carcinoma cells and contributes to cell cycle arrest.  
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 Results 
 
HS and GD cause destabilisation of Cdc25A and other cell cycle regulators 
 
BxPC-3 cells were treated with HS (41.5 C, 90 min) or with 250 nM GD, or both, and the 
protein expression of Cdc25A, B, and C was investigated. Whereas HS had no effect and GD 
only little effect on the expression of Cdc25 proteins, the combination of HS plus GD 
dramatically suppressed the expression of Cdc25A, B, and C in BxPC-3 cells (Fig 1a). The 
expression of Cdc25A reversed to control level when cells were cultivated for further 6h in 
absence of GD (post-treatment) before cells were lysed for western blot analyses. In contrast, 
Cdc25C levels of BxPC-3 cells were still reduced post-treatment with HS plus GD. The 
protein level of cyclin D1, another cell cycle regulating oncogene, was also down-regulated 
upon combinatorial treatment and also within the post-treatment period.  
To test whether this was a cell line effect the expression of Cdc25s and cyclin D1 was 
analysed also in two other pancreas carcinoma cell lines, PANC-1 and ASPC-1 (Fig 1b, c). 
In PANC-1 HS alone had an already strong suppressing effect on Cdc25A and GD further 
reduced its expression below levels of detection. The removal of GD for a 6h post-treatment 
period reversed the levels of Cdc25A and Cdc25B back to that of control. Post-treatment of 
PANC-1 and ASPC-1 with HS plus GD still suppressed Cdc25C. This indicated that Cdc25A 
and Cdc25C were regulated by a mechanism that was common to all three pancreas 
carcinoma cell lines. Immediately after treatment, also Cdc25B expression responded 
similarly in the three cell lines. In the post-treatment period, Cdc25B levels even increased in 
BxPC-3 cells that experienced combinatorial treatment. Cyclin D1 decreased upon HS in 
PANC-1 and ASPC-1 cells and recovered in ASPC-1 to control levels upon post-treatment 
incubation, whereas in PANC-1 cells cyclin D1 even increased during HS post-treatment. 
    Such as Cdc25C (García-Morales et al. 2007), Wee1 is a client of Hsp90 in HCT116 
colon cancer cells (Tse et al., 2009). Therefore, we tested whether HS & GD treatment would 
affect Wee1 stability also in pancreas carcinoma cell lines. Indeed, Wee1 levels decreased in 
BxPC-3 cells upon treatment with GD, and HS & GD and this caused also the reduction of 
phosphorylated (active) Wee1 kinase and consequently the reduction of the phosphorylation 
level of its target Cdc2 (Fig 2a, b). Furthermore, in PANC-1 cells Wee1 became down-
regulated after treatment with HS, and GD & HS which resulted in decreased phosphorylation 
levels of Cdc2. This implicated that Cdc2 became activated and induced the cell cycle and 
proliferation. In contrast, the down-regulation of cyclinD1, which reflects the status of cycling 
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 and therefore proliferating cells, indicated an attenuation of cell proliferation. The dis-
regulated expression of cell cycle protagonists may induce cell cycle inhibitors to arrest cell 
cycle progression in order to re-orchestrate the cell cycle. Hence, we investigated the 
expression/activation of p53 and p21 in Bx-PC-3 cells after treatment with HS and GD, but 
neither p53 became activated nor p21 induced (Fig. 3a). P53 is a client of Hsp90 (Park et al., 
2011) and therefore, p53 became degraded upon treatment with GD and its expression was 
completely suppressed by the combinatorial treatment with HS. HS causes Chk2 activation 
and induces Cdc25A degradation in HEK 293 and HeLa cells (Madlener et al. 2009) and 
also exposure to UV causes Chk activation and Cdc25A degradation (Chen et al. 2003). In 
BxPC-3 cells the check point kinases Chk1 and Chk2 remained inactive upon HS, GD, or HS 
& GD (Fig. 3b). Ser75 and Ser177 of Cdc25A are specifically phosphorylated by Chk1 and 
Chk2, respectively, tagging it for proteasome-mediated degradation. Since neither of the 
checkpoint kinases became activated, also the constitutive phosphorylation of Cdc25A did not 
increase at the specific amino acid residues.  
To test whether the effects of HS and GD on cell cycle proteins were specific for pancreas 
carcinoma cells the experiments were expanded to breast cancer cell lines. In the highly 
metastatic ER
negative
 breast cancer cell line MDA-MB231 Cdc25 family proteins and Wee1 
were degraded and consequently Cdc2 was de-phosphorylated (Fig. 4a). Also in the ER
positive
 
MCF-7 breast cancer cell line the levels of Cdc25A, Wee1, and Cdc2 phosphorylation were 
reduced. Derivatives of MCF-7 that were made resistant to tamoxifen (TR) and fulvestrant 
(FR) maintained their sensitivity to HS and GD and the expression of Cdc25A and Wee1 and 
the phosphorylation of Cdc2 were down-regulated (Fig. 4b). Hence, HS induced degradation 
of Cdc25s, which was enforced by GD, was a general phenomenon and not limited to 
pancreas carcinoma cells, and Hsp90 protected the proto-oncogene Cdc25A from constitutive 
and high-fever-range induced degradation. This implicates that HS and GD treatment caused 
Cdc25A destabilisation and attenuated cell cycle progression independent of DNA checkpoint 
activators.  
 
Novel Hsp90 inhibitors and specific knock-down destabilise Cdc25A 
 
To obtain additional proof that Cdc25A is a client of Hsp90 in pancreas carcinoma cells 
BxPC-3 cells were treated with two novel synthetic Hsp90 inhibitors, 4- and 7-
tosylcyclonovobiocic acid (4-TCNA and 7-TCNA). While GD binds the N-terminal ATP-
binding pocket of Hsp90 and impairs its chaperone function, the coumarin antibiotic 
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 novobiocin was demonstrated to bind an ATP-binding domain in the C-terminal region of 
Hsp90 and the removal of the noviose moiety together with introduction of a tosyl substituent 
at C-4 or C-7 coumerins provided A-TCNA and /-TCNA as lead compounds (Radanyi et al., 
2008; Marcu et al., 2000; Le Bras et al., 2007). These two analogues were shown to down-
regulate a subset of Hsp90 client proteins in breast, colon, ovarian and endometrial cancer cell 
lines (Radanyi C et al.). 7-TCNA destabilised Cdc25C, which is a bona fide client of Hsp90 
(García-Morales et al., 2007). In combination with HS both, 4-TCNA and 7-TCNA, caused 
the down-regulation of Cdc25C thereby demonstrating the specificity of these inhibitors (Fig 
5). Even more pronounced was the effect of 4-TCNA and 7-TCNA on the expression of 
Cdc25A further indicating that Cdc25A is a client of Hsp90 in BxPC-3 cells.  
        To provide firm evidence that Cdc25A is a client of Hsp90 the mRNA expression of the 
constitutively expressed gene (Hsp90AB1/Hsp90β) was knocked-down by specific shRNA 
(Fig. 6a) and also Hsp90 protein expression was reduced to different extent in the ten 
analysed clones (Fig. 6b). As anticipated, in the knockdown clone (no. 2 from figs 6a, 6b) the 
expression of the client proteins Cdc25A, Cdc25C, Wee1 and p53 was down-regulated (Fig. 
6c). However, HS did not further reduce the expression levels of Wee1, Cdc25C, and Cdc25A 
in the knock-down clone. Most likely, another chaperone overtook the function of Hsp90 and 
protected the client proteins upon HS. It was reported that Hsp70 can replace Hsp90 (Bottoni 
et al., 2009). In future studies we are going to address this issue. Nevertheless, it was 
demonstrated that Hsp90 prevented Cdc25A degradation. BrdU incorporation studies together 
with FACS analyses confirmed that directly after HS BxPC-3 cells were arrested in G1 phase, 
whereas Hsp90 knock-down cells were arrested in G2 and the incorporation of BrdU in these 
cells was inhibited during S phase (Fig. 6d). Therefore, Hsp90 significantly contributes to 
BxPC-3 cell cycle progression and could be therapeutically targeted in pancreas carcinoma 
cells. 
 
GD and gemcitabine additively inhibit Cdc25A and cell proliferation 
 
The only current chemotherapy against pancreas carcinoma is with gemcitabine (GEM). 
Although pancreas carcinoma cells were reported to be devoid of functional DNA 
checkpoints (Myasaka et al. 2007) GEM induced the phosphorylation of Chk2, but not Chk1 
(Fig. 7a). This was accompanied by an inhibition of Cdc25A expression. Therefore, we 
studied whether GD and HS in combination with GEM could support the anti-neoplastic 
effect in pancreas carcinoma cells. The short incubation times of the previous experiments (1h 
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 preincubation with GD followed by 1.5h HS) just served to study the basic cellular 
mechanisms of HS and in this part of the work, we also investigated the effects of GEM and 
GD after longer incubation times. For this BxPC-3 cells were incubated with GEM and GD 
for 8 h, whereas HS still lasted only for 90 min because in clinical applications this is the 
usually applied and tolerated time which does not threat the patients (Skitzki et al., 2009; 
Dewhirst et al., 2005; Kraybill et al., 2002). As shown before, HS or GD alone had no effect 
on Cdc25A expression after this incubation period but the combination of HS & GEM, or GD 
&  GEM, or HS &  GD & GEM reduced the expression of Cdc25A below the levels of GEM 
treatment alone (Fig. 7b). On Cdc25C, GEM had only an effect in combination with HS. In 
long term experiments (72 h) cell numbers were measured but for this, the concentrations of 
GEM and GD were reduced to inhibit BxPC-3 cell proliferation not more than 50 %. In detail, 
5 nM GEM reduced the cell number by approximately 40 % and 10 nM GD by nearly 20 % 
(Fig. 7c). The effect of the combination of 5 nM GEM and 10 nM GD was roughly additive 
reducing the cell number by more than 55 %. A single HS (90 min) at the beginning of the 
experiment had no additional effect in long term experiments. In knockdown cells GEM alone 
reduced the cell number by 53 % which was similar to the cell number reduction achieved by 
GEM & GD in wild type cells. Interestingly, in knockdown cells, HS & GEM further reduced 
the cell number by 70 %. Thus, the exposure to HS and the targeting of Hsp90 strongly 
supported GEM standard treatment of pancreas carcinoma cells. 
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 Discussion 
 
Pancreas cancer cells are highly resistant to various in vitro treatments and also clinical 
therapy regimens are largely ineffective (Jemal et al. 2003). GEM is the main standard agent 
and the major beneficial effect seems to be a palliative one (Bayraktar et al., 2010). Pancreas 
cancer cells tend to acquire resistance to GEM and this was reported to be caused by the 
activation of the NF-kB pathway (Uwagawa et al. 2009, Fujiwara et al. 2011). Undoubtly, 
the resistance to drug treatment involves mutations of p16
INK
 or alternatively, mutations of 
p53 (Okamoto et al. 1994, Chen et al., 2011). Furthermore, disease progression correlates 
with an inactivation of the Chk2 DNA damage check point (Miyasaka et al. 2007). 
Nevertheless, we demonstrate that isolated BxPC-3 pancreas carcinoma cells respond to GEM 
treatment with the phosphorylation of Chk2, Cdc25A degradation, and concomitant cell cycle 
attenuation. Recently it was shown that HS induced Chk2 in HEK293 cells (Madlener et al. 
2009) and hence, the observation that HS did not induce Chk2 phosphorylation in BxPC-3 
pancreas carcinoma cells was unexpected. Thus, the activation of Chk2 by GEM or by HS 
was through distinct pathways, whereby the HS induced pathway remained silent in BxPC-3 
cells. Despite this fact, HS caused cell cycle arrest in a background of inhibited Hsp90 (by 
GD) or reduced Hsp90 expression (by shRNA). However, the attenuation of cell cycle 
progression was transient and only occurred immediately after HS-treatment and this was 
most likely due to disabled DNA checkpoint activation and lack of p21 induction. The Hsp90 
client p53 was also degraded, which however does not play a role in this scenario, because 
p53 is anyway mutated in BxPC-3 cells (Park et al. 2006).  Despite the transient nature of 
cell cycle inhibition, we show that the cell cycle was arrested independent of functional DNA 
check point kinases Chk1 and Chk2. Otherwise, we would have detected the specific and 
destabilising Cdc25A phosphorylations at Ser75 and Ser177. Instead, targeting Hsp90 was 
sufficient to attenuate cell cycle progression and cell proliferation which correlated with the 
destabilisation of the Cdc25 family of phosphatases and other cell cycle regulators like Wee1, 
cyclin D1 and to some extent also Cdc2. We already provided evidence that HS caused the 
degradation of Cdc25A, B, and C in HEK293 and HeLa cells through the activity of Chk2 and 
inhibition of Hsp90 just accelerated the destabilisation of Cdc25A in these cell lines 
(Madlener et al. 2009). Degradation of Cdc25A was due to phosphorylations at Ser75 and 
Ser177 (through p38 and Chk2) and subsequent sequestration of Cdc25A by 14.3.3 proteins 
to the cytoplasm where Cdc25A became ubquitinylated and subjected to proteasomal 
destruction (Madlener et al. 2009, Goloudina et al. 2003, Busino et al. 2004, Busino et al. 
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 2003). Here, we show for the first time that the degradation of Cdc25A depended on the 
inhibition (reduction) of Hsp90 without the necessity to activate Chk2.  
The combination of HS together with the Hsp90 inhibitor GD resulted in an impressive 
suppression of Cdc25A, B, and C particularly in BxPC-3 and PANC-1 cells. This effect was 
not restricted to pancreas carcinoma cells but was also observed in MDA-MB231 and MCF-7 
breast cancer cells and tamoxifen and fulvestrant-resistant derivatives. Also the novel 
synthetic Hsp90 inhibitors 4-TCNA and 7-TCNA strongly down-regulated Cdc25A 
expression, which substantiated the hypothesis that inhibition of Hsp90 can be a strategy to 
combat pancreas cancer cell expansion. We observed that HS did not produce an additional 
effect on Cdc25A-, Cdc25C, or Wee1- degradation in BxPC-3 cells, in which Hsp90 
expression was knocked down by specific shRNA. Thus, another chaperone might have 
slipped in place of Hsp90. To accomplish its chaperon function, Hsp90 forms a dynamic 
complex known as the Hsp90 chaperone machinery with Hsp70 and different co-chaperones 
(Pratt and Toft, 2003). Furthermore, the over-expression of Hsp27 has been shown to 
correlate with the induction of chemoresistance for GEM in pancreatic cancer cells and 
therefore this protein could be a possible marker for predicting the response of pancreatic 
cancer patients to treatment with GEM (Bottoni et al., 2009). This strongly suggests that 
limited Hsp90 levels allow other chaperones, such as Hsp70 or Hsp27, to fill the former 
position of Hsp90 (Bottoni et al., 2009; Yun et al., 2010) on i.e. Cdc25A and (partly) fulfil 
its function. The role of other heat shock proteins after inhibiting Hsp90 will be investigated 
in further studies. 
GEM induced Chk2 and added up to the cell cycle inhibitory effect induced by GD &/- HS. 
This evidenced that a GEM-based therapy can be improved by a combination treatment 
targeting Hsp90 and cell cycle regulators. Hsp90-dependent cell cycle inhibition was only 
short but very strong. This effect was vastly prolonged when GD (+/-GEM) was applied for 
the entire experimental period (which better reflects a clinical setting) despite a single and 
short (90 min) HS exposure. 
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 Materials and methods 
 
Cell culture: BxPC-3, AsPC-1 and PANC-1 pancreatic cancer cell lines and MCF-7 and 
MDA-MB-231 breast cancer cell lines were purchased from ATCC. BxPC-3 and AsPC-1 
cells were cultured in RPMI 1640 medium supplemented with 10 % heat inactivated fetal calf 
serum (FCS), 1 % L-glutamine, 1 % sodiumpyruvate and 1 % penicilline/streptomycin. 
PANC-1 cells were grown in high glucose DMEM medium supplemented with 10 % heat 
inactivated FCS, 1 % L-glutamine and 1 % penicilline/streptomycin. MCF-7 and MDA-MB-
231 breast cancer cells were cultivated in DMEM/F-12 1:1 medium supplemented with 10 % 
heat inactivated FCS, 1 % L-glutamine and 1 % penicilline/streptomycin. Tamoxifen and 
fulvestrant resistance were obtained by treating MCF-7 cells with increasing concentrations 
(up to 500nM) of tamoxifen and fulvestrant, respectively, and the resistant cell lines 
(tamoxifen resistant (TR500-MCF-7); fulvestrant resistant (FR500-MCF-7)) were grown in 
DMEM/F-12 1:1 medium supplemented with 10 % heat inactivated FCS, 1 % L-glutamine, 1 
% penicilline/streptomycin and 500nM of the corresponding anti-estrogen.   
All cells were grown at 37°C in a humidified atmosphere containing 5% CO2. If not 
mentioned otherwise, all media and supplements were obtained from Invitrogen Life 
Technologies (Karlsruhe, Germany). 
 
Heat shock and inhibitor treatment: Cells were grown up to 80 % confluence and after pre-
incubation with 250 nM GD for 1 h, cells were exposed to 41.5°C for 1.5 h in a humidified 
atmosphere containing 5% CO2. After HS treatment cells were prepared for analysis as 
described thereafter. 
 
Western Blotting: After incubation with corresponding compounds and exposure to 41.5°C 
HS cells were harvested, washed twice with cold PBS and lysed in a buffer containing 150 
nM NaCl, 50 mM Tris, 1 % Triton-X-100, 1 mM phenylmethylsulfonylfluride (PMSF) and 
2.5 % PIC (Cat#P8849 Sigma, Munich, Germany). After centrifugation (12 000 x g) for 20 
min at 4°C the supernatant was stored at -20°C until further analysis. Equal amounts of 
protein samples were separated by polyacrylamide gel electrophoresis and electrotransferred 
onto PVDV-membranes (Hybond-P, Amersham), 4°C overnight. Staining membranes with 
Ponceau S controlled equal sample loading. After washing with Tris buffered saline (TBS) pH 
7.6, membranes were blocked in 5 % non-fat dry milk in TBS containing 0.1% Tween-20 for 
1 h. Membranes were incubated with the first antibody (in blocking solution, dilution 1:500-
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 1:1000) by gently rocking at 4°C overnight, washed with TBS containing 0.1% Tween-20 and 
further incubated with the second antibody (peroxidase-conjugated swine anti-rabbit IgG or 
rabbit anti-mouse IgG, dilution 1:2000-1:5000 in blocking solution) for 1 h. 
Chemoluminescence  was developed by the ECL plus detection kit (GE Healthcare, 
Buckinghamshire, UK) and analysed using a Lumi-Imager F1 Workstation (Roche, Basel, 
Switzerland). 
 
Reagents and antibodies: Tamoxifen (Cat# T5648), fulvestrant (Cat# I4409), geldanamycin 
(Cat# G3381), hexadimethrine bromide (Cat# H9268) and puromycin (Cat# P9620) were 
purchased from Sigma (Munich, Germany). Amersham ECLPlus Western Blotting Detection 
System was from GE Healthcare (Buckinghamshire, UK). The synthetic HSP90 inhibitors 4-
TCNA and 7-TCNA were provided by Dr. Mouâd Alami, Université Paris Sud. 
Antibodies: Mouse monoclonal (ascites fluid) anti-β-actin clone AC-15 Cat# A5441 was from 
Sigma (Munich, Germany). Anti cyclin D1 (M-20) Cat# sc-718, p21 (C-19) Cat# sc-397, 
Cdc25A (F-6) Cat# sc-7389, Cdc25B (C-20) Cat# sc-326, Cdc25C (C-20) Cat# sc-327 were 
from Santa Cruz Biotechnologies Inc. (Santa Cruz, CA, USA). Phospho-Wee1 (Ser
642
) 
(D47G5) Cat# 4910, Wee1 Cat# 4936, phospho-Chk2 (Thr
68
) Cat# 2661, Chk2 Cat# 2662, 
phospho-Chk1 (Ser
345
) Cat# 2341, Chk1 Cat# 2345, phospho-p53 (Ser
20
), acetylated-p53 
(Lys
382
) Cat# 2525 and Hsp90 Cat# 4877 were from Cell Signalling (Danvers, MA, USA). 
p53 antibody Cat# 1767 was purchased from Immunotech (Marseille, France), phospho-
Cdc25A (Ser
75
) Cat# ab47279 from Abcam (Cambridge, UK) and phospho-Cdc25A (Ser
177
) 
Cat# AP3046 was from Abgent (San Diego, CA, USA). Anti mouse and anti rabbit IgG were 
from Dako (Glostrup, Denmark). 
 
Quantitative RT-PCR: BxPC-3 cells (0.25 x 10
5
) were seeded in 6 wells and after 24 h 
cultivation they were harvested and homogenised using Qia-shredder (Cat# 79654, Qiagen, 
Hilden, Germany). The cells were further processed according to the instructions of RNeasy 
Mini Kit (Cat# 74104, Qiagen). Final RNA concentration was measured using a NanoDrop 
Fluorospectrometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA). cDNA synthesis 
from 1 µg RNA was performed using Superscript-first-strand synthesis systems for RT-PCR 
(Cat# 11904-018, Invitrogen, Carlsbad, CA, USA). Hsp90AB1 transcript levels were 
investigated by real-time PCR using Taqman detection system (Applied Biosystems, 
Carlsbad, CA, USA). The housekeeping-gene glyceralaldehyde 3-phosphate dehydrogenase 
(GAPDH) served as reference gene. Assay ID numbers of the Taqman gene expression kits 
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 were: GAPDH: HS99999905_m1; HSP90AB1 (this is the constitutively expressed form of 
Hsp90A, which for reasons of simplicity is shortened throughout the manuscript to Hsp90): 
HS01546474_g1. Cycle program (95°C for 10 min to activate polymerase followed by 40 
cycles of 95°C for 15 s and 60°C for 1 min) was started on an Abi Prism 7000 Sequence 
Detection System (Applied Biosystems). Real time-PCR was performed in duplicates for each 
cDNA template and gene investigated. Negative controls, containing water instead of cDNA, 
confirmed the absence of RNA/DNA in all reagents applied in the assay. 
 
Lentiviral shRNA transduction: BxPC-3 cells (1 x 10
4
) were seeded in 24 well plates and 
were cultivated overnight. The next day hexadimethrine bromide (8ng/ml) and 1 x 10
5 
transducing units of the lentiviral shRNA vectors were added. Transduction particles 
(HSP90AB1: TRCN0000008748; clone ID NM_007355.2-232s1c1; negative control: Cat# 
SHC002H) were obtained from Sigma (Munich, Germany). After 24 hours of incubation, 
fresh media and further 24 h later puromycin (10µg/ml) were added to identify resistant 
BxPC-3 Hsp90 knockdown colonies (BxPC-3 knockdown). 
 
Proliferation inhibition analysis: BxPC-3 cells and BxPC3 knockdown (1 x 10
5
) were 
seeded in 6 well plates, cultivated overnight and treated with 5 nM GEM and 10 nM GD, 
respectively. A single HS was performed 1 h after the beginning of the treatment. To avoid 
unspecific effects caused by the solvent, DMSO concentration was the same in all samples 
(0.05%). Cell counts were determined after 72 h using a Casy TTC cell counter (Roche, 
Basel, Switzerland).  
 
BrdU incorporation: BxPC-3 and BxPC-3 knockdown cells were seeded in 6-wells, pre-
treated with GD for 1 h and incubated with 10 µM of BrdU exposed to 41.5°C for 1.5 h. Cells 
were prepared following the instructions of the manufacturer (BrdU Flow Kit Cat# 552598, 
BD Pharmingen), except for the incubation with fluorescent anti-BrdU antibody, which was 
incubated overnight at 4°C (dilution 1:50). Afterwards, the BrdU incorporation was measured 
and analysed by a FACSCalibur flow cytometer. 
 
Statistics: All experiments were performed in triplicate and analysed by t-test (GraphPad 
Prism 5.0 program, GraphPad (San Diego, CA, USA). 
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 Figure legends 
 
Figure 1 
Western blot analysis of the Cdc25 phosphatases and cyclin D1 in (a) BxPC-3, (b) PANC-1 
and (c) AsPC-1 pancreatic cancer cells. After pre-incubation with 250 nM GD for 1 h, cells 
were exposed to 41.5°C for 1.5 h. Cells were lysed directly after HS (left panel “treatment”) 
or after 6 h post-incubation in the absence of GD (right panel “post-treatment”). The obtained 
protein samples were applied to SDS-PAGE. Western blot analysis was performed with the 
indicated antibodies. Equal sample loading was confirmed by Ponceau S staining and β-actin 
analysis. 
 
Figure 2 
Western blot analysis of the cell cycle regulators Cdc2 and Wee1 in (a) BxPC-3 and (b) 
PANC-1 pancreatic cancer cells. After pre-incubation with 250 nM GD for 1 h, cells were 
exposed to 41.5°C for 1.5 h. Cells were lysed directly after HS (left panel “treatment”) or 
after 6 h post-incubation in the absence of GD (right panel “post-treatment”). The obtained 
protein samples were applied to SDS-PAGE. Western blot analysis was performed with the 
indicated antibodies. Equal sample loading was confirmed by Ponceau S staining and β-actin 
analysis. 
 
Figure 3 
Western blot analysis of (a) p53 and p21 and (b) the checkpoint kinases Chk1 and Chk2 and 
the site-specific phosphorylation of Cdc25A (as indicated) in BxPC-3 pancreatic cancer cells. 
After pre-incubation with 250 nM GD for 1 h, cells were exposed to 41.5°C for 1.5 h. Cells 
were lysed directly after HS and the obtained protein samples were applied to SDS-PAGE. 
Western blot analysis was performed with the indicated antibodies. Equal sample loading was 
confirmed by Ponceau S staining and β-actin analysis. 
 
Figure 4 
Western blot analysis of different cell cycle regulators in (a) MDA-MB-231 and (b) MCF-7, 
tamoxifen resistent (TR500-MCF-7) and fulvestrant resistent (FR-MCF-7) breast cancer cells. 
After pre-incubation with 250 nM GD for 1 h, cells were exposed to 41.5°C for 1.5 h. Cells 
were lysed directly after HS (a, left panel “treatment”; b) or after 6 h post incubation in the 
absence of GD (a, right panel “post-treatment”). The obtained protein samples were applied to 
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 SDS-PAGE. Western blot analysis was performed with the indicated antibodies. Equal sample 
loading was confirmed by Ponceau S staining and β-actin analysis. 
 
Figure 5 
Western blot analysis of Cdc25A and Cdc25C in BxPC-3 pancreatic cancer cells. After pre-
incubation with 50 µM 4-TCNA and 7-TCNA, respectively, for 1 h, cells were exposed to 
41.5°C for 1.5 h. Cells were lysed directly after HS and the obtained protein samples were 
applied to SDS-PAGE. Western blot analysis was performed with the indicated antibodies. 
Equal sample loading was confirmed by Ponceau S staining and β-actin analysis. 
 
Figure 6 
Knockdown of Hsp90AB1 with specific shRNA. (a) mRNA levels of Hsp90AB1 of BxPC-3 
scrambled control (1) cells and different knockdown clones (2-11). RNA of lentiviral 
transduced clones was isolated, transcribed into cDNA and subjected to quantitative real 
time-PCR using specific primers for Hsp90AB1 and GAPDH (as internal control). 
Experiments were performed in duplicate. (b) Western blot analysis of Hsp90 of BxPC-3 
scrambled control cells (1) and different knockdown clones (2-11). Equal sample loading was 
confirmed by Ponceau S staining and β-actin analysis. (c) Western blot analysis of different 
cell cycle regulators in BxPC-3 control cells (Co) and BxPC-3 knockdown cells (k.d.) Cells 
were exposed to 41.5°C for 1.5 h and lysed directly after HS and the obtained protein samples 
were applied to SDS-PAGE. Western blot analysis was performed with the indicated 
antibodies. Equal sample loading was confirmed by Ponceau S staining and β-actin analysis. 
(d) Effects of HS on cell cycle distribution of BxPC-3 wildtype and knockdown cells. Cells 
were incubated with 10 µM of BrdU, exposed to 41.5°C for 1.5 h and prepared following the 
instructions of the manufacturer (BrdU Flow Kit, BD Pharmingen). The BrdU incorporation 
was measured and analysed by a FACSCalibur flow cytometer. Experiments were performed 
in sextuple. Asterisks indicate significance compared to the corresponding control (p<0.05) 
and error bars indicate ±SD.  
 
Figure 7 
Effects of GEM on BxPC-3 pancreatic cancer cells in combination with GD/HS. (a) BxPC-3 
cells were treated with 0.5 µM GEM for 2, 4 and 8 h. (b) After pre-incubation with 250 nM 
GD and 0.5 µM GEM for 1 h, BxPC-3 cells were exposed to 41.5°C for 1.5 h. After 8 h post-
incubation in the presence of GEM/GD, cells were lysed and the obtained protein samples 
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 were applied to SDS-PAGE. Western blot analysis was performed with the indicated 
antibodies. Equal sample loading was confirmed by Ponceau S staining and β-actin analysis. 
(c) Proliferation inhibition of BxPC-3 wildtype and BxPC-3 knockdown cells upon treatment 
with 5 nM GEM and 10 nM GD for 72 h. A single HS (41.5°C for 1.5 h) was carried out 1 h 
after treatment start. Experiments were performed in triplicate. Asterisks and triangles 
indicate significance compared to the corresponding controls (p<0.05) and error bars indicate 
±SD. 
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